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ABSTRACT 
Genetic predictors for epilepsy development, treatment response and dosing  
Antiepileptic drug (AED) treatment is the first line strategy for seizure control in the 
majority of individuals with epilepsy but remains challenging, not least because of 
interindividual variability in efficacy, tolerability and dosing. The studies presented in this 
thesis set out to explore that variability from a genomic perspective in patients with newly 
diagnosed epilepsy from across the UK. Single nucleotide polymorphisms (SNPs) in genes 
encoding drug metabolising enzymes (DMEs) may be associated with the dose of 
carbamazepine (CBZ) required for seizure control. A cohort of 159 individuals who were 
seizure-free for 12 months on a stable dose of CBZ monotherapy was genotyped for 51 SNPs 
across six DMEs. Haplotype analysis identified 8 haplotype blocks across the genes. No single 
SNPs or haplotype blocks were associated with CBZ dose. Thus, it is unlikely that genetic 
variability in DMEs accounts for the individual differences in CBZ dose requirement.  
 A splice site SNP (rs3812718) in the SCN1A gene was previously shown to influence 
maximum doses of AEDs. This SNP was genotyped in 817 patients and tested for association 
with maximum and maintenance doses of several AEDs. An association was identified 
between rs3812718 and maximum AED dose, with an interaction analysis suggestive of a 
drug specific effect. These findings suggest that this SCN1A variant contributes to variability 
in the limit of tolerability to AEDs.       
 Response to AED treatment is multifactorial and likely to be influenced by multiple 
genes. Five SNPs previously reported to predict treatment outcome in epilepsy were 
genotyped in 772 patients and the resulting data, together with data from an Australian 
cohort, incorporated into a predictive algorithm. The algorithm failed to predict treatment 
outcome in general but was partially successful in identifying responders to CBZ and 
valproate. These five SNPs may be relevant to the prognosis of epilepsy, particularly when 
treated with specific AEDs.        
 Primary generalised epilepsies (PGEs) are highly heritable and believed to be 
polygenic in origin. Predictive algorithms were employed to explore genetic influences on 
seizure (absence vs. myoclonus) and epilepsy (PGE vs. focal) type using 1,840 SNP genotypes 
available from 436 patients with PGE. Although the algorithms failed to distinguish PGE 
patients on the basis of genetic variants, they showed improved association over univariate 
methods of analysis. Such an approach may be suitable for future investigations using large 
genomic datasets.          
 A recent genome-wide association study identified multiple genetic variants that 
approached genome-wide significance for association with 12 month remission from 
seizures. Five of these SNPs were genotyped in an independent cohort of 424 patients and 
tested for association with remission and time to remission. No significant associations were 
found, questioning the validity of the original observation or the method of replication. 
Further work is required to understand this outcome.      
 In conclusion, the genetic bases of epilepsy, AED response and AED dose 
requirement are multigenic and thus far undetectable using traditional association studies in 
modestly-sized patient cohorts. Further advances in genomic, bioinformatics and statistical 
methodologies are required before the genetic contribution to heterogeneity in epilepsy-
related phenotypes can be translated into improved clinical care.  
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1.1 Epilepsy 
Epilepsy is a common serious neurological disorder experienced by millions and a cause 
of substantial morbidity and mortality. The disorder is found in all ages from neonates to the 
elderly and affects approximately 0.75% of the population with an estimated prevalence of 8.5 
per 1,000 individuals (www.who.int/mediacenre/factsheets/fs999). In the UK the prevalence 
rate is 6.2 per 1,000 population and it is diagnosed in about 80 individuals each day (Shorvon, 
2009)(www.who.int/mediacenre/factsheets/fs999). Costing around two billion pounds a year, 
and known for its potentially devastating social consequences and poor health outcomes, 
untreated epilepsy is also a critical public health issue. The long standing stigma associated 
with epilepsy has resulted in many persons having lower employment and education levels 
and lower socioeconomic status (Duncan et al., 2006).s Additional issues include higher 
psychological distress, more physical injuries such as fractures and burns, and increased 
mortality than the general population (Shneker and Fountain, 2003, Fisher et al., 2005). 
The history and treatment of epilepsy dates back some 4000 years (Chaudhary et al., 
2011), with the term epilepsy originating from the Ancient Greek word ‘epilambanein’, which 
means “to seize” or “to attack”. In these ancient times however, epilepsy was considered to 
have a religious origin; among existing theories were demonic possession and divine 
experience. Hippocrates became the first physician to define epilepsy as a “disease” and 
originally attributed the disorder to brain dysfunction (Fatovic-Ferencic and Durrigl, 2001). 
He was also the first to accurately describe epilepsy symptoms in both adults and children 
(Magiorkinis et al., 2010, Chaudhary et al., 2011). 
The early remedies used to treat epilepsy were mainly empirical and reflective of this 
early notion of a spiritual basis (Magiorkinis et al., 2010). A more rational scientific view of 
epilepsy didn’t appear until the 17th century when advancements in anatomy, physiology, and 
chemistry of the modern era were established and wherein nerve action was first associated 
with seizure causation (Magiorkinis et al., 2010, Chaudhary et al., 2011). 
 Today epilepsy is considered to be one of the most common serious neurological 
conditions and is defined as “a disorder of the brain characterised by an enduring 
predisposition to generate epileptic seizures”: and requiring the occurrence of at least one 
epileptic seizure (Fisher et al., 2005). Epilepsy is currently not considered a uniform disorder 
but a manifestation of underlying brain dysfunction that comprises of a collection of several 
seizure-related syndromes, varying in their aetiologies, clinical features, treatment, and 
prognosis (Shneker and Fountain, 2003, Engel, 2006b).  
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1.1.1 Aetiology of epilepsy 
The key manifestation of all epilepsies is recurrent seizures, though the aetiologies 
that give rise to these seizures are notoriously diverse, varying both worldwide and with age 
(Beck and Elger, 2008). Epilepsy is commonly associated with overt causes, these are often 
referred to as symptomatic or structural aetiologies and include central nervous system (CNS) 
tumors, neurodevelopmental abnormalities, CNS trauma and inflammation (Shneker and 
Fountain, 2003, Beck and Elger, 2008). In the UK the most common causes of epilepsy were 
cerebrovascular disease (15%), cerebral tumour (6%), alcohol-related (6%) and post-traumatic 
(2%) basis (Sisodiya and Duncan, 2004, Steinlein, 2008).  
 In a small number of patients a mutation in a single gene suffices to cause chronic 
seizures and this group of rare monogenic or Mendelian epilepsies thus are genetic in origin. 
More than 200 Mendelian epilepsies exist, however, in total they only account for around 1% 
of all epilepsy cases (Steinlein, 2008, Bhalla et al., 2011). In addition to the symptomatic and 
rare monogenic epilepsies there is a large group of common epilepsies that have a yet unknown 
aetiology (approximately two-thirds of all epilepsy cases). These epilepsies are thought to have 
some genetic contribution though are assumed polygenic and have an overall multifactorial 
basis (Sisodiya and Duncan 2004; Steinlein 2008). 
 
1.1.2 Classification system 
The classification of epilepsy is important for understanding its natural history, 
prognosis, diagnostic testing and treatment (Shneker and Fountain, 2003). Several 
classification systems have been proposed over the years and these continue to evolve over 
time to modify those definitions that predate modern neuroimaging, genomic technologies, 
and current concepts in molecular biology (Engel, 2006a, Berg et al., 2010). The most recent 
universally employed classifications of epilepsy seizures and syndromes were published by 
the International League Against Epilepsy (ILAE) in 1981 and 1989 respectively  and although 
a new ILAE Classification system has since been proposed in 2001 and more recently in 2010; 
these latest versions remain complex and thus controversial as to their superiority for clinical 
usage (Commission on Classification and Terminology of the International League against 
Epilepsy, 1981, Commission on Classification and Terminology of the International League 
against Epilepsy, 1989, Berg et al., 2010). See Table 1.1 for the ILAE classification of seizures 
(Berg et al., 2010). 
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Table 1.1 Classification of seizures (based on 1989 ILAE 
classification). Adapted from Engel et al 2001) 
  
1 Generalised seizures 
1.1 Tonic-clonic seizures  
 
1.2 Clonic seizures 
      1.2.1 Without tonic features 
      1.2.2 With tonic features 
 
1.3 Typical absence seizures 
1.4 Atypical absence seizures 
1.5 Myoclonic absence seizures 
1.6 Tonic seizures 
1.7 Spasms 
1.8 Myoclonic seizures 
 
1.9 Eyelid myoclonia 
       1.9.1 Without absences        
 1.9.2 With absences 
 
1.10 Myoclonic atonic seizures 
1.11 Negative myoclonus 
1.12 Atonic seizures 
 
2 Focal seizures 
2.1 Focal sensory seizures 
With elementary sensory symptoms  
With experiential sensory symptoms  
 
2.2 Focal motor seizures 
With elementary clonic motor signs 
With asymmetrical tonic motor seizures  
With typical (temporal lobe) automatisms  
With hyperkinetic automatisms 
With focal negative myoclonus 
With inhibitory motor seizures 
 
2.3 Gelastic seizures 
2.4 Hemiclonic seizures 
2.5 Secondarily generalised seizures 
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1.1.3 Seizures in epilepsy 
Epileptic seizures have been defined as the transient occurrence of signs and/or 
symptoms due to involuntary, abnormal excessive or synchronous neuronal activity in the 
brain as defined by the ILAE (Shneker and Fountain, 2003, Fisher et al., 2005). Epileptic 
seizures are first broadly classified into partial seizures or generalised seizures, and this 
division is based entirely on the site of the abnormal neuronal activity or seizure initiation, and 
then separated further by their individual clinical presentations (Shneker and Fountain, 2003). 
Partial seizures originate in a small area of the brain (one or more localised foci) and can 
individually be characterised according to degree of impairment or loss of consciousness 
during seizure onset. Generalised seizures on the other hand occur simultaneously in both 
cerebral hemispheres, with no localised foci, they produce loss of consciousness, either briefly 
or for a longer period of time and are individually characterised by presence of motor activity 
(Browne and Holmes, 2001, Shorvon, 2009). Both seizure types are classified using their 
specific clinical and encephalogram (EEG) manifestations (Browne and Holmes, 2001).  
 There are three broad categories of partial seizures: i) simple partial seizures, where 
individuals remain fully conscious, ii) complex partial seizures, where consciousness is 
impaired or lost and iii) partial seizures with secondary generalisation (partial seizures that 
spread across the entire brain and evolve into a generalised seizure (Browne and Holmes, 2001, 
Shneker and Fountain, 2003). Generalised seizures are divided into two overall categories: 
either as i) presenting major motor symptoms, as for generalised tonic-clonic seizures (GTCS), 
atonic seizures, tonic seizures, clonic seizures and myoclonic seizures or ii) having a lack of 
motor activity, as for typical and atypical absence seizures (Browne and Holmes, 2001, 
Shneker and Fountain, 2003).  
 
1.1.4 Pathogenesis  
 Normal cerebro-cortical function in humans has been well characterised, but the 
neurochemical basis of the processes underlying seizure generation is not well defined 
(Duncan et al., 2006). Seizures in epilepsy are thought to result from multiple mechanisms 
that appear diverse in nature, making their pathogenesis difficult to clarify (March, 1998). A 
common consideration however is that seizures are possibly the end-result of many different 
pathological processes that disrupt the normal function of the brain (McCormick and 
Contreras, 2001).  
 At a basic level, it is increasingly becoming evident that epileptogenic activity is most 
likely to be the consequence of a disruption of mechanisms that control the balance between 
excitation and inhibition in selected brain regions (Dichter and Ayala, 1987, Scharfman, 
2007). The transition from normal brain neural networks to hyper-excitable networks, a 
CHAPTER ONE
   
8 
 
process known as epileptogenesis is also not yet completely understood. Theories suggest a 
greater spread in the activation and recruitment of neurones in addition to enhanced 
connectivity, enhanced excitatory transmission, a failure of inhibitory mechanisms and 
changes in intrinsic neuronal properties (March, 1998, Duncan et al., 2006). 
 
1.1.5 Epilepsy and its syndromes 
The 1989 ILAE classification system defines epileptic syndromes as “an epileptic 
disorder characterised by a cluster of signs and symptoms customarily occurring together; 
these include type of seizure, aetiology, anatomy, precipitating factors, age of onset, severity, 
chronicity, diurnal and circadian cycling and sometimes prognosis” . In the widely used 1989 
ILAE classification (Commission on Classification and Terminology of the International 
League against Epilepsy, 1989), epilepsies are principally divided according to overall seizure 
type i.e. whether they are i) Generalised epilepsies, ii) Localisation-related epilepsies, iii) those 
that on the basis of clinical features cannot be assigned to either focal or generalised categories 
(unclassified) and iv) special syndromes, then sub-divided according to causation. There are 
three main causes used for classification; symptomatic epilepsies are those presumed to have 
an acquired cause, genetic epilepsies are those with a presumed genetic basis and crypotogenic 
epilepsies are presumed symptomatic but have an overall unknown cause (Commission on 
Classification and Terminology of the International League against Epilepsy, 1989).  Refer to 
Tables 1.1 and 1.2 for 1989 Classifications.  
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Table 1.2 Classification of Epilepsies and Epileptic Syndromes and Related Seizure 
Disorders (based on 1989 ILAE classification)  
 
1 Localisation-related (local, focal, partial) epilepsies and syndromes 
           1.1 Idiopathic (with age related onset) 
Benign childhood epilepsy with centrotemporal spikes 
Childhood epilepsy with occipital paroxysms 
Primary reading epilepsy 
            1.2 Symptomatic 
Chronic progressive epilepsia partialis continua 
Syndromes characterized by seizures with specific modes of 
precipitation 
Temporal lobe epilepsies 
Frontal lobe epilepsies 
Parietal lobe epilepsies 
Occipital lobe epilepsies 
1.3 Cryptogenic 
2 Generalised epilepsies and syndromes 
2.1 Idiopathic (with age-related onset) 
Benign neonatal familial convulsions 
Benign neonatal convulsions 
Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsy with generalized tonic-clonic seizures on awakening 
Other generalized idiopathic epilepsies 
Epilepsies with seizures precipitated by specific modes of activation 
2.2 Cryptogenic or symptomatic 
West syndrome 
Lennox-Gastaut syndrome 
Epilepsy with myoclonic-astatic seizures 
Epilepsy with myoclonic seizures 
2.3 Symptomatic 
Nonspecific etiology 
Early myoclonic encephalopathy 
Early infantile epileptic encephalopathy with suppression burst 
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Other symptomatic generalised epilepsies 
Specific syndromes 
Epileptic seizures complicating other disease states 
3 Epilepsies and syndromes undetermined whether focal or generalised 
3.1 With both generalised and focal seizures 
Neonatal seizures 
Severe myoclonic epilepsy of infancy 
Epilepsy with continuous spike waves during slow-wave sleep 
Acquired epileptic epilepsies 
Other undetermined epilepsies 
3.2 Without unequivocal generalised or focal features 
 
4 Special syndromes 
4.1 Situation-related seizures 
Febrile convulsions 
Isolated seizures or isolated status epilepticus 
Seizures occurring only with acute metabolic or toxic events 
 
(Commission on Classification and Terminology of the International League Against 
Epilepsy, 1989) The 1989 classification of syndromes was adopted in this thesis, due to the 
primary use of these definitions for patient classification for the various UK epilepsy cohorts 
 
 
 
1.1.6 Epidemiology 
Epilepsy affects approximately 50 million people globally. The prevalence of active 
epilepsy is approximately 5-10 per 1000 population in most locations (Sander, 2003a). In the 
UK, epilepsy is diagnosed in about 80 individuals each day; 350,000 have active epilepsy 
(defined as the occurrence of a seizure during the previous 2 years and/or the taking of 
antiepileptic drugs) and 100,000 have refractory epilepsy (Sander, 2003a). However studies 
have shown that the disorder is not evenly distributed, with the age-adjusted incidence of 
epilepsy in developed countries ranging from 24 to 54 new cases per 100,000 population  and 
a higher rate presumed for developing countries (recent reports of 49.3 to 190 per 100,000 
population)(Sander, 2003a)(www.who.int/mediacentre/factsheets/fs999 ). In the UK, around 
450,000 individuals have epilepsy and the age-standardised prevalence is estimated as 7.5 per 
1000 population (Sisodiya and Duncan, 2004). 50% of individuals who develop epilepsy do 
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so before the age of 15 years though prevalence increases with age (around 3 per 1,000 in 
under 16s and 12 per 1,000 in over 65s) (www.who.int/medicentre/factsheets/fs                
999/en/index.html).       
 
1.1.7  Co-morbidities and risk factors 
There are numerous comorbidities that complicate both the assessment and treatment 
of epilepsy. These include psychological and/or psychiatric problems, having a learning 
disability and/or a concomitant medical condition(s) (Shneker and Fountain, 2003, Duncan et 
al., 2006). The disorder is additionally often associated with serious physical implications from 
a heightened accumulation of brain damage and/or neurological deficits. Individuals with 
epilepsy thus generally carry a greater risk of injury and/or sudden unexpected death in 
epilepsy (known as SUDEP) than that of the general population (Duncan et al., 2006). 
Although most people with epilepsy are able to lead a normal emotional and cognitive life, 
neurobehavioral problems can be found in a large number of patients (Torta and Keller, 1999).  
 
1.2 Prognosis of epilepsy 
The risk of recurrence is greatest in the first few months after a first seizure years 
(Hauser et al., 1998). About 50% of those who have suffered a single unprovoked seizure have 
a further seizure within 5 years (Hauser et al., 1998) and about 75% of those with two initial 
unprovoked seizures suffer further seizures within the first four years (Hauser et al., 1998, 
Sisodiya and Duncan, 2004). In general however, the prognosis for complete seizure control 
is good as approximately 70% of patients do eventually achieve long-term remission within 
the first 5 years of diagnosis (Sander, 1993, Cockerell et al., 1997). Prognostic factors include 
age of onset, number of seizures in the early stages of the condition, early response to 
antiepileptic drugs (AEDs) and certain epilepsy specific EEG findings (Sander, 1993, Kwan 
and Brodie, 2000a, MacDonald et al., 2000, Kwan and Brodie, 2001a). In accordance with the 
association between early seizure control and long-term remission the prospect of seizure 
cessation has also been indicated to decrease as time elapses (Brodie and French, 2000, 
MacDonald et al., 2000, Kwan and Brodie, 2001a, Sander, 2003a).   
 AEDs are highly successful in suppressing seizures in most but little is known about 
the role of AED treatment on the outcome of epilepsy (Duncan et al., 2006). The recent 
assumption is that an inherent element to both treatment response and outcome may exist and 
so for some chronic epilepsy patients, remission could be impossible from onset (MacDonald 
et al., 2000, Sander, 2003a).  
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1.3 Treatment of epilepsy 
 Pharmacotherapy is the mainstay of treatment for people with epilepsy 
(Panayiotopoulos and International League against Epilepsy., 2005). Non-pharmacological 
options include ketogenic diet, vagal nerve stimulation and brain surgery, although these are 
only feasible in selected individuals and are usually considered once drug treatment has failed; 
with the latter used as a last resort in severe or chronic epilepsy cases (Sander, 2004, Duncan 
et al., 2006).  
 
1.3.1 Pharmacological management  
AEDs are primarily intended to prevent epileptic seizures and generally function to increase 
inhibition, decrease excitation, and/or prevent aberrant burst firing of neurones that is often 
associated with seizure generation. The ultimate goal of pharmacological management in 
epilepsy is to achieve complete seizure freedom as quickly as possible (Vajda, 2007), without 
any drug-related adverse effects (AEs) (i.e. nausea, dizziness, weight gain), adverse drug 
reactions (ADRs) (i.e. hepatotoxicity, haemotoxicity, dermatotoxicity and teratogenicity) 
(Sander, 2004, Mann and Pons, 2007) and using only a single AED (Beghi and Perucca, 1995). 
As previously mentioned AEDs are greatly effective in abolishing seizures in up to 
70% of patients (Kwan and Brodie, 2000a, 2001a). Significant seizure control reduces the 
morbidity and premature mortality (Sander and Bell, 2004); (Mohanraj et al., 2006) often 
associated with unpredictable and continuous seizures, and so greatly enhances overall quality 
of life (Birbeck et al., 2002). 
 
1.3.2 Antiepileptic drug treatment 
There are currently over 20 AEDs available, differing in their chemical structure 
and/or mode of action (Table 1.3). The majority of the available AEDs were developed in the 
1980-1990’s (Schachter, 2007) and several new AEDs are in clinical trials or have been 
recently approved (Bialer and White, 2010). These drugs have been developed either through 
serendipity, such as the early discovery of the anticonvulsive properties of bromide and 
barbiturates (Porter and Rogawski, 1992), or through the screening of new compounds in 
experimental animal models of epilepsy. The progress in these animal studies and drug trials 
have, over the past 20 years, allowed the introduction of numerous AEDs to the clinic (Duncan 
et al., 2006, Smith et al., 2007). 
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1.3.3 History and effectiveness of anticonvulsants 
 Drugs introduced up to the early 1970s included the benzodiazepines (BZDs) (such as 
diazepam), carbamazepine (CBZ), ethosuximide (ESM), phenytoin (PHT) and valproic acid 
(VPA) (Schachter, 2007). These early AEDs are known as older generation drugs and were 
considered an advancement over the initially available barbiturates, due to their markedly 
improved tolerability and a broader spectrum of efficacy against different seizure types 
(Schachter, 2007).  A more rational approach was taken to subsequent AED development 
(Kupferberg, 2001, Smith et al., 2007). This produced the following ‘new generation of 
AEDs': felbamate (FBM), gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), 
oxcarbazepine (OXC), pregabalin (PGB), topiramate (TPM), tiagabine (TGB), vigabatrin 
(VGB) and zonisamide (ZNS) (Schachter, 2007) and more recently lacosamide (LCM), 
eslicarbazepine (ESL), rufinamide (RUF) and retigabine (RTG) (Bialer et al., 2007, Bialer and 
White, 2010). Of these TGB and VGB were designed with specific mechanisms of action 
(Bialer et al., 2007, Bialer and White, 2010).  
 Despite this ever-growing list of anti-seizure agents, issues with efficacy and tolerability 
largely remain (Kwan and Brodie, 2001a). The available evidence indicates that efficacy and 
tolerability to drug treatment in epilepsy has not substantially improved (Loscher and Schmidt, 
2011). There is no compelling evidence that third-generation AEDs, have made clinically 
relevant advances in the day to- day tolerability of current epilepsy treatment. Some AEDs of 
these newer drugs do however have advantages; namely linear pharmacokinetics (PK), an 
improved tolerability profile, lessened drug interaction potential, a lower risk of 
hypersensitivity reactions and fewer AED-associated AEs (Perucca, 2001a, Loscher and 
Schmidt, 2011).  Data in this regard thus remains to be accumulated over the coming years 
before any definite conclusions on the success of modern AEDs can be drawn. 
 
1.3.4 Pathways of drug action  
Several distinct molecular and cellular events occur during a seizure that involve 
sodium (Na+), calcium (Ca2+) and potassium (K+) ions (McNamara, 1994). These are not only 
critical for normal neuronal function and signaling pathways, but are also important in the 
initiation of seizures, spread of seizure activity and arrest of the seizure (McNamara, 1994). 
Na+ conductance is important for the initiation and maintenance of seizure activity as is Ca2+ 
conductance, which also contributes to neuronal injury, and K+ conductance is essential in the 
arrest of seizure discharge (McNamara, 1994, Scharfman, 2007). Synaptic transmission also 
plays a critical role in maintaining the balance between excitation and inhibition, and so 
perturbation in this process can likewise lead to seizure generation (Scharfman, 2007). The 
principal neurotransmitters involved in synaptic transmission are gamma-aminobutyric acid 
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(GABA) and the excitatory amino acid glutamate (Scharfman, 2007). 
 To exhibit antiepileptic activity, a drug must act on one or more target molecules in 
the brain, such as ion channels, neurotransmitter transporters and neurotransmitter metabolic 
enzymes (Kwan et al., 2001). These interactions modulate the bursting properties of neurones 
and reduce synchronisation in localised neuronal ensembles (Kwan et al., 2001). Although the 
mechanisms of action of many AEDs are not fully understood, they are broadly categorised 
according to the following three general modes of action (Kwan et al., 2001) (based on their 
basic cellular mechanisms) i) modulation of voltage-dependent ion channels (including Na+, 
Ca2+, K+ channels), ii) enhancement of GABA-mediated inhibitory neurotransmission and iv) 
attenuation of excitatory, glutamate-mediated transmission (Meldrum, 1996, Kwan et al., 
2001, Schachter, 2007). For many of the newer AEDs multiple molecular mechanisms of 
action have been identified (White, 1999). 
 
1.3.5 The gamma-aminobutyric acid inhibitory system  
 The potentiation of inhibitory neurotransmission is one of the main mechanisms of AED 
action and several AEDs exert their effects, at least in part, by actions on the GABAergic 
system (Kwan et al., 2001, Benarroch, 2007). In the CNS, inhibition is principally mediated 
by the neurotransmitter GABA, which functions through binding to chloride-permeable 
ionotropic GABAA receptors (mediators of fast inhibition) and metabotropic GABAB 
receptors (mediators of slow inhibition) (Benarroch 2007). Dysfunction of GABAA receptor-
mediated fast inhibition is an important pathophysiological mechanism of increased neuronal 
excitability and has been identified in the process of epileptogenesis (Benarroch 2007; Olsen 
and Avoli 1997). Loss-of-function of the receptor, through mutations in GABAA subunit genes 
have additionally been linked to various epilepsy syndromes (Olsen and Avoli, 1997, Baulac 
et al., 2001, Wallace et al., 2001a, Bianchi et al., 2002, Macdonald et al., 2004).  
 Benzodiazepines, barbiturates, FBM and TPM, all modulate this pathway by facilitating 
GABA-ergic neurotransmission through increasing GABAA receptor function (Kwan et al., 
2001). AEDs may alternatively enhance synthesis of the GABA neurotransmitter (as with 
VPA and GBP), decrease GABA degradation (as with VPA and VGB), or prevent GABA re-
uptake into neurones and glia (as with TGB) (Kwan et al., 2001).  
 
1.3.6 Glutamate neurotransmission 
 Excitatory neurotransmission in the brain is mediated by excitatory amino acids. 
Glutamate is the principal excitatory neurotransmitter in the mammalian brain and exerts it 
effect through one of four glutamate receptors (the ionotropic, NMDA, kainate and AMPA 
receptors and the metabotropic mGluR receptor) found in the CNS (Meldrum, 2000). 
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Abnormal glutamate receptor function has been observed in several experimental seizure 
models and has been implicated in both the initiation and spread of epileptic seizures 
(Meldrum, 1995, Chapman, 1998, 2000). Because of the role of glutamate in the 
pathophysiology of seizures and the substantial evidence that glutamate receptor antagonists 
are protective in various animal models, great effort has been devoted toward the development 
of novel AEDs targeting the glutamate system (Meldrum, 2000, Meldrum and Rogawski, 
2007). Of the drugs mentioned above only FBM and TPM appeared to reduce the glutamate 
action via the blockade of ionotropic glutamate receptors in addition to their primary action 
on GABA neurotransmission (Upton, 1994, Macdonald and Kelly, 1995, Meldrum, 1996). 
Recently however perampanel has been developed and approved as a selective AMPA 
receptor (major ionotropic glutamate receptor subtype) antagonist for the treatment of partial 
onset seizures (Rogawski, 2011, Krauss et al., 2012). 
 
1.3.7 Neuronal ion channels 
 The K+, Na+ and Ca2+ neuronal voltage-gated ion channels maintain neuronal function 
through shaping the sub-threshold electrical behaviour of the neurones, allowing action 
potential firing, and regulating neuronal responsiveness to synaptic signals and pre-synaptic 
neuronal neurotransmitter release (Scharfman, 2007). These channels are subsequently central 
to deregulation in neuronal signaling as evident in the generation of seizure discharges. The 
vast majority of the newer and established AEDs can thus exert their anticonvulsant effects 
through ion channel modulation (Bialer and White, 2010). Na+ channel targeting AEDs 
include CBZ, ESL, FBM, PHT, LCM, LTG, OXC, RUF, TPM, VPA and ZNS; K+ channel 
AEDs include RTG and TPM and Ca2+ channel AEDs include ESM, FBM, GBP, LEV, PGB, 
LTG, TPM, VPA (Shorvon, 2010).  
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Table 1.3 Proposed mechanisms of action of antiepileptic drugs 
Drug  Main mode of action 
Benzodiazepines BZD Potentiate GABA-mediated inhibition  
Carbamazepine CBZ Blocks voltage-gated Na+ channels 
Clobazam CLB Increases inhibition by GABAA 
Ethosuximide ESM Blocks T-type Ca 2+ channels 
Felbamate FBM Potentiates GABA-mediated inhibition and blocks 
voltage-dependent Na+ channels 
Gabapentin GBP Binds to the α2δ subunit of neuronal 
voltage-gated Ca 2+ channels inhibiting calcium flow 
Lamotrigine LTG Blocks voltage-gated Na+ channels 
Levitiracetam LEV Binds to synaptic vesicle protein SV2A 
Lacosamide LCM Blocks voltage-gated Na+ channels 
Oxcarbazepine OXC Blocks voltage-gated Na+ channels 
Perampanel PRM Blocks AMPA glutamate receptor 
Phenobarbital PB Augments the inhibitory effect of GABA by prolonging 
the Cl- channel opening at the GABAA receptor 
Phenytoin PHT Blocks voltage-gated Na+ channels 
Pregabalin PGB Calcium channel blocker, binds to channel to inhibit 
calcium flow 
Retigabine RTG Modulation of K+ channel, prolonging channel opening 
Rufinimide RFM Blocks voltage-dependent Na+ channels 
Sodium 
Valproate 
VPA Blocks voltage-dependent Na+ channels, facilitates the 
effects of GABA and reduces T-type Ca 2+ currents 
Tiagabine TGB Blocks GAT1,GABA transporter thus inhibits neuronal 
and glial reuptake of GABA to increase the availability 
of GABA and inhibit postsynaptic neurons 
Topiramate TPM Blocks voltage-gated Na+ channels and Ca 2+ channels, 
enhances GABAergic neurotransmission and inhibits 
carbonic anhydrase 
Vigabatrin VGB Enhancing biosynthesis and preventing degradation of 
GABA by inhibiting GABA transaminase, resulting in 
elevated brain levels of GABA  
Zonisamide ZNS Blocks voltage-gated Na+ channels 
Data taken from Loscher and Schmidt 1999, Schachter et al 2007 and Kwan et al 2001 
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1.3.8 Principles of treatment 
The licensing of many new AEDs in the last 20 years has presented a greater choice 
of AEDs for physicians and accordingly patients with epilepsy now have a better chance of 
achieving optimum treatment than in the past (Perucca, 2002a). Due to differences in 
individual efficacy, drug PK, side-effects and drug interactions between the different AEDs 
(Brodie and Kwan, 2001, Schachter, 2007), it is often difficult to predict which drug will be 
the best tolerated and most likely to provide the best seizure control in a given individual 
(Perucca, 2001a, 2002a).  
Several patient characteristics are currently used to divide patients into subpopulations 
to aid drug selection. The effectiveness of the newer AEDs was determined with regulatory 
trials and post marketing studies in patients with defined seizure types (Schachter, 2007). 
Based on clinical trial data, mechanisms of action, and clinical experience, certain AEDs are 
generally preferred for focal epilepsy and other AEDs are preferred for generalised epilepsy 
(Perucca, 1999, Vajda, 2007). Therefore, the first step in selecting among the currently 
available AEDs for a particular patient is to determine his or her seizure type(s) and/or epilepsy 
syndrome (Schachter, 2007) (http://guidance.nice.org.uk /CG20/Guidance). Additional 
subpopulations are based on age, gender, medical comorbidities, concomitant medications, 
individual lifestyle, individual preference, childbearing potential, likelihood of AEs, and the 
licensed indication of the drug (http://gui dance.nice.org.uk/CG20/Guidance).  
 
1.3.9 Clinical use  
First-line AEDs are generally started at a low dosage and drug dose is titrated up 
gradually to a target dose. If seizures continue, titration is continued until seizures are 
controlled or up to the maximum tolerated dose (dose at which AEs appear in a given 
individual)(Brodie and French, 2000). If the drug is ineffective at this maximum tolerated 
dose, it is discontinued, but slowly (tapered off through dose reduction) and replaced by an 
alternatively appropriate AED; again selected based on seizure type, epilepsy type, specific 
syndrome etc. (Perucca, 2001a, Brodie and Kwan, 2002, Schachter, 2007).  
 Existing National Institute for Health and Clinical Excellence (NICE) guidelines on the 
management of epilepsy indicate that individuals should preferably be treated with a single 
AED, where possible. Clinicians are also recommended to maintain treatment with a single 
AED to avoid the complications that arise with the use of multiple drug combinations 
(http://guidance.nice.org.uk/CG20/Guidance). With AED monotherapy compliance is often 
enhanced, overall medication costs are usually less and there are generally fewer idiosyncratic 
reactions, teratogenic effects, and other dosage and/or drug interaction related side effects 
(Brodie and Kwan, 2001). AED monotherapy successfully controls seizures in the majority of 
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patients (Leppik, 2000). A significant number of patients with more severe forms of epilepsy 
do however require multiple drug treatment or polytherapy (Brodie and French, 2000, Leppik, 
2000, Sander, 2004). Many patients however still require seizure management with a 
combination of drugs (Brodie and Kwan, 2001). Such ‘combination therapy’ (also known as 
adjunctive or ‘add-on’ therapy) is usually considered when all attempts at monotherapy have 
not resulted in seizure freedom (http://guidance.nice.org.uk /CG20/Guidance)(Duncan et al., 
2006).  
 Typically if monotherapy is poorly tolerated or ineffective at the maximum tolerated 
dose, the strategy is to switch to another first-line drug. Second-line options are used when all 
first-line drugs fail (http://guidance.nice.org.uk/CG20/Guidance) (Mattson et al., 1985, Kwan 
and Brodie, 2000a, 2001a, Sander, 2004). With combination therapy, an additional drug is 
usually titrated to a tolerable and effective dosage before the first AED is tapered (Duncan et 
al., 2006). There is a lack of clarity with the dose at which a drug should be deemed ineffective 
and when alternative AEDs or combination therapy should be considered (Kwan and Brodie, 
2000b, Brodie and Kwan, 2002, Kwan and Brodie, 2004). For combination therapy however 
there is now suggestion that the mechanism of action of each AED should be taken into 
consideration (Brodie and Kwan, 2001, Sander, 2004).  
 
1.3.10 Effectiveness of pharmacotherapy in clinical practice 
Differences in treatment response with particular AEDs, in terms of variation in 
clinical efficacy, dosing and tolerability, between individuals with seemingly similar disorders 
is a very common phenomenon among all pharmacotherapeutics (Dlugos et al., 2006). 
Prognosis with AED treatment thus varies considerably among the different types of epilepsy 
(Semah et al., 1998) and may also differ even between patients with the same epilepsy 
syndrome (Schmidt and Loscher, 2005). Better remission is generally evident for secondary 
generalised attacks when compared to partial seizures (Mattson et al., 1985). In addition most 
studies have reported prognosis to be poor in patients with multiple seizure types, associated 
neurological deficit and behavioral or psychiatric disturbance (Sander, 1993). The longer 
patients continue to have seizures after their initial diagnosis, the lower the probability of 
achieving remission (Annegers et al., 1979, French, 2002). Of the 70% of individuals 
responsive to AED therapy, nearly 50% are seizure free with initial treatment, and a further 
16% of patients who find the first drug to be ineffective in suppressing seizure activity can 
expect freedom from seizures with additional AED treatment (Kwan and Brodie, 2000a). 
Those who fail treatment with a second AED are however thought to have a small chance of 
ever obtaining seizure freedom (Kwan and Brodie, 2000b, McCorry et al., 2004).  
 The use of AEDs in clinical treatment is often complicated and in some cases 
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problematic, even for responsive individuals (Perucca, 2001a) and this can sometimes be 
attributed to AED pharmacology. Some older and newer generation AEDs present different 
activity spectra and a narrow therapeutic index (Sander, 2004), some with highly variable and 
nonlinear PK, sub-optimal response rates and a propensity of many AEDs (particularly the 
older generation) to cause drug interactions. Consequently even though there are over 20 
AEDs (old and new generation) available, which continues to grow steadily, the 60-70% 
response rate in epilepsy remains. The failure to achieve seizure freedom in a substantial 
minority of individuals is perhaps the most important issue with current AED therapy (Kwan 
and Brodie, 2000a). Additional serious issues in AED utilisation include the occurrence of 
AEs, as virtually all AEDs show common side effects and/or idiosyncratic reactions (Sander, 
2004, Perucca and Meador, 2005, Schachter, 2007, Zaccara et al., 2007). There is also the 
challenge of identifying the most effective and best tolerated dose of a specific drug(s) for 
individual patients, which can vary greatly among individuals and is currently impossible to 
predict (Kwan and Brodie, 2001a, Perucca, 2002b).  
 
1.4 Treatment failure in epilepsy 
 Individuals that fail to achieve remission with long term AED treatment are referred to 
as having drug-resistant or refractory epilepsy (also referred to as a pharmaco-resistant 
phenotype) (Kwan and Brodie, 2000a). Drug resistant individuals are usually treated with 
multiple AEDs that in combination can often have adverse sedative, behavioral and/or 
psychiatric effects (Kwan and Brodie, 2002, Elger, 2003). There is also a greater risk of 
cognitive impairment with prolonged drug use, the likelihood of which increases with seizure 
frequency, duration and severity (Cramer, 1994, Vermeulen and Aldenkamp, 1995, Kwan and 
Brodie, 2001b).  
 What causes epilepsy to become ‘refractory’ has so far remained elusive. Several 
clinical/environmental prognostic factors have been implicated however as previously 
discussed for AED treatment response the biological basis of ‘refractoriness’ is a multifactorial 
and variable phenotype with a genetic and clinical basis. As AEDs are principally required to 
traverse the blood–brain barrier (BBB) and then secondly bind to one or more target molecules 
to exert their particular therapeutic effect two theories have emerged from these 
pharmacological pathways in an attempt to explain treatment failure in epilepsy (Remy and 
Beck, 2006). These are the drug transporter and drug target hypotheses. The transporter theory 
proposes an overexpression of efflux transporters at the BBB (i.e. Pgp efflux protein), that 
leads to a surge in active efflux of AEDs, thus decreasing their concentration in the CNS, 
despite adequate AED exposure and/or measured serum levels (Loscher and Potschka, 2002). 
The target theory on the other hand proposes a reduction in AED target sensitivity (i.e. 
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molecular targets of AEDs such as the neuronal channels) in epileptogenic brain (Remy et al., 
2003). This altered channel sensitivity would then cause reduced efficacy of a given AED at 
its molecular target (Remy et al., 2003). 
 
1.4.1 Indications of resistance to antiepileptic drugs 
 The identification of refractory epilepsy is not only important for clinical decision 
making i.e. for doctors to consider alternative non-pharmacological treatment options for 
patients, but is a vital step towards understanding disease pathophysiology, determinants of 
natural history, predictors of prognosis and it can also benefit the development of novel 
treatment strategies (Kwan and Brodie, 2010). Despite many research studies investigating 
this clinical phenomenon, a precise definition to identify people with treatment resistance has 
remained elusive for many years and this has resulted in use of diverse criteria by different 
clinicians and researchers (Annegers et al., 1979, Kwan and Brodie, 2000a, Berg and Kelly, 
2006).  
 The most recent description proposed by the ILAE defines refractory epilepsy as 
“failure of adequate trials of two tolerated and appropriately chosen and used AED schedules 
(whether as monotherapies or in combination) to achieve sustained seizure freedom” (Kwan 
et al., 2010). Complete failure with two or more AED monotherapies characterises individuals 
with intractable epilepsy. Combining a wide range of two or perhaps three different AEDs was 
effective in some of these difficult to treat individuals (Stephen et al., 2001, Stephen and 
Brodie, 2002), although robust data evaluating the effectiveness of AED combination therapy 
is currently scarce (Pearce et al., 2008).  
 
1.4.2 Management of drug-resistance in epilepsy 
New AEDs are being developed to address the issue of treatment-resistance in the 
epilepsy population (French et al., 2004, Bialer and White, 2010). However there is emerging 
evidence that better results can be obtained by more appropriately combining modern AEDs 
(that offer novel mechanisms of action and fewer drug interactions) with complementary 
modes of action (Moeller et al., 2009). This suggestion however remains to be proven with 
robust drug efficacy data (Pearce et al., 2008, Poolos et al., 2012). Efficacy of new AEDs used 
as adjunctive therapy in patients unresponsive to established AEDs has been investigated in 
several controlled trials. However, none of the new AEDs have produced a high percentage of 
seizure freedom in these studies (Cramer et al., 1999, Barcs et al., 2000, Cramer et al., 2001, 
French et al., 2003, Callaghan et al., 2011) thus treatment outcome in refractory epilepsy 
remains poor, with responder rates (50% seizure reduction) found to range from 15-50% in 
these studies. More recent evidence has also shown the probability of remission in people with 
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intractable epilepsy as around 5% per year (Callaghan et al., 2007, Choi et al., 2008).  
 
1.4.3 Predicting drug response: clinical markers for drug resistance 
Phenotypic markers for distinguishing those patients who appear unresponsive to 
AEDs from those able to successfully achieve seizure control (Loscher, 2005a, Tate and 
Sisodiya, 2007) would allow early consideration of non-drug therapies (Cockerell et al., 1995, 
MacDonald et al., 2000, Dlugos et al., 2001, Mohanraj et al., 2006). This, for the most severe 
cases at least (where individuals are inevitably likely to require surgery due to severity of 
seizures) would potentially prevent some of the devastating consequences associated with 
intractable epilepsy (Brodie, 2005a).  
 Pretreatment seizures have long been identified as a predictor of outcome, with a 
larger number of pre-treatment seizures universally associated with a poorer response to early 
AED treatment (Camfield et al., 1996, Kwan and Brodie, 2000a). High seizure frequency 
evident during the early stages of AED treatment is also considered to indicate poor seizure 
control and is similarly used to envisage the likelihood of developing pharmacoresistance 
(Brodie, 2005a). In addition there is good evidence that seizure type or syndromic diagnosis 
is associated with likelihood of seizure control (Semah et al., 1998). Individuals presenting 
with idiopathic generalised seizures more likely to become seizure free than those with 
symptomatic or cryptogenic epilepsies (Koster et al., 2009). Further potential risk factors for 
refractory epilepsy include seizure clusters, family history, febrile convulsions, environmental 
factors such as traumatic brain injury, and psychiatric comorbidity (Petsche et al., 1972, Hitiris 
and Brodie, 2006, Mohanraj et al., 2006). 
 
1.4.4 Inherent role in drug resistance 
Despite identification of several clinical and environmental factors that appear to 
contribute to the biological basis of drug-resistance in epilepsy, the prognostic value of most 
of these factors is rather limited, and none can explain multidrug resistance alone (Brodie, 
2005a, Loscher, 2005a). Other influential features beyond those contributing to the aetiology 
of epilepsy have therefore been implicated in the multifaceted basis of AED response (Petsche 
et al., 1972, Depondt, 2006b, Koster et al., 2009, Johnson et al., 2011b). The interindividual 
variation often seen in response to AEDs between individuals who appear to have the same 
epilepsy phenotype suggests that genetic factors could also contribute to the AED responsive 
and resistance phenotypes (Sisodiya, 2003, 2005). The influence of genes on outcome of drug 
treatment is a rapidly evolving field (Weinshilboum, 2003) and may help to explain this 
variability in clinical outcome as well as enlighten the general unpredictability of epilepsy 
treatment (Spear, 2001, Sisodiya, 2005). 
CHAPTER ONE
   
22 
 
1.5 Pharmacogenetics 
Even with the medical advances of the 20th Century, optimal drug treatment remains 
elusive for many of the world’s common and high impact diseases including hypertension, 
cancer and diabetes (McLeod and Evans, 2001, Spear et al., 2001). The efficacy and toxicity 
of many major therapeutic agents is substantially heterogeneous when viewed across the 
globe, thus treatment response and failure in patient groups is hugely unpredictable 
(Mancinelli et al., 2000, McLeod and Evans, 2001, Shastry, 2006). Any given drug can be 
effective in some patient groups but ineffective in others, and some individuals experience 
AEs and/or ADRs whereas others are unaffected. This interindividual variability in response 
to most, if not all, drugs is well known and poses a serious problem in current medical 
treatment (Wolf et al., 2000, McLeod and Evans, 2001). 
 Potential causes for differences in drug response include the nature and severity of the 
disease being treated, the individual’s age and race, organ function, concomitant therapy, drug 
interactions, and concomitant illnesses (Evans and Johnson, 2001). However, even when these 
factors are taken into account, considerable variation remains unexplained (Vinken et al., 
1999). Over the past decades, much evidence has emerged indicating that a significant portion 
of this variability is genetically determined (Vinken et al., 1999, Mancinelli et al., 2000).  
 
1.5.1 The history of pharmacogenetics 
Although genetic differences among people have long been recognised to influence 
drug response phenotypes of individuals, research efforts have only begun to focus on the 
genetics of drug response in the last few decades, with previous focus being largely orientated 
towards disease predisposition (Goldstein, 2005). Leveraging the knowledge of an individual's 
genetic makeup initially gave the possibility to predict susceptibility to monogenic diseases 
and later proved particularly valuable for common diseases with a complex multifactorial 
nature (McLeod and Evans, 2001). A similar approach has since been taken for predicting the 
complexity of response to particular treatments, in order to match patients with the right 
medications given at the right doses (Goldstein, 2005). The relatively new field of studying a 
patient’s response to a specific drug alongside their genetics is known as pharmacogenetics 
(PGx) (Weinshilboum, 2003).  
 PGx is characterised by the profiling of differences between individuals’ DNA to 
identify definitive relationships between the structure and function of pharmacologically 
relevant genes and the drug response phenotypes observed in patients (McLeod and Evans, 
2001). The overall goal of PGx is to better understand the genetic variation that determines 
heterogeneity in drug effects, to predict how individuals may respond to drugs, and to 
ultimately translate this to clinical practice (Evans and Relling, 2004). In the last ten years the 
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remarkable progress in human genomics and molecular genetics has initiated a surge in PGx 
research (Ferraro and Buono, 2005) and the discovery of genetic markers of phenotypes for 
response to medications has become one of the fastest growing fields in clinical and 
translational biomedical research (Wang et al., 2011).  
 PGx originated in the 1950’s where early clinical observations identified patients with 
large differences in their response to “standard” drug doses, often with individual variations 
in plasma or urinary drug concentrations. This was followed by the discovery of drug-
metabolizing enzymes (DMEs) and the realisation that such variation was largely due to 
inherited differences in metabolism (Weber, 2001, Weinshilboum and Wang, 2006). The 
genes of DMEs formed the first candidate genes for variable drug response. DME genes 
encode enzymes that metabolise drugs and their products and have evolved to neutralise toxins 
and/or to control concentrations of signaling molecules in endogenous pathways (Nebert and 
Dieter, 2000, Goldstein et al., 2003).  
 Researchers first described the role of genetic differences in determining biochemical 
traits through the disposition of succinylcholine, isoniazid, and antimalarial drugs such as 
primaquine (Weinshilboum, 2003). They were able to distinguish that prolonged paralysis 
following the use of succinylcholine was the result of a variant of the butyryl-cholinesterase 
enzyme, that hemolytic anemia due to the antimalarial drug primaquine resulted from a variant 
form of the enzyme glucose-6-phosphate dehydrogenase, and that peripheral neuropathies 
caused by the anti-tuberculosis drug isoniazid were a consequence of genetic differences in 
the enzyme N-acetyltransferase (Weber, 2001, Johnson, 2003, Weinshilboum, 2003).  
 The field of PGx has since developed and expanded to cover more complex drug 
response phenotypes (Goldstein, Need et al. 2007). Today PGx is considered a rational and 
systematic genetic approach to identifying specific genetic sources of drug response variability 
(Evans and McLeod, 2003, Weinshilboum, 2003). Understanding the molecular basis and 
functional consequences of these genetic variants on drug response phenotypes has the 
potential to enlighten the use of many medications, optimising their efficacy and preventing 
toxic effects during routine drug therapy (Evans and Relling, 1999). 
 
1.5.2 The potential for tailored drug therapy 
Decisions about the choice of drug and appropriate dosage are at present largely based 
on information derived from population averages (Mancinelli et al., 2000). As polymorphisms 
with functional consequences are identified, the potential for clinicians to utilise 
interindividual variation in a patient’s genetics in the clinical setting for a more personalised 
approach to treatment becomes markedly greater (Vinken et al., 1999, Feero et al., 2010, Wang 
et al., 2011). This involves classifying patients with the same phenotypic disease profile into 
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smaller sub-populations, defined by genetic variations associated with disease, drug response, 
or both, with the assumption that drug therapy in these genetically defined sub-populations 
may be more efficacious than treating a broad population (Mancinelli et al., 2000).  
Advances in genetic testing, and their transference to the clinic, generates the 
possibility of more effective dosing of medications across various therapeutic areas (Meisel et 
al., 2000, Johnson, 2003, Bhathena and Spear, 2008). An individualised approach to treatment 
decisions may also lead to improved tolerability to medications thus can enhance regimen 
adherence, improve drug safety and ensure optimum drug therapy across patient groups (Spear 
et al., 2001). The identification of genomic predictors for treatment response may additionally 
help with the discovery and development of new medications (Evans and Relling, 1999). 
Overall there is increasing evidence that PGx will continue to be extremely important in health 
care in the near future (Wolf et al., 2000) (Roses, 2000).  
 
1.5.3 Principles of pharmacogenetics 
Pathways controlling drug disposition or drug PK describe the course of a drug and/or 
metabolite through the body (Rang, 2003), whilst pathways controlling the efficacy of a drug, 
or drug pharmacodynamics (PD), refers to the relationship between the drug and its effect at 
target sites (Evans and McLeod, 2003, Rang, 2003). Drug PK pathways encompass the 
combined processes of drug uptake or absorption, drug distribution, protein binding, drug 
metabolism, and drug excretion (Evans and McLeod, 2003, Rang, 2003, Weinshilboum, 
2003). PD pathways involve processes of drug interaction with therapeutic targets at the 
cellular level and the effect of drugs on the body, i.e. any resulting biological or therapeutic 
outcomes (Evans and McLeod 2003). 
 Genetic variation can affect the genes encoding proteins influencing both drug PK and 
PD processes (Goldstein et al., 2003, Goldstein, 2005, Nebert, 2008). This mainly consists of 
i) genes that encode DMEs and transporters which function in drug elimination and 
distribution/excretion respectively and ii) genes encoding channels, receptors and/or enzymes 
on which drugs act or modulate to elicit their effects (Roden and George, 2002, Goldstein et 
al., 2003, Bhathena and Spear, 2008). Some genetic variation within these genes can 
potentially affect protein function or expression thus can influence a drugs normal disposition 
or action.  Many of the PK and PD proteins for a particular drug thus form key components to 
PGx research (Goldstein et al., 2003, Johnson, 2003). 
 
1.5.4 Genetic variation  
Any two individuals are greater than 99% identical in their DNA sequence 
(www.hapmap.org), however much variation exists between individuals (Nebert, 2008). 
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Genetic variation refers to the differences in DNA sequences between individuals, of which 
there are many types (Jazwinska, 2001), with single nucleotide polymorphisms (SNPs) being 
among the most common sources of naturally occurring variation in the human genome 
(McLeod, 2005, Orr and Chanock, 2008). Alternative classes of DNA variation include 
microsatellites, copy number variants (CNVs), insertion/deletion polymorphisms and 
mutations (Roses, 2000, Jazwinska, 2001, McLeod, 2005, Orr and Chanock, 2008). For 
common diseases, genome-wide linkage studies have had limited success, due to their 
complex genetic architecture (Sachidanandam et al., 2001). In the human population most 
variant sites are rare, but common polymorphisms can explain most of the heterozygosity 
(Inaba et al., 1995, Beckmann et al., 2007). There is clear evidence that common gene variation 
contributes to complex traits including drug response phenotypes and with the ease of studying 
these, common variants have dominated PGx thus far (Jazwinska, 2001, Johnson, 2003, 
Goldstein, 2005, Ferraro et al., 2012). 
 
1.5.5 Single Nucleotide Polymorphisms  
A significant effort towards large-scale characterisation of human SNPs has been 
initiated in the last decade (Brookes, 1999). The Human Genome Project (HGP) launched in 
the USA in the 1990s, was a multi-country effort to sequence the entire human genome in 
order to identify and catalog genetic similarities and differences in human beings (www. 
http://hapmap.ncbi.nlm.nih.gov)(Sachidanandam et al., 2001).  Advances in technologies have 
since allowed genetic association studies in complex diseases/traits to take advantage of results 
of the HGP (McPherson et al., 2001). 
 SNPs comprise a large set of bi-allelic genomic variants (single base pair changes) of 
which there are an estimated 10 million in the human genome and they appear approximately 
every 300 base pairs (bp) on average and most commonly, these variations are found in the 
DNA between genes (http://ghr.nlm.nih.gov/handbook/genomic research/ snp). SNPs account 
for at least 90% of human sequence variation in the human genome (http://ghr.nlm.nih.gov/ 
handbook/genomicresearch/snp)(Pang et al., 2009) with the rest attributable to insertions or 
deletions of one or more bases, repeat length polymorphisms and rearrangements 
(Sachidanandam et al., 2001). As SNPs are extraordinarily abundant they offer a powerful 
means of assessing genetic association, allowing essentially any gene to be explored for 
variants that may associate with a disease or traits (Ferraro et al., 2012). 
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1.5.6 Genetic markers   
 The majority of genetic variation in the human genome is not pathogenic or of any 
biological significance (McCarthy and Hilfiker, 2000). The challenge for association studies 
is to identify the most influential polymorphic alleles. To sequence variants across whole 
genomes or all SNPs in a pathway of candidate genes is impractical. Most association studies 
genotype only a small proportion of marker SNPs in a target region (be that the whole genome, 
or within a set of candidate genes). Because alleles at different loci are sometimes found 
together more (or less) often than expected by chance based on their frequencies, non-random 
association can exist between allelic variants or SNPs in proximity to each other (Wall and 
Pritchard, 2003). These SNPs also tend to travel together in blocks through evolutionary time, 
a phenomenon known as linkage disequilibrium (LD)(Hirschhorn and Daly, 2005). Genomic 
patterns of LD are used to select a set of marker SNPs, known as tagging SNPs (tSNPs) that 
are statistically associated with other SNPs in the genome. Tagging SNPs alone are then typed 
to economically represent genomic variation across the entire region of interest (Goldstein et 
al., 2003, Wall and Pritchard, 2003, Hirschhorn and Daly, 2005).  
 Association studies are greatly facilitated by LD-based methods (Hirschhorn and Daly, 
2005) that systematically represent variation in candidate genes (or the whole genome) 
(Goldstein et al., 2003). The more recent possibility of determining LD patterns on a genome-
wide scale through the HapMap project has allowed the economical representation of genomic 
variation as a whole and enabled more efficient genome-wide research (Goldstein et al., 2003, 
Hirschhorn and Daly, 2005).  If a risk polymorphism exists it will either be genotyped directly 
(as a selected marker or tSNP) or be in strong LD with a genotyped tSNP (Collins et al., 1997, 
Kruglyak, 1999, Servin and Stephens, 2007). Genetic variants found to be associated with a 
disease or trait using LD based studies may thus not be directly causal or influential, but may 
be statistically correlated (in LD) with an another important variant (McCarthy and Hilfiker, 
2000, Goldstein and Weale, 2001, Mullen et al., 2009). 
 
1.5.7 Genomic location of polymorphisms and functional affect  
 Not all polymorphisms are functional i.e. have the potential to cause a biological change 
(Harley and Narod, 2009). The position and type of SNP usually defines most of their 
biological effect: SNPs may occur in the coding portion of the genes (exons), intervening 
sequences (introns) or between two genes (intergenic regions)(Shastry, 2002). Most SNPs 
(around 75%) occur in non-coding regions and are of unclear consequence (Sachidanandam 
et al., 2001, Harley and Narod, 2009). These include introns found within genes as well as 
intergenic regions between genes, and form the majority of the human genome (Tabor et al., 
2002). Although like intronic variants intergenic region SNPs also have no known function 
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(Tabor et al., 2002), some are also thought to impact gene expression or splicing (McLeod, 
2005). Most recent research by the Encode Project (www. concerning non-coding regions has 
confirmed that much non-coding DNA has a regulatory role (Birney et al., 2007). The 
remaining 25% of variants occur in gene coding regions (exons) (Harley and Narod, 2009).  
 Only 50% of exonic SNPs result in an amino acid change (non-synonymous SNPs) that 
can potentially alter protein function (Shastry, 2002). The remaining 50% are synonymous 
SNPs and also result in a nucleotide change, but because of redundancy in codon usage, these 
have a neutral substitution that may not affect protein function (Shastry, 2002, Shastry, 2004, 
Harley and Narod, 2009). Non-coding SNPs can also alter protein function by altering the 
regulation of gene expression (Shastry, 2003, Harley and Narod, 2009, Pang et al., 2009). 
SNPs in the promoter region may alter promoter activity thus affecting gene transcription and 
SNPs close to binding sites for splicing machinery may alter RNA splicing, and subsequently 
affect amino-acid transcription (Sauna et al., 2007, Hunt et al., 2008, Harley and Narod, 
2009)(Gray et al., 2000, Harley and Narod, 2009). 
 SNPs provide a powerful tool for association of loci at specific sites in the genome with 
complex traits (Bentley, 2000, Risch, 2000b) however most SNPs are not directly associated 
with causing disease instead they represent useful biological markers for analysing a particular 
disease or trait (Judson et al., 2000). It has been estimated that there are 50,000–250,000 SNPs 
that have a biological effect on one or more of the estimated 30,000 genes (Risch, 2000a) and 
in some cases, the biological effect may increase susceptibility to one or more diseases (Gray 
et al., 2000).  
 Due to their prevalence SNPs have been the variant type of choice for association 
studies in common diseases and complex traits (Beckmann et al., 2007). In addition to SNPs 
as a common source of genetic variation, the rare variant hypothesis has emerged. It is thought 
that multiple rare SNPs or additional variants of low genomic frequency may be the drivers of 
disease, and this has recently emerged in genomic studies for several complex traits (Tabor et 
al., 2002, Ferraro et al., 2012), with the theory that variants with very severe functional 
consequences are usually more infrequent. In addition to SNPs the human genome also 
contains another abundant source of polymorphism resulting in larger insertions, deletions or 
duplications known as copy number variations (CNVs). At least 10% of the genome is subject 
to copy number variation. CNVs are far less numerous to SNPs but can affect from one kb to 
several mega bases of DNA per event, adding up to a significant fraction of the genome, and 
so more likely to have a functional role in the aetiology of a trait (Beckmann et al., 2007). 
Several complex disorders have already been associated with CNVs including susceptibility 
to HIV-1, lupus and Crohn disease and are expected to potentially impact other complex traits 
including the inter-individual drug response (Ouahchi et al., 2006) as well as susceptibility to 
infection or cancer (Beckmann et al., 2007).  
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1.5.8 Candidate gene approach 
The majority of research studies for complex disease traits have focused on the use of 
a priori hypotheses generated from knowledge of the pathways underlying disease traits for 
the selection of genomic variants for investigation (Tabor et al., 2002). This approach provides 
a narrow spectrum of candidate genes that are selected due to their potential role in the 
aetiology of the disease and are used for investigating the genetic influence on a complex trait 
(Tabor et al., 2002). 
 Rather than rely on markers that are evenly spaced throughout the genome without 
regard to their function or context in a specific gene the candidate approach focuses on the 
biological understanding of the phenotype, tissues, genes and proteins that are likely to be 
involved in the disease/trait (Tabor et al., 2002). Thus far the candidate gene approach has 
been widely and frequently used as a design strategy in PGx studies, using knowledge of 
pharmacological action, drug disposition and/or disease pathogenesis for gene selection and 
so adopting a priori hypotheses about the origin of the inherited variability in drug response 
(Evans and Johnson, 2001, Roden and George, 2002, Goldstein et al., 2003, Daly, 2010b).  
 Gene-association studies usually determine whether there are differences between 
case and control groups (i.e. phenotype groups; drug responders versus non-responders) with 
regards to the prevalence of a potentially functional and phenotypically influential gene variant 
(Tabor et al., 2002). SNP genotyping is a tool for genetic analysis that is used for uncovering 
the association of an allele(s) at specific locus in the genome with the potential to cause a 
change in protein expression or function, with diseases or phenotypic traits such as drug 
response (Shi et al., 1999, Bentley, 2000). This typically involves genotyping candidate gene 
variants in clinically relevant populations and comparing the frequencies of the alleles or 
genotypes at the site of interest in both patient groups (Shi et al., 1999, Tabor et al., 2002). 
Due to the complexity of drug response, PGx studies can involve multiple candidate gene-
association studies and these can involve the use of hundreds of genes and 1000’s of SNPs 
(Wang, 2010).  
 
1.5.9 Polygenetics in drug response and the emergence of pharmacogenomics 
The genetic basis of many monogenic (single gene mutation) rare inherited disorders 
is known (over 6000 rare monogenic disorders and their genes successfully identified thus 
far), (http://www.ncbi.nlm.nih.gov/omim). The attention of human genetics has now shifted 
towards the basis of more common complex diseases or traits with multiple genetic 
(polygenic) and environmental components contributing to susceptibility (Hirschhorn et al., 
2002). Causal alleles for monogenic disorders are highly penetrant and often lead to severe 
phenotypes (Hirschhorn and Daly, 2005). By contrast, the alleles that underlie complex traits 
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usually have more subtle effects on disease risk and may involve non-coding regulatory variant 
alleles that are likely to have a modest impact on protein expression (Hirschhorn and Daly, 
2005). The phenotype for complex traits is determined by the sum total of, and/or interactions 
between, multiple genetic and environmental factors. Each of the many genetic determinants 
are expected to make only a small contribution to overall heritability (Hirschhorn and Daly, 
2005) owing to their multifactorial nature (McCarthy and Hilfiker, 2000) and subsequently 
have a relatively small individual effect on disease risk (Jazwinska, 2001, Reich and Lander, 
2001, Weinshilboum, 2003). This is referred to as the common disease/common variant 
(CDCV) hypothesis (Carlson et al., 2004). The inherited basis of drug response has similarly 
been difficult to elucidate especially for drugs whose PD and/or PK pathways are poorly 
defined (Nebert, 2008, Nebert et al., 2008a, Goldstein, 2009).  
 Because most drug effects are determined by several gene products that influence the 
metabolism, disposition and efficacy of medications, inherited differences in these PK and PD 
genes have increasingly been shown to alter drug response and there is a growing perspective 
that the inherited basis of drug action is polygenic in nature (Johnson and Evans, 2002, Evans 
and McLeod, 2003). As drug response is equally as complex as disease genetics (McCarthy 
and Hilfiker, 2000), relative risk estimates for genetic influences on drug action are also 
expected to be low, owing to its multifactorial nature (McCarthy and Hilfiker, 2000). In 
support of this, several pharmacogenomic markers have been identified to date, each of which 
confers only about a two-fold increased likelihood of response due to common allelic variants 
(Poirier et al., 1995, Drazen et al., 1999, McCarthy and Hilfiker, 2000). 
 Polygenic determinants of drug effects have accordingly become increasingly 
important for PGx (Evans and Relling, 1999) and PGx research has recently transformed into 
a genomics-based field, (Evans and Johnson, 2001) leading to a new term, pharmacogenomics. 
The field of “pharmacogenomics” aims to utilise a genome-wide approach to identify the 
network of genes that govern an individual’s response to drug therapy (Goldstein et al., 2003, 
Daly, 2010b). With current advances in genomic technology providing more sophisticated 
molecular tools for the detection of genetic polymorphisms and the wealth of new data 
emerging from the HGP, scanning the whole genome to identify and directly examine 
numerous common gene variants for any association with clinical response phenotypes (drug 
efficacy and toxicity) has rapidly become viable, and forms the basis of pharmacogenomics 
research (Nebert, 1999, Evans and Johnson, 2001).  
 
1.5.10 Whole genome association approach  
In spite of their success in the identification of genes with important contributions to 
drug response (Grant and Hakonarson, 2007, Daly, 2010a), candidate-gene studies have been 
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subject to several criticisms, the most important being that i) many significant findings of 
association in candidate-gene studies have not been replicated when followed up in subsequent 
association studies and ii) though candidate-gene studies are based on the ability to predict 
plausible candidate genes and variants through assumed functional potential, current 
knowledge is not always sufficient to make these predictions. This is evident in AED PGx, 
where several AEDs have broad mechanism of action and for several AEDs pharmacological 
pathways are not completely characterised (Mann and Pons, 2007, White et al., 2007). As only 
a small number of genes can be studied at a time it is difficult to isolate the numerous genetic 
variants that are suspected to influence complex traits (Goldstein et al., 2003) and these may 
therefore only represent a fraction of the possible genetic risk factors that are actually involved 
in drug effects (Hirschhorn and Daly, 2005).   
 Because of this progression in genomic research, a whole genome approach has 
rapidly become an alternative methodology to identify novel associations with common 
diseases (Hirschhorn and Daly, 2005) and genome-wide association studies (GWAS) have 
increasingly been applied to pharmacogenomics (Grant and Hakonarson, 2007, Gurwitz and 
McLeod, 2009, Daly, 2010a). The conventional genome-wide association (GWA) approach is 
a hypothesis-free, systematic search of SNPs (to function as genetic markers) across the 
genome (Guessous et al., 2009)(www.genome.gov/GWAStudies). 
 As no assumptions are made in GWAS with regards to the genomic location of 
potentially causal or influential variants, this approach represents an unbiased yet 
comprehensive option that can be attempted even in the absence of convincing evidence 
regarding the function or location of the causal genes (Hirschhorn and Daly, 2005). GWA 
approaches enable the detection of novel and less obvious genes, and this may be particularly 
useful for pharmacogenomics research into drug-target genetics, which is less well understood 
than that of drug metabolism (Daly, 2010a). Figure 1.1 summarises the main advantages and 
disadvantages of both the candidate gene and GWA approach to genetic association studies.  
 
Since 2007, a range of pharmacogenomics GWA studies have been published (di Iulio 
and Rotger, 2012). These have either identified novel associations between drug responses and 
clinically relevant loci, or have confirmed previous associations (Daly, 2010a) (Table 1.4). 
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1.5.11 Clinical application  
In spite of the significant association in drug response and disease that have been 
described over the years (Wang et al., 2011) the translation of these pharmacogenomics/PGx 
discoveries to the clinic has not been as rapid as was hoped. Only a few commercial tests are 
currently available (Evans and Relling, 2004, Weinshilboum and Wang, 2006, Swen et al., 
2007). Recent instances of PGx information for individualised treatment (Table 1.5) include, 
trastuzumab treatment for HER2 overexpressing breast cancer, (Zanger, 2010) and more 
recently HLA-B*5701 testing to avoid abacavir hypersensitivity (di Iulio and Rotger, 2012).  
 One of the main challenges faced by PGx research is that the influence of genetic 
markers on therapeutic outcome is often lacking and/or non-reproducible (Colhoun et al., 
2003, Swen et al., 2007). Past research indicates that of the 166 putative associations that have 
been studied three or more times, only 6 have been consistently replicated (Hirschhorn et al., 
2002). Several reasons can be attributed to this irreproducibility that characterises genetic 
association studies whether they have employed a candidate gene or whole genome approach 
(Hirschhorn et al., 2002, McCarthy and Hirschhorn, 2008) and these include; i) the 
heterogeneity of disease phenotype, ii) the underestimation of the complexity of common 
complex traits iii) the small effect sizes of alleles  of common risk variants, and iv) relatively 
small numbers of patients in PGx studies (Johnson, 2003, Evans and Relling, 2004). 
 
1.6 Epilepsy pharmacogenetics 
Inadequate seizure control (Kwan and Brodie, 2000a), AEs, ADRs (Depondt, 2006b, 
Zaccara et al., 2007) and variability in individual responses to the same AED doses (Loscher, 
2002) encapsulate pharmacotherapy for a number of people with epilepsy (Depondt, 2006b) 
and represent global barriers to optimal AED treatment (Sisodiya 2005). Furthermore, the 
optimal doses of AEDs may differ four-fold among individuals (Loscher et al., 2009). The 
recent expansion of the field of PGx has allowed the study of drug response in a number of 
common complex traits across several disease domains including epilepsy (Depondt, 2006a). 
Epilepsy represents an ideal disease for PGx study due to its high prevalence, wide variety of 
phenotypes, variable treatment outcomes and at least some knowledge of the main pathways 
of drug action and drug distribution (Depondt, 2006b).  
 In current clinical practice AEDs are primarily used according to existing guidelines 
for the management of epilepsy in the general population and they are selected on the basis of 
known drug response profiles as well as patient and disease characteristics (Brodie and French, 
2000, Perucca et al., 2001, Sander, 2004, Schachter, 2007). In the UK the NICE guidelines 
(http://guidance.nice.org.uk/CG20/Guidance) are referred to for general AED prescribing. 
Basing AED choice on anticipated efficacy is somewhat empirical and initial AED selection 
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using this approach is currently effective in around 50% of patients (Kwan and Brodie, 2000a, 
Depondt, 2006b).  
 In parallel to the difficulties inherent with basing AED choice on anticipated efficacy, 
dosing decisions are also largely reliant upon trial and error (Dlugos, Buono et al. 2006). For 
most AEDs a broad range of doses is used in clinical therapy and final maintenance doses are 
reliant on individual response. PGx thus additionally offers the potential to influence AED 
dosing regimens by perhaps using patient genotype to predict a patient’s optimal dose for 
seizure control without causing ADRs and also how quickly drugs can be titrated up (Depondt, 
2006b, Dlugos et al., 2006, Duncan et al., 2006). Furthermore, as a significant number of 
individuals continue to experience seizures despite multiple drug treatment, an increase in the 
understanding of epilepsy and drug-action mechanisms, may shed light on the genetic factors 
contributing to refractory epilepsy (Kasperaviciute and Sisodiya, 2009). PGx research might 
similarly predict which patients are likely to become refractory to drug treatment early on 
during the course of disease and this will encourage early surgical consideration to improve 
the overall outcome for these difficult to treat individuals (Depondt and Shorvon, 2006). PGx 
research could likewise provide a more rational basis for selecting AEDs at the outset of 
therapy (Dlugos et al., 2006). 
 
1.6.1 Candidate genes for epilepsy pharmacogenetics  
 In line with PGx research in other disorders, most association studies in epilepsy to date 
have concerned candidate genes and focused on genetic variation across PK and PD pathways 
(Depondt, 2006a). Much of the PGx data in the field of epilepsy deals particularly with the PK 
of AEDs and PGx knowledge beyond PK genes (i.e. DMEs and transporters) remains limited 
(Depondt, 2006a, c, Kasperaviciute and Sisodiya, 2009). Since drug response to most AEDs 
is multifactorial, whole genome screening is expected to be more fruitful in epilepsy PGx than 
selecting potential candidate genes for AED response (Depondt, 2006b). The present direction 
of epilepsy PGx is therefore moving rapidly towards whole genome strategies to investigate 
common genetic polymorphisms (Kasperaviciute and Sisodiya, 2009).  
 There are three important categories of candidate genes with a potential influence on 
AED response that have been studied in epilepsy PGx to date; i) genes encoding drug 
transporters of which AEDs proposed substrates; ii) genes encoding DMEs involved in the 
breakdown of AEDs; and iii) genes encoding AED targets and their related pathways 
(Depondt, 2006b, Klotz, 2007).   
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Table 1.5 Pharmacogenetic tests integrated into drug labels 
Success stories for pharmacogenetics; examples of drugs for which biomarkers of clinical 
relevance have been identified. Table taken and adapted from (Tauser, 2012). 
Drug indication Pharmacogenetic 
biomarker 
Comments 
 
 
Mandatory, required predictive pharmacogenetic tests in drug label  
Trastuzumab 
HERCEPTIN® 
Metastatic BC 
HER2/neu 
over-expression 
Improve drug efficacy: clinical 
benefit is limited to the 
responsive patients, whose tumors 
overexpress the drug-target 
HER2/neu 
 
Lapatinib 
TYKERB® 
Metastatic BC 
HER2/neu 
over-expression 
Improve drug efficacy: clinical 
benefit limited to tumors 
overexpressing HER2/neu  
 
Cetuximab 
ERBITUX® 
Metastatic CRC 
EGFR expression Improve drug efficacy: clinical 
benefit limited to patients with 
EGFR-positive tumors  
 
Dasatinib 
SPRYCEL®; 
Imatinib 
GLEEVEC® 
ALL (adults) 
Philadelphia 
chromosome 
positive 
Disease confirmation and patients’ 
selection: BCR-ABL 
translocation  
 
Maraviroc 
SELZENTRY® 
HIV (adults) 
CCR-5 
C-Cmotif receptor 
Disease confirmation: infection 
with CCR-5-tropic HIV-1 and 
resistance to other antiretrovirals 
 
Recommended predictive pharmacogenetic tests in drug label  
Warfarin 
COUMADIN® 
Thrombo-embolism 
CYP2C9 and 
VKORC1 
(-1639G>A) 
Improve drug efficacy and safety: 
avoid increased risk of 
bleeding to patients homozygous 
or heterozygous for CYP2C9*2 
or CYP2C9*3 alleles by 
prescribing differentiated doses 
Pharmacogenetic test: 
“Nanosphere Verigene Warfarin 
Metabolism Nucleic Acid Test; 
therapeutic algorithm based on 
genotype and clinical factors 
(http://www.WarfarinDosing.org.) 
 
Carbamazepine 
TEGRETOL® 
Epilepsy 
HLA-B*1502 
allele 
Improve drug safety: avoid serious 
dermatologic reactions 
(Stevens–Johnson syndrome and/or 
toxic epidermal necrolysis). 
 
Available from: http://www.intechopen.com/books/clinical-applications-of pharmacogenetics/ 
pharmacogenomics-matching-the-right-foundation-at-personalized-medicine-in-the-right-genomic-
era- 
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1.6.2 Novel computational methods; an approach to solving issues in complex 
data analysis 
Linkage analysis has been successfully used by statisticians to locate genes 
responsible for simple monogenic diseases (Rodin et al., 2011). Unlike rare Mendelian 
diseases however, multiple genes are likely to influence or confer susceptibility to common 
complex diseases and traits. Interactions between these genes and between genes and the 
environment also exist (Ritchie and Motsinger, 2005, Rodin et al., 2011), the cumulative effect 
of which is thought to contribute to complex disease phenotypes. This multifactorial basis of 
complex disease has led to several difficulties in data analysis, mostly because of statistical 
and computational issues (Ritchie and Motsinger, 2005). In complex disease analysis a 
relatively large number of genetic variants are investigated for disease association in a bigger 
sample size of individuals, leading to significant statistical concerns (Zhang and Rajapakse, 
2009, Motsinger-Reif et al., 2010). Such analytical issues have thus far made the identification 
of definitive influential factors for many disease traits difficult (Moore et al., 2004, McCarthy 
et al., 2008). With complex diseases and traits having potential genetic contributions from 
thousands of variants and with current genotyping technology reporting millions of 
polymorphisms, the statistical challenge of detecting small polygenic effects using large 
volumes of genetic data whilst also controlling for false positive signals has become apparent 
(Baksh and Kelly, 2007).  
Traditional parametric statistical approaches for gene discovery and genetic analysis, 
such as logistic regression, typically evaluate the effects of individual SNPs in isolation, thus 
assuming independence between variants (Risch and Merikangas, 1996, Hoppe, 2005).  Such 
marker-by-marker approaches ignore the multigenic nature of complex disease and also fail 
to account for the interplay of many genes that is likely to contribute to the genetic composition 
of complex traits (Hirschhorn et al., 2002, Pander et al., 2010, Rodin et al., 2011, Vanneschi 
et al., 2011). (Ritchie and Motsinger, 2005). This illustrates the challenge of analysing data 
for complex traits and the need for accurate classification and prediction algorithms.  
 
1.6.3 Pharmacokinetic variation and metabolising enzymes 
More than 30 families of DMEs can be found in humans (Evans and Relling, 1999, 
Ingelman-Sundberg et al., 1999) and nearly all of these have genetic variants, many of which 
translate into functional changes in the proteins they encode (Weinshilboum, 2003). Hepatic 
metabolism consists of two established phases; phase I reactions (oxidation, reduction and 
hydrolysis) and phase II reactions (conjugation reactions between an endogenous molecule 
such as glucuronic acid and a drug metabolite) and both pathways function to produce 
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metabolites that are usually more water soluble than the parent compound, thus enhancing 
their excretion from the body (Nagasawa and Nakahara, 1992).  
 Metabolism in the liver by the cytochrome P450 (CYP) metabolising enzymes 
represents the most common route of drug turnover, and it has long been known that fast- and 
slow-metabolising variants in the genes encoding these enzymes can lead to under- and over-
dosing of drugs (Evans and Johnson, 2001, Wilkinson, 2005).  The CYP super-family is thus 
considered the most important class of DMEs and up to 80% of all prescribed drugs undergo 
initial metabolism (Phase I reactions) through oxidation reactions catalysed by these enzymes 
(Eichelbaum et al., 2006).  
 Inherited differences in individual DMEs are typically monogenic traits, and the 
clinical importance of enzyme variants, i.e. their influence on the therapeutic effects of 
medicinal drugs, depends on allele-frequency, the effects of the polymorphisms on protein 
function (i.e. whether the biological activity of the enzymes are altered), and the importance 
of the enzyme for the activation or inactivation of drug metabolites (Evans and Johnson, 2001, 
Kirchheiner and Seeringer, 2007). Polymorphic CYP450 enzymes can either; reduce 
enzymatic activity to slow down metabolism and cause an over-accumulation of a drug or its 
metabolites resulting in drug toxicity (Park et al., 1995, Kitteringham et al., 1998) or reduce 
efficacy of medications that require a polymorphic enzyme for activation as this can reduce 
it’s function (Kitteringham et al., 1998, Evans and Johnson, 2001).  
 The metabolic pathways involved in the elimination of most AEDs have largely been 
defined (Ramachandran and Shorvon, 2003, Saruwatari et al., 2010). Functional 
polymorphisms in the genes of AED metabolising enzymes are expected to give rise to 
interindividual differences in metabolic profile and to influence drug levels in the plasma. This 
can also lead to differences in AED efficacy and/or toxicity (Ramachandran and Shorvon, 
2003). Detoxification of AEDs occurs via hepatic (metabolism) and/or renal (excretion) routes 
(Klotz, 2007, Anderson, 2008). Most AEDs are eliminated from the body initially through 
biotransformation in the liver by several different DMEs before their elimination via the 
kidneys (Klotz, 2007, Anderson, 2008), Due to the major role of CYP450 genes as Phase I 
metabolising enzymes for many AEDs, these may influence interindividual variability in the 
PK of AEDs and have been the focus of several candidate gene studies in AED PGx to date 
(Loscher et al., 2009, Saruwatari et al., 2010). 
 Functional polymorphisms underlying alleles with variable metabolism rates are 
known for several CYP450 genes and these variants have the potential to result in 
interindividual differences in AED concentration, and in their effectiveness and/or the 
occurrence of ADRs (Daly, 2003). Of the various polymorphic CYP species however, only 
CYP2D6, CYP2C9 and CYP2C19 have shown any clinical significance to date (Ingelman-
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Sundberg, 2004b, Klotz, 2007) and only CYP2C9 and CYP2C19 variants are relevant to AED 
metabolism (Kirchheiner and Seeringer, 2007, Klotz, 2007).  
 Polymorphisms are also known to exist in all the major phase II enzyme systems 
including N-acetyltransferases (NAT1 and NAT2), uridine glucoronyltransferases (UGTs), 
sulfatases and glutathione-s-transferases (GSTs) (Ferraro and Buono, 2005), however the 
contribution of phase II enzymes to AED metabolism is currently less-well characterised than 
that of phase I (Ferraro and Buono, 2005, Depondt, 2006b). The UGT superfamily of 
conjugating enzymes are one of only a few phase II DMEs that are known to contribute to 
AED metabolism (Ferraro and Buono, 2005, Depondt, 2006b). Members of the UGT1 
superfamily act upon approximately 35% of all drugs metabolised by phase II DMEs, 
including several AEDs such as CBZ, VPA, LTG, OXC, TPM and ZNS (Ferraro and Buono, 
2005, Szoeke et al., 2006, Saruwatari et al., 2010). UGTs conjugate their substrates with a 
glycosyl group (glucuronidation), a major conjugation pathway responsible for increasing the 
water solubility and enhancing the elimination of a variety of drugs (Nagar and Blanchard, 
2006, Saruwatari et al., 2010). Genetic polymorphisms in UGT enzymes may modify their 
glucuronidation capacity, a phenomenon seen in an increasing number of studies of a variety 
of substrates (Inaba et al., 1995, Miners et al., 2002, Guillemette, 2003). Most of the 
metabolism of VPA and LTG occurs via this glucuronidation pathway, rather than via the 
CYP450 enzymes (Nagasawa and Nakahara, 1992). Knowledge of the genetic mechanisms 
underlying variability in glucuronidation capacity is however currently limited and only a few 
clinically relevant genetic polymorphisms in UGTs have been described thus far (Guillemette, 
2003). 
 Additional phase II enzymes with a major role in AED metabolism include GSTs 
(Guillemette, 2003, Hayes et al., 2005) and microsomal epoxide hydrolase (mEH) (Depondt, 
2006a, Klotz, 2007, Saruwatari et al., 2010). GST is an essential enzyme of defense and 
detoxification and another hepatic conjugating phase II enzyme. GSTs catalyse the 
conjugation of glutathione (GSH) for detoxifying and aiding the elimination of a wide range 
of therapeutic agents (Whalen and Boyer, 1998, Hayes et al., 2005, Saruwatari et al., 2010) 
and play an important role in metabolising AEDs (Tang et al., 1996, Bu et al., 2007, Shang et 
al., 2008). The mEH enzyme encoded by the EPHX1 gene is a biotransformation enzyme that 
also metabolises reactive epoxide intermediates (often formed during phase I metabolism) to 
more water-soluble derivatives and is a candidate for variation in response to CBZ, PB and 
PHT (Nagasawa and Nakahara, 1992, Depondt, 2006b). 
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1.6.4 Pharmacokinetic variation and transporter proteins 
Drug transporters function to regulate the absorption, distribution, and excretion of 
many medications (Evans and McLeod, 2003) through regulating both inward and outward 
transport of drugs and their metabolites (Daly 2010). These proteins also show considerable 
genetic variation, including many potentially functional polymorphisms (Goldstein et al., 
2003, Leabman et al., 2003). The membrane bound efflux transporter super-families form a 
category of major transport proteins and include ATP-binding cassette (ABC) proteins, and 
the solute carrier proteins (SLC), with the ABC proteins being among the most extensively 
studied transporters involved in drug disposition and effects (Borst et al., 2000, Evans and 
McLeod, 2003). Genetic variation in the genes encoding these proteins are expected to alter 
the rate of drug uptake, distribution or efflux and can result in variable drug concentrations, 
effectiveness and/or occurrence of side effects (Goldstein et al., 2003, Cox, 2010).  
 Functional polymorphisms in genes encoding drug transporters, of which AEDs are 
proposed substrates, may alter the cerebral uptake, distribution or efflux of AEDs, and thus 
can result in interindividual differences in the concentration of AEDs in the brain, thereby 
impacting on effectiveness and/or AEs (Depondt and Shorvon, 2006). The blood brain barrier 
(BBB) is a physical and metabolic barrier between the CNS and the systemic circulation, 
which serves to regulate and protect the microenvironment of the brain (Gillham et al., 1990, 
Scherrmann, 2002). Any therapeutic agents required to target neurological pathways are 
required to penetrate the BBB to achieve efficacy (Gillham et al., 1990, Scherrmann, 2002). 
 The ATP-binding cassette or ABC transporter super-family function as active pumps 
facilitating the efflux of foreign substances from cells across luminal membrane borders 
(Abbott et al., 2002). Within the ABC superfamily are the multidrug transporter proteins 
(MDRs), encoded by the ABCB genes, multidrug resistance-associated proteins (MRPs) 
encoded by the ABCC genes and breast cancer-resistance protein (BCRP) encoded by the 
ABCG2 gene (Robey et al., 2008). These are expressed in endothelial cells of the BBB and in 
choroid plexus epithelial cells of the blood-cerebrospinal fluid (CSF) barrier, where they limit 
brain accumulation of many lipophilic drugs and so appear to provide a defense mechanism 
to the brain (Fromm, 2000, Loscher and Potschka, 2002).  
 ABC transporters were initially found to influence clinical refractoriness to the effects 
of several drugs, including chemotherapeutics for the treatment of cancer (Schinkel, 1997). 
Although most AEDs are quite lipophilic, allowing penetration into the brain, such multidrug 
efflux transporters may similarly limit the brain uptake of AEDs by mediating their extrusion 
(Kwan and Brodie, 2005) and could prevent AEDs from reaching sufficient concentration 
(Elger, 2003, Kwan and Brodie, 2005, Loscher and Potschka, 2005a, c). Reports of Pgp 
overexpression in epileptogenic brain tissue promoted it as a candidate gene for refractory 
epilepsy. Genetic variations in ABC multidrug transporters are thought to play a role in drug-
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resistant epilepsy by determining the expression of efflux transporters regulating the levels of 
AEDs in predisposed individuals (Ramachandran and Shorvon, 2003).  
 
1.6.5 Pharmacodynamic variation and drug target genes 
Progress on the PGx of drug target proteins has been slower than studies on drug 
metabolism and transport. However, the revolution in human genomics has provided new 
insights into this area (Daly, 2010b). There has been a recent increasing focus on genetic 
polymorphisms in drug targets, with an interest in defining their impact on drug efficacy and/or 
toxicity. The main candidate protein categories comprise of receptors, transporters, channel 
proteins and enzymes and include genes encoding i) direct targets of a drug such as a receptor 
or enzyme, ii) signal transduction proteins, downstream proteins and other proteins involved 
in the pharmacological response of a drug and iii) proteins associated with disease risk or 
pathogenesis that is altered by the drug (Evans and Johnson, 2001).  
 PD gene variants are often considered as likely causes of variability when drug 
response appears independent of dose i.e. when PK influences can be ruled out (Vinken et al., 
1999). Studies have revealed that the genetic polymorphisms in many PD genes can alter their 
sensitivity to specific medications (Evans and Relling, 1999). Functional polymorphisms in 
these genes thus may have a profound effect on drug efficacy and/or toxicity (Johnson, 2001, 
Roden and George, 2002, Evans and McLeod, 2003). 
 Review of literature concerning drug target PGx studies reveal that although numerous 
single gene/single variant associations have been identified, providing 'proof of concept' that 
genetic variability in PD factors contributes to the variability in drug response, has so far 
proved unsuccessful. Inconsistencies are evident across studies and the data are not as yet 
clinically useful in most cases (Evans and Johnson, 2001, Johnson, 2001). Such apparent 
discordance among studies also suggests the inability of a single polymorphism is highly 
predictive of response, and thus it seems unlikely that a single polymorphism in a single gene 
would explain a high degree of drug response variability across drug therapy (Evans and 
Johnson, 2001, Johnson, 2001). Given that most drug responses involve a large number of 
proteins, a polygenic, or genomic approach to PGx study may provide more reproducible 
results (Evans and Johnson, 2001, Johnson, 2001, Goldstein et al., 2003). 
 Genetic variation in AED target proteins affects the PD of specific AEDs and could 
potentially contribute to interindividual variation in AED response (Depondt and Shorvon, 
2006, Ferraro et al., 2006). AED targets or PD candidate genes, as sources of genetic variation, 
have only recently been the focus of AED PGx (Depondt and Shorvon, 2006). The main 
candidates in this category are the genes encoding the targets of currently utilised AEDs, 
namely neuronal ion channel subunits and elements of neurotransmitter pathways (Kwan et 
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al., 2001, Depondt, 2006b). Several first-line AEDs including CBZ, LTG and PHT are thought 
to primarily act through binding to and modulation of voltage-gated Na+ (NaV) channel 
subunits (Ragsdale and Avoli, 1998), therefore the genes encoding neuronal NaV channels 
have been prime candidates for PGx study (Depondt and Shorvon, 2006, Loscher et al., 2009).  
 Mutations in the α-subunit of the NaV channel were first associated with familial and 
sporadic epilepsies (Wallace et al., 2001b) and early observations indicated that these NaV 
channel mutations could also affect the clinical response to AEDs in genetic epilepsies 
(Guerrini et al., 1998). Dravet syndrome, caused by de novo mutations in the SCN1A gene, is 
characterised by a marked aggravation of seizures upon treatment with LTG (Guerrini et al., 
1998). Other major targets for PGx study include subunits for potassium channels, calcium 
channels, GABA and glutamate receptors, GABA transporters, GABA transaminase and 
synaptic vesicle protein 2A (SV2A) (Lynch et al., 2004). Additional PD molecules of potential 
significance to clinical response include genes for effector components of the downstream 
pathways associated with AED target binding and action (Gillham et al., 1990, Ferraro et al., 
2006). 
 
1.6.6 Epilepsy or disease related candidate genes 
Prognosis studies of epilepsy suggest that the underlying molecular disease 
pathogenesis is an important determinant of outcome or response to AED treatment (Depondt 
and Shorvon, 2006). Differences in AED response can be seen between types of epilepsy, 
seizure types and particular seizure syndromes (Semah et al., 1998).  Any genes causing 
epilepsy are thus potential candidates for genetic variation that may also influence differences 
in AED response (Spear, 2001, Depondt, 2006a). In recent years at least a dozen genes have 
been identified in rare forms of monogenic epilepsies (Graves, 2006). Whether by design or 
coincidence, drugs often act upon gene products that play a role in the molecular pathology of 
a particular disease, and so this class of epilepsy-causing genes (Na+, Ca2+ and GABA receptor 
subunit genes) not surprisingly overlaps with common AED targets (Ferraro and Buono, 2005, 
Depondt, 2006a). Animal models with mutations in these epilepsy associated genes, have 
accordingly demonstrated changes in sensitivity to several AEDs (Picard et al., 1999, Lucas 
et al., 2005). Disease susceptibility genes that do not encode actual AED targets are can also 
predispose to drug response (Depondt, 2006a, Depondt and Shorvon, 2006).  
 
1.6.7 Current epilepsy pharmacogenetic research effort  
Over the last two decades, a considerable effort has been made to unravel the genetic 
basis of variable response to AEDs (Nakajima et al., 2005, Loscher et al., 2009). Clinical 
efficacy for AEDs involves preventing seizure occurrence through identifying optimum drug 
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dosing regimens during AED administration, whilst also avoiding issues of tolerability. 
Substantial evidence from studies of the PK pathways (metabolism and transport) of AEDs 
also indicate that genetic variation may additionally affect clinically effective drug dose 
(Klotz, 2007). 
 The majority of PGx studies have until recently aimed at identifying PK variation in 
the multidrug resistance phenotype of epilepsy (Loscher and Delanty, 2009, Johnson et al., 
2011b) and this has largely focused on drug transporter candidate genes (Depondt and 
Shorvon, 2006). The biological basis of ‘refractoriness’ is however thought to most likely be 
multifactorial and variable (Tate and Sisodiya, 2007). As AEDs are required to traverse the 
BBB and bind to one or more target molecules to exert their particular therapeutic effect, two 
PGx theories have emerged in an attempt to explain treatment failure in epilepsy (Remy et al., 
2003, Remy and Beck, 2006). Firstly the drug transporter PK hypothesis, which is almost 
entirely focused around the Pgp efflux protein that was overexpressed in epileptic brain tissue 
from patients with drug resistant epilepsy and secondly the more recent drug target PD 
hypothesis that proposes ion channel and/or neurotransmitter dysfunction in AED resistance 
(Sills et al., 2002, Sills, 2004, Tate and Sisodiya, 2007). Experimental evidence from animal 
studies of drug resistance originally associated altered NaV channel pharmacological 
sensitivity and electrophysiological properties between responsive and pharmacoresistant 
models of refractory epilepsy (Remy et al., 2003, Loscher, 2005c, Remy and Beck, 2006).  
The genes studied in regard to this phenotype of response include those encoding the 
efflux proteins; ABCB1, ABCC2, ABCG2 and BCRP, encoding MDR, MRP and BCRP 
respectively and the RLIP transporter gene; RLIP76 (these form the prominent transporter 
hypothesis for drug resistance). The drug target proteins studied include the NaV channel 
encoding genes SCN1A, 2A, 3A and a number of GABAA receptor genes (drug target 
hypothesis)(Tate and Sisodiya, 2007). Recent research has additionally implicated the 
astrocytic GABA transporter GAT-3 (encoded by GAT3) with drug responsiveness (Meldrum 
and Rogawski, 2007, Kim et al., 2011a). GAT3 variation was associated with the 
pharmacoresistance phenotype in a recent candidate gene association study (Kim et al., 2011a) 
and the GAT-3 protein has also been proposed as a potential drug target for new AED 
development (Meldrum and Rogawski, 2007, Kim et al., 2011a). 
 The drug transporter hypothesis of multidrug resistance (Loscher and Delanty, 2009) 
proposed that increased brain expression of efflux transporters could either be a result of 
prolonged or frequent seizures, as demonstrated in rodent models of epilepsy (Loscher and 
Potschka, 2005b, Loscher and Brandt, 2009), and/or be due to a genetic contribution, such as 
polymorphisms in the encoding genes (Loscher and Potschka, 2005a, Loscher and Brandt, 
2009). Numerous PGx studies have implicated ABCB1 polymorphisms in multidrug resistant 
epilepsy, with several indicating that ABCB1 polymorphisms that affect the expression or 
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functionality of Pgp such as the well-known 3435C>T polymorphism (Siddiqui et al., 2003), 
are more frequent in AED non-responders than responders (Loscher et al., 2009, Schmidt and 
Loscher, 2009). This finding could not be reproduced in many other studies for AED 
responsiveness (Loscher et al., 2009) including a meta-analysis effort using over 3000 refrac-
tory epilepsy patients and controls across multiple populations (Bournissen et al., 2009, 
Haerian et al., 2011). There is also a matter of debate on which AEDs are transported by the 
human Pgp transporter (Luna-Tortos et al., 2008, Loscher et al., 2011). The association 
between ABCB1 3435C>T and pharmacoresistance in epilepsy is thus unclear with only three 
of the published studies showing positive associations (Tate and Sisodiya, 2007, Robey et al., 
2008, Loscher et al., 2009).  
A number of associations have additionally been reported for DME genes, the most 
prominent being; PHT dose-related toxicity and CYP2C9 polymorphisms. This was one of the 
first positive associations of genetic variation altering the metabolism of AEDs (Mamiya et 
al., 2000). Several in vitro studies have illustrated that CYP2C9*2 and *3 genotypes have a 
decreased capacity for PHT metabolism (Saruwatari et al., 2010, Depondt et al., 2011). 
Numerous different reports of PHT toxicity have demonstrated low activity with the 
homozygote CYP2C9*3 genotype and heterozygote genotype for both CYP2C9 and CYP2C19 
enzymes (Kasperaviciute and Sisodiya, 2009). CYP2C9/19 genotyping may in theory 
influence AED dosing (Gardiner and Begg, 2006), however is not routinely used as a clinical 
guide, in part because it only explains a limited proportion of dosing variation (Anderson, 
2008, Kasperaviciute and Sisodiya, 2009, Loscher et al., 2009, Depondt et al., 2011). 
Genotype associations were also demonstrated for EPHX1 and more recently UGT1A4 and 
UGT2B7, however these were again of limited proven strength for clinical application 
(Saruwatari et al., 2010). 
 The PD hypothesis for drug-resistance in epilepsy (Remy et al., 2003, Remy and Beck, 
2006) proposes altered pharmacological sensitivity of the NaV channel (Remy, Gabriel et al. 
2003) leading to reduction in AED sensitivity (Remy, Gabriel et al. 2003; Remy and Beck 
2006). The hypothesis suggests NaV channel polymorphisms can alter the subunit composition 
or structure (Remy and Beck, 2006) through modifications in the transcription of channel sub-
units as a result of persistent seizures, (Remy and Beck, 2006). Most experimental studies 
investigating the molecular basis of altered drug target sensitivity have focused on 
transcriptional changes of ion channel subunits in response to seizures (Remy and Beck, 2006, 
Volk et al., 2006, Bethmann et al., 2008, Loup et al., 2009). Whether these structural changes 
are indeed influenced by polymorphisms in drug target genes has not been as widely described 
in literature (Nakajima et al., 2005).  
 Since the 2003 implication by Remy et al, NaV gene variants, particularly the NaV α1 
subunit gene (SCN1A) have received further attention (Gillham et al., 1990, Tate et al., 2005, 
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Tate et al., 2006, Abe et al., 2008, Kwan et al., 2008). A functionally validated polymorphism 
located in SCN1A in a retrospective dosing study provided the first evidence that drug target 
(PD pathway) polymorphisms may additionally be influential in the responsiveness to AED 
treatment (Tate et al., 2005). This proof of concept study prompted a handful of additional 
investigations concerning the relevance of NaV gene variation to both AED efficacy and AED 
resistance (Abe et al., 2008, Kwan et al., 2008). As of yet no definite evidence confirming a 
major role of SCN1A in AED responsiveness can be found (Loscher et al., 2009, Manna et al., 
2011). Table 1.6 summarises some of the main research studies carried in epilepsy PGx to 
date. This includes recent data from studies on SCN1A (2013). 
 
1.6.8 Pharmacogenomics and AEDs 
Despite numerous studies conducted in epilepsy PGx, there is an absence of 
conclusive data to explain drug responsiveness and to inform treatment decisions (Nakajima 
et al., 2005, Johnston et al., 2009, Kasperaviciute and Sisodiya, 2009). As discussed in sections 
1.4.9, 1.4.10, overall, advancements in understanding of human genetics and improvements in 
genomic technology have shed some light on the response to pharmacological treatment, to 
aid the clinical management of several common complex traits and disorders (Ritchie, 2012). 
Pharmacogenomics studies have observed a number of successes in recent years, most of 
which concern pharmacotherapy for cancer i.e. EGFR tyrosine kinase inhibitors (TKIs) in the 
treatment of lung cancer (Yi et al., 2009) and HER2-directed therapies in the treatment of 
HER2-positive early-stage breast cancer (Grant and Hakonarson, 2007, Arteaga et al., 2012, 
Ritchie, 2012). Additional PGx successes include the use of the analgesic codeine (Crews et 
al., 2012), anticoagulant therapy with warfarin (Johnson et al., 2011a) and abacavir therapy 
for HIV. 
 The first impact of pharmacogenomics in clinical epilepsy was the discovery of the 
HLA-B*1502 polymorphism as a strong predictor of CBZ induced Stevens–Johnson 
syndrome (SJS), in people of Chinese and south Asian ancestry (Ferrell and McLeod, 2008). 
Testing for HLA-B*1502 in at-risk ethnic populations is now recommended by regulators 
globally, including in the United States, United Kingdom, and Canada (Ferrell and McLeod, 
2008, Kasperaviciute and Sisodiya, 2009, Johnson et al., 2011b).  Moreover since this 
clinically proven association in Chinese and south-Asian patients, the HLA-A*3101 variant 
(Alfirevic et al., 2006) was identified in European patients and demonstrated to significantly 
associate with CBZ hypersensitivity (McCormack et al., 2011, Yip et al., 2012). The HLA-
A*3101 variant has thus also been proposed as a clinically relevant marker to predict 
hypersensitivity reactions (McCormack et al., 2011, Yip et al., 2012). Screening for the HLA-
B*1502 allele in patients of Asian descent in order to prevent CBZ and PHT-induced SJS 
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(Ferrell and McLeod, 2008) has now been incorporated into standard medical practice (Chen 
et al., 2011). Though impressive, this remains the only epilepsy PGx finding that has resulted 
in clinical application so far (Kasperaviciute and Sisodiya, 2009).  
To summarise, advances have been made in identifying genetic markers of AEs in 
terms of severe cutaneous reactions but there has been little progress in predicting AED 
efficacy (Kasperaviciute and Sisodiya, 2009, Johnson et al., 2011b). Progress for epilepsy PGx 
is thus lagging behind when compared to many polygenic neurological conditions and PGx 
data generated to date has had little impact on current AED treatment guidelines (Ferraro and 
Buono, 2005, Loscher et al., 2009). No definite predictors of drug efficacy are known and 
current treatment for unresponsive individuals remains largely based on trial and error of 
existing medications (Kasperaviciute and Sisodiya, 2009). 
 
1.6.9 Epilepsy pharmacogenetic studies: research limitations and design issues 
Several possible reasons have been proposed for the limited success in discovering 
susceptibility loci for AED response as well as the numerous failed attempts to replicate the 
few potential risk alleles identified (Nakajima et al., 2005, Baksh and Kelly, 2007). Among 
the reasons for the lack of success in general, are the overall lack of clarity in study findings 
due to the retrospective design and analysis and small cohort size and/or short duration of 
follow-up (Johnson et al., 2011b). Additional problems include general methodological 
limitations associated with complex outcomes (Cardon and Bell, 2001, Hirschhorn et al., 2002, 
Colhoun et al., 2003, Depondt, 2006b, McCarthy et al., 2008). Of particular concern with 
epilepsy PGx studies are i) the diversity in the definition of AED resistance, ii) the 
heterogeneity of the study populations and ii) the lack of a multigenic approach associated 
with candidate gene based research (Ferraro et al., 2006, Kasperaviciute and Sisodiya, 2009, 
Johnson et al., 2011b). The latter of these has produced disappointing results in many genetic 
studies (Colhoun et al., 2003, Goldstein et al., 2003, Grant and Hakonarson, 2007, di Iulio and 
Rotger, 2012).  
In terms of the issue of heterogeneity of study cohorts, this is often due to i) differences 
in clinical phenotype definitions used for selecting participants between study sites (i.e. 
definitions used to classify epilepsy syndromes and epilepsy severity: chronic long-term 
epilepsy versus newly treated epilepsy patient populations, with the former predominantly 
used in the majority of PGx reports), and ii) differences in the clinical treatment regimens used 
between studies (i.e. dosing strategies and drug selection decisions used by neurologists), 
(Johnson et al., 2011b). 
 Another likely reason for the lack of progress in identifying genetic contributions to 
drug efficacy in epilepsy is the small effect size of variants detected to date (Cavalleri et al., 
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2011). Even when a study has been successfully replicated, the effect of any given 
polymorphism on drug response is often lower than initially described (Ioannidis, 2003). Such 
studies have commonly tested for associations between single candidate genes or single SNPs, 
and therefore only explain a fraction of the variability in drug response, with accordingly 
limited plausibility and clinical utility (Goldstein, 2009, Cavalleri et al., 2011). This approach 
and its inherent limitations explains why only a handful of PGx markers are actually useful 
for individualising treatment in clinical practice (Ikediobi et al., 2009). The fact that the classic 
candidate gene approach does not take into account the full complexity underlying drug 
response is another possible explanation for the lack of positive findings to date (Ritchie and 
Motsinger, 2005). Drug response is now widely considered to be the joint effect of multiple 
polymorphisms, gene-gene interactions (epistasis)(Hardy and Singleton, 2009), and the 
interplay with environmental factors (gene-environment interactions) (Hirschhorn et al., 
2002).  
SNPs with small effect sizes in combination are more likely to underpin the 
multifactorial basis of drug efficacy and tolerability (CDCV hypothesis) (Gillham et al., 1990, 
Evans and McLeod, 2003, Iyengar and Elston, 2007) and a genomic approach for the 
identification of these genetic variants is more appropriate (Depondt and Shorvon, 2006, 
Baksh and Kelly, 2007). Study design and data analysis, employing wide-scale mapping of 
biologically relevant loci in much larger cohorts (through large collaborations and consortia 
meta-analysis) (Cavalleri et al., 2011), and/or employing GWAS may help nullify some of the 
previous failures of candidate gene studies in AED response and enable replication studies to 
validate any previously reported true effects (Baksh and Kelly, 2007). Wide-scale mapping of 
large sections of the genome in PGx (www.genome.gov/GWAStudies) (Nagasawa and 
Nakahara, 1992, Hardy and Singleton, 2009, Daly, 2010a, Wang, 2010, Wang et al., 2011), is 
growing, and genome-wide efforts for epilepsy PGx, are likewise expanding. The first 
examples of the application of GWAS have however only just emerged and both of these 
concern cutaneous drug reactions and were prompted by the discovery of the clinically 
important HLA-B*1502 variant (McCormack et al., 2011, Ozeki et al., 2011b).   
Despite limited clinical significance and difficulties in replication across epilepsy PGx 
findings, many of the SNPs and gene associations found to date appear relevant and warrant 
further consideration. For future PGx studies in epilepsy to have sufﬁcient power to detect 
genetic variants with small effect sizes, much larger sample sizes are required (Crowley et al., 
2009, Johnson et al., 2011b). Recent developments in genetic technology do however hold 
great promise for the field of epilepsy. With an increasing number of robust associations found 
in different diseases to date and the rise in GWAS being applied to neurological conditions, 
the status of pharmacogenomics/PGx for epilepsy is likely to change rapidly (Kasperaviciute 
and Sisodiya, 2009, Mullen et al., 2009, Rees, 2010). 
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1.6.10 Machine learning 
To deal with these issues many researchers have begun to explore more powerful 
statistical methodologies capable of dealing with both the problem of detecting small, multiple 
associations and the analysis of high-dimensional data (Moore et al., 2004, Hoppe, 2005, 
Rodin et al., 2011) and this includes the machine learning (ML) data mining method (Hastie 
et al., 2001, Koster et al., 2009). The ML approach to data analysis of pharmacogenomics data 
typically involves three-steps, i) selection of variables (SNPs), ranked in order of effect on 
drug response phenotype, ii) modelling step involving generation of a predictive model using 
SNPs and any other relevant factors, iii) evaluation of generated models using conventional 
statistical analysis methods (Koster et al., 2009). Typical ML approaches applied to genomic 
studies model data using Bayesian networks, which allow the inferential exploration of 
previously undetermined relationships among genetic and clinical variables, and describe 
these relationships, once identified, using a hypothesis or model-free approach (Hoppe, 2005, 
Zhang and Rajapakse, 2009, Rodin et al., 2011). Data mining methods generally involve the 
development of disease association models that allow integration of the interactions between 
multiple SNPs in addition to clinical variables and disease phenotype, and so overcome the 
main limitation of traditional statistical approaches through their ability to model high-
dimensional data (Hoppe, 2005, Wilke et al., 2005). Additional advantages of ML algorithms 
include robustness of parametric assumptions, high power and accuracy, ability to model non-
linear effects, and the availability of numerous well-developed algorithms (Moore and Ritchie, 
2004, McKinney et al., 2006).   
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Table 1.6          Summary of genes and SNPs associated with antiepileptic drugs so far 
DRUG DOSING STUDIES 
Gene Genetic 
polymorphisms 
AED Associated drug 
parameter 
Reference  
PHASE I DRUG METABOLISING ENZYMES 
CYP2C9 
 
 
 
CYP2C9/
C19 
CYP2C9*1/*2 
 
CYP2C9*2 
 
CYP2C9/C19 
PHT 
 
PHT 
 
PHT                           
PB 
VPA 
PHT 
Maintenance dose 
 
Altered metabolism 
 
PHT clearance 
PB clearance 
VPA clearance 
PHT dosage 
(van der Weide et 
al., 2001) 
(Odani et al., 1997) 
 
(Lee et al., 2007) 
(Goto et al., 2007) 
(Wu et al., 2010) 
(Hung et al., 2004) 
CYP2C19 CYP2C19*2/*3  PHT 
ZNS 
CLB 
PHT/PB 
PHT clearance 
ZNS clearance 
Efficacy to CLB  
Pharmacokinetics 
(Seo et al., 2008b) 
(Okada et al., 2008) 
(Yukawa and 
Mamiya, 2006)  
 
CYP3A5 
 
CYP3A5*3 
genotype 
CBZ Concentration 
Pharmacokinetics 
(Park et al., 2009) 
(Seo et al., 2006) 
GSTM1/ 
GSTT1 
GSTM1 
null genotype 
null genotype 
VPA 
CBZ 
Hepatotoxicity (Fukushima et al., 
2008a) 
(Ueda et al., 2007) 
PHASE II DRUG METABOLISING ENZYMES 
UGT2B7 UGT2B7 -
161C>T 
 
LTG 
 
Concentration to daily 
dose ratio 
(Blanca Sanchez et 
al., 2010)  
EPHX1 
 
Try113His and 
His139Arg 
 
CBZ 
 
Maintenance dose 
 
Metabolism; increased 
and decreased CBZ 
diol:CBZ epoxide 
ratios  
(Makmor-Bakry et 
al., 2009) 
(Nakajima et al., 
2005) 
 
DRUG TARGET PROTEINS 
SCN1A IVS5-91G>A 
 
 
CBZ/PHT 
 
PHT 
Maximum dose  
 
Maintenance dose 
(Tate et al., 2005) 
 
(Tate et al., 2006) 
  CBZ No association with 
CBZ dosage 
(Zimprich et al., 
2008) 
DRUG EFFICACY STUDIES 
DRUG TRANSPORTER PROTEINS 
ABCB1 
 
 
ABCB1 
 
 
 
ABCB1, 
ABCC2,  
C3435T 
 
 
C3435T 
 
 
 
Multiple 
variants 
Multiple 
 
 
Multiple 
 
 
 
Multiple 
Association with 
refractory epilepsy 
 
No association with 
resistance to AEDs in 
a meta-analysis 
 
No association with 
drug resistance 
(Siddiqui et al., 
2003) 
 
(Bournissen et al., 
2009) 
 
 
(Kim et al., 2009) 
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ABCG2 Including 
C3435T 
  
RLIP76 Multiple Multiple No association with 
AED treatment 
response 
(Soranzo et al., 
2007) 
DRUG TARGET PROTEINS 
GAT-3 Multiple Multiple AED resistance  (Kim et al., 2011a) 
SCN1A 
 
SCN1A 
 
SCN2A 
 
 
SCN1A 
 
 
SCN1A 
SCN2A 
SCN3A 
 
 
 
SCN1A 
SCN2A 
SCN3A 
 
 
 
 
SCN1A 
GABA 
GABRA1 
 
 
 
 
 
 
Multiple 
genes and 
SNPs  
IVS5-91G>A 
 
rs229877 
 
rs17183814 
 
 
IVS5-91G>A 
 
 
Several SNPs 
including;  
IVS5-91G>A 
rs2298771 
rs17183814 
 
Multiple  
SNPs including 
SCN1AIVS5-
91G>A and 
SCN2AIVS7 -
32A>G 
 
Multiple 
including  
SCN1AIVS5-
91G>A, 
rs2290732 
rs2298771 
GABRA1 
rs2290732 
 
Five SNPs: 
SCN4B, SCN4B 
KCNQ4, 
GBBR2, 
SLC1A3 
CBZ 
 
Multiple 
 
 
 
 
Multiple 
 
 
Multiple 
CBZ resistance 
 
Association with 
epilepsy 
Association with 
multidrug resistance 
 
No association with 
responsiveness 
 
No association with 
responsiveness: Multi-
centre meta-analysis 
 
 
 
Association with AED 
non-responsiveness 
No association with 
with SCN1A/3A 
 
 
 
Association with CBZ 
tolerability and or 
efficacy and SCN1A 
SNPs and  GABRA1; 
rs2290732 
 
 
 
 
Prediction of AED 
treatment response by 
five SNP model 
(Abe et al., 2008) 
 
(Lakhan et al., 2009) 
 
 
 
 
(Manna et al., 2011) 
 
 
(Haerian et al., 2011) 
 
 
 
 
 
 
(Kwan et al., 2008) 
 
 
 
 
 
(Zhou et al., 2012) 
 
 
 
 
 
 
 
 
(Petrovski et al., 
2009) 
AED= antiepileptic drug, PHT= phenytoin, PB= phenobarbital, VPA= valproate, ZNS= 
zonisamide, CLB= clobazam, CBZ= carbamazepine, LTG= lamotrigine, SNP= single 
nucleotide polymorphism 
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1.7 Research justification and aims of the thesis 
Elucidating the basis of AED response would both aid the understanding of 
pathogenic mechanisms underlying drug resistance in epilepsy and additionally allow the 
development of innovative rational treatments for people with refractory epilepsy (Sisodiya, 
2005). The optimum drug therapy in epilepsy however continues to trail behind that of many 
other common, complex disorders (Kasperaviciute and Sisodiya, 2009).    
 The majority of candidate association studies are characterised by irreproducibility 
often attributed to a lack of statistical power and are most likely due to weak genetic effects 
and/or population specific gene-gene and/or gene-environment interactions (Hirschhorn et al., 
2002). The confirmed signals emerging from GWA scans and subsequent replication efforts 
similarly remain only signals (McCarthy, Abecasis et al. 2008). A substantial body of 
experimental evidence now supports a multifactorial, polygenic basis for common traits 
(Ferraro et al., 2012).  Research indicates the significance of capturing the interactions between 
genetic factors and other variables including phenotypes, environment and drugs (Baksh and 
Kelly, 2007, Kim et al., 2011a, Rodin et al., 2011). A number of studies have already applied 
powerful statistical methods that use data mining approaches such as ML classification 
methods and ML based methods for detecting epistatic and additional genetic interactions to 
PGx and pharmacogenomics data (Ritchie and Motsinger, 2005, Wilke et al., 2005, Rodin et 
al., 2011) and studies are now emerging for the characterisation of the genetic variables 
underlying refractory epilepsy (Petrovski et al., 2009, Johnson et al., 2011b). The promising 
results indicated by initial studies for refractory epilepsy moreover advocate further 
consideration of ML approaches and interaction data analysis methodologies for investigating 
AED efficacy (Cavalleri et al., 2011, Johnson et al., 2011b).  
 
1.7.1 Research goals 
The intention of this PhD thesis was to explore genetic contribution to drug response 
phenotypes in epilepsy, with the purpose of identifying and/or validating genetic markers 
influencing drug efficacy and optimal dosing. To achieve these research goals several lines of 
previous PGx and pharmacogenomic evidence for the genetic contribution to individual 
responsiveness in epilepsy treatment were followed. ML methodologies have recently been 
applied to PGx data from patients with epilepsy and such approaches were additionally 
explored and assessed for utility using epilepsy phenotype data from UK patients.  
 Data currently available for epilepsy PGx is limited by the use of heterogeneous 
populations consisting of different epilepsy phenotypes, varying definitions of drug 
responsiveness, retrospective data and mainly individuals with long standing epilepsy (often 
exposed to multiple drugs and thus a greater chance of the existence of uncontrollable genetic 
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and environmental influences from continuous drug exposure and or seizure related 
neurological damage). The majority of AEDs differ in their pathways of drug action and 
distribution and also dosage and titration. Including patients with multiple AED treatment can 
also confound the effective detection of a genetic influence on response to a single drug. The 
studies presented in this thesis thus also aimed to provide a set of genetic investigations using 
a more homogenous epilepsy population.  
 
1.7.2 Specific aims and thesis outline 
 
The specific research aims are listed below and each one is tackled in the individual 
research chapters that follow. 
 
Aim 1: To characterise genetic variation across DMEs responsible for the metabolism of CBZ 
to identify markers for optimal AED dosing in newly treated epilepsy (Chapter 3) 
 
Aim 2: To establish the contribution of a single functional SNP in the SCN1A gene to 
optimal dosing of AEDs in individuals with newly treated epilepsy (Chapter 4) 
 
Aim 3: To assess the validity and predictive value of a ML-based multi-genetic model 
for classifying treatment outcome with AEDs, using an independent cohort of patients 
with newly treated epilepsy (Chapter 5) 
 
Aim 4: To explore the utility of ML approaches for the identification of influential 
markers for classifying primary generalised epilepsy (Chapter 6) 
 
Aim 5: To validate the findings of a recent GWAS (Speed et al., 2013) that reported 
significant genetic influences on the likelihood of achieving 12 months seizure 
freedom, using an independent cohort of newly treated epilepsy (Chapter 7) 
 
The following chapter (Chapter two) presents experimental methods common to two or more 
research chapters. Methodologies specific to each research aim are described in the respective 
results chapter. 
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2.1 Materials 
2.1.1 Consumables 
 100% ethanol was used for sterilisation and cleaning of the nanodispenser for both PCR 
and extension reactions. PCR reagents included Hot Star Taq® enzyme, deoxyribonucleotide 
triphosphate (dNTP) mix, magnesium chloride (MgCl2) and polymerase chain reaction (PCR) 
buffer (PCR reagent set purchased directly from Sequenom (Hamburg, Germany). The 
following consumables for MassARRAY genotyping (extension reaction) were also 
purchased from Sequenom: the iPLEX® Gold Reagent Kit (iPLEX® Gold SNP genotyping 
assay for single base primer extend) containing; shrimp alkaline phosphatase (SAP) buffer, 
SAP enzyme, iPLEX Termination mix, iPLEX buffer, iPLEX enzyme, Clean Resin kit (for 
removing PCR impurities) consisting of resin (28g) and a 384-well dimple plate for resin 
application, and 10 x 384 SpectroCHIP® Arrays (for allele detection).   
 All primers were supplied by Metabion (Martinsried, Germany). 96-channel tips with 
a volume of 30µL were required for the liquid handler Matrix as were Matrix reagent 
reservoirs; these were also purchased from Qiagen. The Quant-iT PicoGreen® dsDNA reagent 
kit v 1.0 was purchased from Invitrogen Ltd, (Paisley, UK). Ultrapure agrose powder and 20x 
Tris-HCl-EDTA was obtained from Invitrogen Ltd (Paisley, UK). Ethidium bromide and 0.5x 
Tris-EDTA (TE) buffer were purchased from Sigma-Aldrich Ltd (Gillingham, UK). The 100 
base pair (bp) DNA molecular weight marker XIV used for all electrophoresis was purchased 
from Roche Applied Science (Burgess Hill, UK). 384-well micro-plate adhesive polymerase 
chain reaction (PCR) films and films for general plate sealing were purchased from ABgene 
(Loughborough, UK). 96-well polystyrene plates were purchased from Sarstedt (Leicester, 
UK). Costar 96-well solid, flat bottom plates for Picogreen® DNA quantification were 
purchased from VWR International Ltd (Lutterworth, UK). All other generic reagents and 
consumables were available as standard and were obtained from University stores; and these 
were purchased from standard supply companies such as Sigma.  
 
2.1.2 Equipment 
 Pipettes: Small volumes were dispensed using single channel pipettes (with 2.5µl, 20µl, 
200µl and 1000µl volumes) and multichannel pipettes (with 10µl and 50µl volumes) from 
Eppendorf (Cambridge, UK). Ultra-purified laboratory water: Molecular biology grade 
purified water for all experimental procedures was obtained using the ELGA PURELAB water 
system (minimum 18.2 MΩ/cm resistivity) (ELGA, Marlow, UK).  
 DNA quantification: Genomic DNA samples were quantified either using the 
NanoDrop 1000 Spectrophotometer (Thermo Scientific Inc., Hemel Hempstead, UK) and/or 
the Beckman Coulter DTX880 multimode detector (Beckman Coulter Ltd., High Wycombe, 
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UK). DNA amplification and primer extension: For all MassARRAY genotyping projects G-
Storm Thermal Cycler GS-4 Kappa from G-storm (Ringmer, UK) was used for both genomic 
amplification and primer extend cycles.  
 Genotyping: Equipment required for MassARRAY® genotyping was mainly 
specialised Sequenom® technology and purchased directly from Sequenom®. Dispensing 
post-PCR samples was carried out using a Sequenom® Matrix Liquid handler (a 96-channel 
pipetting robot that provides pre-programmed optimised pipetting schemas for all 
MassARRAY applications), and a Sequenom® MassARRAY nanodispenser was used to 
transfer iPLEX® Gold reaction products on to a Sequenom® SpectroCHIP. A Sequenom® 
MassARRAY READER real-time (RT) Matrix-assisted laser desorption/ionisation-time of 
flight mass spectrometry (MALDI-TOF) instrument (specifically designed for genomic 
applications) was used to read SpectroCHIPs containing experimental samples and 
Sequenom® SpectroAcquire computer software was used to visualise all genotype data.  
 
2.2 Patient cohorts 
Patients used in the various studies were principally from two distinct UK cohorts; the 
SANAD cohort and the Glasgow cohort. An Australian cohort was also used in some analyses, 
comprising patients from both the Department of Medicine, University of Melbourne Hospital, 
Melbourne and the Department of Medicine and Epilepsy Research Centre, Austin Health, 
Heidelberg, Victoria. All patients were identified as having a diagnosis of epilepsy (as defined 
by the ILAE) and were treated with AEDs for seizure control. Patients of non-European 
ancestry were excluded. Clinical information for each cohort was contained in electronic 
databases generated from clinical trial data or hospital notes.  
 
2.2.1 Glasgow cohort 
 The Glasgow cohort consisted of 893 patients attending the epilepsy outpatient clinic at 
the Western Infirmary in Glasgow. Individuals had newly treated epilepsy (n=462) or long 
term/chronic epilepsy (n=427), and had been treated with a wide range of AEDs, as 
monotherapy or polytherapy. DNA was extracted from venous blood samples using a standard 
phenol-chlorophorm method (Szoeke et al., 2009) and all individuals provided informed 
consent for the collection and pharmacogenetic analysis of DNA (approved by the West Ethics 
Committee; North Glasgow University Hospitals NHS Trust in September 2002 (ref: 
02/119(2)). All samples were aliquots of original DNA stored at the Western Infirmary in 
Glasgow. Aliquots were stored in 1mL cryovials at the Wolfson Centre for Personalised 
Medicine, Liverpool.  
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2.2.2 Glasgow cohort clinical data 
 Although a cross-sectional outpatient clinic cohort, a large proportion of these 
individuals had participated in randomised monotherapy trials (Stephen et al., 2007). Drug 
response phenotypes in the Glasgow cohort were identified by retrospectively reviewing the 
prospectively collected clinical data from a database generated from trial and/or hospital notes. 
Patient phenotype data that was available in the clinical database included general 
demographic details (i.e. date of birth (DOB), gender) and the following clinical information 
and phenotype data; previous drug treatment, epilepsy type, date of first ever seizure, pre-
treatment seizures, EEG and imaging results, and AED treatment history including initial AED 
and subsequent AEDs until last follow up, with dates of withdrawal and dosage for each AED. 
Of these patients, individuals were not considered for genetic analysis in this thesis if they had 
long-standing epilepsy (i.e. not newly treated with AEDs), were not monotherapy patients, and 
their ethnic origin was non-European.  
 
2.2.3 SANAD cohort 
 The SANAD cohort was drawn from patients who had participated in the Standard and 
New Antiepileptic Drug study, an un-blinded, multicentre, randomised trial comparing the 
efficacy, tolerability and cost-effectiveness of established and newer AEDs in patients with 
newly-diagnosed epilepsy from epilepsy centres across the UK (Marson et al., 2007a, 2007b). 
More than 2,400 patients were recruited in the trial and followed-up prospectively for a 
minimum period of two years from initiation of the first ever AED.  
 985 SANAD participants gave informed consent to the collection and analysis of DNA, 
approved by the North-West Multicentre Research Ethics Committee in August 2002 (ref: 
MREC 02/8/45). DNA was extracted from blood and or saliva samples using a standard 
phenol-chloroform extraction method and purity and concentration confirmed by 
spectrophotometry. SANAD DNA samples were stored at the Welcome Trust Sanger Centre, 
Cambridge and subsamples of these were stored and available for experimental use in 
Liverpool. All 985 samples were considered for genetic analysis except those of non-European 
ancestry and those without epilepsy.  
 
2.2.4 SANAD cohort clinical data 
 Neurological history and seizure history was recorded at recruitment. Seizures and 
epilepsy syndromes were classified by ILAE classifications. Patients were seen for follow up 
at 3 months, 6 months, 1 year, and at successive yearly intervals from the date of randomisation 
and details of drug treatment and effectiveness were recorded. Where patients ceased attending 
hospital clinics, follow-up information was obtained from general practitioners, or directly 
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from the patient via a telephone interview.  
 Due to the nature of the SANAD trial, a large amount of clinical and phenotype data 
was collected. The following clinical data was available for patient selection and subsequent 
data analysis: 
 
i) Neurological disease history i.e. the presence of a learning disability, neurological 
deficit, neurological disorder, head Injury, meningitis/encephalitis, intracranial 
surgery, acute symptomatic seizures or family history of epilepsy 
ii) Epilepsy type i.e. LRE, IGE, UNC,  
iii) Seizure type and syndromic diagnosis (where available)  
iv) EEG and CT/MRI results  
v) Treatment history (untreated or monotherapy) 
vi) Seizure history i.e. recent seizure occurrence  
vii) AED history; initial or randomised drug, dosage history and withdrawal details if 
applicable (including dates of treatment and each study visit).  
 
Data collected for the SANAD trial included dates for each follow up visit and drug 
treatment history during follow up period. Due to the outcomes of interest of the trial, (time to 
first seizure, time to 12-month remission or treatment failure, time to withdrawal due to 
inadequate seizure control, and time to withdrawal for unacceptable AEs or ADRs), seizure 
history i.e. dates of occurrence, number, type was also recorded as were reasons for drug 
withdrawal, and 12 month remission status. 
 
2.2.5 Additional Australian cohort  
 Clinical data was provided from a population of Australian individuals for the purposes 
of research studies 6 and 7 of this thesis. The Australian cohort consisted of patients 
prospectively recruited from clinics in Victoria, Australia; Royal Melbourne Hospital and the 
Austin Hospital on the basis of being newly treated with AEDs (Petrovski et al., 2009), as part 
of a multicentre collaboration study of epilepsy aeiteolgy and seizure types (the Epilepsy 
Genetics Consortium; EPIGEN) (Cavalleri et al., 2007). All patients were of self-identified 
European Australian ethnicity and were recruited after obtaining written informed consent. 
Individuals were all diagnosed with epilepsy (ILAE) and were followed up prospectively. 
Patient treatment response was phenotyped once individuals reached their 1-year follow-up 
with their initial AED treatment. In total clinical and genetic data was provided for n=427 
patients on the basis of having primary generalised epilepsy (PGE) or LRE. All DNA 
genotyping was done using the Illumina GoldenGate platform at Duke University, Durham, 
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NC, USA (Cavalleri et al., 2007). 
 
2.2.6 Australian cohort clinical data 
 Patient phenotype data that was provided included age of onset, initial drug treatment, 
epilepsy syndrome type and seizure type. Patients with PGE were classified with the following 
syndromes, subsyndromes and seizure types; juvenile myoclonic epilepsy (JME), juvenile 
absence epilepsy (JAE), childhood absence epilepsy (CAE), CAE generalising to JME (CAE 
-> JME), CAE -> JAE, CAE/JAE, idiopathic generalised epilepsy (IGE) excluding JME (non-
JME IGE), mesial temporal lobe epilepsy associated with hippocampal sclerosis and all other 
focal neocortical epilepsies. The seizure classifications used were; GTCS; occurring only in 
the context of a syndromic diagnosis of an IGE, myoclonic seizures, absence seizures, 
secondarily GTCS and partial seizures (either simple or complex). Patients with any epilepsy 
type who also had a history of febrile convulsions (FS) were also included (Cavalleri et al., 
2007). 
 
2.3 DNA preparation and storage 
 All available DNA samples (985 SANAD and 893 Glasgow) were quantified and 
aliquots of between 50-200µL were prepared for later experimental use.  
 
2.3.1 DNA quantification using spectrophotometry  
 All Glasgow samples were quantified using the NanoDrop 1000 spectrophotometer. The 
NanoDrop 1000 Spectrophotometer accurately measures double-stranded DNA (dsDNA) up 
to 3700 ng/µL without dilution. To do this, the instrument automatically detects the high 
concentration and utilises the 0.2 mm path length to calculate the absorbance. The machine 
was blanked using a 1.5µL volume of 0.1 x TE buffer and the recommended volume of 1.5µL 
of each stock DNA sample was placed on the spectrophotometer for a measurement of DNA 
concentration. The Nanodrop spectrophotometer additionally provides two DNA purity 
readings based on sample absorbance. The 260/280 ratio of a sample is the ratio of absorbance 
at 260 and 280 nm and is used to assess the purity of DNA. A ratio of ~1.8 is generally accepted 
as “pure” for DNA, and if the ratio is substantially lower, it may indicate the presence of 
protein, phenol or other contaminants that also absorb strongly at or near 280nm. The 260/230 
ratio of a sample is the ratio of absorbance at 260 and 230nm. This is a secondary measure of 
nucleic acid purity with values for “pure” nucleic acid often being higher than 260/280 values. 
These ratios are commonly in the range of 1.8-2.2 and if appreciably lower, this may indicate 
the presence of co-purified contaminants. 
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Table 2.1  Quantification method using Nanodrop Spectrophotometer.  
Table taken manufacturer’s instructions (http://nanodrop.com) (© 2008 Thermo Fisher 
Scientific) 
Detection 
limit (ng/µL) 
Approximate 
upper limit (ng/µL) 
Typical reproducibility (minimum 5 
replicates) 
(SD=ng/µL; CV= %) 
2 3700 ng/µL 
(dsDNA) 
sample range 2-100 ng/µL:  2 ng/µL 
sample range >100 ng/µL:  2% 
 
 
 
2.3.2 DNA quantification using Picogreen 
 All SANAD samples were quantified using Picogreen®. PicoGreen® is an 
ultrasensitive fluorescent nucleic acid stain for quantifying double-stranded DNA (dsDNA) in 
solution. Free dye does not fluoresce, but upon binding to dsDNA it exhibits a >1000-fold 
fluorescence enhancement. This allows the quantification of as little as 25 pg/mL of dsDNA. 
The PicoGreen® DNA quantification method was better suited to the SANAD samples, which 
were of low concentration in comparison to the Glasgow samples and additionally assumed to 
be of less purity. The major disadvantages of using the 260 nm absorbance method is the large 
relative contribution of nucleotides and single-stranded nucleic acids to the absorbance signal, 
the interference caused by contaminants commonly found in nucleic acid preparations, the 
inability to distinguish between DNA and RNA, and the relative insensitivity of the assay.  
 
2.3.3 Picogreen methodology 
 The Quant-iTTM Picogreen® manufacturer’s instructions were followed for quantifying 
all available SANAD DNA samples. For this a standard curve was first generated using diluted 
Picogreen® and standardised DNA (lambda stock DNA at 100 ug/mL provided in the kit), 
from which the unknown concentration of all SANAD DNA samples was calculated. The 
Picogreen® reagent stock provided was first diluted to a working solution using 1 x TE (100uL 
Picogreen® reagent added to 19.9 mL TE solution). A standard curve was then generated 
using lambda standard DNA diluted 50 fold (1.47µL of 1 x TE solution added to 30µL of 
DNA); see Table 2.2 for dilutions used to generate a high-range standard curve.  
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Table 2.2  Dilution factors used for Picogreen® quantification.  
Volume of Standard 
DNA (µL) 
Volume of 1xTE (µL) Volume of 
picogreen working 
solution (µL) 
Final 
concentration 
100 0 100 1 ug/mL 
10 90 100 100 ng/mL 
1 99 100 10 ng/mL 
0.1 99.9 100 1 ng/mL 
0 100 100 Blank 
 
 
 
These were added to the first row of a 96-well plate. The remaining wells were filled 
with 99µL of diluted Picogreen® solution and 1µL of DNA of unknown concentration. After 
mixing and incubation (as detailed in the protocol), the fluorescence of each well was 
measured using the Beckman Coulter DTX880 multimode detector and the concentration of 
each DNA sample calculated from the standard curve. 
 
2.3.4 DNA sample dilution and storage 
 All DNA stock (Glasgow and SANAD) was stored at 80 °C. All working stock solutions 
were diluted to a concentration of 20 ng/µL for experimental use and stored at -20°C.  
 
2.4 Single nucleotide polymorphism selection 
2.4.1 Resources for selection of genes and single nucleotide 
polymorphisms 
 Several freely accessible online genomic databases are available as a resource for the 
investigation of common genetic variation in human genes including the HapMap website 
(www.HapMap.org), database SNP (dbSNP) function of the National Centre for 
Biotechnology Information (NCBI) website (www.ncbi.nlm.nih.gov/projects/SNP/), the 
UCSC Genome Browser Human Genome Browser Gateway website (genome.ucsc.edu/cgi-
bin/hgGateway) and the Ensemble Human Genome Browser  
(www.ensembl.org/Homo_sapiens/Info/Index).  
 These resources were used to locate information concerning human genes and or single 
SNPs to be investigated and allowed visualisation of gene regions and genetic variation within 
loci. Information that was extracted was mainly dependent on the requirements of the research 
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project, but included i) all known polymorphic sites for a particular gene, ii) their population 
minor allele frequency (MAF), iii) chromosome location, and iv) type or location in the 
corresponding gene (synonymous, non-synonymous, 5’UTR, 3’UTR). Information on those 
in LD and on clinical relevance, i.e. previous association with a particular condition, or 
previously demonstrated to associate with a therapeutic drug was also recorded 
(ww.pharmgkb.org; (www.ncbi.nlm.nih.gov/pubmed)).  
 Any potential transcriptional or regulation changes due to a SNP (i.e. location in a 
transcription factor binding site (TFBS), DNA methylation region, histone and polymerase 
binding region) was also investigated through functions available on the UCSC Genome 
Browser and the Ensemble Human Genome Browser.  
 
2.5 Genotyping using Sequenom MassARRAY 
2.5.1 Sequenom MassARRAY platform and reaction overview  
 The main method used for high-throughput SNP genotyping was the Sequenom® 
MassARRAY matrix-assisted laser desorption/ionisation-time of flight mass spectrometer 
(MALTI-TOF) platform. Although several high-throughput SNP genotyping technologies are 
available, Sequenom Mass ARRAY provides affordable and accurate custom genotyping 
assays, with a modest multiplexing methodology (Gabriel et al., 2009). The MassARRAY® 
MALTI-TOF platform uses a single base homogenous reaction format that can throughput 
>100,000 genotypes per day. This utilises multi-plex PCR reactions, a single termination mix, 
provides universal reaction conditions for all SNPs, requires small reagent volumes, and 
generates allele-specific products with distinct masses for subsequent mass spectroscopy 
detection. The iPLEX® reaction allows the design of assays at a multiplexing level of 36-plex.  
 
There are several key tasks involved in genotyping using the Sequenom® MassARRAY 
system: 
 Primer and multiplex design 
 DNA amplification 
 Preparation of iPLEX® Gold reaction products 
 Transfer of processed iPLEX® Gold reaction products to SpectroChip® arrays 
 Assay design, plate design, and setup using Sequenom® design software 
 Use of Sequenom® mass spectrometer for the acquisition of reaction spectra  
 Use of TyperAnalyzer software for the analysis of spectral data 
 The Sequenom® SNP assay is based on a locus-specific PCR reaction followed by a 
locus-specific primer extend reaction (Tang et al., 1999). During the primer extension or 
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iPLEX® reaction, an oligonucleotide primer anneals immediately upstream of the 
polymorphic site being genotyped. The primers and amplified target DNA are then incubated 
with mass-modified dideoxynucleotide terminators. The primer is extended dependent upon 
the template sequence and results in allele specific differences in mass between extension 
products, the mass of which is determined by the use of MALDI-TOF mass spectrometry. The 
molecular mass of extension products is used to indicate which alleles are present at the 
polymorphic site of interest. The primer mass for each reaction is translated into a genotype 
using Sequenom® software (SpectroTYPER) (Gabriel et al., 2009). Genotyping using 
Sequenom® MassARRAY genotyping was performed as stated in the manufacturer’s 
instructions, an overview of which is provided below. 
 
2.5.2 MassARRAY required components and consumables  
 The MassARRAY reaction can be performed in both 96- and 384-well plate format and 
with automated liquid handling process (for 384-well format). All experimental work 
performed required single wells (per sample and SNP assay) ranging from 150 up to 2000 
reactions, thus a 384-well format using the automated liquid handler matrix was undertaken 
for all genotyping studies. All reagents and equipment for MassARRAY are listed in sections 
2.1.1 and 2.1.2, respectively. 
 
2.5.3 Primer and assay design   
 The online Sequenom MassARRAY Designer software was used to electronically 
design PCR and extension primers for a SNP of interest (https://mysequenom.com/Tools). The 
software also provided a plex design function to manually balance multiplex levels of SNP 
groups to minimise the number of reactions (Gabriel et al., 2009). The primer design process 
involved the automatic checking and avoidance of primer combinations and non-template 
extension products that could result in non-specific extension and has a proven design 
efficiency of >95% for all confirmed SNPs (Gabriel et al., 2009).  
 The reference sequence (rs) number for all SNPs of interest was typed into the rs 
sequence retriever function, which then retrieved genomic sequences for each specified SNP 
from the NCBI dbSNP database in FASTA format. The input FASTA file typically includes 
500 base pairs of specific genomic sequences, 250 upstream and downstream from the SNP 
of interest. The SNP sequences were then passed through four additional functions involved 
in the SNP design and checking process, with SNPs resulting in non-specific extension 
excluded at each stage of the process (Gabriel et al., 2009): 
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i) The ProxSNP sequence-mapping step compared input sequences against the NCBI database 
and looked for registered SNPs that were proximal to the SNP of interest. The genome 
assembly version selected for all MassARRAY genotyping experiments was always Genome 
build 36 and the formatted sequences selected were SNP/MNP sequences.  
 
ii) The PreXTEND SNP validation / amplicon design step then aligned the input sequences 
from the ProxSNP mapping step against the genome build to determine the best location for 
PCR primers that would result in a unique amplification product containing the target for the 
extension primer. Genome build 36 was again employed and the designable sequences chosen 
were uniquely mapped.  
 
iii) The Multiplexed iPLEX Assay Design step then designed multiplexed genotyping assays 
and the multiplexed design was used for ordering PCR & extension primers as well as 
importing into the SEQUENOM assay editor of the Typer software. For this function, the stop 
mix selected was iPLEX. The multiplex level allowed a maximum of 36 SNPs and a minimum 
of one SNP per plex. The maximum plex level used was never more than 25 and the minimum 
plex level used was never less than five. Although using a plex level of 36 would maximise 
productivity, a lower plex level was chosen as this was the most reliable in routine laboratory 
genotyping. 
 
iv) The PleXTEND Multiplexed Assay Validation step was the final step that validated all 
designed primers in the entire multiplex by comparing sequences using the Basic Local 
Alignment Search Tool (BLAST; a set of algorithms designed to perform similarity searches 
on all available biological sequence data) to check for potential cross-hybridisation.  
 
2.5.4 Primer pooling 
 All primers for PCR and iPLEX reactions were ordered unmodified and unmixed, with 
standard purification. All primer plexes thus required pooling before use. Prior to any 
pipetting, primers were centrifuged (1200 rpm for 3 minutes) and pipetted up and down to 
ensure sufficient mixing. All pipetting during primer pooling was performed using extended 
sterilised tips. Because the Sequenom MassARRAY platform requires a multistep process, 
checks were put in place for each 384-well plate used. A 384-well assay plate was designed to 
contain approximately 10% negative control wells and duplicate DNA samples. These were 
also placed in unique positions on the plate to be checked for expected results at the end of the 
experiment (i.e., no extension in the negative controls and genotype concordance among 
duplicates). 
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2.5.5 PCR  
 The PCR assay pool of plexes included the multiplexed forward and reverse PCR 
primers for each reaction in one multiplexed assay pool. PCR primers for each plex were 
pooled and diluted to a working concentration of 0.5 μM for each primer in eppendorf tubes. 
For one 384-well reaction plate and a 24-plex reaction, 5uL of each forward primer was mixed 
with 5uL of each reverse primer and 260uL of Nanopure water to give a total volume of 500uL, 
with adjustment in the volume of water for lower or higher plex levels. All diluted working 
stocks and concentrated stocks of primers were stored at −20°C.  
 
2.5.6 DNA preparation and experimental design for PCR 
 For Sequenom genotyping assays, 10-20 ng/µL of genomic DNA per reaction is 
recommended. All working stock was previously prepared at 20ng/µL and this concentration 
was used for all genotyping reactions. A 1uL volume of DNA was transferred from the 
working DNA stock into 384-well PCR reaction plates using a four-channel 10uL pipette. 
Plated DNA was then evaporated, sealed, and stored at −20°C prior to experimental use.  
 
2.5.7 Mix preparation for PCR 
 PCR mix was prepared for each plex in 1mL eppendorf tubes using the reagents 
described in Table 2.3 below (separate tubes for each plex). To account for possible pipetting 
loss 25% extra volume was added (Table 2.3). Volumes were adjusted for a maximum plex 
level of 24 and for half of one 384-well reaction plate, assuming dry DNA is used. All reagents 
were thawed at room temperature then mixed gently before centrifuging (1500 rpm for 1 
minute) prior to use. Due to its unstable nature, the Hot Star Taq enzyme was kept at a low 
temperature and so all reagents were placed on ice throughout preparation. 
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Table 2.3  PCR reaction cocktail solution preparation  
(25% excess volume prepared to allow for pipetting loss) 
Reagent Volume for single reaction Volume for one 24-plex  
(1/2 384 well) 
Nanopure water 2.85µl 684.00µL 
PCR Buffer (10x) 0.625µl 150.00µL 
MgCl2   (25mM) 0.325µl 78.00µL 
dNTP mix (25mM) 0.10µl 24.00µL 
Primer mix (0.5µM) 1.00µl 240.00µL 
Hot Star Taq (5 U/µl) 0.10µl 24.00µL 
Total volume 5.00µl 1200µl 
 
 
 
2.5.8 Transfer of PCR mix and PCR reaction per plex  
 A 5uL aliquot of PCR mix was added to each well of the 384-well reaction plate 
containing dry DNA.  Separate DNA plates were prepared for each plex. One 384-well plate 
generally consisted of two plexes, with half a plate dedicated to each plex. For one plex 
1200uL PCR mix was first transferred into one row of a 96 well plate (total volume of mix 
divided into 8 columns), and 5uL was then transferred to the 384-well reaction plate using a 
multichannel 10uL pipette. The reaction plate was sealed with adhesive PCR film (AB-0558) 
to prevent evaporation and to allow plate to be spun down in a centrifuge (2000rpm for 2 
minute). This ensured the solutions were at the bottom of the wells and any air bubbles were 
removed. 
 The pre-programmed PCR reaction on the G-Storm thermal cycler was then executed. 
The reaction volume was set to 7uL (additional 2uL accounted for air bubbles) and had a 
running time of approximately two hours and thirty minutes. The details of the cycling 
program are summarised below: 
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Cycle program  
1 cycle:  5 min  94°C  (initial denaturation) 
45 cycles:   20 sec 94°C  (denaturation)  
   30 sec 56°C  (annealing)  
   1 min  72°C  (extension)  
1 cycle:  3 min  72°C  (final extension)   
Final step:   indefinite  5°C  (hold) 
 
Once completed, the 384-well plate was removed, sealed with the AB-0558 film, centrifuged 
(2000 rpm for 2 minutes) and stored at 4°C until required. 
 
2.5.9 Post PCR cleanup 
 Treatment with SAP is performed after a PCR reaction in order to remove any 
remaining, non-incorporated dNTPs from the amplification products. SAP dephosphorylates 
unincorporated dNTPs by cleaving the phosphate groups from the 5′ termini, thereby rendering 
them inactive for future reactions. The SAP enzyme solution was prepared for each 384-well 
plate, according to Table 2.4. All reagents were defrosted at room temperature then mixed 
gently before centrifuging (1500 rpm for 1 minute). The reagents were placed on ice 
throughout the solution preparation. 
 
 
Table 2.4  SAP solution preparation (38% excess volume for any pipetting loss) 
Reagent Volume for 
single reaction 
Volume for 384-well plate 
Nanopure Water 2.85µl 1368.00µL 
hME Buffer (10x) 0.625µl 300.00µL 
Shrimp alkaline phosphatase  (SAP) 0.325µl 156.00µL 
  
 
 
 This procedure was performed on a post-PCR automated Matrix Liquid Handler robot 
using the SAP addition program. Prior to running any program on the Matrix Liquid Handler 
robot, a weekly maintenance protocol was performed as stated in the manufacturer’s 
guidelines. A new tip magazine was inserted into the robot for each new program that was 
performed. A liquid handler tip wash program was also initiated prior to running any post-
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PCR program. To transfer the SAP enzyme solution into the 384-well PCR plate, firstly a 96 
well plate was prepared with 10uL of SAP in each well. The Liquid Handler robot SAP 
program was then used to dispense 2μl of the SAP cocktail from the 96-well microplate into 
each individual well of the 384-well post-PCR reaction plate. After SAP cocktail addition, the 
plate was removed from the robot, sealed using the AB-0558 PCR film and centrifuged (2000 
rpm for 2 minutes). SAP treated plates were then placed on the G-Storm thermal cycler for a 
50 min incubation as detailed below. The final reaction volume used was 9µL (additional 2µL 
added to account for air bubbles).  
 
 
1 cycle:  40 min  37°C 
1 cycle:  10 min  85°C 
Final step:  indefinite  4°C      
   
 
 Once the SAP enzyme reaction was completed, the 384-well PCR reaction plate was 
sealed using AB-0558 film, centrifuged (2000 rpm for 2 minutes), then stored at 4°C until 
ready to process for the iPLEX Gold primer extend procedure. 
 
2.5.10 iPLEX Gold primer extend reaction 
 The iPLEX primer extend reaction is a method for detecting single base polymorphisms 
in amplified DNA. Extension primers, buffer, enzyme, and mass-modified dNTPs are added 
to the amplification products. Each extension primer anneals directly 5’ to the SNP locus and 
is extended by one mass-modified nucleotide (present in the iPLEX termination mix) based 
on the alleles present. This results in single base elongation with a corresponding mass increase 
that is measured using the MALDI-TOF MassARRAY platform and SNP genotype assigned 
accordingly. 
 
2.5.11 Primer pooling and dilution 
 A four-step adjustment method based on primer concentration was used for pooling the 
extension primers into multiplexed pools (Table 2.5). Due to the inverse relationship between 
peak intensity and analyte mass, the iPLEX extension primers required adjustment by 
concentration in order to ensure that they were as equal in intensity as possible. For this, the 
primers were adjusted by dividing each plex into four concentration groups based on primer 
mass. The highest mass group was diluted to 7μM, the next groups to 9.3 μM and 11.66 μM, 
and the lowest mass group to 14 μM, as shown in the Table 2.5 below. All diluted working 
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stocks and concentrated stocks of primers were stored at −20°C.  
 
Table 2.5. Preparation of iPLEX Gold Extend primers (total volume 500μL) 
Extension 
primer group 
Final 
concentration/ 
primer 
Volume / primer 
 
24-plex (6 primers) 
(μl) 
1 7μM 8.75μL 52.50 
2 9.3μM 11.63μL 69.78 
3 11.66μM 14.58μL 87.48 
4 14μM 17.5μL 105.00 
Total volume of nanopure water to add (final volume500μL) 185.24μL 
 
 
2.5.12 Cocktail preparation 
 The iPLEX reaction cocktail was prepared for each plex as described in Table 2.6 below. 
Volumes shown are for half of one 384-well plate. All reagents were defrosted at room 
temperature, mixed, centrifuged gently (1500 rpm for 1 minute) and kept on ice throughout 
the cocktail preparation procedure. 
 
 
Table 2.6. iPLEX Gold extend reaction cocktail solution preparation  
   (38% excess volume for any pipetting loss) 
Reagent 
Volume for single 
reaction 
 
Volume for one plex 
Nanopure Water 0.755µl 200.05µl 
iPLEX Buffer (10x) 0.2µl 52.99µl 
Primer mix (0.5µM) 0.2µl 52.99µl 
iPLEX Termination mix 0.804µl 213.03µl 
iPLEX Enzyme 0.04µl 10.6µl 
Total volume 2.0µl 529.67µl 
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2.5.13 Cocktail transfer 
 10uL of the iPLEX cocktail was first added to each well of a 96-well plate and 2 μl of 
the cocktail was subsequently added to each well of the 384-well post-SAP reaction plate using 
the liquid handling robot. After cocktail addition, the plate was sealed using AB-0558 PCR 
film and centrifuged (2000 rpm for 2 minutes) to bring the solution to the bottom of the wells 
and remove any air bubbles before running the extend reaction.  
  
2.5.14 Primer extend 
 The 384-well reaction plate containing the iPLEX cocktail was then placed in the G-
Storm Thermocycler and the iPLEX extend reaction was executed. The reaction volume was 
set to 11uL (additional 2µL added to account for air bubbles). The details of the iPLEX Gold 
extend reaction cycle are summarised below. 
    
  
 
 
Thermal cycling primer extend reaction 
 
Number of cycles  Time  Temperature process   
1 cycle:   30 sec  94°C  (initial denaturation)  
 
40 cycles:   5 sec     94°C (denaturation)  
  5 cycles: 5 sec    52°C (annealing)     
    5 sec     80◦ C (extension)   
1 cycle:   3 min    72°C (final extension) 
Final step:   indefinitely    4°C (hold) 
 
(Note that the 5 cycles sit within the 40 cycles) 
 
Upon completion of the extend reaction cycle, the plate was centrifuged for 2 minutes at 2000 
rpm and stored at 4°C. 
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2.5.15 Post iPLEX reaction conditioning 
 The conditioning or clean-up of iPLEX Gold reaction products is a crucial step for 
optimising the mass spectrometry analysis. SpectroCLEAN is a cationic resin pretreated with 
acid reagents that is added to primer-extend reaction products to remove salts such as Na+, K+, 
and Mg2+ from unincorporated products from the reaction. If not removed, these ions can result 
in high background noise in the mass spectra, thus increasing the likelihood of false data.  
 The SpectroCLEAN resin was transferred from its container to a 384-well dimple plate 
using an elongated spoon and then spread across the whole plate using a plastic scraper. Excess 
resin was then scraped away from the plate and placed back into the original container. The 
resin was then allowed to dry for 15 minutes. Whilst the resin was left to stand, the Matrix 
liquid handler robot was used to add 16µl of Nanopure water to each well of the 384-well post-
iPLEX reaction plate. Once the water addition was complete, the 384-well PCR plate was 
sealed and again centrifuged (2000 rpm for 2 minutes).  
 After removing the plate seal, the 384-well reaction plate was turned upside-down and 
gently placed on top of the resin dimple plate. Holding the sample plate and the dimple plate 
together, they were then both gently flipped over to allow the resin to fall out of the dimple 
plate into the wells of the 384-well reaction plate. The dimple plate was then tapped gently 
until all the resin fell out into the wells of the 384-well reaction plate. Each well was manually 
checked for resin addition. The plate was sealed using AB-0558 PCR film and secured 
between two polystyrene blocks of the Heidolph®-Reax 2 rotator, and rotated for 10 minutes 
on the lowest setting (level 1), to allow the resin to mix thoroughly with the reaction plate 
products. Once completed, the 384-well PCR plate was centrifuged for five minutes at 3000 
rpm to allow the SpectroCLEAN resin to settle down into the wells.  
 
2.5.16 Mass spectrometry 
 The manufacturer’s protocol was followed for arraying the extended products from the 
384-well reaction plate on to a 384-sample SpectroCHIP using the MassARRAY 
Nanodispenser instrument. A small volume (∼25nl) was arrayed by the dispenser onto the 
existing matrix spots on the SpectroCHIP for MALDI-TOF analysis. This process involved 
the capillary action of slotted pins and contact dispensing for nano-volumes (Gabriel et al., 
2009). 
 
2.5.17 MassARRAY spectroscopy methodology 
 The Sequenom MassARRAY MALDI-TOF platform and Sequenom real-time software 
was used in order to detect the extended products. The spotted SpectroCHIP was placed in the 
scout plate (chip holder) of the mass spectrometer, introduced to the MassARRAY reader, and 
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then placed on vacuum and the analyser software started (FlexControl, ServerControl, 
MassARRAY Spectro Caller 3.4, SpectroAcquire 3.4, Typer ChipLinker).  
 A virtual experimental plate was created using Plate and Assay editor on the 
MassARRAY® Spectra Typer software. Typer produces spectral data acquired from 
SpectroCHIPs and analyses each spectrum based on the assay or assays applied to it. An assay 
establishes where mass peaks are expected in a spectrum and how to interpret each peak. Typer 
automatically identifies the genotype in genotyping experiments based on the peaks present in 
a spectrum. Individual samples and assays appropriate for a particular experiment were 
assigned to each well on the virtual plate.  
 The Chiplinker software was used to connect the virtual chip layout created to the chip 
being analysed. Once files were created on ChipLinker software, this was linked to the 
SpectroAcquire software that controls the mass spectrometer and acquires spectral data. The 
total time for detection of one SpectroCHIP is 30 to 60 minutes. Spectral data is automatically 
sent to the MassARRAY Typer Server. These are then analysed by Typer, which combines 
the base caller with a clustering algorithm. 
 
2.5.18 MassARRAY reaction  
 The general principal of the MassARRAY platform is to use MALDI-TOF mass 
spectrometry to determine differences in primer masses due to changes in sequence, i.e. the 
incorporation of different terminator nucleotides at the 3’ end of a primer bound adjacent to a 
variant site (Gabriel and Ziaugra, 2004, Gabriel et al., 2009). The mass spectrometry system 
involves the laser treatment of the spotted sample under vacuum by the MALDI-TOF method. 
This method is a modified version of a standard mass spectrometry technique that involves the 
absorption of most of the incident laser energy, allowing the de-absorption and the ionisation 
of large biomolecules such nucleic acids with minimal damage and ion fragmentation. High 
transmission and sensitivity, along with theoretically unlimited mass range, are some of the 
main advantages of TOF instruments. The theory behind the stages of the MALDI-TOF 
process is described briefly below: 
 
Sample irradiation and ionisation: The spotted samples (embedded in crystalline structure or 
matrix of small organic compounds) are irradiated with a nanosecond of ultraviolet laser 
(wavelength 337 nm). The laser energy causes structural decomposition of the irradiated 
crystal (ionisation) and generates a rapidly expanding matrix cloud.  
 
Electrostatic acceleration: Once the sample molecules are vaporised and ionised, they are 
transferred into a time-of-flight mass spectrometer, where they are separated from the matrix 
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ions by an electric field that results in the disintegration of the crystal molecules. Following 
acceleration through an electric field, the ions drift through a field-free path and finally reach 
the detector in the form of a secondary electron multiplier.  
 
Detection of ions using TOF: The ions are individually detected based on their mass-to-charge 
(m/z) ratios and analysed. Ion masses (m/z ratios) are calculated by measuring their flight time, 
which is longer for larger molecules and shorter for smaller molecules.    
 
2.5.19 Genotyping quality control  
 In addition to the quality control (QC) procedures applied to the sample processing it 
was also necessary to apply separate quality checks on the outputted genotype data, as 
described below. Any samples that failed these QC measures were re-genotyped on a single 
384-well plate, where practicable.   
 
Negative control wells: The control wells (no DNA added) that were included in each 384-
well reaction plate were first inspected to check for contamination. This would indicate false 
positive results and unreliability in the calls assigned to the surrounding samples.  
 
Positive control wells: The duplicate samples that were included in each reaction plate were 
checked for consistency of genotype calls. Any duplicate samples for which there were 
inconsistencies in the assigned genotypes were marked for exclusion from the data analysis. 
The spectra for these samples were also checked to assess the quality of the peaks from which 
bases are called, prior to exclusion.  
 
Spectra check: The Typer software provides a genotype call and spectrum for each sample. 
Each sample spectrum is annotated with the expected location of allele peaks and the un-
extended primer peak. In some cases, contaminant peaks are also indicated. The spectra of 
samples that i) failed genotyping, ii) were either negative or positive controls, and iii) required 
repeating were all checked to assess sample genotyping quality.  
 
Cluster graph check: The cluster graphs that are produced for each assay were examined 
carefully to assess the quality of genotyping of a particular assay. Cluster graphs are useful as 
they provide a visual description of genotype calls for an assay on a SpectroCHIP, thus they 
can help to determine if an assay is reliable. If there were chemistry problems with an assay, 
they usually appear in these cluster graphs. The cluster graphs were also checked before any 
manual calling decisions. 
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Histogram check: the Typer software produces a single histogram summarising the success of 
all included assays. For each experimental run this summary histogram was checked for a 
quick overview of all problematic assays (assays with a large failure percentage).  
 
Manual calling for all failed samples and inconsistencies: For any samples that i) failed 
genotyping (i.e. those for which the software was unable to assign a genotype) or ii) samples 
for which the assigned genotype was questionable, (i.e. negative and positive control samples) 
the spectra were reviewed and genotypes manually assigned where possible. 
 
2.5.20 Pre-analysis quality control 
 Before the genotype data for an experiment was analysed, all data that survived the 
above genotype quality control checks was subject to the following data quality checks: 
 
Patient success: Typically, patients with less than 90% call rate for all genotyped SNPs (i.e. 
with genotype data at fewer than 90% of typed loci) were excluded. 
 
SNP success: Typically, individual SNP assays with a call rate of less than 90% (i.e. 
successfully typed in fewer than 90% of patients) were excluded. 
 
Hardy-Weinburg equilibrium and minor allele frequency: Each of the remaining SNPs were 
tested for deviation from Hardy-Weinberg equilibrium (HWE) using Haploview software 
version 4.1 (Barrett et al., 2005). In general a p-value of less than 0.001 was assumed to 
indicate deviation (a significant difference between observed and expected genotype 
frequencies), and such SNPs were excluded from data analysis. SNPs with a MAF of less than 
0.001 as calculated by the Haploview software, were too low for the reliable detection of any 
genetic association and were also excluded from the analysis. 
 
Comparison of minor allele frequencies to the general population: The frequency of the 
polymorphic allele for each assay was compared to that of the general population (manual 
comparison using frequencies from HapMap), in order to confirm the reliability of the 
genotyping and that the sample population was representative of the general population in 
terms of their genetic structure. 
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2.6 Data analysis 
2.6.1 Statistical analysis 
  The majority of statistical analyses were performed using SPSS software (version 
18.0; SPSS Inc., Chicago, IL, USA). Specific tests performed for each study varied and details 
of these, including the use of additional statistical software can be found within each results 
chapter.  Correction for multiple testing was undertaken by calculation of the false discovery 
rate (FDR) for each test (Benjamini et al., 2001) using the ‘p.adjust’ function in the statistical 
package R, with an FDR <0.05 deemed statistically significant (R Development Core Team 
(2010).)  
 
2.6.2 Bioinformatics analysis 
 Several freely available online tools were used for the purpose of predicting the potential 
biological significance of any associations with genetic variants identified from the statistical 
analysis for each of the studies. This included the use of online genomic databases described 
previously (section 2.4.1) and additional databases specifically allowing the search for TFBSs 
and regulatory regions and/or predicting functional changes in protein coding regions (Pang 
et al., 2009).  
 
2.6.2.1 Fast SNP and PupaSuite  
 Several tools exist to predict regulatory regions and then cross check them with 
databases of known SNPs to highlight which SNPs fall in these regions. These include the 
freely available and widely used Function Analysis and Selection Tool for Single Nucleotide 
Polymorphisms (Fast SNP) (Yuan et al., 2006) and Pupa Suite (Conde et al., 2006), which 
were the main two tools used in the present studies. Each tool uses different means to predict 
the regulatory regions. These tools run programs such as splicing site enhancers (ESE)-Finder 
and Transfac (for locating TFBS) for both the wild type and the variant sequences and check 
whether they differ in their results, i.e. whether one has a predicted ESE within it and the other 
not.  
 PupaSuite (http://pupasuite.bioinfo.cipf.es/) retrieval of the location of SNPs in TFBS, 
ESE, splicing site silencers (ESS), and splice sites (SS) using both Transfac and JASPAR, 
ESE-Finder3.0, ExonScan and GeneID respectively. Fast SNP is a web server that allows users 
to efficiently identify SNPs of potential biological significance according to twelve phenotypic 
risks and putative functional effects, such as changes to the transcriptional level, pre-mRNA 
splicing, protein structure, etc. Fast SNP can be used to find SNPs in genomic and mRNA 
sequences using the following tools; ESS (FAS-ESS), ESE (both Rescue-ESE and ESEfinder), 
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TFBS (TFSearch), and Polymorphisms Phenotyping (PolyPhen) to look at non-synonymous 
SNPs in protein sequences. 
 
2.6.2.2 Predicting presence and functional consequences of 
variants; coding, promoter region, intronic and 
synonymous 
 TFBSs can be found within both promoter and intronic regions of DNA. All non-coding 
variants of potential interest were evaluated for the presence of putative binding sites of known 
transcription factors (TFs) using the following search databases: Transcription Element Search 
System (TESS, http://www.cbil.upenn.edu/tess) and Fast SNP (http://fastsnp.ibms.sinica.edu 
.tw/pages/input_CandidateGeneSearch.jsp). Fast SNP identifies and predicts changes in TFBS 
regions using the TF search tool. 
 The effect of non-synonymous or coding variants on protein function were predicted 
using Sorting Intolerant From Tolerant (SIFT) and Fast SNP. SIFT (http://sift.jcvi.org/) uses 
a sequence alignment method to measure conservation of each amino acid, predicting whether 
a coding SNP will affect protein function (by calculating a scaled probability for the amino 
acid substitution using sequence homology and the physical properties of amino acids). Fast 
SNP utilises the PolyPhen tool for predicting protein structural changes and these predictions 
are based on physical and comparative considerations that estimate the impact of the amino 
acid change on the 3D structure and function of the protein. Fast SNP was also the main tool 
used for analysis of all intronic and synonymous variants in order to assess their potential 
effect on regulatory regions.  
 
2.6.2.3 Machine learning and SAS Enterprise Miner  
 For two of the research studies presented in this thesis (those consisting of a large 
number of SNPs; over 1000), in addition to standard parametric statistical analysis methods 
for detecting genetic association, a ML data-mining approach was adopted in order to i) build 
predictive models through extracting patterns from the large genomic data available, ii) as a 
more appropriate method for analysing high-dimensional and complex genomic data-sets. 
Several well-known ML models were utilised for this, each of which are described in the 
corresponding chapters for these studies (Chapter 5 and 6). In house-software was utilised for 
the ML approach used in Chapter 5 (Petrovski et al., 2009). The additional ML models used 
in Chapter 6 were generated and assessed using SAS® Enterprise Miner data-mining software. 
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3.1.  Introduction 
CBZ is a widely used AED that has been employed as first-line treatment for partial and 
generalised tonic-clonic seizures for over 40 years (Brodie and Dichter, 1997). Like many 
older AEDs, CBZ undergoes predominantly hepatic metabolism and has a recognised 
therapeutic concentration range (Kwan and Brodie, 2001a). It also demonstrates considerable 
inter-individual variability in terms of PK and dosing requirement for effective seizure control, 
with maintenance doses in clinical practice often ranging from 200 to 2000 mg/day (Kwan and 
Brodie, 2001a).    
  
3.1.1 Antiepileptic drug dosing  
Therapeutic doses of AEDs are less well defined than those of drugs prescribed in many 
other disease areas and are typically influenced by titration regimen (Shorvon, 2004). Current 
monotherapy treatment with CBZ involves slow titration of the drug over a six-week period 
to a modest target dose (usually 600mg/day), with subsequent dosage adjustment according to 
clinical response (Shneker and Fountain, 2003). This approach is, however, sub-optimal for 
many patients. Those with a low CBZ dose requirement may develop early adverse effects 
including possible hypersensitivity reactions, whereas those with a high dose requirement are 
likely to be under-dosed for a significant period and subject to ongoing seizure activity. Sub-
optimal dosing may also lead to patients switching to alternative AEDs to achieve an adequate 
response without the complete dosage range being fully explored (Perucca, 2001a).  Thus, 
determining the dose of CBZ that provides maximal seizure control with minimal adverse 
effects for individual patients can be challenging and quality of life is often compromised until 
this is achieved (Depondt, 2006b, Depondt and Shorvon, 2006).    
 There is increasing awareness that dose requirements of AEDs vary greatly from one 
patient to another. This variability has led to the rejection of a standard dose approach to 
treatment and requires consideration of tailored drug therapy (Shorvon, 2004). Development 
of individualised dosing strategies for AEDs such as CBZ has the potential to improve the 
treatment of epilepsy by providing more prompt seizure control and safer drug initiation.  
 
3.1.2 Variability in carbamazepine pharmacokinetics  
For most AEDs, the serum concentration at any given dose can vary up to 50-fold 
between individuals (Perucca et al., 2001). Inter-individual variability in dose requirement 
results, at least in part, from variability in PK factors (Perucca, 2001a) that can be monitored 
through measurements of serum drug concentration (Perucca et al., 2001). Therapeutic drug 
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monitoring (TDM) has been used widely in epilepsy for improving drug efficacy and 
tolerability and promoting individualization of therapy (Nagasawa and Nakahara, 1992). 
However, not all current AEDs are candidates for TDM; the newer-generation of AEDs are 
thought to possess more linear PK and are less likely to cause drug-drug interactions (Clarke 
and McMillin, 2006, Anderson, 2008). Moreover, there remains disagreement regarding the 
value of TDM in routine AED treatment (Perucca et al., 2001, Johannessen et al., 2003).
 Numerous factors are known to influence the serum concentrations and dose 
requirements of therapeutic agents, including age, gender, body weight and co-medications 
(Levy, 2002, Battino et al., 2003, Engel and Pedley, 2008). These patient-specific influences 
on drug PK are reasonably well characterised for AEDs, although their clinical utility is 
generally limited (Perucca et al., 2001, Perucca, 2002b). Variability in PGx genes, i.e. those 
encoding drug transport proteins, metabolic enzymes, and drug targets, are also increasingly 
recognised as contributors to PK heterogeneity (Kirchheiner and Seeringer, 2007).  
 
3.1.3 Variation in metabolising enzymes as determinants of dosing 
Genetic polymorphisms are known to affect the metabolism of many drugs 
(Weinshilboum, 2003, Kirchheiner and Seeringer, 2007, Bhathena and Spear, 2008). This 
contribution to variability in drug metabolism may be reflected in differences in clearance, 
half-life and maximal plasma concentrations and can be corrected by genotype-based dose 
adjustments (Ma et al., 2002, Kirchheiner and Brockmoller, 2005, Crowley et al., 2009). The 
effect of polymorphic metabolism is particularly evident for substrates of CYP isoform 2D6, 
an enzyme that displays a variety of genetically determined phenotypes, including poor, 
intermediate, extensive, and ultra-rapid metabolism (PM, IM, EM and UM, respectively) 
(Wilkinson, 2005, Kirchheiner and Seeringer, 2007). Although none of the current AEDs is a 
substrate for CYP2D6, many undergo extensive Phase I hepatic metabolism mediated by at 
least eight other members of the CYP superfamily (Klotz, 2007). Figure 3.1 below presents 
the main pathways of metabolism known for CBZ (Pearce et al., 2008).   
 CBZ mainly undergoes hepatic metabolism (Eichelbaum et al., 1985), predominantly 
mediated by CYP3A4 and CYP3A5 enzymes (Tomson et al., 1983, Saruwatari et al., 2010). 
Other CYP contributors include CYP1A2 and CYP2C8, with an additional role of the Phase 
II UGT2B7 enzyme, while its principal active metabolite, CBZ-10,11-epoxide (CBZ-E), 
undergoes biotransformation mediated by mEH (Tomson et al., 1983, Saruwatari et al., 2010). 
All of these enzymes have known polymorphisms that potentially influence their metabolic 
activity and could theoretically impact on the PK of CBZ (Kirchheiner and Seeringer, 2007, 
Saruwatari et al., 2010).  
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Figure 3.1 Metabolic pathways and proposed metabolites of carbamazepine 
The main metabolic pathways of carbamazepine and the major metabolites formed during its 
metabolism are shown (separated by boxes). Some of the enzymes proposed to be involved in 
these biotransformation pathways are also highlighted. Figure adapted from Pearce, Lu et al 
2008. 
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3.1.4 Effect of CYP450 variants on carbamazepine pharmacokinetics          
A good example of the functional consequence of AED metabolism by polymorphic 
CYP enzymes is that of PHT and the CYP2C9 and CYP2C19 isoforms (Saruwatari et al., 
2010, Cavalleri et al., 2011). The genes encoding CYP2C9 and CYP2C19 have well-
characterised functional variants that exhibit different drug metabolism phenotypes, similar to 
that of CYP2D6 (Klotz, 2007). Several studies have demonstrated that individuals with 
defective alleles for CYP2C9 or CYP2C19 have reduced PHT metabolism, leading to both a 
lack of efficacy with PHT treatment and in many cases drug toxicity (Klotz, 2007, Anderson, 
2008, Loscher et al., 2009). Other AEDs, including PB, diazepam, VPA and ZNS that are 
substrates for CYP2C9 and/or CYP2C19 have likewise shown reduced metabolism rates in 
individuals with *2/*3 alleles, when compared to those with the wild-type CYP allele (Klotz, 
2007, Anderson, 2008, Seo et al., 2008a, Loscher et al., 2009, Saruwatari et al., 2010).  
 In addition to the CYP2C enzymes, recent PGx evidence has implicated a known 
functional polymorphism in CYP3A5 with altered serum concentrations of CBZ (Park et al., 
2009, Meng et al., 2011) and a lower dose requirement during CBZ treatment (Meng et al., 
2011). CYP3A5*3 SNP (rs776746) encodes a truncated non-functional protein causing a loss 
of CYP3A5 enzymatic activity (Kuehl et al., 2001, Lin et al., 2002, Yamaori et al., 2004) and 
has been associated with altered PK parameters of several CYP3A substrates (Huang et al., 
2004).  
 
3.1.5 Phase II metabolism of carbamazepine 
Further evidence for potential genetic influences on the hepatic metabolism of AEDs has 
recently emerged for UGT2B7 (Chung et al., 2008, Blanca Sanchez et al., 2010). The UGT2B 
enzyme family is highly polymorphic, containing several well characterised functional 
polymorphisms (Burchell, 2003), and may be responsible for inter-individual variation in the 
detoxification of metabolites, including several carcinogens (Desai et al., 2003). In addition to 
CBZ, UGT2B7 also contributes to the glucuronidation of LTG, VPA, OXC and ZNS (Staines 
et al., 2004, Rowland et al., 2006, Chung et al., 2008). The functional UGT2B7*2 variant is 
associated with enhanced metabolism of some opioids and has also been suggested to increase 
the area under the curve (AUC) of VPA (Chung et al., 2008, Blanca Sanchez et al., 2010). A 
UGT2B7 promoter region variant (UGT2B7 -161C>T), believed to be in LD with the 
UGT2B7*2 SNP, has also been reported to alter serum AED concentrations (Blanca Sanchez 
et al., 2010). In this report by Blanca Sanchez and colleagues, the UGT2B7*2 variant was 
associated with LTG concentration/dose ratio in a multivariate model adjusted for potentially 
confounding factors such as age and co-medication with VPA and was found to explain 12% 
of the dose variation (Blanca Sanchez et al., 2010). Although this association was modest in 
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terms of effect size, it is the first study to implicate genetic variations in UGT enzymes with 
variability in AED PK (Chung et al., 2008, Blanca Sanchez et al., 2010).   
 In contrast to UGT2B7, the phase II enzyme mEH has been the focus of several AED 
gene-association studies (Cavalleri et al., 2011). Increasingly, research has shown that 
haplotypes in LD blocks are more precise for detecting un-observed phenotype–genotype links 
than individual SNPs (Zhang et al., 2002, Nakajima et al., 2005). Haplotypic variation within 
the EPHX1 gene encoding mEH has been reported to correlate with plasma concentrations of 
the CBZ metabolites CBZ-diol and CBZ-E in a Japanese study. The CBZ-diol to CBZ-E ratio 
differed greatly depending on the number of variant alleles of two known EPHX1 non-
synonymous polymorphisms: EPHX1-Try113His (337T>G; rs1051740) and EPHX1-
His139Arg (416A>G; rs2234922) (Nakajima et al., 2005). Ratios increased significantly with 
337T>G-bearing haplotypes and decreased significantly with 416A>G-bearing haplotypes 
(Nakajima et al., 2005). These known functional polymorphisms have since been associated 
with maintenance dose in a CBZ monotherapy study when considered in a multivariate model 
with age (Makmor-Bakry et al., 2009).       
 The handful of association studies that have correlated AED PK with genetic variation 
in DMEs suggest that this is an important area that merits further investigation with regard to 
individualization of AED dosing. Relatively few drugs and their corresponding metabolic 
pathways have been explored to date. Those studies that have reported genetic associations 
with dose or PK require replication to verify those associations and provide more definitive 
evidence that the observed effect is real and of sufficient magnitude to be considered clinically 
useful and implementable in a genotype-based dosing strategy.  
 
3.2 Aims 
The principal aim of the study presented in this chapter was to assess the degree to which 
genetic variation in drug metabolism contributes to CBZ dose requirement when used as 
monotherapy in newly treated epilepsy. An association analysis of common variation across 
genes encoding CBZ metabolising enzymes was performed, capturing variation by applying a 
gene-wide tagging methodology and undertaking a haplotype analysis to determine whether 
multiple variants in combination can be used to more successfully identify associations. A 
secondary aim was to use this analysis to validate a previous study that reported a significant 
influence of two functional variants (rs1051740 and rs2234922) in the EPHX1 gene on CBZ 
dosing (Makmor-Bakry et al, 2009). 
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3.3 Methods 
3.3.1 Selection criteria for patient inclusion and study population 
Individuals were selected for the study from both SANAD and Glasgow cohorts on the 
basis of strict inclusion criteria. Patients were required to have a new or recent (within 3 years 
at the time of CBZ initiation) diagnosis of epilepsy and to have achieved optimal seizure 
control (defined as no seizures for a period of at least 12 months) on a fixed dose of CBZ 
monotherapy. This was subsequently referred to as the CBZ maintenance dose. Maintenance 
dose was defined as the uppermost stable dose or unchanged dose over the 12-month seizure-
free period. The study population comprised 77 patients from the SANAD cohort and 90 
patients from the Glasgow cohort (Table 3.1).  
 
3.3.2 Clinical data collection 
Non-genetic information for each patient was extracted from clinical databases, hospital 
notes or clinical trial folders, as appropriate. This included age (at the start of the 12 month 
seizure-free period), sex, epilepsy type and CBZ maintenance dose. Epilepsy type was defined 
as IGE, LRE, or UNC.  
 
3.3.3 Candidate SNP selection 
The aim of candidate SNP selection was to find common genetic variation within DMEs 
relevant to CBZ metabolism that might potentially affect dose requirement. A total of six genes 
were targeted; CYP1A2, CYP2C8, CYP3A4, CYP3A5 (encoding the corresponding CYP 
enzymes), EPHX1 (encoding mEH) and UGT2B7 (encoding the corresponding UGT enzyme).  
 
3.3.4 The International HapMap project 
The objective of the International HapMap Project (www.hapmap.org) was to identify 
and record all genetic differences and similarities within human subjects. This involved 
genotyping at least one common SNP every 5 kilobases (kb) across the genome in 270 
individuals from geographically diverse populations, including the Yoruba people from 
Ibadan, Nigeria, Caucasians of north and west European descent from the Centre d'Etude du 
Polymorphisme Humain (CEPH) research in the USA, 45 unrelated individuals from Beijing, 
China, and 45 unrelated individuals from Tokyo, Japan. The results of the project are freely 
available to researchers for use in genetic association studies. 
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Table 3.1 Characteristics of the carbamazepine patient population       
Clinical characteristics of patients forming the study population included in the analysis* 
(n=159) reported by source cohort and in combination. 
              COHORT 
  SANAD 
 (n=71)  
Glasgow  
(n=88) 
Combined  
(n=159) 
Age (years) Minimum 6 13 6 
 Median 36 32 35 
 Maximum 78 68 78 
Gender (n) Male 38 42 80 
 Female 33 46 79 
Epilepsy type (n) IGE 1** 15 16 
 LRE 65 66 131 
 UNC 5 7 12 
CBZ maintenance  
dose (mg/day) 
Minimum 
 
400 
 
200 
 
200 
 
 Mean  
(± SEM) 
663 
(± 23) 
798  
(± 35) 
738 
 (± 23) 
 Maximum 1400 2000 2000 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy, CBZ = carbamazepine, SEM = standard error on the mean,*8 patients 
from the study population failed minimum genotyping criteria and were excluded     
** Difference in number of IGE patients between the two cohorts can be attributed to the 
design and purpose of the SANAD trial: (individuals with partial epilepsy forming larger 
Arm A; n=1721 and those with generalised and unclassified epilepsies forming smaller Arm 
B; n=716) 
  
 
 
3.3.5 SNP selection methodology 
The CEPH population data were interrogated for variation in all six DME genes using 
HapMap release # 24 (phase II Nov 08; NCBI build 36 assembly) and dbSNP on the NCBI 
website (www.ncbi.nlm.nih.gov). The reference genotyping data from HapMap was used to 
identify all known SNPs across each of the six genes that were present in individuals of 
Caucasian/European ancestry and with a MAF of at least 1%. Chromosomal positions of each 
gene were identified and coordinates extended by 10 kilobases upstream and downstream to 
include the 5’ and 3’ flanking regions. A list of tSNPs and putatively functional variants for 
each DME gene was then prepared, as described below.  
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3.3.6 SNP Tagging SNP approach for representing gene-wide variation 
 Candidate gene SNP association studies for complex traits need to screen a large number 
of SNPs to capture the potentially influential variation across the whole gene (Zhang and Sun, 
2005). However, this is an expensive and time-consuming option for what are often small-
scale studies (Johnson et al., 2001). In contrast, using a haplotype-tagging strategy in which a 
subset of SNPs, each of which acts as a marker for a genomic region (haplotype block) in 
which all variants are thought to be inherited together, reduces the number of SNPs required 
for genotyping (Hirschhorn et al., 2002, Zhang et al., 2002, Chapman et al., 2003). This 
reduces time and cost by avoiding typing redundant SNPs whilst maintaining sufficient 
coverage of genetic variation (Sabbagh et al., 2008).      
 The human genome can be divided into regions with low haplotype diversity and high 
LD, interspersed with regions of high haplotype diversity and low LD (Zhao et al., 2003). In 
regions of low haplotype diversity, typing a smaller number of markers or tSNPs would 
capture most of the haplotypic diversity due to LD between variants, and therefore, could 
potentially capture an association between a human trait and causal loci in each haplotype 
block (Chapman et al., 2003, Zhao et al., 2003). A tSNP is often in strong LD with several 
other SNPs. The assumption is thus that the tSNP selected for genotyping will capture all the 
other SNPs it tags (Zhao et al., 2003). The pairwise tSNP approach thus represents an indirect 
approach to identifying genetic association SNPs by utilising the LD between SNPs in close 
proximity and so it is usually not necessary to genotype all SNPs of interest (Shastry, 2004). 
The pairwise correlation coefficient (r2 statistic) is a commonly used measure to quantify the 
degree of association between two polymorphisms (Chapman et al., 2003, Zhao et al., 2003).   
 
3.3.7 Using Haploview and Tagger to generate a list of tagging SNPs 
Haploview (version 4.1) and Tagger (de Bakker, 2009) were used to select tSNPs that 
capture common variation and putative regulatory regions up and down stream (within 10kb) 
of the DME genes. Haploview is a program designed primarily for haplotype analysis and has 
several functions, including LD and haplotype block analyses, haplotype population frequency 
estimation, single SNP and haplotype association tests, and permutation testing for association 
significance (Barrett et al., 2005). The tagger function in Haploview contains an algorithm that 
performs tSNP selection using the pair-wise method (de Bakker, 2009).  
 
3.3.8 tSNPs and supplementary SNPs selected for genotyping 
For tSNP generation, Caucasian/European genotype data previously downloaded from 
HapMap release # 24 (www.hapmap.org; phase II Nov 2008) for each DME gene (±10kb) was 
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imported into Haploview (as to match the ethnicity of SANAD/GLASGOW study cohort). 
SNPs meeting the following criteria were used; i) MAF ≥ 5%, ii) HWE cut-off p-value > 0.001 
(Barrett et al., 2005), iii) SNP coverage of 80% (using r2=0.8 ensures at least 80% correlation 
between the tSNP and all of the SNPs it tags), iv) ≥80% HapMap genotyping data for each 
common polymorphism, and v) Mendelian inheritance errors in the HapMap CEPH population 
of no greater than 1. An additional set of SNPs with a particularly low MAF (≥ 0.1%) were 
chosen to allow the capture of more SNPs from coding regions and/or those reported in 
previous association studies. The pair-wise Tagger function was then executed.   
 A total of 52 tSNPs were identified across the six genes as follows: 1 from CYP1A2, 
13 from CYP2C8, 8 from CYP3A4, 4 from CYP3A5, 18 from EPHX1, and 8 from UGT2B7 
(Table 3.2). These were then supplemented with a further 42 SNPs (12 CYP1A2, 6 CYP2C8, 
3 CYP3A4, 5 CYP3A5, 12 EPHX1, 4 UGT2B7) reported as either being putatively functional 
in existing literature or located in gene regions with potential functional significance (i.e. exon, 
3’-UTR, 5’-UTR, promoter region, splice site and enhancer site region SNPs) and possessing 
a MAF ≥1% according to the NCBI SNP database (build 126) (Table 3.2). This resulted in a 
list of 94 candidate SNPs across each of the six DME genes being chosen for genotyping. A 
full list of all 52 tSNPs for these SNPs is provided in Appendix 1.3. 
 
 
 
Table 3.2 SNPs and tagging SNPs selected and genotyped for each candidate gene    
DME Gene No of tSNPs 
identified 
No of supplementary 
SNPs 
No of SNPs genotyped 
CYP1A2 1 12 13 
CYP2C8 13 6 19 
CYP3A4 8 3 11 
CYP3A5 4 5 9 
EPHX1 18 12 30 
UGT2B7 8 4 12 
DME = drug metabolising enzyme, No = number, SNPs = single nucleotide             
polymorphisms, tSNPs = tagging single nucleotide polymorphisms  
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3.3.9 Genotyping methods 
The online Sequenom MassARRAY iPLEX assay design software (https://mysequeno 
m.com/Tools/genotyping/default.aspx)(Gabriel et al., 2009) was used for primer and assay 
design for all 94 SNPs, as detailed in Section 2.5.3. Three SNPs (rs7438284, rs11773597 and 
rs45540739 from UGT2B7, CYP3A4 and EPHX1, respectively) were excluded during the 
assay design phase as a result of their predicted potential for cross binding and introduction of 
genotyping errors. These could not be accommodated in any of the five plexes or replaced 
with alternative tSNPs and were thus excluded from the analysis. In total, 91 SNPs within five 
multiplex assays (plexes 1-5), comprising panels of 23, 21, 21, 20 and 6 SNPs respectively 
were produced by the software (Table 3.3). DNA for all 167 patients was genotyped for the 
91 SNPs. PCR conditions and extension primer sequences are listed in Appendix 1.1. 
Genotyping was performed on the Sequenom MassARRAY iPLEX platform (Sequenom, 
Hamburg, Germany) as described in Chapter 2 and in accordance with the manufacturer’s 
instructions (Gabriel et al., 2009).  
 
 
 
Table 3.3 Assay design output of Candidate SNPs  
The 91 candidate SNPs selected for genotyping were placed into 5 SNP plexes by the 
Sequenom MassARRAY iPLEX assay design software 
DME gene SNPs 
 
PLEX 1 
(23) 
PLEX 2 
(21) 
PLEX 3 
(21) 
PLEX 4 
(20) 
PLEX 5 
(6) 
Total 
CYP1A2 2 3 3 4 1 13 
CYP2C8 9 3 3 4 1 20 
CYP3A4 2 3 5 - - 10 
CYP3A5 1 5 - 2 1 9 
EPHX1 7 4 7 8 2 28 
UGT2B7 2 3 3 2 1 11 
DME = drug metabolising enzyme, SNPs = single nucleotide polymorphisms  
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3.3.10 Processing of genotype data for quality control purposes  
A total of 10 positive control samples (duplicates) and two negative control samples 
(water blanks) were included per 384-well reaction plate for each experiment to improve 
reliability of genotype calls. Patient and sample QC measures, as described in section 2.5.20, 
were applied. There was also a purposeful reduction in data dimension prior to analysis in 
order to decrease the number of variables and limit the impact of correction for multiple 
testing. This was achieved by exploring LD structure across the SNP panel in the study 
population. For each pair of highly correlated SNPs (r2 ≥ 0.9), the variant with the fewest 
missing data was retained, whilst the other was excluded. A pair-wise correlation of r2 ≥ 0.9 
allowed accurate model fit with retention of the majority of genetic variation.  
 
3.3.11 Bioinformatics analysis 
In addition to exonic SNPs that may directly influence amino-acid sequence, many SNPs 
are also found in splice sites, enhancer or silencer sites, and TFBS (Pagani and Baralle, 2004, 
Schug, 2008, Kasowski et al., 2010) and may still affect protein expression and the 
transcriptional efficiency of protein coding genes (Prokunina and Alarcon-Riquelme, 2004, 
Pang et al., 2009). Since functional studies are usually time-consuming, they tend to be 
initiated only when a statistically significant association with a phenotype is already 
established and has been replicated (Prokunina and Alarcon-Riquelme, 2004, Pang et al., 
2009). Several online bioinformatics databases were used to predict potential functional and/or 
expression effects of SNPs (Pang et al., 2009). These included FASTSNP (Yuan et al., 2006), 
TESS (Schug, 2008), and SIFT (Ng and Henikoff, 2001, 2003, Ng et al., 2009). Ensemble 
Human Genome Browser and UCSC Genome Browser were also used to visualise and explore 
genetic variation within each of the six genes (see sections 2.4 and 2.7). 
 
3.3.12 Statistical analysis 
  Statistical analysis was performed as described in section 2.6. Haploview (version 4.1) 
was used for haplotype analysis and PHASE software (version 2.1) to infer likely haplotype 
pairs (Stephens et al., 2001, Stephens and Donnelly, 2003, Scheet and Stephens, 2006). 
 CBZ maintenance dose (expressed as mg/day) was the phenotype of interest in this 
analysis. It showed a skewed distribution (Figure 3.2) and was log-transformed to achieve 
normality and to allow parametric statistical testing. Source cohort (SANAD or Glasgow) was 
included as a covariate in the analysis to account for any fundamental differences in patient 
characteristics.  
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3.3.13 Non-genetic univariate association with carbamazepine dosage 
Testing for confounding non-genetic factors that may associate with dose was required 
to exclude their potential influence on inter-individual variability in dose. Initial analysis tested 
for association between CBZ maintenance dose and the following non-genetic variables; age 
at the start of the seizure-free period, sex, epilepsy type, and source cohort (SANAD and 
Glasgow). Univariate linear regression was used for testing age as a continuous variable, and 
analysis of variance (ANOVA) was used for analysing the categorical variables (sex, epilepsy 
type, source cohort and genotype). 
 
3.3.14 Single variant analysis 
All SNPs were analysed individually for association using regression statistics. A 
multiple linear regression model was built for non-genetic factors that proved significant 
(p<0.05) in the initial analysis. Thereafter, the regression model was re-fitted by the inclusion, 
as a covariate, of each of the individual candidate SNP genotypes included in the analysis in 
turn, assuming an additive mode of inheritance. The likelihood ratio test (LRT) was then used 
to compare the initial baseline model (containing non-genetic factors alone) with the genotype 
model (containing non-genetic factors and single SNP genotype), with adjustment for the 
potentially confounding non-genetic factors, to test for association between individual 
candidate SNPs and CBZ maintenance dose. A chi-square distribution test p-value was 
generated to assess the significance of any association. 
 
3.3.15 Haplotype analysis 
In addition to single SNP analysis, a gene-based haplotype analysis was also undertaken 
as an alternative means of detecting genetic associations with dose. As haplotype blocks define 
a region of a chromosome that is unlikely to undergo recombination, they provide greater 
power to detect likely causative alleles within large genetic data sets. In any DNA sample, 
there are two copies of each gene (one maternal and one paternal), which are typically 
different. Genotyping technologies, when applied to DNA from a diploid individual, are able 
to determine which two alleles are present at each locus but not which combinations of alleles 
are present on each of the two chromosomes. Such haplotype information or haplotype phase 
requires determination.         
 All genotype data was entered into Haploview, together with the chromosomal 
location for all SNPs (Barrett et al., 2005). The pattern of LD between each of the included 
SNPs and the haplotype blocks existing across all six genes was visualised using the solid 
spine of LD method for defining blocks of LD. Maximum likelihood estimates of haplotype 
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frequencies from unrelated individuals (the most likely haplotype pair at each block and its 
associated probability), were inferred for each individual using fastPHASE software (Stephens 
et al., 2001, Stephens and Donnelly, 2003, Scheet and Stephens, 2006). Quality control was 
subsequently performed on the generated data. Individuals in whom the fastPHASE assigned 
haplotype-pair had a probability of <90% were first excluded. A common haplotype occurs in 
a population with a frequency of at least 5%. All common haplotypes were included in the 
analysis and rare haplotypes (occurring at a frequency of less than 5%), were grouped together 
for analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Carbamazepine dose distribution  
Distribution of carbamazepine maintenance dose (mg/day) across the study population of 
n=159 individuals. Maintenance dose was defined as the uppermost stable or unchanged dose 
over a 12-month seizure-free period.  
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To test for association between CBZ maintenance dose and variation at each haplotype 
block, a regression-based approach was again employed, where the baseline model was 
compared to the haplotype model using the LRT and again assuming an additive mode of 
inheritance. The haplotype model was the same as the baseline model but in addition to non-
genetic factors this included covariates to represent the haplotype pair assigned to the SNPs 
within the haplotype block for each individual. Further study of each of the phase-generated 
haplotypes across the gene-based haplotype block was only considered if a statistically 
significant association (p<0.05 after FDR) was identified in the initial regression analysis of 
the haplotype blocks.  
 
3.4 Results 
Of the 91 SNPs selected and genotyped, 15 failed genotyping due to an unsuccessful 
PCR and/or iPLEX reaction, 14 had a MAF <0.001, 3 deviated from HWE (HWP=<0.001), 
and 1 was monomorphic (Appendix 1.2). These were excluded from further analysis. With the 
remaining 58 SNPs, an additional effort was made to reduce data dimensionality, with 7 SNPs 
found to be in strong LD (r2≥ 0.9) with other genotyped variants and though not excluded, 
these were not included in the final data analysis. Of the 167 patients who underwent SNP 
genotyping, 8 had a genotype call-rate < 90% and were excluded from the analysis. This left 
51 SNPs and 159 patients (71 SANAD, 88 Glasgow) for the association analysis. Basic 
demographic and clinical characteristics of the study population included in the analysis are 
reported in Table 3.1.         
 Of the remaining 51 candidate SNPs, 16 had previously been typed by the 
International HapMap project (NCBI build 36, dbSNP build 126) and had published MAFs 
that did not deviate from those observed in this study (Appendix 1.2). Several SNPs were 
selected on the basis of a previous report of association in literature. Of these n=3 were 
associated with AED serum concentration and/or dosing in epilepsy (rs776746, rs2234922, 
rs1051740)(Nakajima et al., 2005, Makmor-Bakry et al., 2009, Park et al., 2009, Meng et al., 
2011). The putatively significant CYP3A5*3 variant rs776746 C>T  proposed to affect the 
metabolism of several drugs (Huang et al., 2004) and more recently reported to influence both 
CBZ serum concentrations and dosing (Park et al., 2009, Meng et al., 2011) however failed 
QC (HWP<0.1%), thus was not included in the final analysis.  
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3.4.1 Associations between genetic variants and maintenance dose 
Of the four non-genetic factors considered in this study, only age (P= 0.014) and source 
cohort (P= 0.023) were significantly associated with CBZ maintenance dose, as shown in 
Table 3.4. Older ages and patients from the SANAD cohort appeared to have lower CBZ 
maintenance doses when analysed using a univariate regression model. When age and source 
cohort were included in individual regression models with each SNP genotype, eleven of 51 
SNPs showed association with CBZ maintenance dose (Figure 3.3, Table 3.5a and Table 3.5b). 
Two of the SNPs were non-synonymous coding variants (rs4149229 in EPHX1 and rs7439366 
in UGT2B7), one was a synonymous coding variant (rs2234922 in EPHX1), and the remaining 
SNPs were located in non-coding or intronic regions. None of these associations survived FDR 
correction for multiple testing (Table 3.5). 
 
 
Table 3.4 Univariate analysis of non-genetic factors  
Regression analysis results for association between non-genetic factors associated with 
carbamazepine maintenance dose. A p<0.05 was considered significant.  
Variable Analysis F-statistic P-value 
Age Continuous 1.647 0.014 
Gender Categorical (male / female) 0.589 0.444 
Epilepsy type Categorical (IGE, LRE, UNC) 0.031 0.969 
Source cohort Categorical (SANAD, Glasgow) 5.248 0.023 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy,                    
UNC = unclassified Epilepsy 
 
 
3.4.2 Validation of previous EPHX1 association with CBZ dose 
 In an effort to confirm the previously reported association between CBZ maintenance 
dose and two putatively functional SNPs in EPHX1 (Makmor-Bakry et al, 2009), a further 
regression analysis incorporating age, source cohort, and the genotype of both SNPs was 
performed. Neither SNP in EPHX1 was significantly associated with CBZ dose in isolation 
(uncorrected P= 0.494 for rs1051740, uncorrected P= 0.046 for rs2234922) and the regression 
analysis incorporating both loci was similarly unremarkable. 
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Table 3.5a Genotype associations with carbamazepine dose         
Genotype associations identified by regression analysis; a null and alternative regression 
model was generated for each of the 51 single nucleotide polymorphisms and a chi-square test 
for statistical difference between the two models was performed.  
SNP ID (rs) Gene Uncorrected P-value 
rs4356975 UGT2B7 0.003 
rs3924194 UGT2B7 0.003 
rs4646450 CYP3A5 0.007 
rs2292558 TMEM63A 0.007 
rs4149229 EPHX1 0.010 
rs7439366 UGT2B7 0.012 
rs7375178 UGT2B7 0.014 
rs1934956 CYP2C8 0.019 
rs2246709 CYP3A4 0.026 
rs12721617 CYP3A4 0.029 
rs2234922 EPHX1 0.046 
rs3738040 EPHX1 0.056 
rs11572080 CYP2C8 0.061 
rs11572126 CYP2C8 0.064 
rs28365062 UGT2B7 0.065 
rs2671272 EPHX1 0.088 
rs2071426 CYP2C8 0.091 
rs2275622 CYP2C8 0.120 
rs2854461 EPHX1 0.124 
rs1934980 CYP2C8 0.125 
rs1536430 CYP2C8 0.125 
rs3753660 EPHX1 0.128 
rs762551 CYP1A2 0.160 
rs2275620 CYP2C8 0.175 
rs12333983 CYP3A4 0.185 
rs4646437 CYP3A4 0.192 
SNP = single nucleotide polymorphism, MAF = minor allele 
frequency 
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 SNP = single nucleotide polymorphism, MAF = minor allele frequency 
 
 
 
 
Table 3.5a Genotype associations with carbamazepine dose continued. 
SNP ID (rs) Gene Uncorrected P-value 
rs15524 CYP3A5 0.209 
rs2470890 CYP1A2 0.236 
rs1934952 CYP2C8 0.241 
rs2069525 CYP1A2 0.270 
rs10050146 UGT2B7 0.289 
rs1419745 CYP3A5 0.317 
rs2740574 CYP3A4 0.321 
rs2740168 EPHX1 0.346 
rs11572172 CYP2C8 0.366 
rs2260863 EPHX1 0.390 
rs6976017 CYP3A5 0.419 
rs28365095 CYP3A5 0.429 
rs28365083 CYP3A5 0.434 
rs6600894 UGT2B7 0.448 
rs1051740 EPHX1 0.495 
rs2292566 EPHX1 0.495 
rs1877724 EPHX1 0.515 
rs2234698 EPHX1 0.543 
rs11572079 CYP2C8 0.623 
rs28371764 CYP3A5 0.642 
rs34143170 EPHX1 0.665 
rs1058930 CYP2C8 0.834 
rs2740170 EPHX1 0.841 
rs17861157 CYP1A2 0.938 
rs4149230 EPHX1 0.964 
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Table 3.5b SNP genotypes associated with carbamazepine dose prior to correction 
Of the 51 SNP analysed only variants with P <0.05 (before correction for multiple testing) are 
shown. The reference sequence (rs) numbers for each variant, their location in the respective 
gene and individual allele information is also provided. 
Gene SNP ID 
(rs) 
Location Amino 
acid 
change 
MAF Un-corrected   
P-value 
FDR 
P-
value 
CYP2C8 rs1934956 Intron - 0.116 0.019 0.124 
CYP3A4 rs2246709 Intron - 0.269 0.026 0.145 
CYP3A4 rs12721617 Intron - 0.006 0.029 0.145 
CYP3A5 rs4646450 Intron - 0.182 0.006 0.088 
Flanking 
EPHX1 
rs2292558 Intron - 0.095 0.007 0.088 
EPHX1 rs4149229 Exon P.K416K 0.006 0.007 0.104 
EPHX1 rs2234922 Exon P.H139R 0.163 0.046 0.214 
UGT2B7 rs4356975 Intron - 0.229 0.003 0.069 
UGT2B7 rs3924194 Intron - 0.167 0.012 0.069 
UGT2B7 rs7439366 Exon P.H268Y 0.399 0.010 0.104 
UGT2B7 rs7375178 Intron - 0.396 0.014 0.104 
FDR = false discovery rate, MAF = minor allele frequency, SNP = single nucleotide 
polymorphism 
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Figure 3.3a 
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Figure 3.3b  
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Figure 3.4c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 a, 3.3b, 3.3c Variant genotype and carbamazepine dose 
 
Box and whisker plots of single nucleotide polymorphisms associated with 
carbamazepine maintenance dose (P<0.05, prior to correction for multiple 
testing). Dose is distributed according to individual genotype. Solid lines 
represent the median carbamazepine dose in each group, boxes represent the 
25th and 75th percentile, whiskers represent 5th–95th percentiles, and dots 
represent outliers. 
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3.4.3 Gene haplotype identification and variability in dosing  
Haplotypes within each of the six genes were next investigated to determine whether 
they explained a greater percentage of dose variability than single SNPs. In total eight distinct 
haplotype blocks were identified across the six DME genes. A single block spanned each of 
UGT2B7, CYP1A2 and CYP2C8, two blocks overlapped CYP3A4 and CYP3A5, and the 
remaining three blocks spanned EPHX1 (Figure 3.4). Patients with a haplotype pair allocation 
probability <90% for each block were excluded from the analysis prior to performing a 
regression analysis (2 patients were excluded from Block 1, 2 from Block 2, 1 from Block 3, 
1 from Block 4, 13 from Block 5, 2 from Block 6, 19 from Block 7 and 19 from Block 8). 
Results of the regression analysis for the PHASE generated haplotypes are presented in Table 
3.6. Out of the eight identified haplotype blocks, two showed association with CBZ 
maintenance dose; Block 1 spanning UGT2B7 (P= 0.023) and Block 5 overlapping both 
CYP3A4 and CYP3A5 (P= 0.011).  Both blocks were only modestly associated with CBZ 
maintenance dose and failed to remain statistically significant following FDR analysis (Table 
3.6). Individual haplotypes within each gene were therefore not examined. 
 
3.4.4 Bioinformatics work 
Bioinformatics analysis for the exploration of likely function of each of these 11 SNPs 
was performed despite their failure to remain significantly associated with CBZ dose after 
correction for multiple testing. Such investigations have the potential to identify subtle effects 
that may be lost in a candidate gene association analysis where statistical power is low and 
associations weakened by the need to correct for multiple comparisons. None of the 11 SNPs 
was predicted to have a significant influence on protein function and/or expression. Results 
for bioinformatics analyses can be found in Table 3.7. The SIFT and FastSNP webservers were 
used to evaluate the functional potential of the two non-synonymous variants, and predicted 
no effect of either polymorphism on protein function. FastSNP did, however, predict the 
presence of two 2 ESEs with the variant allele for both the EPHX1 exonic SNPs rs2234922 
and rs4149229 (non-synonymous and synonymous SNPs respectively). In addition to this, 
FastSNP predicted the loss of a TFBS for both the UGT2B7 rs4356975 and CYP3A4 
rs12721617 intronic variants and the exonic UGT2B7 rs7439366 variant (Table 3.7). These 
SNPs were also predicted to be located within a TFBS by TESS. 
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Figure 3.4a 
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Figure 3.4b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 a and 3.4 b                         
Blocks of linkage disequilibrium and haplotypes identified across the six candidate drug 
metabolising enzyme genes. Linkage disequilibrium between each of the 51 SNPs across the 
six candidate genes that were included in the study, as visualised by Haploview v.4.2 (Barrett 
et al., 2005). Haplotype maps were generated using solid spine linkage disequilibrium method 
of block definition (Haploview v.4.2). A total of eight haplotype blocks were identified; 
(blocks 1-8 left to right) spanning the genes UGT2B7, CYP1A2, CYP2C8 (Figure 3.4b), 
CYP3A4 and CYP3A5 and EPHX1 (Figure 3.4a) respectively (3 across EPHX1 and one each 
across the remaining 5 genes). 
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Table 3.6 Regression analysis of haplotype associations with carbamazepine dose 
A chi-square test was used for testing for a statistical difference between a null and alternative 
regression model generated for each of the 8 blocks. A chi-square p-value of <0.05 after 
correction for multiple testing was considered statistically significant. 
Haplotype 
block 
Gene Number 
of SNPs 
Chi-
squared 
value 
Uncorrected   
P-value 
FDR               
P-value 
Block 1 UGT2B7  9 14.658 0.023 0.091 
Block 2 CYP1A2 4 3.282 0.350 0.092 
Block 3 CYP2C8 12 14.118 0.079 0.170 
Block 4 CYP3A4/
CYP3A5 
9 8.192 0.146 0.170 
Block 5 CYP3A4/
CYP3A5 
3 12.982 0.011 0.233 
Block 6 EPHX1 4 8.192 0.085 0.416 
Block 7 EPHX1 2 0.91 0.923 0.416 
Block 8 EPHX1 7 7.652 0.364 0.923 
FDR = false discovery rate, SNPs = single nucleotide polymorphisms 
 
3.5 Discussion and summary 
Despite the introduction of more than 12 new AEDs in the past two decades, drug therapy for 
epilepsy remains sub-optimal, with an estimated 50% of all treated patients experiencing 
ongoing seizure activity, significant AEs, or both. Newer AEDs have a more benign side effect 
profile than their established counterparts but none represents a significant advance in efficacy 
terms. As a result, there is a growing consensus in the epilepsy field that greater efforts should 
be directed at learning to use existing compounds in a more effective manner, rather than 
continually developing new agents of questionable additional benefit. Suggestions for the 
better use of existing AEDs include the investigation of rational polypharmacy and the 
individualisation of drug choice and dosing strategies through the identification and 
implementation of validated biomarkers. This study investigated the potential influence of 
polymorphic variants in DME genes on CBZ maintenance dose. Understanding an individual’s 
dose requirement could help tailor titration schedules and target doses in order to minimise 
early withdrawals due to intolerable AEs and reduce the time to achievement of seizure 
control.  
Hepatic metabolism represents the major elimination pathway for the majority of older 
AEDs and is the primary determinant of inter-individual variability in their PK. Many of these 
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compounds, including CBZ, have a relatively narrow therapeutic concentration range that 
renders them susceptible to clinically meaningful consequences of fluctuations in their serum 
levels. Multiple DMEs are involved in the biotransformation of CBZ (Kerr et al., 1994, Levy, 
1995, Browne, 1998, Ketter et al., 1999, Huang et al., 2004, Staines et al., 2004, Ferraro and 
Buono, 2005, Klotz, 2007). CYP3A4 and CYP3A5 are the principle enzymes involved in the 
phase I metabolism of CBZ to its major and pharmacologically active metabolite CBZ-E, with 
CYP1A2 and CYP2C8 playing a more minor role. Phase II metabolism is predominantly 
mediated by mEH, which converts CBZ-E to CBZ-10,11-diol, while UGT2B7 is the major 
enzyme involved in glucuronide conjugation of the parent compound and its multiple 
metabolites. The genes encoding each of these enzymes harbour polymorphisms that are 
known to influence their catalytic function (Saruwatari, Ishitsu et al. 2010)(Ferraro and Buono, 
2005).           
 This study employed a candidate gene approach using tSNPs plus putatively 
functional variants in an effort to identify genetic influences on CBZ maintenance dose across 
these six DMEs, with adjustment for known non-genetic influences on dose. Modest 
associations with dose were observed with eleven SNPs in five genes, four in UGT2B7, three 
in EPHX1 region (one of which is located within the TMEM63A; a gene flanking EPHX1), 
two in CYP3A4, and one each in CYP2C8 and CYP3A5, but none that survived correction for 
multiple testing. Reducing the dimension of the genetic data by haplotype analysis was 
similarly unsuccessful, with again only modest associations between CBZ maintenance dose 
and haplotype blocks spanning UGT2B7 and CYP3A4/CYP3A5 that failed to survive 
adjustment for multiple comparisons.        
 It is not possible to confidently implicate the predictive influence of genetic markers 
with drug dose without strong statistical evidence. This is however difficult when statistical 
power is limited by analysing a large number of variables in a limited number of patients. 
Although no SNP presented a strong correlation with maintenance dose in the independent 
SNP analysis, of significance is the potential influence of several of these SNPs on gene 
regulation as implicated by the bioinformatics analysis. Three SNPs were located in coding 
regions (1 EPHX1 synonymous, 1 EPHX1 non-synonymous and 1 UGT2B7 non-synonymous 
SNP), but were not predicted to have a direct effect on the function of their respective enzymes. 
The predicted effect on splicing, TFB, and/or protein expression could however signify some 
importance of these coding SNPs. Alternatively the weak dose association with each of the 11 
SNPs could be an indication that the variants are in LD with as yet unidentified genetic variants 
of stronger biological function. Alternatively, the single SNP results may point toward a 
potential role of the respective genes in CBZ response and/or dosing. The EPHX1 non-
synonymous rs2234922 variant that was originally associated with CBZ dose (Makmor-Bakry 
et al 2009) was additionally predicted to alter a TFBS in the bioinformatics analysis, thus again 
  CHAPTER THREE 
 
105 
 
implicating EPHX1 with CBZ dosing. The other intronic SNP is located in the TMEM63A 
gene encoding a transmembrane protein close to EPHX1. Although no significant association 
has been reported for this gene with regards to epilepsy, or any other condition/ disease state, 
the rs2292558 variant has previously been associated with pulmonary arterial pressure in 
patients with chronic obstructive pulmonary disease (Castaldi et al., 2010). As such this SNP 
or gene could have some yet unidentified role in influencing EPHX1 or epilepsy.  
 In single SNP analyses, true associations may be missed because of the incomplete 
information provided by individual variants (Hirschhorn et al., 2002). Multiple markers across 
chromosomal regions are thus increasingly being studied in combination, for the identification 
of relationships between genetic regions and traits of interest, with analysis based on 
haplotypes potentially more efficient than separate analyses of the individual SNPs (Judson et 
al., 2000). Of the eight haplotype blocks identified for the six genes included in this study, 
only one block spanning the gene UGT2B7 and another spanning the gene CYP3A4/CYP3A5 
were modestly associated with CBZ dose. This finding partly supports the results of the single 
SNP analysis, where several UGT2B7 SNPs appeared to associate with CBZ dose. 
Individually, however, these two haplotype blocks only explain a small amount of the 
variability present in CBZ dosing (r2 values of 6.2% and 5.5% for the UGT2B7 and CYP3A 
blocks respectively). This is similar to the variability accounted for by individual SNPs (r2 
values ranging from 3.0% to 7.1% for the 11 SNPs). The benefit of carrying out additional 
haplotype analysis was therefore questionable.      
 These findings were not entirely surprising, given that none of the genes in the panel 
are known to possess alleles of significant functional effect such as those observed in CYP2D6 
or CYP2C9 (Ingelman-Sundberg, 2004b, Wilkinson, 2005). The CYP3A5 gene does possess a 
null allele (CYP3A5*3)(Huang et al., 2004) that has been extensively studied with regard to 
altered drug metabolism (Hustert et al., 2001, Ingelman-Sundberg, 2004a). Although studies 
indicate association of this allele with CBZ serum concentrations, the role of CYP3A5 in CBZ 
metabolism remains controversial (Park et al., 2009, Saruwatari et al., 2010, Meng et al., 
2011). It has also been speculated that the loss of CYP3A5 function is potentially compensated 
by enhanced metabolism mediated by CYP3A4 (Lee Sj Fau - Goldstein and Goldstein, Lamba 
et al., 2002, Huang et al., 2004).       
 Rather than seeking functional variants of large effect size, it was anticipated that this 
study might allow detection of multiple SNPs of small effect size that could be incorporated 
with non-genetic influences on CBZ dose into a predictive multivariate model. Those non-
genetic factors that proved significant in this analysis included age, which would be expected 
to inversely correlate with dose requirement in an adult population (Bourdet et al., 2001), and 
source cohort, which was an interesting observation and one that perhaps reflects the differing 
methods of case ascertainment and drug use in randomised trials and routine clinical care. The 
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present investigation was however unable to detect a genetic influence on CBZ dosing when 
several individual SNPs were investigated, even after accounting for the contribution of non-
genetic factors. This study therefore failed to support the hypothesis that common variants in 
the CBZ PK pathway may influence CBZ dosage in.    
 Two EPHX1 SNPs, rs1051740 and rs2234922, were previously reported as influential 
in CBZ maintenance dosing (Makmor-Bakry et al., 2009). These variants were also typed as 
part of the present study and investigated in the overall genetic analysis and also in isolation 
in an effort to validate the original finding. The failure to validate the results of the study by 
Makmor-Bakry et al 2009 may be explained by the small number of patients (n=167) in the 
current analysis, combined with a large number of variables necessitating extensive correction 
for multiple testing. Power to detect modest associations was therefore limited. The original 
study was also disadvantaged by a small patient cohort (n=70) and only a weak association 
was found by the authors (P= 0.002 uncorrected). In addition to EPHX1 variants, Makmor-
Bakry et al 2009 also investigated single SNPs in each of CYP1A2, CYP2C8, CYP3A4, 
CYP3A5, and UGT2B7, selected on the basis of reported associations and potential 
functionality. They failed to consider wider variations across each gene region. This arguably 
limited their ability to detect associations, given that single SNPs are unlikely to explain 
complex traits. The more sensitive measure of using candidate gene tSNPs in the current study 
was however similarly unsuccessful, perhaps confirming that genetic variability in DMEs 
involved in CBZ metabolism does not play an important role in determining dose requirement.
 It is possible that this study would have possessed greater sensitivity to detect genetic 
associations with CBZ PK had serum drug concentration data been available rather than dose 
data alone. TDM has proven useful for improving the effectiveness and safety of established 
AEDs, particularly for those with non-linear PK, such as PHT, or with considerable PK 
variability, as is the case with CBZ (Eadie, 1998, Anderson, 2008). Serum concentrations are 
more reflective of PK in general and less susceptible to non-genetic influences such as age, 
sex and body weight, all of which are compensated by dose differences. However, serum levels 
were not available for the cohorts in question.  The use of a mixed-effect population PK 
approach has been shown to facilitate the delineation of relevant genetic factors, to estimate 
the magnitude of their effects on the PK variation, and to aid individualised dosing 
(Saruwatari, Ishitsu et al. 2010).       
 Using a candidate gene tSNP approach has advantages over the traditional single gene, 
single variant association method commonly found in PGx studies (Grant and Hakonarson, 
2007, McCarthy et al., 2008) as it increases the likelihood of capturing putatively causative 
SNPs. The trade-off, however, is statistical power to detect associations in studies where a 
large number of genetic variants are typed in a relatively small cohort of patients. As studies 
move toward genome-wide analysis of complex traits, such as drug response, problems arise 
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in how to handle large genetic datasets (in terms of correction for multiple testing) whilst 
retaining sufficient statistical power. Larger and larger cohorts of patients are required but this 
may be unrealistic for some phenotypes. It was evident in this study that the lack of power 
limited the significance of the associations identified, for both single SNP and haplotype 
analyses. Unfortunately, the study was constrained by the availability of patients who met the 
inclusion criteria. Even in two of the largest epilepsy pharmacogenetic cohorts worldwide, 
insufficient numbers of patients were available to allow an association with CBZ dose to 
withstand correction for the multiple testing.     
 The haplotype approach to identifying causative genetic factors for both disease 
association and drug response is relatively new, but the benefits of using gene-based 
haplotypes as genetic markers is becoming clear (Judson et al., 2000). Determination of 
haplotypes or combinations of SNPs that are in LD might offer more power to detect 
associations than simply measuring individual SNPs (Tabor et al., 2002). When the initial test 
of association with genotypes does not reach statistical significance, further exploration of 
haplotype-specific effects is thought to increase the chance that at least one significant 
association will be detected (Colhoun et al., 2003). The ability to preselect SNPs that tag 
common haplotypes might also increase the prior probability of association with a candidate 
gene (Johnson et al., 2001).       
 Unfortunately, in this study, while there were associations between CBZ dose and 
both single SNPs and individual haplotypes prior to correction for multiple testing, these were 
lost thereafter. Thus, using a haplotype-based approach did not improve the sensitivity to 
detect true associations. This may have been because there were no true associations or that 
statistical power to detect such associations was not sufficiently high. There are also major 
issues around the use of simple regression for haplotype analysis. These include haplotype 
uncertainty, when these are derived with computational methods of phase inference, and 
haplotype complexity, in which the power of haplotype analysis is reduced by the large 
number of haplotypes that need to be studied (Zhao et al., 2003). With FastPHASE software, 
an individual is assigned to different haplotype pairs with different probabilities (Scheet and 
Stephens, 2006) and although this study employed a high threshold probability of 90% for 
haplotype uncertainty, the problem still exists.      
 Methods have been developed to reduce the number of haplotypes considered in 
association studies. One such method divides the whole chromosomal region into smaller 
regions for analysis and this generally involves a sliding window which is placed on the 
candidate region, with evidence for association within each window assessed (Zhao et al., 
2003). Using the sliding window, the number of haplotype patterns in each window may be 
significantly less than that in the whole region, so the regression analysis involves fewer 
parameters and thus should have better power if there is an association between haplotype and 
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a disease trait. In addition it is assumed that association near the true disease variants is 
stronger than that in other regions (Zhao et al., 2003). Another common approach is based on 
the assumption that an unknown mutation occurred at some point in the evolutionary history 
and became embedded within the historical structure represented by a tree (cladogram) 
relating different haplotypes, assuming that certain portions of the tree would display the 
phenotypic effect of the mutation while other portions would not (Zhao et al., 2003). This 
second approach groups haplotypes into a smaller number before association analysis.  Thus, 
the cladogram defines a nested analysis of variance that simultaneously detects phenotypic 
effects and localises the effects within the cladogram (Zhao et al., 2003). These other ways 
of analysis were not considered here instead, a simplistic approach of using haplotype block 
structures was employed. This simplistic method is helpful in association analysis using block-
specific haplotypes (Daly and Day, 2001, Zhao et al., 2003) but there is an argument that the 
results depend on the definition of haplotype blocks. This method may also not be efficient if 
there is substantial LD among alleles in different blocks (Gabriel et al., 2002). 
 
Table 3.7 Predicted function for 11 SNPs from FastSNP and SIFT 
TF= transcription factor, SE= splicing enhancer site, SS=splicing silencer site.                        
Risk = Upper and lower risk of functional effect; 0= no effect 1=very low risk, 2=low risk, 
3=medium risk, 4=high risk, 5=very high risk (http://fastsnp.ibms.sinica.edu.tw/pages/input_ 
CandidateGeneSearch.jsp)(http://sift.bii.a-star.edu.sg/)
SNP ID 
(rs) 
Gene Predicted 
functional 
effect FastSNP 
Risk Predicted 
functional 
effect SIFT 
TF site 
change 
SE/SS 
change 
 
rs1934956 CYP2C8 no known 
function 
0-0 - - - 
rs2246709 CYP3A4 no known 
function 
0-0 - - - 
rs12721617 CYP3A4 enhancer 1-2 - yes - 
rs4646450 CYP3A5 no known 
function 
 - - - 
rs2292558 TMEM63A   
/EPHX1 
no known 
function 
0-0 - - - 
rs4149229 EPHX1 Benign 2-3 Tolerated - yes 
rs2234922 EPHX1 splicing 
regulation 
2-3 Tolerated - yes 
rs4356975 UGT2B7 enhancer 1-2 - yes - 
rs3924194 UGT2B7 no known 
function 
0-0 - - - 
rs7439366 UGT2B7 Benign and 
missense; 
splicing 
regulation 
2-3 Tolerated 
 
yes - 
rs7375178 UGT2B7 no known 
function 
0-0 - - - 
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Drug response is a recognised complex, multifactorial phenotype, likely to involve 
several classes of genes of potential influence. This study investigated the importance of 
DMEs in determining the maintenance dose requirement of CBZ by examining numerous 
SNPs across several candidate genes. While there was evidence of a relationship between 
common genetic variation and dose, the associations identified were modest and did not 
survive correction for multiple testing. There are an increasing number of reports showing the 
importance of UGT enzymes, including UGT2B7 and UGT1A4, in AED PK and PD (Blanca 
Sanchez et al., 2010, Saruwatari et al., 2010), which would suggest that the results of this 
analysis have some merit. The lack of statistically significant associations thus does not rule 
out the possibility that associations may exist with other SNPs in the same genes, not least 
because the study design was informed by known genetic variation at the time of conception. 
Variation in DME genes is known to influence the PK and PD of drugs metabolised by 
CYP2D6, CYP2C9, and CYP2C19. In the case of CBZ, however, the principal DMEs are less 
polymorphic and likely to have a more subtle influence on inter-individual variability in drug 
dose, necessitating far larger studies to detect genetic associations. Given their modest 
contribution in this regard, it is debatable whether such studies are worthwhile or clinically 
informative.  
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4.1. Introduction 
Ion channels are pore-forming proteins that regulate the movement of ions across cellular 
membranes and are therefore integral to a wide range of physiological pathways (Catterall, 
1992). NaV channels are responsible for the generation of action potentials in excitable cells 
and those expressed in the brain play a central role in the initiation and propagation of action 
potentials in neurones (Catterall, 1992, Yu and Catterall, 2003). Mutations in this fundamental 
channel unsurprisingly cause a number of disorders of membrane excitability, including 
several genetic epilepsies (Rogawski and Loscher, 2004, Meisler and Kearney, 2005). 
 
4.1.1. Structure and function of the voltage-gated sodium channel 
The NaV channel protein consists of two distinct subunits, denoted α and β (Marban et 
al., 1998) (Figure 4.1). The α-subunit is a large, transmembrane protein composed of 4 
homologous domains that are fundamental to channel function (Marban et al., 1998). These 
domains contain the voltage sensor and pore regions essential to channel gating (i.e. opening 
and closing of the channel) and ion selectivity, respectively (Clare et al., 2000, Meisler and 
Kearney, 2005). The four domains associate within the membrane to form a Na+ permeable 
pore, through which Na+ ions flow during propagation of an action potential (Meisler and 
Kearney, 2005) (Figure 4.2). Each α subunit is also associated with one or more accessory β 
subunits that are important for the modulation of the NaV channel as a whole, regulating cell 
surface expression, voltage dependence and kinetics of the α subunit (Marban et al., 1998, Yu 
and Catterall, 2003). 
Duplication of α-subunit genes during mammalian evolution has generated a number 
of genes encoding active NaV channels that differ in tissue specificity and biophysical 
properties (Yu and Catterall, 2003, Meisler and Kearney, 2005). Ten NaV α subunit genes 
(SCN1A-SCN5A, SCN7A-SCN11A) have been identified in mammals so far, nine of which are 
expressed in the nervous system (Table 4.1.) (Catterall et al., 2005, Leterrier et al., 2010). The 
four genes predominantly expressed in mammalian brain are SCN1A, SCN2A, SCN3A and 
SCN8A, which encode the channels NaV1.1, NaV1.2, NaV1.3 and NaV1.6, respectively. NaV1.3 
expression is mainly restricted to the early stages of development, while NaV1.1 is the major 
NaV channel in inhibitory interneurons and NaV1.2 and NaV1.6 are expressed in the axon initial 
segment of principal excitatory neurons.  
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Figure 4.1   Structure of 
voltage-gated sodium channels 
Representation of the α-subunit 
and β1 and β2 subunits of the 
Nav1.2 channel. The four 
domains of the α-subunit (I-IV) 
are indicated including its 6 
helices or segments (S1-6).  The 
S5 and S6 helices in each 
domain (shown in blue) are the 
pore-lining segments and the S4 
helices (dark purple segments) 
make up the voltage sensors. 
Pink circles in the intracellular 
loops of domains III and IV 
indicate the sites implicated in 
forming the receptor for the 
inactivation gate and the blue 
circle indicates the inactivation 
gate loop. The pre-entrant loops 
in each domain (I-IV) form both 
the ion selectivity filter and outer 
pore mouth. S6 helices of 
domains III and IV (pink 
segments) are regions of 
modulatory drug binding, 
including sodium channel-
blocking AEDs. Figure has been 
adapted from Rogawski and 
Loscher et al 2004. 
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Figure 4.2 Voltage-gated sodium channel gating 
Schematic representation of the different conformational states of a voltage-gated 
sodium channel. The voltage-gated sodium channel exists in four conformations, resting, 
activated (or open), inactivated and closed. The figure shows channel activation and sodium 
ion gating during the propagation of action potentials. The conformational change of the 
channel pore required for channel gating is also represented. Figure redrawn from Joseph et al 
2011. 
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Table 4.1 Mammalian voltage-gated sodium channel subunits 
Tissue distribution and genetic information for mammalian voltage-gated sodium channel 
alpha and beta subunits. Table adapted from Catterall et al 2005. Additional information 
extracted from the Online Mendelian Inheritance in Man (OMIM) website (www.omim.org). 
Channel 
protein 
Subunit name 
 
Gene 
 
Tissue 
distribution 
Alpha     
NaV1.1 Brain type I SCN1A CNS + PNS + heart 
NaV1.2 Brain type II SCN2A CNS 
NaV1.3 Brain type III SCN3A CNS + heart 
NaV1.4 Skeletal muscle SCN4A skeletal muscle  
NaV1.5 Cardiac SCN5A Heart + minor CNS 
expression 
NaV1.6 Brain type IV SCN8A CNS + PNS + heart 
NaV1.7 PN1 SCN9A PNS 
NaV1.8 SNS SCN10A PNS 
NaV1.9 SNS2 SCN11A PNS 
NaX 
 
Atypical heart/glial 
 
SCN6A/7A 
 
Heart + uterus +  
smooth muscle + minor 
CNS expression 
Beta     
NaVβ1 
 
Beta-1 
 
SCN1B 
 
CNS + PNS +  
skeletal muscle + heart 
    
NaVβ2 Beta-2 SCN2B CNS+  PNS+  adrenal 
gland+  kidney 
NaVβ3 Beta-3 SCN3B CNS +  PNS+  heart,  
NaVβ4 Beta-4 SCN4B CNS + PNS+ heart,  
skeletal muscle 
NaV = voltage-gated sodium channel, CNS = central nervous system, PNS = peripheral 
nervous system  
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The essential nature of the NaV channel is further emphasised by the existence of 
inherited disorders (sodium “channelopathies”) caused by mutations in genes that encode these 
vital proteins (Table 4.2) (George, 2005, Kass, 2005). Many mutations of the neuronal NaV 
genes have been described in patients with epilepsy (George, 2005, Kass, 2005). The first of 
these was identified in the SCN1B gene (Escayg et al., 2000, George, 2005, Kass, 2005). 
Genetic defects in SCN1A, SCN2A, SCN3A, SCN9A genes have since been discovered that are 
responsible for several clinically overlapping epilepsy syndromes, namely generalised 
epilepsy with febrile seizure plus (GEFS+), severe myoclonic epilepsy of infancy (SMEI), and 
benign familial neonatal-infantile seizures (BFNIS) (Meisler et al., 2001, Steinlein, 2004, 
Meisler and Kearney, 2005). The majority of the NaV channel mutations related to epilepsy 
can be found in SCN1A (Lossin et al., 2003, Mulley et al., 2003, Lossin, 2009, Meisler et al., 
2010). Over 700 mutations of the SCN1A gene have been identified that cause a range of 
infantile epileptic encephalopathies with varying phenotypic severities, making this the most 
commonly mutated gene in human epilepsy (Lossin, 2009, Meisler et al., 2010). A small 
number of mutations have been identified in the other three principal, brain-expressed α 
subunit genes and only a handful are known for SCN1B (Lossin, 2009, Meisler et al., 2010).  
 
4.1.2. Function of the α–subunit  as a antiepileptic drug target 
The SCN1A encoded NaV1.1 protein functions as a major molecular target for numerous 
clinically important AEDs (Rogawski and Porter, 1990, Ragsdale and Avoli, 1998). Most 
AEDs have multiple cellular targets, however the majority of widely used AEDs have shown 
at least some NaV blocking activity (Kwan et al., 2001). AEDs with NaV channel blocking 
properties include PHT, LTG, CBZ, OXC, ZNS, FBM, TPM and VPA (Rogawski and Porter, 
1990, Kwan et al., 2001). These bind to the NaV channel and facilitate the selective inhibition 
of Na+ currents (Macdonald and Kelly, 1995, Kwan et al., 2001). These currents are involved 
in the repetitive high-frequency spike firing of neurons, which is believed to occur during the 
spread of seizure activity in epilepsy (Rogawski and Loscher, 2004). AEDs have highest 
affinity for the NaV channel protein in the inactivated state and their binding slows the 
otherwise rapid recycling process (Ragsdale and Avoli, 1998, Brodie and Sills, 2011). As a 
result, these drugs produce a voltage-and frequency-dependent reduction in channel 
conductance that limits repetitive neuronal firing with little effect on the generation of single 
action potentials (Ragsdale and Avoli, 1998, Brodie and Sills, 2011). 
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Table 4.2 Inherited disorders of voltage gated sodium channels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Table adapted from George 2005) 
 
 
4.1.3. Binding sites of antiepileptic drugs 
Site-directed mutagenesis experiments show that AEDs and local anesthetics bind to a 
common receptor site in the pore of the NaV channel that is formed in part by three critical 
amino acid residues in transmembrane segment S6 in domains I, III and IV, with the IVS6 
segment playing the dominant role (Catterall, 1999, Rogawski and Loscher, 2004, Catterall et 
al., 2005). Studies using PHT, CBZ and LTG have shown that these drugs contain a common 
motif (two phenyl groups separated by one or two C–C or C–N single bonds), which is thought 
to be crucial to this common binding (Figure 4.3) (Kuo, 1998, Rogawski and Loscher, 2004). 
Muscle sodium channelopathies (SCN4A) 
Hyperkalemic periodic paralysis 
Paramyotoniacongenita 
Potassium-aggravated myotonia 
Painful congenital myotonia 
Myasthenic syndrome 
Hypokalemic periodic paralysis type 2 
Malignant hyperthermia susceptibility 
Cardiac sodium channelopathies (SCN5A) 
Congenital long QT syndrome (Romano-Ward) 
Idiopathic ventricular fibrillation (Brugada syndrome) 
Isolated cardiac conduction system disease 
Atrial standstill 
Congenital sick sinus syndrome 
Sudden infant death syndrome 
Dilated cardiomyopathy, conduction disorder, arrhythmia 
Brain sodium channelopathies (SCN1A, SCN2A, SCN1B) 
Generalized epilepsy with febrile seizures plus 
Severe myoclonic epilepsy of infancy (Dravet syndrome) 
Intractable childhood epilepsy with frequent generalized tonic-clonic seizures 
Benign familial neonatal-infantile seizures 
Peripheral nerve sodium channelopathies (SCN9A) 
Familial primary erythermalgia 
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Evidence from mutational analysis has identified phenylalanine (F1764) and tyrosine (Y1771) 
residues in the S6 domain IV region as crucial for use-dependent block by both PHT and LTG 
(Ragsdale et al., 1996). These residues are brought into the pore during channel gating, thereby 
facilitating drug binding. Mutational analysis has also revealed that the pore-lining residues 
leucine 1465 and isoleucine 1469 in S6 of domain III of S6 may also form a portion of the 
high-affinity binding site for NaV blocking AEDs (Figure 4.1)(Catterall, 2000, Rogawski and 
Loscher, 2004, Yarov-Yarovoy et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Molecular view of sodium channel and proposed site for drug binding 
Experimental evidence has shown that antiepileptic drugs and local anesthetics with sodium 
channel blocking properties bind to receptor sites in the pore that is formed in part by amino 
acid residues in transmembrane segment S6 of domain III and IV of the channel (Catterall 
1999; Ragsdale et al 1998). 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
      
      
Enhanced Na
+ 
channel inactivation 
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4.1.4. Variable response to antiepileptic drug treatment 
AED therapy typically comprises of a low starting dose, which is titrated upwards until 
an individual therapeutic dose whereby seizures discontinue or AEs become intolerable (Lo 
Monte et al., 2011). AEDs are known to have a relatively narrow therapeutic index and to be 
responsible for a wide variety of clinically important AEs (Perucca et al., 2001, Kwan and 
Brodie, 2004, Depondt and Shorvon, 2006, Ferraro et al., 2006, Schachter, 2007). Side effects 
are thus a major cause of medication intolerance and noncompliance, particularly within the 
first six months of therapy, and major AEs are reported to contribute to initial treatment failure 
in around 40% of patients taking established AEDs (Sander, 2004, Cavalleri et al., 2011).  
 
4.1.5. Pharmacodynamic variation and antiepileptic drug response 
Variability in AED dose requirement at an individual patient level can be broadly 
attributed to a combination of genetic and non-genetic factors (Cavalleri et al., 2011). Non-
genetic influences include body mass index, gender and diet and are reasonably well 
characterised, although their clinical utility in terms of dose estimation is limited (Cavalleri et 
al., 2011). Some genetic polymorphisms that affect the PK of AEDs have also been identified 
and shown to influence the AED dose requirement (Tate et al., 2005, Klotz, 2007, Loscher et 
al., 2009, Park et al., 2009), particularly those in the CYP enzyme family (section 3.1).  
Neuronal drug binding involving the NaV channel is the first PD pathway to be directly 
associated with AED dosing (Tate et al., 2005, Kasperaviciute and Sisodiya, 2009). The 
SCN1A gene was originally implicated in AED response through early studies in Mendelian 
epilepsies. These demonstrated that SCN1A mutations can cause Dravet’s syndrome or SMEI. 
SMEI patients are not only resistant to several AEDs but their seizures are typically aggravated 
following NaV channel blocking AED treatment (Guerrini et al., 1998, Mulley et al., 2003, Yu 
et al., 2006, Abe et al., 2008).  
 
4.1.6. SCN1A gene Isoforms 
The SCN1A gene is 81-kb in size and is located on the long arm of chromosome two, 
situated at position 2q24.3. SCN1A is found as part of a cluster of voltage-gated sodium 
channel genes; namely SCN2A, SCN3A, SCN7A and SCN9A (encoding Nav1.2, Nav1.3, Nax, 
and Nav1.7, respectively) (Malo et al., 1994). The Nav1.1 protein (encoded by SCN1A) open-
reading frame is organised into 26 exons and blueprints the instructions for a protein version 
incorporating between 1976 and 2009 amino acids. The variance in possible length is due to 
alternative splice junctions at the end of exon 11 that produce a full-length isoform or two 
shortened versions (Lossin et al., 2002). These differ by 33 bases and result in an 11 amino 
acid difference between the translated proteins. This splicing variability is the cause for the 
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inconsistencies in mutation reports across different research groups, as some are referring to 
full-length Nav1.1, while others reference Nav1.1[-33]; proposed to be more abundant in the 
brain (http://www.scn1a.info/Isoforms). A second alternative SCN1A splicing site or site of 
RNA processing variability can be found in exon 5. Here two mutually exclusive exons, 5N 
and 5A can be found and give rise to a postnatal and an adulthood isoform of the Nav1.1 
channel protein (Copley, 2004). The amino-residue coding DNA sequence of these two 
alternative exons is nearly identical, differing only in three positions (Copley, 2004) (http: 
//www.scn1a. info/Isoforms). 
 
4.1.7. Implication of the SCN1A α-subunit gene in  AED response 
 A direct correlation between SCN1A and AED treatment was first reported in 2005 (Tate 
et al., 2005). The study, using 425 individuals with epilepsy demonstrated that the exon 5 
SCN1A rs3812718 G>A SNP resulted in a significant shift in the maximal dosage of PHT and 
CBZ (Tate et al., 2005). Exon 5 of SCN1A encodes one of several voltage sensor regions of 
the NaV channel (Ragsdale and Avoli, 1998, Tate et al., 2005).  The voltage sensor region 
determines channel gating and so alteration in exon 5 expression can influence sensitivity of 
channels to blockade by AEDs (Tate et al., 2005, Heinzen et al., 2007). Two alternatively 
spliced versions of exon 5 are present in human genomic DNA, exon 5A (adult version) and 
alternative exon 5N (neonatal version), differing by three amino acids in their protein products 
(Tate et al., 2005).  
 This variant, located in the consensus sequence of the 5’ splice donor site downstream 
of exon 5N (exon 5N+5G>A) (Figure 4.4) was suggested to alter the regular splicing of SCN1A 
in humans (Tate et al., 2005). The A allele was proposed to disrupt the consensus sequence of 
the 5N exon, reducing its expression and altering the normal 5N/5A ratio (Tate et al., 2005) 
(Figure 4.4). This was also demonstrated empirically by the study, which presented altered 
5N/5A transcript levels in adult brain tissue from patients with epilepsy (Tate et al., 2005). 
The ancestral G allele is conserved across vertebrates (Zhang 1998) and is present in 
homologous CNS NaV genes that are alternatively spliced within S3-S4 segments in domains 
I-IV. Maximum AED dosage was reported to consecutively decrease in epilepsy patients with 
AA, AG and GG genotypes (Tate et al., 2005) and this was suggested to be due to the level of 
5N expression; with individuals expressing a greater percentage of 5N (those with two copies 
of the ancestral G allele) requiring lower drug doses. 
 
4.1.8. Confirmation of the importance of the SCN1A polymorphism 
Of the few PGx studies that have since investigated the rs3812718 polymorphism, three 
have managed to confirm the original association with AED dosing (Tate et al., 2006). As 
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maximum dose is not an accurate determinant of drug efficacy the original study was repeated 
with maintenance dose data, in a cohort of 71 Chinese patients by the original authors (Tate et 
al., 2006). The subsequent report confirmed that rs3812718 was also associated with PHT 
serum concentration at maintenance dose (Tate et al., 2006). However, a more recent study of 
the SCN1A polymorphism and CBZ dosing by Austrian researchers, who similarly used 
maintenance dose rather than maximum dose in their investigation, found no significant 
difference in mean CBZ dosing between the rs3812718 genotype groups (Zimprich et al., 
2008).  
 
4.1.9. Growing evidence for an influential role of the SCN1A gene 
Since the first SCN1A findings there have been a number of interesting functional studies 
concerning this polymorphism, primarily exploring its consequences on NaV channel activity 
and on response to AEDs (Heinzen et al., 2007, Thompson et al., 2011). Most recently an 
investigation comparing the biophysical properties of NaV channels expressing 5A and 5N was 
performed. The study reported enhanced tonic block and use-dependent block of the 5N 
version of the NaV channel by PHT and LTG, indicating increased sensitivity of channels 
expressing the 5N exon (Thompson et al., 2011). No differences were shown with CBZ 
(Thompson et al., 2011).  
This recent study suggests that the dosing requirement of some AEDs may be altered by 
the SCN1A polymorphism, due to altered channel function, and suggests different 
pharmacological effects of the SCN1A rs3812718 variant dependent on AED. This finding 
may not only help to determine the true drug dose effect of this polymorphism but may explain 
the inconsistent findings surrounding this polymorphism to date. The results additionally 
appear to challenge the original conclusions made by Tate et al (Tate et al., 2005), suggesting 
that there is no effect of rs3812718 genotype on CBZ action (Thompson et al., 2011). This is 
the first direct evidence that variation in PHT dose requirement originally observed by Tate 
and colleagues (Tate et al., 2005) arises in part due to differences in how AEDs interact with 
the alternatively spliced NaV1.1 channel, providing a mechanistic explanation for the 
association between this polymorphism and AED dosage. However, this data questions 
previous experimental evidence that suggests a common binding site of AEDs on the S6 helix 
of domain IV of the NaV channel (Thompson et al., 2011), as implicates exon 5 (encoding the 
S3/S4 helices of domain 1) as the site of drug interaction. 
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Figure 4.4 Alternative splicing of exon 5 and disruption of 5’ splice donor site 
Altered splicing of the SCN1A gene caused by the rs3812718 variant and how this can produce 
NaV1.1 channels with different biophysical properties. This proposed mechanism may explain 
why patients might require different AED doses depending on their genotype. This figure has 
been redrawn from Loscher et al 2009. 
  CHAPTER FOUR 
 
123 
 
The differences in drug block observed in this study were accordingly proposed to result 
from NaV1.1 5N/5A isoform-specific activation and/or inactivation gating (Thompson et al., 
2011). 5N isoforms exhibited greater tonic and use-dependent inhibition by PHT and LTG, 
suggesting that binding sites for these drugs may be altered, and that the pharmacologic 
differences may arise from slower inactivation processes (Thompson et al., 2011).  
  
4.1.10. Summary and research aims 
The possibility of adjusting titration schedule based on genotype could lead to more rapid 
achievement of AED efficacy with adequate tolerability. Although the SCN1A genotype does 
not appear to have a striking influence on maximum PHT, LTG or CBZ doses, initial research 
results for this SNP suggest the potential for identifying patients who can tolerate higher 
therapeutic doses of these drugs. PGx data remains both limited and inconsistent for this drug 
target polymorphism. The growing interest in this gene, in conjunction with the functional 
evidence that has recently emerged, is however encouraging.   
The primary aim of the following study was to examine the pharmacological 
consequence of the rs3812718 SNP by further investigating the association between 
rs3812718 SNP genotype and AED dose. A candidate SNP association study was performed 
to determine the effect of the rs3812718 polymorphism on both maximum and maintenance 
dose data of numerous AEDs, with a sub-group interaction analysis for individual drugs done 
in an attempt to validate the original genetic association with maximal dose of CBZ as reported 
by Tate et al 2005. In addition to the original investigation this present study involved 
maintenance dose data and several AEDs regardless of mechanism. 
 
4.2. Methods 
4.2.1. Patient cohort  
The study included patients from the SANAD cohort (section 2.2.2), assuming they; 
i) were treated with AED monotherapy, ii) had information available for AED treatment 
history (i.e. AED exposure and corresponding dosage data), and iii) had an adequate amount 
of DNA sample available for SNP genotyping. Individuals who had received treatment with 
more than one drug during the study period (i.e. those for whom drugs were substituted 
because of inadequate seizure control and/or AEs) contributed more than once to the analysis. 
 
4.2.2. Outcome and phenotype definitions for patient selection 
The SCN1A rs3812718 G>A SNP was investigated for association with two outcomes, 
maximum dose and, where available, maintenance dose. This data was collected for each of 
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the drugs that individuals had been exposed to. Definitions used in this analysis were; i) seizure 
freedom, defined as at least 12 months of seizure freedom on an unchanged AED, ii) maximum 
dose, defined as the highest dose to which a patient had been exposed during treatment, and 
iii) maintenance dose, defined as the final AED dose that led to at least 12 months seizure 
freedom during monotherapy treatment. Additional data included in the analysis were patient 
age at recruitment, gender, and epilepsy type. Epilepsy type was broadly classified into three 
groups, IGE, LRE and UNC according to the clinical databases from which data was derived. 
 
4.2.3. Data inclusion and extraction 
Maximum dose data reflects the upper limit of drug tolerability and could be used to 
inform individual titration rate. In contrast, maintenance dose data is directly associated with 
treatment response and so is a better indication of treatment success at a particular dose (Tate 
et al., 2006). Data on maximum dose (mg/day) and, where available maintenance dose 
(mg/day), was extracted for each AED to which an individual had been exposed during follow-
up. Maintenance doses were unavailable or disregarded for patients in whom there was no 
remission from seizures or who underwent dosage adjustment; without a single 12 month 
period without seizure freedom, or had other AEDs added, during the remission period. These 
patients were included in the maximum dose analysis only.  
Many of the commonly used AEDs have multiple, overlapping mechanisms of actions 
and most possess at least some NaV channel blocking activity. All AEDs were therefore 
included in the analysis, regardless of drug class or proposed mechanism of action. The 
majority of patients had been exposed to two or more AEDs during the course of follow up, 
usually due to AED switching because of AEs and/or lack of efficacy. Most patients therefore 
contributed more than one maximum dose to the analysis. In total, the patient population was 
exposed to nine different AEDs, those with known NaV channel blocking activity being CBZ, 
LTG, OXC, PHT, VPA and those with another proposed primary mechanism of action being 
GBP, TPM, CLB and LEV (See Tables 4.4 and 4.6 for summary of the drugs included in the 
study). Data for CLB and PHT were excluded from the analysis of maximum dose, due to low 
numbers of patients taking these drugs (n<20). 
 
4.2.4. Genotyping 
The rs3812718 genotype for all 817 patients who met the initial inclusion criteria was 
determined using the Sequenom MassARRAY IPLEX platform in accordance with the 
manufacturer’s instructions and as detailed in chapter 2. The Sequenom platform is designed 
for the analysis of multiple SNPs using a multiplex approach and would not ordinarily be 
employed in a single candidate SNP study. Single SNP studies would typically use TaqMan 
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allelic discrimination assays (Chapter 7) or other such systems. However, in this analysis the 
rs3812718 SNP was genotyped alongside a panel of five other SNPs (reported in Chapter 5) 
that were also being typed in the SANAD cohort and, as such, a multiplex approach was 
deemed most efficient. Thus, a 6 SNP plex was generated using the online Sequenom 
MassARRAY assay designer software (Chapter 2). Table 4.3 shows the Sequenom assay 
design output (https://mysequenom.com/Tools/genotyping/default.aspx) for rs38132718 
alone (Gabriel et al., 2009). 
 
 
 
Table 4.3 Primer sequence for Sequenom genotyping 
Primer sequence for the rs3812718 SNP as designed by the Sequenom Assay design software 
SNP ID (rs)  PCR primer 
sequence-forward 
PCR primer 
sequence-reverse 
Extension primer 
sequence 
rs3812718 
ACGTTGGATGACA
AAGAGCCTATCCTT
TAC 
ACGTTGGATGACA
AAGAGCCTATCCT
TTAC 
CCTATCCTTTACT
CTAATCACTT 
SNP = single nucleotide polymorphism, PCR = polymerase chain reaction 
 
 
 
4.2.5. Statistical analysis 
All analyses of association were carried out using SPSS statistical software version 16.0 
(SPSS Inc., Chicago, IL, USA). In total, three statistical analyses were performed; a univariate 
analysis to identify any non-genetic confounders that may influence the genetic association 
analysis, a regression analysis for the identification of genetic sub-groups that differ in 
maximum or maintenance dosage requirement, and a validation analysis to attempt to replicate 
the findings of the original study (Tate, Depondt et al. 2005). An additive mode of inheritance 
was assumed for all genetic analyses, in line with previous reports of this polymorphism (Tate 
et al., 2005, Tate et al., 2006). 
 
4.2.6. Data preparation 
Since individual doses for different AEDs are not equivalent, it was necessary to 
normalise the dose data prior to analysis. For this purpose, the defined daily dose (DDD) was 
referred to, which is the average maintenance daily dose in adults as defined by the World 
Health Organisation (WHO) (http://www.whocc.no/atcddd/, accessed September 22, 2010) 
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(Table 4.4). Normalised doses were expressed as prescribed daily dose (PDD)/defined daily 
dose (DDD) ratios. All dose ratios were then transformed using the natural log function to 
achieve a normal distribution and this final log-transformed ratio was used for all statistical 
analysis. Prior to the genetic association analyses, the rs3812718 SNP was tested for deviation 
from Hardy Weinberg equilibrium (HWE) using Haploview software version 4.1 (Barrett et 
al., 2005), with a p-value of <0.001 indicating deviation.  
 
 
 
Table 4.4 Defined and prescribed daily doses  
The World Health Organisation (WHO) defined daily dose (DDD) and the range of maximum 
and maintenance doses (prescribed daily doses; PDD) for each drug.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AED = antiepileptic drug, WHO = World Health Organisation,  DDD = defined daily dose, 
PDD= prescribed daily dose  
 
 
 
4.2.7. Univariate analysis of association with non-genetic factors 
To evaluate the individual effect of the SNP, univariate tests of association were 
conducted with the non-genetic factors alone. Age, gender and epilepsy type were tested for 
association with the two dose variables (maximum and maintenance) in turn. Univariate linear 
regression, the independent samples t-test and ANOVA were used for each of the factors 
respectively. Non-genetic factors found to be significant (P<0.05) were adjusted for in the 
association analysis with SCN1A SNP genotype. 
AED WHO 
DDD 
(mg) 
Cohort Maximum 
PDD range (mg/day) 
Cohort Maintenance PDD 
range (mg/day) 
Carbamazepine 1000 200-2800 100-1400 
Gabapentin 1800 600-4800 300-3600 
Lamotrigine 300 25-675 50-675 
Oxcarbazepine 1000 150-3000 450-1500 
Topiramate 300 25-800 37.5-400 
Valproate 1500 100-3000 200-1500 
Levetiracetam 1500 100-3000 - 
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4.2.8. Regression analyses for association with rs3812718 
 The aim of the regression analysis was to investigate whether rs3812718 genotype 
associated with AED dose requirement. For each dose variable (maximum and maintenance), 
two regression models were built and compared using the LRT. The first model, the ‘baseline 
(or non-genetic) model’ included demographic and clinical factors found to be significant in 
the univariate analysis. Dose data for all drugs were included in the regression model as 
covariates. The second model, the ‘genetic model’, was the same as the first but also included 
a covariate representing the SNP.  
 The nature of the SANAD cohort data used in this study meant that some patients 
contributed more than one observation to the analysis of maximum dose. Mixed-eﬀect models 
include additional random-eﬀect terms and are often appropriate for representing clustered, 
dependent data that are either; collected hierarchically, when observations are taken on related 
individuals (such as siblings), or when data are gathered over time on the same individuals. 
For the maximum dose variable, linear mixed models (SPSS-Generalised Linear Model 
function) were thus fitted to capture the hierarchical structure of the data (Everitt and Howell, 
2005) (http://www.wiley.com/legacy/wileychi/eosbs/pdfs/bsa251.pdf).  
 An additional regression analysis was performed to test for possible drug specific genetic 
influence or drug-gene-interaction. If the rs3812718 genotype was found to be significantly 
associated with maintenance and/or maximum dose from the linear regression analysis 
described above, another regression model was fitted that, in addition to SNP genotype and 
non-genetic factors, included interaction terms for each drug as additional covariates. This 
third model was termed the interaction model and was compared to the genetic model, with 
the LRT again employed for testing association and a chi-square distribution p-value of <0.05 
again used to indicate a statistically significant difference. 
 
4.3. Results 
The rs3812718 polymorphism did not deviate from HWE (P>0.001). Of the 817 
individuals for whom DNA was available, 637 had sufficient clinical data to be considered for 
genotyping (28 individuals had no follow up data whatsoever, 138 took two or more drugs in 
combination throughout treatment, 5 had missing dose data, and 9 had some ambiguity in 
either drug administration or dosing). A further 51 patients failed genotyping for the 
rs3812718 polymorphism. The remaining 586 individuals were treated with AED 
monotherapy and had dose and genotype data for inclusion in the data analysis. Patient 
characteristics are summarised in Table 4.5. Frequencies for the SCN1A rs3812718 G>A 
polymorphism in these 586 individuals were 28%, 54% and 18% for the GG, GA and AA 
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genotypes, respectively. Figures 4.5A and 4.5B show the distribution of standardised 
maintenance and maximum dose ratios.  
 
 
 
Table 4.5 Characteristics of the patient population  
  Cohort n=586 
Age (years) Minimum 5 
 Mean (± SEM) 39.26 (± 0.76) 
 Maximum 84 
Gender (n) Male 322 
 Female 264 
Epilepsy type (n) IGE 95 
 LRE 399 
 UNC 92 
Maximum dose  
(PDD/DDD ratio)  
Minimum 0.1 
Mean 0.87 
Maximum 3 
Maintenance dose 
(PDD/DDD ratio)  
Minimum 0.1 
Mean 0.64 
Maximum 2.25 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy, PDD = prescribed daily dose, DDD= defined daily dose, SEM = 
standard error of the mean 
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4.3.1. Results of the maintenance dose analysis 
Maintenance dose data was available for 301 of the 586 patients (Table 4.6 and Figure 
4.5A). Tables 4.7 and 4.8 show results of the univariate analysis for non-genetic investigation 
and regression analyses. Maintenance dose ratio showed no statistically significant association 
with any of the non-genetic variables (P>0.05). Similarly no significant association was 
identified with rs3812718 genotype in the regression analysis (P=0.324, Figure 4.6). 
Distribution of dose ratios for all six AEDs included in the analysis are displayed in Figure 
4.7. 
 
 
 
 
Table 4.6 Dose data for each drug included in the study 
The median and range of maximum and maintenance doses for each drug included in the 
analysis, plus the total number of maximum and maintenance doses for each drug. 
 
 
 
 
 
 
 
Maximum 
Dose data 
(mg) 
Maintenance 
dose data (mg) 
Total 
maintenance 
doses (n) 
Total 
maximum 
doses (n) 
Carbamazepine 
Median 
Range 
800 
2600 
 
600 
1300 
53 168 
Gabapentin 
Median 
range 
 
1800 
4200 
 
1200 
3300 
30 96 
Lamotrigine 
Median 
Range 
 
200 
650 
150 
625 87 211 
Oxcarbazepine 
Median 
Range 
 
1200 
150 
 
900 
1050 21 57 
Topiramate 
Median 
Range 
 
150 
775 
 
150 
363 
66 143 
Valproate 
Median 
Range 
 
1000 
2900 
 
1000 
1300 44 97 
Levetiracetam 
Median 
Range 
1500 
2900 
- 
- - 23 
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Table 4.7 Univariate analysis of non-genetic factors and maintenance dose ratio 
 Analysis F-statistic P-value 
Age Continuous 0.77 0.73 
Gender Categorical (male / female) 1.02 0.31 
Epilepsy 
type 
Categorical (IGE, LRE, UNC) 1.02 0.36 
 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy 
 
 
 
 
 
 
 
Table 4.8. Contribution of clinical and genetic variables to maintenance dose  
Covariate Parameter t-statistic Parameter  
P-value 
Non-genetic model 
Individual drugs only 
CBZ 
OXC 
TPM 
VPA 
GBP 
LTG 
0.03 
0.40 
-0.11 
0.02 
0.25 
0a 
0.73 
0.00 
0.12 
0.76 
0.01 
. 
Genetic model 
Individual drugs plus SNP 
CBZ 
OXC 
TPM 
VPA 
GBP 
LTG 
rs3823728 
-0.25 
-0.22 
 0.17 
-0.35 
-0.21 
 0.00 
-0.04 
0.03 
0.41 
-0.10 
0.03 
0.25 
0a 
-0.04 
LRT P-value   0.32 
LRT = Likelihood Ratio Test, 0a = parameter set to 0 by SPSS as redundant in model 
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4.3.2. Results of the maximum dose analyses 
Multiple maximum dose data was available from some individuals and so in total 795 
different maximum doses for n=586 individuals were included for analysis (168 CBZ, 96 GBP, 
211 LTG, 23 LEV, 57 OXC, 143 TPM, 97 VPA) (Table 4.6). Univariate analysis for testing 
association of maximum dose ratio with non-genetic factors is shown in Table 4.9. Epilepsy 
type was found to be associated with maximum dose ratio (P=0.044) (Table 4.9). A higher 
average maximum dose PDD/DDD ratio was evident in individuals with LRE when compared 
to those with UNC. No associations were found with either age or gender. 
The results of the regression analysis for standardised maximum dose for each drug are 
presented in Table 4.10. When the non-genetic model and model including epilepsy type and 
SNP were compared using the LRT, a significant association was found with maximum dose 
ratio (P= 0.022; Table 4.10, Figure 4.8). Figure 4.9 shows the distribution of maximum dose 
ratios for all six AEDs included in the analysis. 
 
 
 
Table 4.9 Non-genetic association with maximum dose ratio 
 Analysis F-Statistic P-value 
Age Continuous 0.990 0.54 
Gender Categorical (male / female) 1.802 0.11 
Epilepsy type Categorical (IGE, LRE, UNC) 3.141 0.04 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy 
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Table 4.10 Contribution of clinical and genetic variables to maximum dose ratio 
Covariate Parameter Regression  
coefficient 
Parameter  
P-value 
Individual drugs and clinical 
variables 
IGE 
LRE 
UNC 
CBZ 
OXC 
TPM 
VPA 
GBP 
LEV 
LTG 
0.06 
0.03 
0a 
-0.01 
0.14 
-0.09 
-0.03 
0.12 
0.12 
0a 
0.06 
0.25 
. 
0.61 
0.00 
0.00 
0.23 
0.00 
0.02 
. 
Genetic model 
Individual drugs plus clinical 
covariates plus SNP 
IGE 
LRE 
UNC 
CBZ 
OXC 
TPM 
VPA 
GBP 
LEV 
LTG 
rs3823728 
0.06 
0.03 
0a 
-0.01 
0.14 
-0.09 
-0.04 
0.12 
0.12 
0a 
0.02 
0.06 
0.25 
. 
0.63 
0.00 
0.00 
0.21 
0.00 
0.02 
. 
0.17 
LRT P-value   0.02 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy, LRT = Likelihood Ratio Test, 0a = parameter set to 0 by SPSS as 
redundant in model 
 
 
  
 
4.3.3. Results of drug interaction analysis for maximum dose ratio 
Since a statistically significant association was identified with maximum dose ratio in 
the initial genetic analysis, this suggested a potential contribution of the SCN1A SNP to AED 
maximum dose requirement and an interaction analysis was subsequently performed to 
investigate whether AED influenced the effect of SNP genotype. Table 4.11 presents the 
results of LRT for the genetic model comparisons. This regression analysis compared the 
genetic regression model described above with a model additionally containing interaction 
terms for each drug. This also showed a statistically significant association with maximum 
AED dose ratio (P= 6.46 x10-4; Table 4.11). Box plots for each AED dose ratio association 
with rs3812718 genotype are presented in Figure 4.11a and b.  Table 4.12 presents the mean 
maximum dose ratio for each genotype group also stratified by individual AED. 
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Table 4.11 Regression analysis of interaction effects with maximum dose ratio  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGE = idiopathic generalised epilepsy, LRE = localisation-related epilepsy, UNC = 
unclassified epilepsy, LRT = Likelihood Ratio Test, 0a = parameter set to 0 by SPSS as 
redundant in model 
 
 
 
 
 
  
 
 
 
Covariate Parameter Regression  
coefficient 
Parameter  
P-value 
Individual drugs and 
clinical variables 
IGE 
LRE 
UNC 
CBZ 
OXC 
TPM 
VPA 
GBP 
LEV 
LTG 
rs3823728 
0.06 
0.03 
0a 
-0.01 
0.14 
-0.09 
-0.04 
0.12 
0.12 
0a 
0.02 
0.06 
0.25 
. 
0.63 
0.00 
0.00 
0.21 
0.00 
0.02 
. 
0.17 
Genetic model 
Individual drugs plus 
clinical covariates 
plus SNP 
IGE 
LRE 
UNC 
CBZ 
OXC 
TPM 
VPA 
GBP 
LEV 
LTG 
rs3823728 
CBZ * rs3823728 
OXC * rs3823728 
TPM * rs3823728 
VPA * rs3823728 
GBP * rs3823728 
LEV * rs3823728 
LTG * rs3823728 
0.06 
0.03 
0a 
-0.02 
0.14 
-0.08 
-0.06 
0.15 
0.13 
0a 
0.02 
0.01 
0.00 
-0.01 
0.02 
-0.04 
-0.01 
0a 
0.06 
0.23 
. 
0.53 
0.02 
0.05 
0.24 
0.00 
0.12 
. 
0.47 
0.69 
0.94 
0.69 
0.61 
0.37 
0.86 
. 
LRT P-value   0.0006 
  CHAPTER FOUR 
 
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11a  Box plots for distribution of maximum dose ratios with genotype 
Distribution of maximum dose ratios of AEDs lamotrigine, carbamazepine, oxcarbazaepine 
and topiramate, based on SCN1A rs3812718 genotype groups. Boxes represent 25th and 75th 
percentile, solid lines represent the median dose ratio and whiskers represent minimum and 
maximum dose ratio in each genotype group. 
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Figure 4.11b Box plots for distribution of maximum dose ratios with genotype 
Distribution of maximum dose ratios of AEDs gabapentin, valproate, and levetiracetam, based 
on SCN1A rs3812718 genotype groups. Boxes represent 25th and 75th percentile, solid lines 
represent the median dose ratio and whiskers represent minimum and maximum dose ratio in 
each genotype group. 
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Table 4.12 Mean maximum dose ratio for each genotype group stratified by 
individual antiepileptic drug 
 
 
 
 
4.4. Discussion 
A previous report has implicated the SCN1A rs3812718 G>A variant in influencing 
the maximal dose of two established Na+ channel blocking AEDs (PHT, CBZ) administered 
to individuals with epilepsy. Although not all attempts to validate the potential significance of 
this SNP in several independent PGx investigations were successful in identifying a similar 
association with AED dosing, the evidence produced by a number of recent functional studies 
is promising.  
Despite failure to replicate the original association with CBZ, the present investigation 
provides support for the role of rs3812718 in maximum AED dosing. The effect of this 
polymorphism on maximum and maintenance doses of AEDs was examined, irrespective of 
their primary drug target, using a normalised drug dose (PDD/DDD ratios). A significant 
association between AED maximum dose ratio and the rs3812718 polymorphism was 
identified in this investigation, suggesting the variant genotype of this SNP may influence 
AED maximum dose in newly-diagnosed epilepsy. Individuals with the rs3812718 variant AA 
genotype showed a significantly higher PDD/DDD ratio than those with the rs3812718 GG 
genotype (Table 4.10, Figure 4.8). In contrast no significant genotype effect on dosing was 
observed for maintenance dose (Table 4.7, figure 4.6). 
 rs3812718 Genotype 
 
Antiepileptic drug 
GG GA AA 
Lamotrigine 0.88 0.81 1.02 
Carbamazepine 0.78 0.81 0.93 
Oxcarbazepine 1.11 1.13 1.19 
Topiramate 0.70 0.73 0.67 
Gabapentin 1.11 1.12 0.94 
Valproate 0.80 0.75 0.93 
Levetiracetam 0.95 1.30 1.03 
  CHAPTER FOUR 
 
142 
 
4.4.1. SCN1A genotype affects maximal antiepileptic drug dosage 
The association between SNP genotype and maximum AED dose identified in this study 
appears to confirm the initial hypothesis that polymorphisms in NaV channel genes can 
influence the dosing of AEDs.  The original study by Tate et al 2005 reported that for both 
PHT and CBZ, average maximum dose differed by genotype in the order AA>AG>GG (Tate 
et al., 2005). The rs3812718 polymorphism was also shown to affect the proportion of 
alternative transcripts in brain tissue from individuals with a history of refractory epilepsy, 
which could in turn affect channel sensitivity to sodium blocking activity of AEDs (Tate et al., 
2005, Tate et al., 2006). The authors thus proposed that common polymorphisms in SCN1A 
alter the sensitivity of the NaV channel to Na+ channel blocking drugs (Tate et al., 2005, Tate 
et al., 2006). The present investigation included dose data from several different classes of 
AEDs including the previously associated AED CBZ, and so was not confined to those known 
to exhibit Na+ channel blocking activity, though association was still evident.  
 
4.4.2. Non-specific effect of the SCN1A variant on maximum dose 
The mechanism of action of most AEDs is not completely understood (Kwan et al., 
2001). The majority of commonly utilised AEDs are generally classed into three main types 
based on their individual molecular site of action, mainly; i) those modulating voltage-
dependent ion channels (Na+, Ca2+, K+), ii) those enhancing GABA mediated inhibitory 
neurotransmission, and iii) those involved in the attenuation of excitatory (particularly 
glutamate-mediated) transmission (Meldrum, 1996, Kwan et al., 2001). Out of the seven AEDs 
analysed CBZ, LTG and OXC are known to principally modulate NaV channels (Kwan et al., 
2001, Schachter, 2007). On the other hand VPA and TPM have been proposed to display a 
number of mechanistic pathways. In addition to NaV blocking properties they are also 
associated with Ca2+ blockade and facilitation of the effects of the inhibitory neurotransmitter 
GABA (Kwan et al., 2001, Schachter, 2007). GBP appears to bind to the α2δ subunit of 
neuronal voltage-gated calcium channels, but has been suggested to have some NaV blocking 
activity. LEV is associated multiple mechanisms. In addition to the novel mechanism of SV2A 
protein binding, LEV has actions on neuronal GABA- and glycine-gated currents and K+ 
currents, though it’s exact mechanism of action is unknown. The hypothesis of the present 
investigation was that the functional SCN1A variant which has previously been demonstrated 
to affect the pharmacological and/or structural properties of the NaV channel (Thompson et 
al., 2011), and alter maximum dose for PHT and CBZ could also alter therapeutic dosage 
requirements of some and/or all these additional AEDs (Tate et al., 2005, Tate et al., 2006).  
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4.4.3. Evidence for drug-gene interaction and differential drug effect 
 A recent study concerning the NaV channel and SCN1A rs3812718 variant demonstrated 
an alteration in NaV channel sensitivity to LTG and PHT but not CBZ, suggesting a differential 
effect of the rs3812718 splicing variant on the binding properties of the NaV channel 
(Thompson et al., 2011). The variant NaV1.1-5N channel was shown to exhibit greater tonic 
and use-dependent inhibition by PHT and LTG than the NaV1.1-5A channel, suggesting that 
binding sites for these AEDs could slow down inactivation processes, which result in 
pharmacologic differences between AEDs (Thompson et al., 2011). At therapeutically relevant 
concentrations, the NaV1.1-5N channel was more sensitive to PHT and LTG. The authors 
proposed an alteration in LTG and PHT dose requirement due to this increase in channel 
sensitivity (Thompson et al., 2011).   
The interaction analysis performed for maximum dose in the present investigation 
identified a stronger genetic effect when drug type was taken into account. This appears to 
confirm the original SNP association reported by Tate et al 2005 and also implies that this 
association may additionally be influenced by the AED administered (Thompson et al., 2011). 
Due to the low numbers of individuals that were prescribed each of the individual AEDs in 
the present study, however, this finding could not be fully stratified by drug type. And so, 
although the present findings present a strong statistical association (P<0.01) between 
genotype and dose when drug interaction was considered, one cannot accurately distinguish 
which AEDs were most influenced by rs3812718 genotype. The present results can however 
be taken to signify that a drug specific genotype effect may exist. Further investigation is 
necessary for more conclusive evidence for drug-SNP interaction in AED maximum dosing.   
Finally, the original association reported with CBZ maximum dose and rs3812718 was 
not validated. No association between CBZ maximum dose and genotype was evident from 
the interaction regression analysis or when CBZ was tested alone (Interaction regression P = 
0.598; ANOVA P = 0.207; Figure 4.11a and b; Table 4.12). This implies lack of influence of 
rs3812718 on CBZ maximum dose. 
 
4.4.4. rs3812718 variant genotype does not influence maintenance dose  
Maintenance dose can be used as a measure of the dose at which optimum response is 
observed (Patsalos and Bourgeois, 2010, Talati et al., 2011), and presumed to reflect dose at 
which seizures were controlled in this study. Maximum dose is, in contrast, most likely a 
measure of an individual’s tolerability to an AED (Dlugos et al., 2006). Maintenance dose may 
therefore be a more informative measure of seizure control than maximum dose and a more 
accurate depicter of clinical effect (Tate et al., 2006). This was acknowledged by the authors 
of the original report (Tate et al., 2006), who in a subsequent study attempted to correlate 
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maintenance dose of PHT with rs3812718 genotype and presented a modest SNP-dose 
association. The present analysis similarly examined maintenance dose for several AEDs, 
though failed to find an association between AED maintenance dose and the rs3812718 SNP.   
Reasons for the lack of association with maintenance dose in the present analysis 
includes; the limited availability of maintenance dose data. In addition, there were 
considerably fewer individuals with maintenance dose data than maximum dose data in the 
present study (n=301 vs. n=795, respectively). This was not surprising given the stringent 
definition of maintenance dose, the fact that only 60-70% of all newly-diagnosed patients can 
expect to achieve a 12 month remission, and that multiple maximum doses were available for 
some patients.           
 This methodology for dose analysis was for the most part beneficial, as it allowed the 
combination of data from different AEDs. Dose standardisation however can dilute drug 
specific genotype associations, i.e. AEDs that primarily block the NaV channel as presumed in 
the original hypotheses (Tate et al., 2005, Tate et al., 2006). Although stratification by drug 
adjusts for a drug specific dose-SNP effect, an interaction analysis was only performed if an 
association was identified in the initial linear regression analysis of SNP vs. dose and this was 
not the case with maintenance dose.  
 The original PGx study concerning rs3812718 in AED dosing was the first publication 
presenting the potential effect of a primary AED target polymorphism on the clinical use of 
anticonvulsant drugs (Tate et al., 2005) and was strengthened by functional evidence from 
brain tissue expression data (Tate et al., 2005, Heinzen et al., 2007, Thompson et al., 2011). 
Other studies have investigated the rs3812718 SNP, with one showing association with LTG 
dosing in Caucasians, and also a significantly higher frequency in epilepsy patients compared 
to controls, implying that this polymorphism may additionally contribute to the pathogenesis 
of epilepsy (Krikova et al., 2009). The AA genotype has also been shown to be significantly 
more frequent in Japanese patients resistant to CBZ treatment (Waldegger et al., 1999). 
  In another study, no relationship was found in 377 Chinese patients between NaV 
blocking AEDs and rs3812718 genotype (Kwan et al., 2008). More recently a study by Mann 
et al 2011 investigating CBZ and OXC in drug-resistant and drug-responsive subjects from 
Italy similarly concluded no major role of the SCN1A rs3812718 polymorphism as a 
determinant of AED response (Manna et al., 2011). The failure to identify an association with 
CBZ in the present analysis could be attributed to the possibility that the effect size of the 
original association may have been overestimated. If the original relationship identified 
between CBZ and PHT and the variant allele of rs3812718 was only modest in size, it may 
not have been detected in the present patient population, which was smaller than that used in 
the original study (CBZ treated patients n=168 and n=425 respectively).  
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Despite the lack of consistency in PGx data surrounding the SCN1A rs3812718 
variant, and failure to replicate the original association with CBZ, the present investigation 
provides support for the role of rs3812718 in maximum AED dosing. However, it is likely that 
only a small proportion of the variation in AED dose can be explained by the variant. Because 
of the complexity of drug response phenotypes it is expected that additional genetic factors 
are also involved in the variability of AED dosing, and this could additionally explain the lack 
of consistency in previous studies. Most previous investigations solely involved NaV channel 
blocking drugs and patients with unknown (or at least unstated) causes of epilepsy. Different 
cohorts are also likely contain different ratios of genetic or non-genetic epilepsy syndromes, 
and so the influence of rs3812718 on AED dosage may be obscured or outweighed in some 
patient populations. Discrepancies between these studies may thus mainly result from varying; 
i) cohort size, ii) heterogeneity of epilepsy syndromes in population samples, or iii) differences 
in ethnic backgrounds (so far Caucasian, Chinese and Japanese patient cohorts have been 
investigated). Finally some studies have shown that in experimental epilepsy models there is 
a significant change in expression of NaV channels in response to seizures, and so seizure 
frequency, and/or epilepsy severity may also be a contributing factor to changes in response 
to AEDs (Gastaldi et al., 1997, Aronica et al., 2001). 
 The report by Tate et al 2006 identified an association between rs3812718 with serum 
concentrations of PHT at maintenance dose, with no associations observed for maximum dose 
(Tate et al., 2005, Tate et al., 2006). This additional drug concentration data eliminated PK 
factors as a source of variation, revealing a relationship with maintenance dose. This could 
explain our findings, in that the lack of concentration data may be masking any genotype effect 
on maintenance dose. Serum AED levels, if available, may be more successful for identifying 
associations between the SCN1A variant and drug doses or treatment outcomes in future 
analyses.  
 Limitations have also been recognised in the original investigation that potentially 
confound the dependability of the observations reported. The main issue being the sole use of 
maximum dose data by the authors. Maximum tolerated dose could be a useful indicator of 
individual dose ceiling, however, in the treatment of epilepsy moderate doses of AEDs are 
usually sufficient for seizure control and patients may never reach their individual limit of 
tolerability. Maintenance dose data can serve as a more accurate and informative measure of 
clinical response. Another potential confounding factor in the original report was the inclusion 
of both monotherapy and polytherapy patients which could affect the reliability of any 
associations observed. AEDs are highly susceptible to drug-drug interactions (Patsalos and 
Perucca, 2003, a, Perucca, 2006), therefore are associated with altered serum drug 
concentrations, often necessitating dosage adjustment, and can also influence AED tolerability 
(Johannessen et al., 2003, Anderson, 2008). Age and concomitant medication are additional 
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factors that can greatly impact drug PK thereby altering the amount of AEDs required by 
individual patients. The original authors likewise did not provide basic data such as age at 
onset of treatment, disease aetiology and syndrome type (discussed above).  Considering 
these limitations, one can argue that, the rs3812718-AED dose association is unproven. The 
results presented in this study in combination with the recent positive associations and latest 
functional evidence may however still provide a link between patient genotype for drug target 
variants and AED response.  
In summary, our data suggests that the SCN1A rs3812718 G>A polymorphism may 
influence maximum dose of AEDs. However, the modest effect size would question its clinical 
utility. Further analysis of the effect of this polymorphism on individual NaV blocking AEDs 
may be useful. The validation of the original hypothesis of Tate et al 2005, 2006, by identifying 
a genotype-dose association is promising, and indicates the relevance of drug target 
polymorphisms in individual AED treatment. Nevertheless, the necessity for consistent results 
to confirm the true effect of rs3812718 on AED dosing remains. Replication of the current 
results of SCN1A genotype-drug and dose associations using a broad selection of AEDs is 
required. Likewise future investigations utilising dosage, and serum concentration data, ideally 
in a larger cohort of patients, with homogeneous epilepsy phenotypes could prove beneficial 
to the SCN1A rs3812718 polymorphism story. 
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5.1. Introduction 
The majority of PGx research concerning AED response has, until recently, focused 
on a relatively small number of SNPs in a few selected candidate PK and PD genes (Depondt, 
2006b, Loscher et al., 2009), an overview of which has been given in an earlier chapter 
(Chapter 1). However, many PGx investigations, including those in the epilepsy field, now 
routinely include multiple genes implicated in both disease pathogenesis and the PK and PD 
pathways of drugs (Grant and Hakonarson, 2007, Petrovski et al., 2009, Motsinger-Reif et al., 
2010, Cavalleri et al., 2011). This has led to an interest in relevant analytical methods for 
modeling large volumes of data that take into account the complex, multifaceted network of 
genes involved in such drug response phenotypes. Accurate classification and prediction 
algorithms from systems biology methodologies are thought to help meet this data analysis 
challenge (Baksh and Kelly, 2007). These are not only designed to allow for the multigenic-
multifaceted nature of drug response data and gene-network interactions, but are also 
considered better for the statistical challenge of detecting multiple, small associations in high-
dimensional data and thus may ensure more efficient data analysis (Hirschhorn et al., 2002, 
Ritchie and Motsinger, 2005, Baksh and Kelly, 2007, Pander et al., 2010, Rodin et al., 2011, 
Vanneschi et al., 2011).  
 
5.1.1. Systems biology approach to genomic analysis 
A systems biology approach to analysis of pharmacogenomics data typically involves three-
steps; i) selection of variables (SNPs), ranked in order of effect on drug response phenotype, 
ii) a modelling step involving the generation of a predictive model using SNPs and other 
relevant factors, and iii) evaluation of generated models using conventional statistical analysis 
methods (Koster et al., 2009).  
 
5.1.2. Machine learning methods in genomic prediction 
  ML is a computer-based data mining method derived from the field of artificial 
intelligence and concerned with the design and development of algorithms to allow machines 
to learn, make predictions, or extract knowledge from data. It represents a powerful approach 
to identifying non-linear/complex patterns in high-dimensional datasets (Hastie et al., 2001, 
McKinney et al., 2006, Zhang and Rajapakse, 2009) and makes intelligent decisions based on 
knowledge from data or to make predictions on new data (Hastie, Tibshirani et al. 2001) 
(Figure 5.1).  
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Figure 5.1 The machine learning approach to data inference 
A schematic representation of the computer based machine-learning approach to data analysis. 
This entails learning or data inference from existing data of known values (training data). 
Algorithms are then generated and used to make predictions for new data of unknown values. 
 
 
 
 
Typical ML methods applied to genomic studies model data using Bayesian networks, 
which allow the inferential exploration of previously undetermined relationships among 
genetic and clinical variables, and describe these relationships once identified (an hypothesis- 
or model-free approach) (Hoppe, 2005, Zhang and Rajapakse, 2009, Rodin et al., 2011). In 
recent decades ML approaches have been successfully applied to computational biology and 
bioinformatics (Hastie et al., 2001, Larranaga et al., 2006, Zhang and Rajapakse, 2009) and 
are now becoming routine in the biological domains of genomics, proteomics, microarrays and 
systems biology (Bhaskar et al., 2006a, Larranaga et al., 2006).  
 ML approaches can be used for the development of prediction models that allow 
integration of the interactions between multiple genetic variables i.e. SNPs in addition to 
clinical variables and disease phenotype and so overcome the main limitation of traditional 
statistical approaches through their ability to model high-dimensional data (Hoppe, 2005, 
Wilke et al., 2005). Additional advantages of ML methods include robustness of parametric 
assumptions, high power and accuracy (useful for extracting information from underpowered 
association studies), ability to model non-linear effects, and the availability of numerous well-
developed algorithms (Moore and Ritchie, 2004, McKinney et al., 2006). ML models for data 
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classification may better identify patterns of genetic variants that associate with phenotypes of 
interest in high-dimensional data (Lee et al., 2008).  
 
5.1.3. Supervised and unsupervised learning methods 
Learning scenarios for ML application can be categorised as either supervised or 
unsupervised (Hastie et al., 2001). In unsupervised learning, there is no outcome measure, and 
the goal is to describe how the data are organised or clustered (objects are often classified by 
a similarity measure that defines how closely related those objects are). The goal of supervised 
learning is to predict the value of an outcome measure based on a number of input measures 
or features (i.e. using prior knowledge from existing data for training). The classifier is then 
used to generalise from new instances (Hastie et al., 2001, Kotsiantis, 2007, Emmert-Streib 
and Dehmer, 2010). Supervised learning algorithms usually produce classifiers in the form of 
a function (Emmert-Streib and Dehmer, 2010) and are more relevant and applicable to the 
mining of genetic data for disease association analysis (McKinney et al., 2006). 
 
5.1.4. Machine learning prediction models or classifiers 
In a typical supervised ML scenario, an outcome measurement (i.e. cardiac arrest/no 
cardiac arrest) is predicted based on a set of features such as diet and clinical measurements. 
There is also a training set of data in which the outcome and feature measurements can be 
observed for a set of seen or known objects (i.e. patients) (Hastie et al., 2001). Using this 
training data, a prediction model (or classifier) is built using a function that enables prediction 
of outcome to be made for new unseen objects (Hastie et al., 2001). Several methods exist for 
assessing ML classification models. Model performance is usually assessed by how well the 
classifier can predict outcomes for independent test datasets based on the rules it has learned 
from the training data (Hastie et al., 2001, Larranaga et al., 2006). Other common methods of 
assessment include cross-validation and bootstrapping. Figure 5.2 shows a schematic 
representation of ML classification models and the main stages involved in model building. A 
more detailed description of the development and assessment of ML models for disease 
classification, including details of several ML approaches commonly applied to genomic data, 
can be found in Chapter 6.  
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Figure 5.2 Building machine learning classification models 
Classification 
Model 
Classification Model 
Classification 
Model 
We start off with a data matrix, and a corresponding 
class vector which indicates the class of each sample 
We build a classification model 
Once you have a classification model built on known 
data this can be then applied to newly acquired data 
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5.1.5. Machine learning algorithms for genomic classification 
The use of systems biology data analysis methods derived from ML have steadily 
grown in genomics over the last two decades (Hastie et al., 2001, Emmert-Streib and Dehmer, 
2010). ML approaches, known as classification algorithms, are well suited to genomic data 
and are widely employed (McKinney et al., 2006, Kotsiantis, 2007, Rodin et al., 2011). 
Classification algorithms are able to predict (or assign) a class (e.g. case or control) to each 
data point, based on the values of potentially predictive variables (e.g. SNPs) and additionally 
build a model capturing the relationships between the variables (Kotsiantis, 2007, Rodin et al., 
2011). Classification algorithms were first applied to SNP data within bioinformatics for the 
prioritisation of candidate polymorphisms by predicting their likely impact on disease 
susceptibility (Shah and Kusiak, 2004, Rodin et al., 2011, Zhao et al., 2011).  
 There are numerous ML approaches available for both selecting informative features 
and/or combining them into a classifier, ranging from simple linear classifiers to complex 
nonlinear functions (Hastie et al., 2001, Kotsiantis, 2007). Examples of those commonly found 
in multi-locus traits (i.e. diabetes, heart disease, alcoholism and breast cancer) include multi-
factor dimensionality reduction (MDR)(Ritchie and Motsinger, 2005, Vanneschi et al., 2011), 
neural networks (Lucek and Ott, 1997, Motsinger et al., 2006), random forest (RF) (Yoon et 
al., 2003, Bureau et al., 2005), support vector machine (SVM) (Yoon et al., 2003, Yu and 
Shete, 2005) and k-nearest neighbor (kNN), for which complex disease data is only just 
emerging (Szymczak et al., 2009). Examples of the application of these ML approaches can 
also be found for gene discovery in GWAS data from multiple sclerosis and type II diabetes 
(Szymczak et al., 2009, Ban et al., 2010, Goldstein et al., 2010).  
 
5.1.6. Machine learning approaches in pharmacogenetics 
ML approaches have also recently been proposed for modeling SNP data to produce 
PGx SNP classifiers, which may be more effective for predicting treatment outcome in drug 
response data than the standard linear regression data modeling approach (Pander et al, 2010). 
Whilst there is a large amount of literature on the development of ML approaches for the 
analysis of high dimensional data, much of this research is in the context of disease status, 
susceptibility and activity, whereas the application of ML approaches to PGx data is a 
relatively new phenomenon (Simon, 2005, Simon and Wang, 2006, Pander et al., 2010). The 
development of predictive models incorporating the interplay of numerous genetic factors 
(amongst other features) potentially contributing to this multi-genic phenotype presents an 
ideal strategy for confirming which genes and/or gene-gene or gene-environment interactions 
are of most significance, and is thus potentially a critical step on the road to individualised 
prescribing and new drug discovery (Simon and Wang, 2006). 
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 PGx studies utilising ML methods are still emerging (Lee et al., 2008, Pander et al., 
2010). A number of recent examples of the application of ML algorithms to 
pharmacogenomics data from several important disease domains can be found. These include 
predicting treatment response to chemotherapeutics in oncology (Ad et al., 2002, Ritchie and 
Motsinger, 2005, Simon, 2005, McKinney et al., 2006, Simon and Wang, 2006, Wang, 2007, 
Lee et al., 2008), anti-retroviral therapy (Altmann et al., 2007), toxicity to statin therapy 
(Ritchie and Motsinger, 2005) and, more recently, predicting warfarin dose (Cosgun et al., 
2011). 
 
5.1.7. Machine learning methods for detecting epistatic interactions   
As discussed previously, gene-gene interactions or epistasis is a well-known challenge 
in data analysis for complex traits and has been recognised as a problem that needs to be 
addressed in PGx (Ritchie and Motsinger, 2005, Pander et al., 2010). A growing number of 
researchers are now considering the use of data-reduction ML techniques previously used for 
advanced genetic interaction or environmental factor analysis, including the MDR method 
mentioned above (Moore et al., 2004, Moore and Ritchie, 2004, Ritchie and Motsinger, 2005, 
McKinney et al., 2006, Moore et al., 2006). MDR is a ML method specifically designed to 
identify interacting combinations of genetic variants associated with increased risk of 
common, complex, multifactorial human disease (Ritchie et al., 2003, Moore, 2004). 
 
5.1.8. Application of machine learning to epilepsy pharmacogenetics 
The application of ML approaches is one of the latest developments in epilepsy PGx. 
So far there are only three published examples of the development of predictive models for 
treatment response in epilepsy research. These include two investigations utilising the MDR 
data reduction method (Kwan et al., 2008, Jang et al., 2009, Kim et al., 2011b) and a single 
study applying a ML data-mining approach (Petrovski et al., 2009).  
 
5.1.9. kNN machine learning method in epilepsy pharmacogenetics 
 A ML data-mining approach was applied in a recent, proof of principle study 
examining PGx data from patients with epilepsy (Petrovski et al., 2009). The study utilised a 
kNN algorithm to develop a multi-SNP classification model that was proposed to predict 
response to initial AED treatment in Australian patients with newly treated epilepsy, with a 
predictive accuracy of 83.5%. A total of 4041 SNPs from 279 candidate genes were genotyped 
in 115 patients, five of which were ranked as having the most influence on treatment outcome 
(Petrovski et al., 2009). The ML supervised learning kNN algorithm was then used to develop 
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a classification model based on the genotype of these five SNPs (Petrovski et al., 2009). The 
kNN classifier algorithm was designed and implemented using in-house software by the 
original authors (Petrovski et al., 2009). The predictive value of the model was subsequently 
confirmed in two small, independent Australian cohorts. It was reported to have a sensitivity 
of >80% and in each of these replication cohorts, the multigenic model proved to be more 
accurate in predicting drug responsiveness than any of the single SNPs alone (Petrovski et al., 
2009).  
 
5.1.10. Summary and research aims 
 As discussed previously, a substantial proportion of people with epilepsy continue to 
have seizures despite treatment with appropriate AEDs (Kwan and Brodie, 2000a, Duncan et 
al., 2006, Szoeke et al., 2006). It is not currently possible to accurately predict the likelihood 
of seizure control with any given AED treatment. Success or failure in terms of efficacy 
consequently cannot be adjudged until a therapeutic dose is reached, often many weeks or 
months after treatment initiation (Kwan et al., 2010). As such, the identification of biological 
markers that may provide improved prediction of treatment response in an individual patient 
is likely to be of significant clinical value. The Australian multigenic kNN classifier not only 
represents a successful application of a ML approach to epilepsy PGx data but also identified 
biological markers that might prove clinically significant to AED response. However, this 
classifier requires validation in larger cohorts and application across different populations and 
health care systems to adequately assess its reliability prior to consideration for use in clinical 
care.  
 There were two main aims of this study; (i) to assess the broader clinical utility of the 
Australian multigenic kNN model, and (ii) to assess relevance of the five SNPs comprising the 
classifier to treatment response in non-Australian populations. On that basis, the Australian 
classifier was applied to genetic data from two independently collected UK cohorts to assess 
whether it could successfully classify treatment outcome. The relative influence of the five 
SNPs on treatment outcome was also tested both individually and collectively in these patients. 
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5.2. Methods 
5.2.1. Source populations 
Patients from three independent cohorts of newly treated epilepsy were included in 
this analysis, the Australian cohort in which the multigenic kNN model was originally derived 
(Petrovski et al., 2009) and two UK cohorts (Glasgow and SANAD cohorts). The UK cohorts 
are described in detail in the general methods section (section 2.2). Patients were initially 
selected from UK cohorts if they: (i) were newly treated for epilepsy, (ii) were treated with 
AED monotherapy during their first year of treatment, (iii) had sufficient clinical information 
available, defined as at least one year of follow-up with detailed drug, dose, and outcome 
information, (iv) were of self-reported European ancestry, and (v) had provided a DNA sample 
for genotyping. 
 
5.2.2. Data extraction 
Clinical information was extracted from patient databases and or clinical notes for 
each of the UK cohorts and included age at recruitment, gender, epilepsy type, seizure type(s) 
and also drug treatment history for first 12 months of treatment (including AEs and reasons 
for switching AED). Epilepsy type was classified into three categories, IGE, LRE and UNC.  
 
5.2.3. Phenotype definitions for patient selection 
Response to AED treatment in the UK cohorts was determined in accordance with the 
definitions used to phenotype the Australian cohort in the original study (Petrovski et al., 
2009). Patients were considered to be “responders” if they remained free from seizures 
throughout the first 12 months of AED treatment. Seizures arising in the first month of 
treatment (i.e. during drug titration) and those associated with short-term non-compliance with 
medication or significant provocation (e.g. sleep deprivation) were discounted. In contrast, 
patients who continued to experience unprovoked seizures during the first year of therapy 
despite adequate AED exposure were considered to be “non-responders”. Where the first ever 
AED was discontinued within the initial 3 months of treatment as a result of intolerable AEs, 
the second AED was considered the ‘initial drug’ for the purposes of this analysis. Patients in 
whom clinical information was insufficiently detailed to allow a confident classification of 
response or who were suspected to be non-adherent with medication were excluded from the 
analysis, as in the original study (Petrovski et al., 2009). 
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5.2.4. Study populations 
 Treatment outcome phenotypes for the Glasgow and SANAD cohorts were identified 
by interrogation of the trial or clinical databases and/or clinical notes. A total of 285 and 520 
individuals were included for analysis from Glasgow and SANAD cohorts, respectively. 
 
5.2.5. Genotyping 
  The five SNPs that comprised the Australian multigenic classifier were rs658624 and 
rs678262 from the SCN4B gene and rs2808526, rs4869682, rs2283170 from the GABBR2, 
SLC1A3 and KCNQ1 genes respectively. All 285 samples from the Glasgow cohort were 
genotyped for these five SNPs at the Australian Genome Research Facility using an iPLEX 
Gold assay on the Sequenom MassARRAY compact analyser (Sequenom Inc., San Diego, 
California, USA) (Petrovski et al., 2009). SANAD samples (n=520) were genotyped in the 
Department of Molecular and Clinical Pharmacology, University of Liverpool on a Sequenom 
MassARRAY iPLEX platform in accordance with the manufacturer’s instructions (Gabriel et 
al., 2009) and as described in detail in section 2.5.  
 
5.2.6. The development of the Australian kNN multigenic model  
 The methods involved in the development and validation of the Australian multigenic 
kNN classifier model (Petrovski et al., 2009) were used for model development for this 
investigation and are described in detail in the original report (Petrovski et al., 2009). For model 
generation in the present study, the SANAD cohort was randomly stratified into training (70% 
of patients, n=343) and test (30% of patients, n=148) datasets in a manner similar to that 
originally described for the Australian cohort (Petrovski et al., 2009). The 70% training dataset 
was used for model development (training set patients are used to identify optimum parameters 
for accurate patient classification and testing association of five SNPs with patient outcome) 
and a 30% test dataset for assessing the predictive potential of the model. Each patient in the 
test dataset (30% of patients) was positioned in an N-dimensional space (in this case N=5, 
representing the SNP genotypes in the five SNP model) defined by the training dataset (70% 
of patients), with response predicted by simple majority of known treatment responses amongst 
its k-nearest neighbours (i.e. the individuals with the most similar genetic profiles at this 
combination of five SNPs). The number of nearest neighbours found to give optimal prediction 
of drug response in the Australian cohort was k = 9. A 20% cross-validation methodology was 
adopted for building the kNN model on the training dataset, where the training dataset is 
divided into five equally sized groups, each of which is excluded in turn and the remaining four 
groups used to test the model. This cross-validation step in the initial model development also 
allowed the determination of the optimal number of k- nearest neighbours to use (Petrovski et 
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al., 2009). An overview of the kNN procedure, as used to develop the five-SNP classifier is 
illustrated in Figure 5.3. 
 
5.2.7. Statistical analysis for assessment of cohort differences  
The initial statistical analysis examined patient demographics and drug treatment 
outcomes across the UK and Australian cohorts to identify differences that might confound 
subsequent analyses. Age at enrolment was assessed using ANOVA, while gender, initial 
AED, epilepsy type and drug treatment response were all assessed using Chi-square tests. Each 
of the five SNPs was also assessed for independent association with AED response in each of 
the two UK cohorts using the Cochran-Armitage test for trend. Any systematic differences 
identified in the demographic or genetic variables (SNPs) were adjusted for prior to any 
subsequent model assessment. 
 
5.2.8. Approaches for classifier assessment 
Several methods exist for assessing ML classification models. The Australian 
multigenic kNN classifier model was evaluated in the UK cohorts in three ways: (i) treating 
UK patients as independent test sets and using Australian patients to predict response in UK 
patients, (ii) re-deriving the kNN classifier using the SANAD cohort as both training and test 
datasets, and (iii) testing the performance of the kNN model in UK training datasets using a 
cross-validation n-1 approach. 
Given that the kNN model is not based on a fixed algorithm, but rather a five-
dimensional training dataset, its reliability is dependent on similar frequencies of drug 
response in the training and test datasets. When comparing the original Australian cohort with 
the two UK cohorts, there was a difference in treatment response frequencies between the 
groups. In the Australian cohort, 28% of patients were unresponsive to their initial AED, 
compared with 47% and 52% in the Glasgow and SANAD cohorts, respectively (Table 5.1). 
As a result, using the Australian cohort as the kNN training dataset to predict treatment 
response in either of the UK cohorts was expected to result in an over-estimation of the number 
of responders (i.e. false positives). Therefore, in addition to a direct test of the Australian five-
SNP model, a secondary analysis using predictions derived from the UK cohorts themselves 
was required to obtain a realistic understanding of the influence of this combination of five 
SNPs on treatment outcome in newly treated epilepsy patients from the UK. 
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5.2.9. Data stratification to account for UK cohort differences 
Due to differences between the Australian and UK cohorts, the Glasgow and SANAD 
cohorts do not represent direct validation cohorts for the Australian cohort (Table 5.1). Thus, 
to allow evaluation of whether the five SNPs from this kNN model are relevant for treatment 
response in Glasgow and SANAD patients, the UK datasets were first stratified by age, gender, 
epilepsy type, response to AED treatment, and initial AED (Table 5.1). Initial AED was 
arranged into two groups, patients whose initial treatment was with either CBZ or VPA (n=118 
and n=123 for the Glasgow and SANAD cohorts respectively), and those who were initially 
treated with one of the newer generation drugs such as GBP, LTG, or TPM (n=51 and n=123 
for Glasgow and SANAD cohorts, respectively) (Tables 5.2-5.8). The latter group was known 
as the ‘other AED treatment’ group.  
CBZ and VPA were the two most commonly prescribed initial AEDs in the Australian 
cohort (96% of the patients), whereas Glasgow patients were largely treated with either LTG 
or VPA (approximately 40% and 30% of total, respectively) and SANAD patients mostly 
received LTG or CBZ (approximately 30% and 25% of total, respectively) (Table 5.1). 
Stratification on the basis of initial AED thus controlled for this difference between the 
Australian cohort, when used as the training dataset, and the UK cohorts as test datasets. It 
also allowed determination of whether, the five kNN SNPs are universal markers of treatment 
response or selective for specific drugs (i.e. CBZ/VPA). For the purposes of the leave-one-out 
(n-1) cross-validation analysis, the Glasgow and the SANAD cohorts were additionally sub-
divided into those initially treated with LTG (n=112 and n=97, respectively). The SANAD 
training and test datasets also included some patients treated with OXC (n=29 and n=12, 
respectively) and these were included in the CBZ group. 
 
5.2.10. Australian kNN model validation in UK cohorts 
  In this analysis the original Australian cohort (n=115) was treated as the training 
dataset and each of the UK cohorts (Glasgow n=285, SANAD n=491) was used as independent 
test datasets for which predictions were made. This is a direct approach for model testing and 
was used in validation of the original Australian classifier using two independent Australian 
populations (Petrovski et al., 2009) (Figure 5.3, Figure 5.4). 
 
5.2.11. Re-deriving the five-SNP kNN model in the SANAD cohort 
This secondary analysis comprised a UK only prediction, with the aim of developing 
and testing a kNN model using UK training and test cohorts (70% and 30% respectively), in a 
similar manner to the original Australian model development (Petrovski et al., 2009). The 
SANAD training dataset was first investigated for association between the five SNPs and AED 
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response and subsequently used to predict response of the patients in the test dataset. This 
ensured that patients in training and test datasets are well-matched, particularly with regard to 
frequency of AED response. The kNN parameters used for this replication were identical to 
those employed in the original Australian study (i.e. five SNPs [N] and nine nearest neighbours 
[k]). Investigators running the model were blinded to the treatment responses of the test 
dataset. 
 
5.2.12. kNN model validation in a UK population 
To investigate whether the five SNPs were predictive of treatment response in the UK 
cohorts a leave-one-out approach (n-1) was adopted. Individual patients within each of the UK 
cohorts were classified using a kNN model built on a “leave-one-out” training dataset 
comprising the remaining samples (n-1) in that cohort to determine the overall performance 
of the five-SNP model. With this cross validation method, the kNN model used the genetic 
profiles of the remaining patients to predict the individual test patient that was left out, and 
this was then repeated for all of the Glasgow and SANAD patients. In addition to accounting 
for differences in response frequencies between the Australian and UK cohorts, this approach 
also eliminated any population genetic differences between the Australian and UK patients at 
these five SNPs. In the leave-one-out cross validation approach, the individual being predicted 
did not contribute to the training dataset prediction, thus ensuring model optimisation for the 
modestly sized UK cohorts whilst avoiding over-fitting.  
 
5.2.13. Statistical analysis for assessing model performance 
  All model development and application processes were performed in Melbourne 
(Department of Medicine, University of Melbourne) and data analyses were performed in both 
Liverpool and Melbourne. Model assessment was performed with the kNN model using SAS 
Enterprise Miner software (SAS Institute Inc., Cary, NC) and SPSS version 18. Logistic 
regression was also performed for confirmation of the leave-one-out analysis results (SAS 
Enterprise Miner, SPSS version 18). For each model, the likelihood of predicting successful 
treatment outcome was determined by calculation of the odds ratio (with 95% confidence 
interval), positive and negative predictive values (with 95% confidence intervals), and 
Pearson’s chi-squared p-value.  
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5.2.14. Biological significance of the Australian five-SNPs 
  In addition to the genetic analyses, each of the five SNPs was investigated to identify 
potential biological significance using several freely accessible online genomic databases. The 
HapMap website (www.HapMap.org, data source Rel#24/phase II Nov 08), dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP/), Haploview version 4.1, and the UCSC Human 
Genome Browser (www.genome.ucsc.edu/cgi-bin/hgGateway) were used for extracting 
information on genomic structure (section 2.4.2), including LD structure (section 3.2.4). 
Regulatory changes were investigated through utilities available on these browsers and using 
online bioinformatics analysis tools, Fast SNP and TESS, for further functional and 
transcriptional analysis (Yuan et al., 2006) (section 3.2.7). 
 
5.3. Results 
5.3.1. Comparison of Australian and UK cohorts  
Comparing the clinical characteristics of the Australian cohort (Petrovski et al., 2009) 
and the Glasgow and SANAD cohorts showed that both initial AED and drug response 
frequency were different between the Australian and UK patients (P <0.0001; Table 5.1). In 
addition, the SANAD cohort had a significantly higher frequency of unclassified epilepsy 
compared to both Australian and Glasgow cohorts (P <0.001), whereas there were no 
significant differences in epilepsy type between the Australian and Glasgow cohort.  
 
5.3.2. Single SNP associations with treatment outcome 
  Of the 285 Glasgow patients, four failed genotyping at one or more of the five SNPs, 
leaving 281 available for subsequent analysis. Of the 520 SANAD patients, 491 were 
successfully genotyped for each of the five SNPs. Since the genotypes at the five SNPs 
employed in the multigenic model were proposed to predict or influence AED response, these 
were also independently tested for association in both UK cohorts to account for any single 
SNP influence on AED response. No association was identified with this independent SNP 
analysis (Table 5.2). A similar lack of association was noted in the original Australian cohort 
(Petrovski et al., 2009). 
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5.3.3. Results of the UK replication of the Australian five-SNP kNN model  
The results of approach one, where both UK populations were treated as independent 
test datasets (and Australian patients used as the training dataset) for model validation showed 
that the Australian kNN classifier did not predict treatment response when applied directly to 
either UK cohort. A kNN model built on five SNP genotypes and drug response phenotypes 
from the original Australian cohort (n=115) failed to usefully predict treatment response, on 
the basis of genotype alone, in either the Glasgow (n=281) or SANAD (n=491) cohorts (both 
P >0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4  Summary of the general approach employed for the development of 
classification or predictive models using machine learning methods 
Several basic steps encompass the development of predictive models. These often involve the 
pre-processing of large and/or complex data for the selection of the most influential variables 
and thereon model testing and parameter optimisation. 
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 Table 5.1.  Characteristics and comparison of the Australian cohort with the Glasgow and SANAD cohort
   Australian 
(n=115) 
Glasgow (n=285) SANAD  
(n=491) 
P-value 
Age  Mean (±SD)  43 (±19.7) 41 (±14.7) 39 (±18.3) ns 
Sex N (%) Male 61 (53.0%) 157 (55.1%) 269 (54.8%) ns 
  Female 54 (47.0%) 128 (44.9%) 222 (45.2%)  
Initial AED N (%) CBZ 66 (57.4%) 26 (9.1%) 123 (25.0%)* <0.0001 
  VPA 44 (38.3%) 92 (32.3%) 50 (10.2%)  
  LTG 2 (1.7%) 115 (40.4%) 139 (28.3%)  
  Other 3 (2.6%) 52 (18.2%) 179 (36.5%)  
Epilepsy type N (%) IGE 27 (23.5%) 92 (32.3%) 80 (16.3%) <0.001† 
  Focal 84 (73.0%) 185 (64.9%) 332 (67.6%)  
  UNC 4 (3.5%) 8 (2.8%) 79 (16.1%)  
Outcome at 12 months  N (%) Responder 128 (71.9%) 152 (53.3%) 234 (47.7%) <0.001 
  Non-responder 50 (28.1%) 133 (46.7%) 257 (52.3%)  
AED = antiepileptic drug, CBZ= carbamazepine, IGE= idiopathic generalised epilepsy, LTG= lamotrigine, N= number, ns= non-significant, 
SD= standard deviation, UNC= unclassified epilepsy, VPA= valproate. *Includes 35 patients initially treated with oxcarbazepine, †Statistical 
difference between SANAD cohort and both Australian and Glasgow cohorts 
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5.3.4. Results of the UK cohort developed kNN classifier 
  This analysis used SNP genotypes and drug responses in the SANAD training dataset 
(n=343) to re-derive the kNN classifier, albeit using the original parameters, and to use it to 
predict treatment response, in a blinded manner, in a test dataset (n=148) of patients, also from 
the SANAD cohort. When using the SANAD training dataset (Table 5.3) to predict response 
in the SANAD test dataset, the kNN five-SNP classifier (using nine nearest neighbors) 
correctly identified 26 responders and 52 non-responders but incorrectly identified 26 non-
responders as responders (false positives) and 44 responders as non-responders (false 
negatives) (P = 0.4; Table 5.3). Using only those patients that were initially prescribed either 
CBZ or VPA (n=50), the re-derived kNN classifier was internally predictive in the SANAD 
training dataset (Table 5.3), but again failed when applied to the SANAD test dataset, correctly 
classifying 10 responders and 14 non-responders but incorrectly identifying 10 non-responders 
as responders (false positives) and 16 responders as non-responders (false negatives) (P = 0.7; 
Table 5.3).  
 
5.3.5. Results of the cross validation analyses 
A “leave-one-out” cross validation analysis was performed in each of the two UK 
cohorts by predicting treatment response for each individual patient using five SNP genotypes 
in the remainder (n-1) of the respective cohort. The Glasgow cohort consisted of all 
successfully genotyped patients (n=281). Thus, for the Glasgow cohort, prediction was based 
on treatment response and SNP genotypes in a dataset comprising 280 patients. In the SANAD 
cohort, prediction was based on the training dataset of 342 patients (n=343 minus one). The 
148 patients forming the SANAD test dataset were excluded from this analysis on the basis 
that investigators were blinded to treatment outcome in this sub-group. 
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Table 5.2. Uncorrected SNP genotype association with treatment outcome  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Glasgow cohort SANAD cohort* 
SNP AED P -value for trend Odds ratio (95% CI) P-value for trend Odds ratio (95% CI) 
rs2283170 CBZ/VPA 0.8 1.0 (0.6 – 1.9) 0.6 1.2 (0.7 – 1.8) 
 LTG 0.6 1.1 (0.7 – 2.0) 0.2 0.7 (0.4 – 1.2) 
 Other AED 0.004 0.3 (0.1 – 0.7) 0.8 1.1 (0.7 – 1.7) 
rs2808526 CBZ/VPA 0.3 0.8 (0.4 – 1.3) 0.8 1.0 (0.7 – 1.6) 
 LTG 0.4 1.3 (0.7 – 2.2) 0.7 0.8 (0.6 – 1.5) 
 Other AED 0.9 1.1 (0.4 – 2.2) 0.3 0.8 (0.5 – 1.3) 
rs4869682 CBZ/VPA 1.0 1.0 (0.6 – 1.7) 0.1 1.4 (0.9 – 2.1) 
 LTG 0.3 0.8 (0.5 – 1.3) 0.3 0.8 (0.5 – 1.3) 
 Other AED 0.8 0.9 (0.4 – 2.0) 0.5 1.2 (0.8 – 1.8) 
rs658624 CBZ/VPA 0.2 1.4 (0.8 – 2.4) 0.5 1.1 (0.7 – 1.8) 
 LTG 0.3 1.4 (0.8 – 2.3) 0.6 0.9 (0.6 – 1.4) 
 Other AED 0.5 1.1 (0.6 – 2.8) 0.8 0.8 (0.5 – 1.3) 
rs678262 CBZ/VPA 0.4 0.8 (0.5 – 1.4) 0.1 0.7 (0.5 – 1.1) 
 LTG 0.07 0.6 (0.4 – 1.0) 0.5 1.2 (0.7 – 1.9) 
 Other AED 0.2 0.6 (0.3 – 1.4) 0.3 1.3 (0.8 – 1.9) 
AED= antiepileptic drug, CBZ= carbamazepine, CI= confidence interval, LTG = lamotrigine, SNP= single nucleotide 
polymorphism, VPA = valproate, p-value for trend calculated by Cochran-Armitage test. Glasgow cohort numbers: 
CBZ/VPA=118, LTG=112, Other AED=51. SANAD cohort numbers: CBZ/VPA=173, LTG=139, Other AED=179, *Thirty five 
patients initially treated with oxcarbazepine were included in the carbamazepine group 
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Table 5.3. Predictive performance of the 5-SNP kNN model on the SANAD test dataset (n=148) on the basis of initial AED 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 AED = antiepileptic drug, CBZ = carbamazepine, CI = confidence interval, kNN = k-nearest neighbour, NPV = negative predictive value, PPV = 
positive predictive value, SNP = single nucleotide polymorphism, VPA = valproate, TP = true positive (responders correctly classified as responders); 
FP = false positive (non-responders incorrectly classified as responders), TN = true negative (non-responders correctly classified as non-responders); 
FN = false negative (responders incorrectly classified as non-responder), *Twelve patients initially treated with oxcarbazepine were included in the 
carbamazepine group
AED n TP FP TN FN PPV (95% CI) NPV (95% 
CI) 
Odds 
ratio 
(95% CI) 
P -value 
CBZ/VPA* 50 10 10 14 16 50% (23.7-
76.3) 
47% (25.2-
69.4) 
0.9 (0.28-
2.72) 
0.7 
Other AED 98 16 16 38 28 50% (28.5-
71.5) 
58% (41.6-
72.1) 
1.4 (0.58-
3.17) 
0.3 
Combined 148 26 26 52 44 50% (32.8-
67.2) 
54% (41.1-
66.7) 
1.2 (0.60-
2.32) 
0.4 
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 In the Glasgow cohort, the five SNP combination was found to be significantly 
predictive of treatment response in those patients initially prescribed either CBZ or VPA 
(positive and negative predictive values of 67% and 60% respectively, P = 0.003) but not those 
prescribed any other AED (LTG, P = 0.3; all other AEDs, P = 0.8; Table 5.4). In the SANAD 
cohort, the leave-one-out analysis showed a similar drug specific association. The five-SNP 
combination showed positive and negative predictive values of 69.1% and 55.6% in SANAD 
patients initially prescribed either CBZ or VPA (P = 0.008) and positive and negative 
predictive values of 57.4 and 60.5%, respectively, in those initially prescribed other AEDs 
(namely GBP, LTG or TPM; P = 0.02). The results indicate that these five SNPs are associated 
with treatment response in UK patients (Table 5.4), particularly when CBZ or VPA is used as 
the first AED, even though the independent kNN model (described in section 5.3.3) failed to 
have predictive value. 
 
5.3.6. Logistic regression and permutation analysis for drug specific prediction  
  A logistic regression analysis was also performed to confirm the association identified 
in the leave-one-out cross-validation. A fully-fitted logistic regression model incorporating all 
five SNPs was built using the SANAD training dataset (n=343) which supported observations 
from the leave-one-out analysis that the five classifier SNPs are predictive of treatment 
response in patients initially prescribed CBZ or VPA. A regression model that was developed 
for patients from the SANAD training dataset who initially received CBZ or VPA (n=123) 
appeared to show a successful prediction of treatment response with positive and negative 
predictive values of 69% each (P = 2.5x10-5) and model specificity and sensitivity values of 
58% and 38.5%, respectively (Table 5.5). The regression model was less powerful when 
developed on patients prescribed other AEDs and when applied to the training dataset as a 
whole (n=343), with positive and negative predictive values of 63% and 59% (P = 0.007) and 
61% and 58% (P = 0.0006), respectively (Table 5.5).   
A permutation test for the fully fitted logistic model was subsequently performed to 
identify the likelihood of over-estimation caused by this analysis due to the limited numbers 
of patients (n=123) in the SANAD training dataset treated with either CBZ or VPA. The 
permutation results showed that randomised logistic regression models, using the same 
number of CBZ/VPA responders and non-responders would have been unlikely to achieve a 
p-value < 2.5x10-5 based on five SNP profiles by chance (P < 0.05). 
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Table 5.4. Predictive performance of the ‘leave-one-out’ kNN approach in SANAD and Glasgow cohorts on the basis of initial AED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AED= antiepileptic drug, CBZ= carbamazepine, CI= confidence interval, kNN= k-nearest neighbour, LTG = lamotrigine,  
NPV = negative predictive value, PPV = positive predictive value, VPA= valproate, TP= true positive (responders correctly classified as 
responders), FP= false positive (non-responders incorrectly classified as responders), TN= true negative (non-responders correctly 
classified as non-responders), FN = false negative (responders incorrectly classified as non-responders), *Twenty nine patients initially 
treated with oxcarbazepine were included in the carbamazepine group
Cohort AED n TP FP TN FN PPV (95% CI) NPV (95% CI) Odds ratio (95% CI) P -value 
Glasgow CBZ/VPA 118 49 24 27 18 67% (51.8-79.6) 60% (40.6-76.8) 3.1 (1.4-6.6) 0.003 
 LTG 112 35 30 25 22 54% (38.0-69.0) 53% (34.8-70.8) 1.3 (0.6-2.8) 0.3 
 Other AED 51 15 17 8 11 47% (25.9-68.9) 42% (17.6-70.8) 0.6 (0.2-2.0) 0.8 
SANAD CBZ/VPA* 123 29 13 45 36 69% (48.6-84.3) 56% (41.3-69.0) 2.8 (1.3-6.1) 0.008 
 LTG 97 18 12 40 27 60% (36.4-80.0) 60% (43.8-73.9) 2.2 (0.9-5.3) 0.06 
 Other AED 123 21 17 52 33 55% (34.6-74.3) 61% (47.1-73.7) 1.9 (0.9-4.2) 0.06 
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Table 5.5. Predictive performance of the fully-fitted logistic regression model in the SANAD training dataset 
  
 
 
 
 
 
 
 
 
AED= antiepileptic drug, CBZ= carbamazepine, CI = confidence interval, NPV= negative predictive value, PPV= positive predictive value,  
VPA= valproate, TP = true positive (responders correctly classified as responders), FP = false positive (non-responders incorrectly classified as 
responders) TN= true negative (non-responders correctly classified as non-responders), FN = false negative (responders incorrectly classified as 
non-responders), *Twenty nine patients initially treated with oxcarbazepine were included in the carbamazepine group
AED n TP FP TN FN PPV (95% CI) NPV (95% CI) Odds ratio (95% CI) P -value 
CBZ/VPA* 123 49 22 36 16 69% (53.5-81.3) 69% (50.9-83.2) 5.0 (2.3-10.9) 2.5 x 10-5 
Other AED 220 26 15 106 73 63% (42.9-80.2) 59% (49.6-68.2) 2.5 (1.2-5.1) 0.007 
Combined 343 66 42 137 98 61% (48.6-72.3) 58% (49.9-66.2) 2.2 (1.4-3.5) 0.0006 
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5.4. Discussion 
  The exploration of high-level relationships between numerous genetic variants with 
minimal relative risks is characteristic of the current status of common complex trait 
investigations. The analysis of genomic data from such investigations has presented 
researchers with several unprecedented challenges (Kwan and Brodie, 2000a, Lee et al., 2008, 
McCarthy et al., 2008), including that of detecting multiple, small associations in high-
dimensional data. Investigating numerous gene variants simultaneously is often not successful 
using existing mathematical and computational approaches. Making inferences based on the 
combination of several lower dimensional methods may not provide a correct understanding 
of real data occurrences. Moreover, important variants and/or other biological information 
may be obscured. Predictive models with the capacity to incorporate a collection of weak 
effects, along with their ability to model potentially complex interactions, offer an attractive 
alternative to multiple single SNP analyses (Lee et al., 2008).    
 The supervised classification learning method of data analysis is one form of statistical 
modeling applied to genomic data to obtain genomic prediction models for different groups of 
biological subjects. A previous “proof-of-concept” study developed a multigenic 
pharmacogenomics kNN model that successfully predicted response to initial AED treatment 
in an Australian cohort of patients with newly-diagnosed epilepsy. This was subsequently 
validated in two additional cohorts of patients, also from Australia (Petrovski et al., 2009). 
The kNN supervised classification learning approach was originally described by Fix and 
Hodges (Fix, 1951, Silverman and Jones, 1989) and has since become an important 
classification and clustering tool with diagnostic applications in a number of medical research 
fields. These include diagnostic and sub-class classification in cancer (Furey et al., 2000, Su 
et al., 2001, West et al., 2001, Crimins et al., 2005), immunoassay based anti-nuclear antibody 
tests (Binder et al., 2005), microarray experiments (Kim et al., 2004), drug toxicity (Martin et 
al., 2006), and rheumatoid arthritis (Liu et al., 2009). 
The aim of the analysis described in this chapter was to assess the broader utility of 
the Australian multi-SNP model by applying it to two independently collected cohorts of 
patients with newly treated epilepsy from the UK. Definitions of response were adopted from 
those used in the development of the original model and patient cohorts were accordingly 
stratified by clinical characteristics. For each of the UK cohorts, the multigenic classifier failed 
to significantly predict response to the first well-tolerated AED when; i) the original Australian 
cohort was used as the training dataset, and ii) when the classifier was re-driven in UK patients 
alone. The failure of direct replication was not entirely surprising. Possible explanations 
include differences in drug response frequencies, differences in phenotypic definitions and 
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methods of ascertainment, genomic population differences, differing drug policies, failure to 
re-calibrate the kNN parameters, or a false positive signal in the original study. These are 
discussed briefly below. 
 
5.4.1. Importance of drug response frequencies 
  As discussed previously, classification algorithms involve a training dataset of known 
outcomes on which a predictive model is built and, from this, new predictions or classifications 
can be inferred. The kNN approach positions the training dataset in an nth dimensional space 
within which new cases/data can be placed and subsequently assigned a value or classification. 
Thus, the frequency of outcomes, in this case response or non-response to AED treatment, 
within the training dataset can affect the classification of any new cases that are presented. 
The kNN model using the Australian training dataset (identified as having fewer cases of 
treatment failure than UK cohorts) was thus expected to result in an over-estimation of the 
number of responders (false positives) in the Glasgow and SANAD cohorts, thereby affecting 
model classification reliability. This discordance in treatment response was arguably the most 
significant confounder in the attempt to directly validate the original multi-genic classifier. 
 
5.4.2. Differences in data collection and treatment response classification 
  The Australian cohort constituted a series of newly diagnosed patients enrolled into a 
prospective PGx study at first clinical presentation. In contrast, the SANAD cohort comprised 
a sub-set of randomised clinical trial patients (believed to be representative of the trial 
population as a whole) who were belatedly consented for the donation of DNA and whose 
clinical information, albeit prospectively collected, was extracted from a trial database that 
was not designed with a PGx study in mind. The Glasgow cohort comprised a variety of 
individuals attending outpatient clinics and participating in randomised clinical trials, who 
were retrospectively consented for donation of DNA and whose clinical information was not 
collected in a systematic manner. These differences in recruitment and data collection 
procedures may have introduced inconsistencies in the classification of responder and non-
responder status, particularly in the UK cohorts where the clinical information was not 
specifically collected for PGx purposes. The principal concern in this regard is a lack of 
sensitivity to exclude seizures occurring in the drug titration period or arising from non-
compliance or acute provocation (i.e. sleep deprivation or alcohol misuse) during the first 12 
months of follow-up. This might explain, at least in part, the significantly greater frequency 
of non-response in the Glasgow and SANAD cohorts.  
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5.4.3. Genomic population differences between UK and Australian cohorts  
Another important consideration with regard to study design was the assumption that 
the five kNN SNP markers originally identified in an Australian population would extrapolate 
directly to UK patients. Although most Australian patients were considered to be of European 
descent, and patients who self-identified as being of non-European ancestry were excluded, it 
is possible that subtle ethnic differences existed between the cohorts. Under such 
circumstances, a discrete set of genetic variants might be more weakly associated with the trait 
of interest (or with unidentified causal variants) in one population than in another.  
 
5.4.4. Differences in initial AED treatment between cohorts 
A clear difference between the Australian and UK cohorts was observed in the relative 
frequencies of individual AEDs used as initial treatment. The Glasgow cohort was largely 
recruited via a drug trial comparing VPA and LTG (Stephen et al, 2007), with almost 50% of 
Glasgow patients initially exposed to LTG. The SANAD cohort also showed a high proportion 
of patients receiving LTG as the first well-tolerated AED, which was unsurprising given that 
this drug was included in both arms of the SANAD trial (Marson et al., 2007a, b). In contrast, 
96% of the Australian cohort was initially prescribed either CBZ or VPA. These simple 
differences in drug treatment policy may be sufficient to explain the failure to directly validate 
the kNN model in UK patients.  
 
5.4.5. Adapting model parameters of the Australian kNN five-SNP 
classifier for UK replication 
  An additional confounder may have been the use of kNN model parameters that were 
employed in the original Australian study. These were accordingly derived from a cohort that 
was significantly smaller (n=115) than either of the two UK cohorts employed in the current 
analysis. Failure to re-calibrate the kNN parameters in order to accommodate larger training 
datasets with differing response frequencies may have impacted on the accuracy of treatment 
response prediction. In the kNN classifier, the number of nearest neighbours (k) by which 
classification occurs, is unsurprisingly dependent on the size and phenotype frequency of the 
training dataset and prediction is based on a simple majority phenotype amongst those nearest 
neighbours. In a larger training dataset, it is possible that fewer nearest neighbours would be 
required for accurate prediction in test datasets. For example, where the nearest four 
neighbours are responders and next nearest five neighbours are non-responders, using k=9 
would result in the prediction of non-response, whereas using k≤7 would result in the 
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prediction of response. Failure to re-calibrate kNN parameters despite differences in treatment 
response between the Australian and UK cohorts was a potentially significant limitation. 
 
5.4.6. Unreliability of the original Australian association 
Finally, there is also a possibility that the original findings in the Australian cohort 
constituted a false positive signal. This seems somewhat unlikely, given the clear association 
in this analysis between 5-SNP genotype and response to treatment with either CBZ or VPA 
in UK cohorts when analysed using both a “leave-one-out” method and a fully-fitted logistic 
regression. This finding, together with the validation in two independent Australian epilepsy 
cohorts reported in the original study, lends weight to the significance of these SNP genotypes 
as biomarkers of response to initial drug therapy in newly treated epilepsy. Whether the 
classifier is truly specific for CBZ and VPA alone or is indicative of treatment responsiveness 
in general remains to be determined. Making the distinction will require significantly larger 
cohorts of patients and a more consistent approach to recruitment and data collection.  
 
5.4.7. Cross-validation validated the predictive capacity of the five SNPs 
comprising the Australian kNN classifier 
Despite failure of direct validation of the kNN classifier, a further attempt was made 
to explore the significance of these five SNPs in UK patients. This was performed using a 
cross-validation “leave-one-out” approach where each of the UK cohorts acted as their own 
training dataset. This negated many of the confounders described above that could have 
potentially impacted on findings of the direct validation method. The analysis was again 
stratified by initial AED in an effort to determine whether the five SNPs originally identified 
in the Australian cohort were selectively predictive for CBZ or VPA as initial treatment (96% 
of Australian patients received these drugs as first ever AED). This approach proved 
successful, with the “leave-one-out” analysis indicating that the five SNPs had a collective 
predictive capacity for both Glasgow and SANAD patients treated with either CBZ or VPA 
but not other AEDs. A subsequent permutation test confirmed that the randomized, fully fitted 
logistic regression model developed on the SANAD training dataset, and using the same 
number of CBZ/VPA responders and non-responders, would have been unlikely to achieve a 
p-value < 2.5x10-5. This suggested that the association with CBZ/VPA treatment response in 
a logistic regression model was unlikely to have occurred by chance.  
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5.4.8. Biological significance of the five-SNPs  
  The relative success, when using the “leave-one-out” approach, of these five SNPs in 
predicting response to CBZ or VPA as the initial AED in UK patients suggests that they 
possess biological significance. The SNPs were originally identified from an initial panel of 
4,041 SNPs across 279 candidate genes, selected on the basis of a known or putative 
involvement in epilepsy susceptibility, a high expression level in the brain, or an involvement 
in AED pharmacology (Petrovski et al., 2009). The biological investigation that followed our 
genetic analyses showed that the variants were comprised of two SNPs in the SCN4B gene 
(encoding the 4 subunit of the voltage-gated sodium channel) and one each in the GABBR2 
gene (encoding GABAB receptor subunit 2), KCNQ1 gene (encoding the Kv7.1 subunit of the 
delayed rectifier potassium channel), and SLC1A3 gene (encoding excitatory amino acid 
transporter 1) (Table 5.6). Two of the genes (SCN4B and KCNQ1) are reported to have limited 
expression in brain tissue (Waldegger et al., 1999, Yu et al., 2003), all five SNPs are located 
in intronic regions of their respective genes (Kent et al., 2002), and investigation of the 
genomic structure using www.hapmap.org (release # 24) failed to identify any biologically 
functional variants with a minor allele frequency ≥ 1% in European populations that were in 
strong linkage disequilibrium (r2≥0.8) with any of these specific SNPs. Further bioinformatics 
analysis using online tools for functional analysis (Yuan et al., 2006) and assessment of TFBSs 
(Kent et al., 2002) were similarly unremarkable, although all SNPs except rs678262 (in 
SCN4B) were shown to be located in TF binding domains. The rs2283170 SNP in KCNQ1 
was additionally predicted to effect an alteration in TF binding characteristics. As such, the 
functional significance of these SNPs and the explanation for their association with treatment 
response in newly treated epilepsy remains unclear. The fact that these SNPs were selectively 
predictive for response to CBZ and VPA but no other AEDs with similar mechanisms of action 
also remains unexplained. 
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Table 5.6. Genomic information for the five-SNPs comprising the kNN classifier 
Gene SNP Location Alleles  Amino acid 
change 
HapMap  
MAF 
KCNQ1 rs2283170 Intron A>G - 0.339 
GABBR2 rs2808526 Intron A>G - 0.450 
SLC1A3 rs4869682 Intron G>T - 0.460 
SCN4B rs658624 Intron T>C - 0.458 
SCN4B rs678262 Intron G>C - 0.346 
 
 
 
 
5.4.9. Summary 
  In summary, this analysis suggests that the “proof of concept” kNN model, developed 
in an Australian cohort of newly-diagnosed epilepsy, is not directly applicable to other 
epilepsy populations, even those that might be considered ethnically comparable. The model 
has multiple limitations when applied to populations that differ from the one used in its 
construction, particularly where response frequencies, drug policies, phenotype determination 
and methods of ascertainment differ. Nevertheless, the combination of the five SNPs reported 
in the original Australian study does appear to have a collective influence in predicting 
response to treatment with either CBZ or VPA in UK patients. This observation, although drug 
specific, should encourage additional replication attempts with larger cohort sizes to better 
understand the potential of this multi-SNP model as a biomarker of early seizure control in 
new-onset epilepsy patients treated with these two drugs. 
 
 
MAF = minor allele frequency, SNP = single nucleotide polymorphism 
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6.1. Introduction 
 As discussed in Chapter 1, epilepsy is a complex and heterogeneous disorder, for 
which rare and common genetic forms exist. Common genetic epilepsies are, clinically and 
genetically, a heterogeneous group of complex seizure disorders. Thus, defining the genetic 
contribution to common epilepsy syndromes has proven to be a formidable task (Dibbens et 
al., 2007, Rees, 2010). In Chapter 5, a ML approach was used to build PGx classifiers to 
predict responsiveness to AED treatment. The study described in this results chapter applied 
this previously used statistical methodology to analyse available genomic and clinical 
phenotype data for individuals with common genetic forms of epilepsy in order to investigate 
the genetic contribution to these complex syndromes. 
 
6.1.1. Complex genetic forms of epilepsy 
 It is estimated that there is an underlying genetic predisposition for epilepsy in 
approximately half of individuals (idiopathic epilepsies), with monogenic epilepsies 
accounting for less than 1 percent (Kearney, 2012). The remaining majority are idiopathic or 
primary generalised epilepsies (PGEs) and non-acquired focal epilepsies (NAFE) that have a 
strong genetic basis with a complex inheritance pattern in which multiple and environmental 
factors contribute to epilepsy risk, though these complex genetic epilepsies are poorly 
understood (Tan et al., 2004).  
 
6.1.2. Primary generalised epilepsy syndromes 
 The PGEs classically fall into several common and rare recognisable sub-syndromes. 
Rare IGE syndromes include Benign Myoclonic Epilepsy of Infancy (BMEI), Early Onset 
Absence Epilepsy, Myoclonic Astatic Epilepsy (MAE), Epilepsy with Myoclonic Absences, 
Eyelid Myoclonia with Absences and Absence Status Epilepsy (Gardiner, 2005). The common 
PGEs sub-syndromes are characterised by some or all of the three following seizure types; 
typical absence seizures, myoclonic jerks and generalised tonic-clonic seizures (GTCS), which 
can occur in different combinations but typically with one seizure type predominating (Engel, 
2006a). Childhood Absence Epilepsy (CAE), Juvenile Absence Epilepsy (JAE), Juvenile 
Myoclonic Epilepsy (JME) and Epilepsy with Generalised Tonic-Clonic Seizures (GTCS) 
represent the four more common PGE sub-syndromes. (Shneker and Fountain, 2003, Engel, 
2006a).  
 
6.1.3. Classifying complex inheritance or common PGE sub-syndromes 
 Common PGE has a typical electroencephalographic (EEG) pattern with paroxysms 
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of generalised spike and wave and polyspike discharges, which is the hallmark of the 
syndrome and the onset of these common PGEs is usually before the age of 16 (Sander, 
2003b). Several features confound the genetic analysis of the more common PGE sub-
syndromes (Gardiner, 2005). In particular, each sub-syndrome are themselves heterogeneous 
in their phenotypic presentation and are often found to overlap (Sander et al., 2000). Different 
PGE sub-syndromes can be found within a single pedigree (Gardiner, 2005) and different 
generalised seizure types may emerge in the same patient over time, adding further 
complication (Sander et al., 2000). CAE typically begins between 4 and 10 years of age 
(Crunelli and Leresche, 2002, Gardiner, 2005). The main seizure type in CAE is typical 
absence seizures but, in about 50% of patients, GTCS can also occur although very few 
individuals additionally experience myoclonic jerks (Sander, 2003b). JME represents 5–10% 
of epilepsy as a whole and individuals most commonly present between the ages of 8 and 26 
with myoclonic jerks predominantly of the upper limbs (Greenberg et al., 1992). Over 90% 
also have GTCS and 30% have typical absences (Crunelli and Leresche, 2002). This overlap 
in seizure types suggests commonality in genetic predisposition between the PGE sub-
syndromes (Janz et al., 1992, Sander et al., 2000). Age at onset and main seizure type are thus 
used to classify the more common PGEs into the four main sub-syndromes (Panayiotopoulos 
and International League against Epilepsy., 2005). Despite these distinct features however, 
accurate diagnosis of the sub-syndromes is not always possible from the first presentation and 
so a number of patients with PGE are often difficult to classify (Gardiner, 2005).  
 
6.1.4. Genetic studies for primary generalised epilepsy; the picture so far 
 Since most of the individual genes involved in complex disorders and/or traits are 
thought to only have a small impact on the clinical phenotype, their identification has 
presented a major challenge for disease genetics (Hirschhorn et al., 2002). PGEs are similarly 
thought to arise from additive or interactive effects of more than one susceptibility gene 
(Dibbens et al., 2007) and so progress in identifying the underlying genetic causes, like most 
common, complex traits, has been slow (Dibbens et al., 2007, Frankel, 2009). Currently ~20 
genes are known to cause Mendelian forms of human epilepsy (Robinson and Gardiner, 2004) 
and, as might be expected for a disorder of neuronal hyper-excitability, at least two thirds of 
these encode ion channels (Frankel, 2009). This research suggested ion channel defects as a 
common pathogenic pathway in a multitude of epilepsies and led to the hypothesis of 
epilepsies being channelopathies (Berkovic et al., 2006). Although no directly causative ion 
channel genes have been identified for complex PGEs, this channelopathy concept has 
provided important positional clues for the pathogenesis of several common PGE sub-
syndromes (Gardiner, 2005, Dibbens et al., 2007).       
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Table 6.1 provides a summary of several of these key genetic studies.  
 Ion channel targets of current genomic studies have included voltage-gated channels 
Na+, K+, Ca2+, and Cl- and the ligand-gated channels; nicotinic acetylcholine and GABAA 
receptors (Gardiner, 2005). The most important epilepsy gene to be discovered to date is 
thought to be the previously discussed SCN1A sodium channel gene (Chapter 4). SCN1A is 
the most prevalent gene causing Mendelian forms of epilepsy and is the most studied in 
epilepsy. SCN1A mutations have been identified in the familial syndrome of Generalised 
Epilepsy with Febrile Seizures Plus (GEFS+) as well as severe myoclonic epilepsy (SMEI) or 
Dravet Syndrome (Gardiner, 2005, Mulley et al., 2005). GEFS+ is a heterogeneous autosomal 
dominant disorder (also recognised as a complex epilepsy phenotype) in which family 
members exhibit multiple epilepsy phenotypes including absence, myoclonic, generalised 
tonic-clonic or partial seizures, as well as febrile seizures (FS), with the FS being 
phenotypically simple or complex (Mulley et al., 2005). SMEI is also a FS disorder but with 
a more severe phenotype. Mutations for GEFS+ were first identified in SCN1A, and these were 
shown to alter amino acids within the voltage-sensing S4 segments of the channel, the 
functional effects of these were altered channel inactivation and a persistent inward sodium 
current (Gardiner, 2005). 
 Most of the mutations associated with SMEI are however more critical as they 
introduce a stop codon with truncation of the protein and predicted to have a loss of function. 
The SCN1A gene has not only lead the way in channelopathy research for the genetic 
epilepsies, currently presenting the only definitive marker for a phenotype of epilepsy (SMEI), 
but has also provided insight into the overlap and multigenetic complexity that can underlie 
these common forms of genetic epilepsies. Another important candidate in PGE is the genes 
of the GABAA receptor subunit gene(s), namely GABRG2 and GABRA1 (Baulac et al., 2001, 
Gardiner, 2005, Rees, 2010). The subunits encoded by GABRG2 and GABRA1 are associated 
with monogenic forms of IGE and also the GEFS+ phenotype. Mutations in the GABA 
receptor genes have also been implicated with JME (Gardiner, 2005, Rees, 2010). 
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Table 6.1. Genes implicated in complex idiopathic generalized epilepsies  
Summary of genes associated with complex idiopathic generalised epilepsies so far. Genes are 
presented for the sub-syndromes of juvenile myoclonic epilepsy, childhood absence epilepsies 
and generalised epilepsies with febrile seizures plus. Data extracted from Huber et al 2009 and 
Rees et al 2010  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCN1A = sodium channel α1 subunit, SCN1B= sodium channel β1 subunit, CACNB4 = 
voltage-dependent calcium channel β4, CACNA1H = voltage-dependent T-type calcium 
channel α1H, BRD2 = bromodomain containing protein 2, CLCN2 = chloride channel gene 
2, GABRA1 = GABAA receptor α1 subunit, GABRG2 = GABA(A) receptor ϒ2 subunit, 
GABRD = GABAA receptor δ subunit, GABRB3 = GABAA  receptor β3 subunit, EFCH1 = 
protein with an EF-hand, ME2 = malic enzyme 2, GEFS
+ = generalised epilepsy with febrile 
seizures plus, JME = juvenile myoclonic epilepsy, CAE = childhood absence epilepsy 
 
 
  
 
 
 
 
 
Gene Chromosomal 
localisation 
Complex Epilepsy 
phenotype 
SCN1A 2q24  GEFS+ 
SCN1B 19q13.1  GEFS+ 
CACNB4 2q22–23  JME 
CACNA1H 16p13.3 CAE 
BRD2 6p21.3 JME  
CLCN2 3q26 CAE 
EFHC1 6p12-p11 JME  
GABRA1 5q34 JME, CAE 
GABRG2 5q34 CAE, GEFS+                                
GABRD 1p36.3 GEFS+ 
GABRB3 15q11.2 CAE                               
EFCH1/myoclonin 1 6p12 JME 
ME2 18 JME 
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 CACNA1H encodes the T-type calcium channel that is critically involved in the 
thalamo-cortical network (Mulley et al., 2003, Mulley et al., 2005). CACNA1H has 
additionally been studied extensively in regards to complex PGE genomics and rare variants 
altering ion channel properties of the encoded T-type calcium channel protein have been 
observed in patients with PGE in several studies (Chen et al., 2003, Heron et al., 2004, Heron 
et al., 2007). Variants in CACNA1H, were initially associated with CAE (Chen et al., 2003) 
but the relationship has since been extended to other epilepsy phenotypes (Heron et al., 2004). 
Variation in CACNA1H has consistently been shown to contribute to the pathogenesis of 
epilepsies with complex genetics, but no variants in CACNA1H have been described that are 
sufficiently pathogenic to cause epilepsy on their own (Dibbens et al., 2007).   
 As in genetic investigations of drug response in epilepsy (section 1.5), several loci and 
variants have been studied as possible candidates for complex PGE syndromes but the majority 
have yielded negative results, with few being pursued any further (Steinlein, 2004, Tan et al., 
2004, Kearney, 2012). In those reporting an initial positive association, replication studies 
have invariably failed to confirm the relationship (Steinlein, 2004, Tan et al., 2004). Failures, 
particularly in replication studies, are deemed to be due to the inherent effects of phenotypic 
variability, complex inheritance and genetic heterogeneity (Tan et al., 2004, Dibbens et al., 
2007). One recognised assumption is that because of the polygenic nature of PGE, an 
individual most likely develops PGE only if sufficient variation is present (Dibbens et al., 
2007). Under this hypothesised model, only a subset of a large population of susceptibility 
variants needs to be present. However, to explore this hypothesis requires association studies 
with much larger sample sizes than currently employed (Dibbens et al., 2007), perhaps in the 
order of thousands or tens of thousands of subjects (Mulley et al., 2005, Mullen et al., 2009, 
Ferraro et al., 2012). This lack of power is considered a major issue for complex disease 
genetic association studies in general (Weller et al., 2006, Mullen et al., 2009).  
 
6.1.5. Recent advancements in disease genomics 
 Greater success in the identification of genes for PGE may be achieved with unbiased 
genome-wide surveys in large study populations (Kearney, 2012). Human genomics has 
moved towards a whole genome approach in the investigation of the genetic architecture of 
complex traits in an effort to resolve the lack of power or resolution in traditional genetic 
linkage studies (sections 1.4.9 and 1.4.10) (Ferraro et al., 2012, Kearney, 2012). GWA studies 
for complex generalised epilepsies have revealed significant linkage at the loci 2q34 and 
13q31.3 for myoclonic and absence seizures, respectively (Ferraro et al., 2012, Kearney, 2012, 
Leu et al., 2012).  
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 The role of CNVs as rare forms of variation has been extensively investigated and has 
shown a collective contribution to the etiology of a variety of common neurological diseases 
with complex genetics and has also been implicated in several types of epilepsy. More 
recently, CNV hotspots have been investigated in the non-Mendelian genetic epilepsies 
(Mefford and Eichler, 2009, Mefford et al., 2010, Sisodiya and Mefford, 2011, Kearney, 
2012). Microdeletions in the chromosomal region 15q13.3 encompassing the CHRNA7 gene 
(coding for the alpha-7 subunit of the nicotinic acetylcholine receptor) were identified in 
approximately 1% of 1,223 PGE patients (Helbig et al., 2009). As such, 15q13.3 
microdeletions appear to constitute the most prevalent risk factor for PGEs identified to date 
(Helbig et al., 2009, Mulley and Dibbens, 2009). In line with current genomic research (section 
1.5), recent results from epilepsy genetics have stimulated interest in assessing the contribution 
of both rare and common variants to the aetiology of epilepsy through the utility of whole-
exome and whole-genome sequencing in individual patients and this is the next step in 
examining the basis of epilepsy genomics (Ferraro et al., 2012, Kearney, 2012). 
 
6.1.6. A machine learning approach to disease or phenotype classification 
 The univariate nature of linkage mapping, candidate gene analysis and SNP-based 
disease association studies does not adequately account for the genetics of PGE syndromes, 
which have so far proven to be too heterogeneous for the detection of strong associations. ML, 
as described in Chapter 5, is an alternative and efficient way for extracting hidden information 
in a given dataset (Lee et al., 2008). The main advantages being, i) its ability to extract 
relationships from high-dimensional data, and ii) efficiency in simultaneously analysing, 
numerous, often highly interactive variables, of small effect. This may, in turn, allow greater 
analytical power in cohorts of limited sample size (Lee et al., 2008). 
 Several steps are involved in the appropriate application of ML approaches (Figure 
6.1, 6.2). The processes prior to model development are feature selection for identifying and 
removing as many redundant variables as possible (Yu & Liu, 2004) and instance selection 
for ﬁltering noisy data (Kotsiantis, 2007, Derrac et al., 2012). These processes enable models 
to operate faster and more effectively (Larranaga et al., 2006, Kotsiantis, 2007, Joaqu et al., 
2010).  
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Figure 6.1  An overview of the supervised machine learning process 
The supervised approach to machine learning entails the input of data with known values for 
model development or training. Figure reproduced from Kotsiantis et al 2007. 
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6.1.7. Development and assessment of machine learning models 
 Once a ML model has been built, it requires evaluation and interpretation and this 
forms the next stage in model development (Larranaga et al., 2006). The final overall 
performance of a learning method relates to its prediction capability on independent test data 
(Hastie et al., 2001). Assessment of this performance is extremely important in practice, since 
it guides the choice of model and gives a measure of the quality of the chosen model (Hastie 
et al., 2001). This requires estimating the expected test error and/or prediction accuracy (the 
percentage of correct predictions divided by the total number of predictions) for a model. From 
this, the performance of different models can be estimated in order to choose the best one, 
with prediction error usually estimated on new unseen datasets (Hastie et al., 2001).  
 The best approach for model development and evaluation is to separate the dataset 
into three randomly divided individual patient datasets; (i) a training dataset, (ii) a validation 
dataset, and (iii) a test dataset (Hastie et al., 2001, Mansmann and Winkelmann, 2002, 
Kotsiantis, 2007, Lee et al., 2008). The training dataset is used to fit the models, the validation 
dataset is used to estimate prediction error for model selection and optimization, and the test 
dataset is used for assessment of the generalisation error of the chosen model (Mansmann and 
Winkelmann, 2002, Kotsiantis, 2007, Petrovski et al., 2009). The test dataset is usually kept 
hidden and used only at the end of the data analysis for a true, unbiased test of prediction 
accuracy (Hastie et al., 2001). The number of observations in each of the three parts can 
depend on the signal-to-noise ratio in the data and the size of the training dataset (Hastie et al., 
2001). 
 Additional techniques that can be used to partition data for initial model development 
include cross-validation (CV) and leave-one-out CV (e.g. the kNN ML method described in 
Chapter 5). CV is the simplest method for estimating prediction error and involves dividing 
the training dataset into mutually exclusive and equally-sized subsets, with each individual 
subset subsequently trained on the composite of all other subsets (the average error rate of 
each subset is therefore an estimate of the error rate of the model) (Hastie et al., 2001, 
Mansmann and Winkelmann, 2002, Kotsiantis, 2007). In the latter CV method, all test subsets 
consist of a single instance (Kotsiantis, 2007).  
 
6.1.8. Application of machine learning to complex disease genetics  
 A number of classification-based ML methods are available (Kotsiantis, 2007). These 
include logical or symbolic techniques, such as classification trees, decision learning trees 
(DLTs), perception-based techniques such as NNs, and statistical techniques such as kNN and 
SVM (Kotsiantis, 2007)(Table 6.2). Several of these MLAs, particularly MDR (Ritchie and 
Motsinger, 2005, McKinney et al., 2006), NN (Lucek and Ott, 1997, Motsinger et al., 2006), 
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RF (Yoon et al., 2003, Bureau et al., 2005) and SVM (Yoon et al., 2003, Yu and Shete, 2005), 
have previously been used for the study of multi-locus association traits (Dinu et al., 2007), 
including diabetes, coronary heart disease, alcoholism and breast cancer (Yu and Shete, 2005, 
Bhaskar et al., 2006b, Silva et al., 2011). 
 
6.1.9. The kNN machine learning approach can successfully identify high-
order patterns in complex disease traits 
 The Australian multigenic pharmacogenomic classifier study, described in Chapter 5, 
exemplifies a recent and successful attempt at applying ML approaches to a large amount of 
genetic data (Cavalleri et al., 2007, Petrovski et al., 2009) namely common variation in the 
form of SNPs, to predict AED response in epilepsy patients. The kNN classifier is one of the 
most well-known classifiers that is based on the instances contained in the training dataset 
(Cover and Hart, 1967, Joaqu et al., 2010). Thus, the effectiveness of the classification process 
relies on the quality of the training data (Joaqu et al., 2010). Its main drawback is its relative 
inefficiency when the size of the dataset to be used in the modeling process increases 
(Kotsiantis, 2007). Instance and feature selection, which aid data-reduction, are thus also 
commonly used alongside the kNN ML algorithm. Thus, while supervised learning approaches 
have previously been reported to obtain reliable results in pharmacogenetics (Petrovski et al., 
2009), they have not as yet been used to identify genetic predictors of epilepsy or epilepsy 
syndromes, such as PGE. 
 
6.2. Purpose of investigation  
 A number of patients with PGE are often difficult to classify (Reutens and Berkovic, 
1995). There are sub-syndromes of JME in which patients present not just with myoclonic 
jerks but also with or without typical absence seizures and GTCS (Gardiner, 2005). CAE is 
mainly characterised by typical absence seizures that persist into adolescence (Crunelli and 
Leresche, 2002, Gardiner, 2005), but GTCS can emerge in a significant percentage (up to 
90%) of CAE cases when the absence seizures persist into adulthood (Crunelli and Leresche, 
2002). CAE can also evolve into JME, with an estimated 18% of all JME patients having an 
initial diagnosis of CAE (Delgado-Escueta, 2007). With this overlap in seizure types, 
distinguishing between PGE sub-syndromes can be problematic and making a precise clinical 
diagnosis may not be possible at the first presentation. Accuracy in classification is however 
important for the correct prognosis of individual PGE patients and for initiation of the correct 
treatment, particularly as several AEDs have been shown to exacerbate specific seizure types 
(Bergey, 2005, Beydoun and D'Souza, 2012).  
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 A recent attempt has been made to reduce the inherent heterogeneity in non-Mendelian 
PGEs using neurobiologically defined traits, such as seizure types rather than syndrome 
categories, for the purposes of genetic study (Greenberg and Subaran, 2011, Ferraro et al., 
2012). This approach may help cut across phenotypically complex PGE syndromes and 
facilitate identification of the underlying susceptibility genes (Greenberg and Subaran, 2011). 
Patients can be segregated into groups according to strict demographic and/or clinical 
categories (i.e. age at onset, gender, and seizure type) for studying genetic variants (Ferraro et 
al., 2012). Each of these factors may have unique genetic signatures. Separating patients into 
clinical categories that allow such factors to be analysed independently may be a better 
approach than lumping people into often arbitrarily assigned syndromic sub-groups (Ferraro 
et al., 2012). 
 
6.2.1. Aims  
 The aim of the study described in this chapter was to apply ML approaches to a large 
cohort of patients with newly-diagnosed, complex, non-Mendelian PGEs in an effort to 
identify the underlying genetic signature of these common epilepsy syndromes, and thereby 
aid in sub-syndromic diagnosis. The potential biological significance of any identified variants 
was also explored. The specific research objectives were: 
 
Objective 1: to use ML algorithms to build predictive models for the identification of genes 
and/or gene variants as potential markers for the differentiation of individuals presenting with 
CAE, JAE and JME on the basis of seizure types. 
 
Objective 2: to use ML algorithms to build predictive models for the identification of genes 
and/or gene variants as potential markers for the differentiation of individuals with PGE and 
focal epilepsies (or LREs). 
 
In each case, the kNN ML algorithm (Petrovski et al., 2009) (Chapter 5) was employed. An 
additional aim was to explore a number of other ML approaches and identify the ML approach 
with the best overall performance when applied to this particular genomic dataset.  
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6.3. Methods 
6.3.1. Study populations  
 Clinical and genetic data from two independent cohorts of newly treated PGE patients 
were employed in the analysis; SANAD study patients (Marson et al., 2007a, b) and a cohort 
recruited at two epilepsy centres in Australia (The Royal Melbourne Hospital in Melbourne 
and Austin Health in Heidelberg) (Cavalleri et al., 2007, Petrovski et al., 2009). Genotype and 
clinical data was available for a total of 436 patients with newly treated PGE, 296 from 
Australia and 140 from the UK (Table 6.3). For Objective 2, LRE patients acted as non-PGE 
controls, with a total of 760 LRE patients (628 SANAD and 132 Australian) possessing 
sufficient clinical and genetic data for initial inclusion (Table 6.4). Clinical information on 
PGE patients was extracted from hospital notes and existing databases in order to identify 
syndromes, sub-syndromes and seizure types.  
 
 
 
Table 6.3 Characteristics of UK and Australian patient cohorts for PGE (seizure 
classification cohort) 
   Australian 
 (n=136) 
UK  
(n=68) 
Total 
(n=204) 
Age at 
randomisation  
Mean 
(±SD) 
 12 (±8.27) 19 (±11.6) 14 (±10.0) 
Sex n (%) Male 59 (43.4%) 35 (51.5%) 94 (46.1%) 
  Female 77 (56.6%) 33 (48.5%) 110 (53.9%) 
Epilepsy 
syndrome  
n (%) CAE/JAE 94(69.1%) 32 (47.1%) 126 (61.8%) 
  JME 42(30.9%) 36 (52.9%)  78 (38.2%) 
SD = standard deviation, CAE = childhood absence epilepsy, JAE = juvenile absence 
epilepsy, JME = juvenile myoclonic epilepsy 
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Table 6.4 Characteristics of UK and Australian newly treated epilepsy patient 
cohorts for classification of epilepsy type 
   Australian 
(n=428) 
UK 
 (n=189) 
Total 
(n=617) 
Age at 
randomisation 
Mean 
(±SD) 
 13 (±8.4) 28 (±17.4) 23 (±18.1) 
Sex n (%) Male 192 (64.8%) 104 (35.1%) 296 (48.0%) 
  Female 236 (73.5%) 85 (26.5%) 321 (52.0%) 
Epilepsy type  n (%) PGE 296 (69.3%) 131 (30.7%) 427 (69.2%) 
  LRE 132 (71.7%) 58* (31.5%) 184 (29.8%) 
* Removal of 570 patients from total LRE available to maintain consistent ratio of Australian 
to UK patients with LRE 
  
 
 
6.3.2. Phenotyping and patient inclusion for objective one 
 For objective 1, all patients were classified into the following 2 groups, based on 
seizure type: Group 1 - patients with typical absence seizures (with or without GTCS) but not 
myoclonic jerks, and Group 2 - patients with myoclonic jerks (with or without GTCS) but not 
typical absence seizures. Patients with GTCS alone were excluded (n=88) (Table 6.3). Of the 
total PGE cohort (n=436), individuals were also excluded from the analysis if they exhibited 
both myoclonic jerks and typical absence seizures (n=71), if they exhibited both focal and 
generalised seizure types (n=7), or if there was evidence of CAE later evolving into JME 
(n=60). Finally, six additional patients were removed at the QC stage due to inadequate 
phenotype data and/or missing genotypes. In Group 1, no distinction was made between 
patients diagnosed with either CAE or JAE. The remaining 204 individuals (136 Australian, 
68 SANAD) thus had PGE characterised by either myoclonic jerks (n=78) or typical absence 
seizures (n=126), with or without GTCS (Table 6.3). 
 
6.3.3. Phenotyping and patient inclusion for objective two 
 For objective 2, all patients considered for inclusion in the study had PGE or LRE, 
with unclassified epilepsies excluded. Of the 436 available PGE patients, 427 (296 Australian, 
131 SANAD) were included in the analysis, with 9 patients again removed after QC due to 
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inadequate phenotype data and/or missing genotypes. Of the 760 available LRE patients, only 
190 (132 Australian, 58 SANAD) were included in the analysis. This was a significant but 
deliberate exclusion considered necessary to achieve consistency in the ratio of Australian to 
SANAD patients in both PGE and LRE groups (Table 6.4). 
 
6.3.4. Patient stratification 
 For each of the research objectives, the respective patient groups were randomly 
allocated into a developmental dataset and a test dataset. Datasets were matched where 
possible for age, gender and cohort of origin (Australian or SANAD) to eliminate the influence 
of demographic variables. The developmental datasets were used to build predictive classifiers 
and the test datasets used to assess the predictive capacity of those classifiers.  
 
6.3.5. Developmental and test datasets for objective one and two 
 For the distinction of seizure types, i.e. typical absence seizures and myoclonic jerks, 
162 patients (80%) were allocated to the developmental dataset and 42 patients (20%) were 
allocated to the test dataset. The developmental dataset was further split into training (65%; 
n=105) and validation (35%; n=57) datasets. For the distinction of PGE patients from non-
PGE controls, a larger initial cohort was available, which allowed a more optimal sub-division 
into the required datasets. Thus, 447 patients (72%) were allocated to the developmental 
dataset and 170 patients (28%) were allocated to the test dataset. The developmental dataset 
was further split into a training (62%; n=277) and validation (38%; n=170) datasets. 
 
6.3.6. Genotyping and genetic variants 
 Australian patients had been genotyped on the Illumina GoldenGate™ platform for 
4,041 candidate SNPs from 279 candidate genes in a previous multiple candidate gene study 
(Cavalleri et al., 2007) that also formed the basis for the Australian five-SNP 
pharmacogenomic classifier described in Chapter 5 (Petrovski et al., 2009). The 279 candidate 
genes were selected on the basis of suspected involvement in epilepsy, as part of an 
international collaboration to detect variants that may influence the development and treatment 
of common forms of epilepsy (Cavalleri et al., 2007). The gene panel included all known 
members of the voltage-gated sodium and calcium channel families, selected chloride and 
potassium channels, and key receptors, metabolic enzymes, and transporters of the major 
neurotransmitters (GABA, glutamate and acetylcholine) (Cavalleri et al., 2007). In contrast, 
SANAD patients were genotyped on the HumanHap660 Illumina bead chip (Illumina 660™) 
at the Wellcome Trust Sanger Institute (Cambridge, UK), yielding 550,000 genome-wide 
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tSNPs and 120,000 additional SNPs targeting CNVs.  
 
6.3.7. Quality control methods and SNP inclusion  
 Available genetic data, as described above, was interrogated to identify a total of 2,087 
SNPs that were common to both SANAD and Australian patients. Genetic data for all 2,087 
SNPs were subjected to QC procedures before inclusion in the analysis. SNP QC included; i) 
comparison of genotyping consistency, ii) deviation from HWE, and iii) consistency in MAF. 
A total of 1,840 SNPs survived QC and were used in the subsequent model building and data 
analyses.  
 
6.3.8. Statistical analysis and machine learning modeling software 
 HWE and MAF for the initial QC checks were performed using SAS® Enterprise 
Miner version 5.3 software (SAS®). Statistical analysis was performed using the online 
Cochran-Armitage test for trend (http://ihg.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl) and 
the Chi-square test in SPSS. ML methods were explored and employed in the development of 
predictive models using SAS®, with the kNN ML approach executed using the kNN algorithm 
as described in Chapter 5 (Petrovski et al., 2009). 
 
6.3.9. Model development using SAS® Enterprise Miner  
 Many different data-mining algorithms and tools are currently available. A variety of 
supervised learning classification-based methods are available on SAS® Enterprise Miner for 
the development of predictive models for pattern recognition. These differ not only in the type 
of data they prefer (i.e. continuous, categorical, heterogeneous) but also in complexity of the 
data (i.e. interactions and relationships that may exist within data), use of functions, 
approaches used for algorithm generation, and overall data classification. No single supervised 
learning method is best suited for a particular dataset, so several algorithms were applied in 
this analysis. The different ML approaches used are briefly described in Table 6.2. Each SAS® 
data-mining approach was applied to the training dataset and this was used for the initial model 
fitting. Next, the validation dataset was used to monitor and tune the model weighting and for 
initial model assessment. Finally, the test dataset was used to determine the predictive capacity 
of the model.  
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6.3.10. k-Nearest Neighbour approach for model development  
 The kNN ML approach for classifying objects (described in Chapter 5) is based on 
closest training examples in the feature space (Hastie et al., 2001). An observation is classified 
by the average of the observations that are its k nearest neighbours, (k is a positive integer, 
typically small) and the nearest neighbour is the one with the smallest Euclidean distance in 
the nth-dimensional feature space (Hastie et al., 2001, Kotsiantis, 2007, Petrovski et al., 2009). 
The contributions of the neighbours are weighted, so that the nearer neighbours contribute 
more to the average observation than the more distant ones (Kotsiantis 2007; Petrovski, 
Szoeke et al. 2009). The neighbours are identified from observations made in nth-dimensional 
space for the training dataset, in which the correct classification is known (Kotsiantis 2007; 
Petrovski, Szoeke et al. 2009). The best choice of k is dependent upon the data; generally, 
larger values of k reduce the effect of noise on the classification but make boundaries between 
classes less distinct (Kotsiantis 2007; Petrovski, Szoeke et al. 2009). The optimum k for any 
given classification model is determined by various techniques, including cross validation. In 
the analyses described below, k was optimised in the validation dataset, which represented 
35% of the total developmental dataset (or 38% in the PGE vs. LRE analysis) (Kotsiantis 2007; 
Petrovski, Szoeke et al. 2009). 
 
6.3.11. Model building process  
 Initially for objective 1, all genomic data (n=1,840 SNPs) was used to build 
classification models. This was undertaken as part of a preliminary explanatory analysis. 
However, only a subset of SNPs (selected by a specific data filtering method) were later 
employed in formal classification models for both objectives. This was for an effort to reduce 
data complexity as to allow more efficient data analysis, and for the application of the kNN 
approach which preferentially functions on a smaller set of variables (Petrovski et al., 2009). 
The stages of data analyses for each classification task were; (i) cohort stratification, (ii) 
independent univariate analysis for all SNPs, (iii) application of SAS® ML approaches to the 
(a) training, (b) validation, and (c) test datasets (objective one), (iv) a performance test for 
each model using the Chi-square test (objective one), (v) feature selection using the Golub test 
to reduce SNP number, (vi) re-application of ML methods to each dataset using the SNP 
subset, (vii) application of the kNN approach, and finally, (viii) a performance test for each 
subset SNP model using the Chi-square test.  
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 In total, 6 different ML algorithms were run to predict PGE seizure type. These were 
DLT, NN, Logistic Regression (LOGREG), Ensemble, Partial Least Squares and SVM. Where 
an ML approach failed to generate a result because it was unsuited to the data, an alternative 
ML method was applied. Individual models were developed using only the developmental 
dataset (training and validation datasets). 
 
6.3.12. Dimension reduction and SNP selection using the developmental 
dataset 
 Data reduction procedures are of vital importance to ML and data mining (Czarnowski 
and Jȩdrzejowicz, 2008). Most ML algorithms employ a data reduction step whereby any 
irrelevant attributes are removed and a subset of variables are selected according to their 
influence on the outcome variable. These are often found to be embedded in ML programs 
(Moore et al., 2010). Identification of a suitable subset of SNPs was achieved by randomly 
assigning each patient in the developmental dataset into one of five independent groups, with 
equal numbers of cases with absence and myoclonic seizures or LRE and PGE in each group 
(Table 6.5). For each of these five groups, the SNPs were ranked according to their influence 
on seizure type/epilepsy type using the Golub score (Golub et al., 1999). The Golub score 
methodology has been described previously (Petrovski et al., 2009) (Figures 6.2 and 6.3, Table 
6.5). Only the SNPs that ranked among the top 30 in two or more of the five independent 
groups was selected for further analysis.  
 
6.3.13. Application of kNN approach 
 The kNN approach used previously for the investigation of drug response phenotypes 
(Chapter 5) involved an n-1 leave-one-out cross validation for model optimisation and initial 
assessment. In the current analysis, however, this step was performed in specific validation 
datasets, representing 35% and 38% of the development datasets for objectives 1 and 2, 
respectively. This was performed by randomly dividing data into five equally sized groups, 
stratified by seizure (objective 1) or epilepsy (objective 2) type. The prediction model was 
then fitted to four of the subgroups and validated by calculation of prediction error in the fifth 
subgroup. This process was repeated each of the five subgroups in turn and final estimates of 
the prediction error combined (Tables 6.11. and 6.14).  
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6.3.14. Optimisation and assessment 
 The performance of each of the ML models was first internally assessed using the 
validation dataset. This allowed optimisation of the models and was additionally critical to the 
selection of the best model parameters. For the kNN classifier approach, a cross-validation 
method was used at this stage (Chapter 5). Independent validation of the ML models was 
performed on the test datasets for each objective (20% of total population for objective 1, 28% 
for objective 2) to confirm the predictive accuracy of the models. This involved re-running 
each of the ML approaches, including kNN, using only test dataset patients. This step was 
performed on both the full SNP set (n=1,840) and the filtered SNPs. 
 Sensitivity indicates a test’s ability to correctly classify those with the phenotype of 
interest and is analogous to the true positive rate. Specificity measures the ability of a test to 
correctly classify those without the phenotype of interest and is akin to the true negative rate 
(Kotsiantis, 2007). Classification accuracy of each model on the validation and test datasets 
was measured to determine the chance likelihood of the predictions; a 2x2 contingency table 
was generated and the difference between actual (TP, TN) and predicted values (FP, FN) 
assessed using Fisher’s exact test (www.langsrud.com/fisher.htm). Sensitivity and specificity 
values of ≥80% and PPV of ≥80% were used to indicate good model performance (Petrovski 
et al., 2009). Sensitivity, specificity and positive (PPV) and negative (NPV) predictive values 
were calculated for each of the models using the true positive (TP), false positive (FP), true 
negative (TN) and false negative (FN) rates automatically generated by each of the SAS® ML 
models. For the kNN model, the TN, TP, FN, FP values were calculated manually using the 
actual and predicted outcome generated by the algorithm (Larranaga et al., 2006).  
 
6.3.15. Investigation of the biological significance of SNPs  
 In addition to the genetic analyses, each subset of SNPs identified after the data 
reduction stage (i.e. those found to be most predictive of seizure type for objective 1 and 
epilepsy type for objective 2) were subject to bioinformatics analysis to identify their potential 
biological significance (see section 2.4.2 and 3.2.7) (fastsnp.ibms.sinica.edu.tw) 
(www.ensembl.org)(www.cbrc.jp/research/db/TFSEARCH.html)(Yuan et al., 2006) (section 
3.2.7). Information was also extracted on genomic structure; including gene/SNP LD structure 
(section 3.2.4).  
 
6.3.16. Application of the Golub score method in each classification task 
 For objective 1 of the top 30 SNPs in each of the Golub subgroups, 10 SNPs were 
found in three of the five subgroups and one in four of the five subgroups (Figure 6.2). This 
subset of SNPs (N=11) was subjected to ML modeling for seizure type. For objective 2 one 
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SNP was found across all five subgroups, seven were found in four of the five subgroups, five 
in three subgroups, and three SNPs in two of the five subgroups (Figure 6.3) and this subset 
of 16 SNPs (N) was subjected to ML modeling for epilepsy type. 
 
6.3.17. Statistical analysis 
Chi-square statistics (SPSS) and Cochran-Armitage test for trend (http://ihg.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl) were used for all univariate analyses, with P≤0.05 
indicative of statistical significance for both single SNP association and model assessment 
 
 
 
 
Table 6.5 Random stratification of PGE patients  
Patients were stratified into five independent groups with equal number of individuals with 
each seizure or epilepsy phenotype for the application of the Golub filtering approach 
 
 
 
 
 
 
 
 
 
PGE = primary generalised epilepsy JME = myoclonic seizures, ABS = absence seizures, 
PGE= primary generalised epilepsy; LRE= localised related epilepsy 
 
 
 
 
 
 
 
 
 
 
Seizure 
classification 
Group1  
n=32 
Group2 
n=32 
Group3 
n=32 
Group4 
n=33 
Group5 
n=33 
JME 12 12 12 13 13 
ABS 20 20 20 20 20 
Syndrome 
classification 
Group1 
n=90 
Group2 
n=90 
Group3 
n=90 
Group4 
n=89 
Group5 
n=88 
PGE 62 62 62 62 61 
LRE 28 28 28 27 27 
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Figure 6.2 Random stratification of the developmental cohort into five independent 
groups for the application of the Golub filtering approach for seizure type 
The top 30 ranked single nucleotide polymorphisms within each of the five independent cross-
validation subgroups were partitioned from the training set. Arrows and colours indicate 
common SNPs across three or more of the five groups that were selected for the additional 
model development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group1 Group2 Group3 Group4 Group5
rs6962852 rs1672997 rs2475377 rs1982673 rs1672997
rs13210420 rs38540 rs488192 rs17184707 rs678957
rs7099034 rs17124538 rs6489330 rs6777084 rs1592669
rs6495228 rs741160 rs10927888 rs1457784 rs1457784
rs6478676 rs8042482 rs4660468 rs4987852 rs6489330
rs1108877 rs1641021 rs1051640 rs3769931 rs1688015
rs3776587 rs2363838 rs3766553 rs6962852 rs10736084
rs2241103 rs1982673 rs6599229 rs550270 rs3737964
rs4987852 rs12622156 rs7340612 rs3738028 rs9292637
rs2469510 rs12053903 rs626785 rs3744353 rs3738028
rs2436134 rs1571930 rs7556152 rs2241103 rs4340440
rs1982673 rs6962852 rs12679786 rs1801133 rs488192
rs4813156 rs17465037 rs10494834 rs1426223 rs2241103
rs577935 rs525797 rs1435260 rs7108848 rs7252014
rs1457784 rs2252525 rs3864884 rs6489330 rs9607658
rs3738028 rs1426223 rs2237866 rs7167588 rs1317433
rs9485526 rs807515 rs797733 rs12319670 rs3744353
rs17033829 rs2436134 rs17465037 rs1405948 rs577935
rs757200 rs1020740 rs525797 rs6478676 rs10153455
rs488192 rs2190524 rs2014141 rs488192 rs1426223
rs1941637 rs6954291 rs951241 rs2045388 rs11061995
rs535532 rs2039290 rs13210420 rs1415482 rs936642
rs12622156 rs3766553 rs4646437 rs3971872 rs3787870
rs11061995 rs797733 rs11061995 rs9390754 rs2579931
rs741160 rs7260329 rs2469510 rs4660468 rs6902106
rs7125 rs4987852 rs5950884 rs2237866 rs751994
rs2239941 rs1363345 rs2045388 rs2014141 rs701492
rs17345592 rs17033829 rs2337980 rs951241 rs1288386
rs10494834 rs751994 rs10425651 rs1592669 rs3923156
rs626785 rs3864884 rs6478676 rs3025643 rs1415482
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Figure 6.3 Random stratification of the developmental cohort into five independent 
groups for the application of the Golub filtering approach for epilepsy type 
The top 30 ranked single nucleotide polymorphisms within each of the five independent cross-
validation subgroups were partitioned from the training set. Arrows and colours indicate 
common SNPs across two or more of the five groups that were selected for additional model 
development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group1 Group2 Group3 Group4 Group5
rs740805 rs2184226 rs2184226 rs2184226 rs4456611
rs1126617 rs4740788 rs10815018 rs1126617 rs2184226
rs2184226 rs10873637 rs740805 rs2076317 rs2278751
rs2817239 rs17646890 rs324649 rs4566829 rs4316580
rs2076317 rs2165208 rs4896857 rs10280428 rs2165208
rs2472299 rs10280428 rs10280428 rs2469510 rs10043074
rs10280428 rs2832499 rs10510403 rs3851100 rs4740788
rs6680280 rs13550 rs15524 rs4660468 rs9292637
rs7433956 rs6017731 rs4646450 rs4926386 rs10510403
rs10815018 rs4316580 rs4667792 rs7775073 rs4566829
rs4740788 rs10491734 rs1859690 rs7780181 rs10841795
rs324649 rs10520162 rs2181274 rs1859690 rs10280428
rs362848 rs3821767 rs1439806 rs324649 rs816547
rs2278751 rs10815018 rs4926386 rs911562 rs7844150
rs7775073 rs7179733 rs2303716 rs12985786 rs1432128
rs9451192 rs3798256 rs17784350 rs10510403 rs1481031
rs4896857 rs1363345 rs2076317 rs4740788 rs10815018
rs2181274 rs1859690 rs7017612 rs3923156 rs3851100
rs7844150 rs209337 rs4926286 rs6467694 rs17646890
rs420817 rs10502243 rs2789539 rs258704 rs1057908
rs1432128 rs5065 rs1126617 rs15524 rs2623998
rs15524 rs3851100 rs7844150 rs2606357 rs956572
rs17109405 rs15524 rs3804506 rs3743075 rs2565065
rs10207194 rs464028 rs10867084 rs2156634 rs1891395
rs10873637 rs740805 rs898417 rs3739722 rs12490937
rs3821197 rs2156634 rs1481031 rs2283970 rs2254764
rs4687770 rs2181274 rs4412433 rs9380409 rs10873637
rs10491734 rs10510403 rs209337 rs17317854 rs2076317
rs816547 rs4236482 rs3851100 rs2469517 rs4303728
rs6445704 rs4935752 rs12985786 rs12420938 rs1042389
rs4926386 rs3773364 rs6458841 rs11694911 rs3856094
rs956572 rs9380409 rs17646890 rs5065 rs2299637
rs2268582 rs3827199 rs2109422 rs4652707 rs2156634
rs9294430 rs16985442 rs363472 rs4236482 rs11178226
rs11759284 rs16027 rs12145027 rs4456611 rs1126617
rs1859690 rs1481031 rs7544118 rs1485175 rs12996382
rs159914 rs3805455 rs2283970 rs210131 rs911562
rs954785 rs4426954 rs4646437 rs7844150 rs7124411
rs6441061 rs2296063 rs2597909 rs2832439 rs1439806
rs525797 rs6073991 rs16929470 rs12198870 rs12420938
rs802333 rs2832442 rs2278751 rs11759284 rs209337
rs3743075 rs1865806 rs420817 rs1439806 rs7433956
rs797733 rs210139 rs2817239 rs7357341 rs1731017
rs857958 rs7017612 rs13210420 rs6879020 rs3804504
rs2789539 rs1126617 rs6863386 rs4936536 rs2665691
rs4660468 rs2303716 rs12420938 rs2565065 rs740805
rs872013 rs16030 rs10841795 rs209337 rs3743075
rs4316580 rs816547 rs4468579 rs1917810 rs6777084
rs10510403 rs3809208 rs6431631 rs928765 rs2281845
rs2303716 rs324649 rs3766781 rs10043074 rs10488602
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6.4. Results 
6.4.1. Development of a classifier for seizure type using all 1,840 SNPs 
 Since the original 1,840 SNPs were selected from epilepsy related genes (Cavalleri et 
al., 2007), the first stage of the model building process was a univariate test to identify any 
individual SNPs associated with seizure type. From these SNPs five SNPs were found to have 
a p-value of 0.01 or below, before correction for multiple testing. All 1840 SNPs were 
subsequently used in ML model development. When all 1,840 SNPs were investigated, good 
performance was found with the training dataset across all ML models, with SVM being the 
most accurate and showing the lowest error (no incorrect classifications in the training dataset) 
(Table 6.6). However, none of the models were able to accurately classify seizure type in either 
the validation or test datasets, as shown in (P>0.05). This poor overall model performance was 
expected, given the large number of SNPs employed. This task was mainly performed for the 
purpose of model exploration and to assess the benefit of the subsequent data reduction stage 
to predictive modeling.  
 
6.4.2. Univariate results seizure type and training data 
 The results of the independent analysis of association between each of the 11 SNPs 
with seizure type in the training dataset is illustrated in Table 6.7.  All SNPs showed 
association with seizure type (uncorrected for multiple testing) in the training data, with three 
SNPs showing a Chi-square of P of <0.01. The performance of each of the ML models 
developed on combining all 11 SNPs is presented in Table 6.8. With this multi-SNP analysis, 
a lower prediction error was observed across all four models, (P=<0.05 in the training and 
validation datasets) in most cases. The NN approach appeared to be the most accurate model, 
correctly identifying 29 typical absence and 17 myoclonic jerk cases but incorrectly 
identifying 6 myoclonic jerks as typical absence (false positives) and 7 typical absence cases 
as myoclonic jerks (false negatives); P=4.2x10-27 in the training dataset). Although predictive 
in the training and validation sets, none of the ML models were able to accurately classify 
individuals in the test dataset (all p-values >0.05; Table 6.8).  
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Table 6.6 Classification of seizure type using 1840 SNPs and SAS ML models 
  Predictive performance of each SAS machine learning model on training n=103, validation n=59 and test (n=42) data subsets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ML= machine learning, DLT= decision learning tree, NN= neural network, LOGREG= logistic regression SVM= support vector machine, NPV= negative 
predictive value, PPV = positive predictive value, TP = true positive (CAE/JAE correctly classified as CAE/JAE), FP= false positive (JME incorrectly classified 
as CAE/JAE), TN= true negative (JME correctly classified as JME), FN= false negative (CAE/JAE incorrectly classified as JME), CAE= childhood absence 
epilepsy, JAE= juvenile absence epilepsy, JME= juvenile myoclonic epilepsy  
ML model n Data subset TP FP FN TN PPV(%) NPV(%) Sensitivity(%) Specificity(%) P-value 
DLT 103 Training  64 24 0 15 100.0 38.5   6.2 X10-8 
 59 Validation 31 18 5 5 86.1 21.7   0.49 
 42 Test 22 14 4 2 61.1 33.3 84.6 12.5 0.76 
NN 103 Training  64 39 0 0 100.0 0.0   1 
 59 Validation 36 23 0 0 100.0 0.0   1 
 42 Test 42 26 0 16 100.0 0.0 61.9 - 1 
LOGREG 103 Training  46 14 18 25 71.9 64.1   4.5x10-4 
 59 Validation 20 12 16 11 55.6 47.8   0.50 
 42 Test 9 7 17 9 56.3 34.6 34.6 56.3 0.82 
SVM 103 Training  64 0 0 39 100.0 100.0   2.6x10-29 
 59 Validation 30 16 6 7 83.3 30.4   0.34 
 42 Test 21 15 5 1 58.3 16.7 34.6 56.3 0.96 
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Table 6.7 Independent analysis of 11 SNPs and seizure type n=162 
Chi-square test for association between genotype and seizure type in the training data set 
SNP ID (rs)  
P-value 
Training set 
SNP ID (rs) 
P-value 
Test set  
rs65652852  0.20 rs6962852 1x10-4 
rs488192  0.53 rs488192 2.2x10-3 
rs6489330  0.26 rs6489330 0.01 
rs2241103  0.98 rs2241103 0.01 
rs4987852  0.11 rs4987852 0.01 
rs1457784  0.69 rs1457784 0.01 
rs3738028  0.43 rs3738028 0.01 
rs11061995  0.43 rs11061995 0.02 
rs6478676  0.95 rs6478676 0.02 
rs1982673  0.78 rs1982673 0.02 
rs1426223  0.68 rs1426223 0.04 
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Table 6.8 Classification of seizure type using 11 SNPs and SAS machine learning models 
Predictive performance of each SAS machine learning model on training n=103, validation n=59 and test n=42 data subsets 
 
ML = machine learning, DLT = decision learning tree, NN = neural network, LOGREG = logistic regression SVM= support vector machine, NPV = negative 
predictive value, PPV = positive predictive value, TP = true positive (CAE/JAE correctly classified as CAE/JAE), FP = false positive (JME incorrectly classified 
as CAE/JAE), TN = true negative (JME correctly classified as JME), FN = false negative (CAE/JAE incorrectly classified as JME), CAE = childhood absence 
epilepsy, JAE = juvenile absence epilepsy, JME = juvenile myoclonic epilepsy
ML model n Data subset TP FP FN TN PPV (%) NPV (%) Sensitivity (%) Specificity (%) P-value 
DLT 103 Training  49 11 15 13 81.7 46.4 76.6 54.2 1.7 x10-6 
 59 Validation 26 10 10 13 72.2 72.2 72.2 56.5 0.03 
 42 Test 19 9 17 7 67.9 29.2 52.8 43.8 0.70 
NN 103 Training  64 1 0 38 98.5 100.0 100.0 97.4 1.7 x27 
 59 Validation 29 6 7 17 82.9 80.6 80.6 73.9 4.2x 10-5 
 42 Test 20 9 6 7 69.0 53.8 76.9 43.8 0.14 
LOGREG 103 Training  59 9 5 30 86.8 85.7 92.2 76.9 4.3 x10-13 
 59 Validation 31 8 5 15 79.5 86.1 86.1 65.2 7.2 x 10-5 
 42 Test 20 10 6 6 66.7 50.0 76.9 37.5 0.26 
SVM 103 Training  61 10 32 9 65.6 47.4 85.9 22.0 6.1 x10-14 
 59 Validation 2 11 12 34 15.4 14.3 14.3 75.6 2.2 x 10-4 
 42 Test 24 13 2 3 64.9 60.0 92.3 18.8 0.27 
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6.4.3. kNN analysis of seizure type  
 Prior to application of the kNN algorithm, the 11 SNPs were independently tested for 
association with seizure type in the patients (n=42) forming the test dataset (Table 6.9) and no 
association was identified. For the kNN approach, the developmental dataset (n=162) was 
randomly allocated into five validation groups (V1-V5; n=32) with equal numbers of typical 
absence and myoclonic jerks cases in each group (Table 6.10). A single group (e.g. V1) was 
then used as a validation group and the remaining groups (V2-V5) as the training dataset to 
make a prediction. This process was repeated with each of the five validation groups in turn, 
with V1-V5 each used as the validation dataset on one occasion only. An average predictive 
performance estimate across the five runs was then generated. The training dataset was 
therefore built on an average of 130 patients, with 32 individuals used as a validation dataset 
for independent cross-validations. This allowed the determination of the best k (i.e. number of 
nearest neighbours) and avoided model over-fitting. A k=13 was found to be optimal, with the 
best predictive performance value and lowest p-value. The model parameters were therefore 
N=11 (11 SNPs) and k =13 (13 nearest neighbours).  
 The classifier was predictive of seizure type in the test dataset but not at a statistically 
significant level (model P=0.06). Table 6.10 shows the development and performance data for 
the kNN model using the training (n=162) and the test dataset (n=42). In summary, five 
individuals were correctly classified as having myoclonic jerks and 24 individuals were 
correctly classified as typical absence, two typical absence cases were incorrectly classified as 
myoclonic jerks (false positive) and 11 myoclonic jerk cases were incorrectly classified as 
typical absence (false negative). Test cohort PPV and NPV were 71% and 69% respectively. 
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Table 6.9 Independent analysis of 11 SNPs and seizure type in the test data set 
 
SNP = single nucleotide polymorphism, P-values uncorrected 
 
 
Table 6.10 Results of the kNN machine learning approach for seizure type  
Performance of the kNN 20% and n-1 cross validation in the training (n=162) and test dataset 
(n=42) respectively 
 
TP= true positive (CAE/JAE correctly classified as CAE/JAE), FP= false positive (JME 
incorrectly classified as CAE/JAE), TN = true negative (JME correctly classified as JME), FN 
= false negative (CAE/JAE incorrectly classified as JME, kNN= k-Nearest Neighbour,  
V= 20% cross validation subset of validation cohort, TP = true positive, FP = false positive, 
TN= true negative, FN= false negative, Sens= sensitivity, Spec= specificity PPV= positive 
predictive value, NPV= negative predictive value, CAE= childhood absence epilepsy,  
JAE= juvenile absence epilepsy, JME = juvenile myoclonic epilepsy 
SNP ID (rs)  Odds ratio  P-value 
rs65652852  0.592 0.20 
rs488192  1.649 0.53 
rs6489330  0.718 0.26 
rs2241103  1.39 0.98 
rs4987852  1.518 0.11 
rs1457784  0.768 0.69 
rs3738028  1.18 0.43 
rs11061995  1.839 0.43 
rs6478676  0.914 0.95 
rs1982673  1.528 0.78 
rs1426223  0.913 0.68 
kNN 
model 
TP FP FN TN Sens  
(%) 
Spec  
(%) 
PPV 
(%) 
NPV 
(%) 
Two tail    
P-value 
V1 5 4 7 16 41.7 80.0 55.6 69.6 0.20 
V2 9 0 3 20 75.0 100.0 100.0 87.0 8x10-6 
V3 7 2 5 18 58.3 90.0 77.8 78.3 6x10-3 
V4 4 1 9 19 30.8 95.0 80.0 67.9 0.07 
V5 7 0 6 20 53.8 100.0 100.0 76.9 4x10-4 
V1-5; 
n=162 
32 7 30 93 51.6 93.0 82.1 75.6 2x10-10 
n=42 5 2 11 24 31 92 71 69 0.06 
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6.4.4. Univariate association of SNP genotype with epilepsy type  
All 16 SNPs were assessed for independent association with epilepsy type. The results of the 
Chi-square test of association performed on the developmental dataset (n=447) is shown in 
Table 6.11. Univariate analysis showed that all SNPs had some association with epilepsy type 
with five SNPs showing a Chi-square p-value of <0.01.  
 
6.4.5. Development of a classifier for epilepsy type 
 For objective 2, the same approach was taken for model development and SNP 
analyses as described for objective 1. The performance of each of the ML models in the 
developmental dataset is presented in Tables 6.12a and 6.12b. The accuracy and sensitivity of 
each ML model in predicting epilepsy type in the test dataset is also presented in Table 6.12. 
When all 16 SNPs were investigated, each of the ML models was able to predict PGE with 
good predictive accuracy in the training dataset (P =<0.05) but as in objective 1, the majority 
of models failed to accurately classify epilepsy type in either the validation or test datasets. 
Modest associations were observed with NN and Ensemble models in the test datasets (P 
=0.017 and P =0.034, respectively) but overall predictive performance was poor (sensitivity 
=70.3% and 65.3%, PPV =75.5% and 71.3 %, respectively). 
 
 
 
TABLE 6.11 Independent analysis of 16 SNPs and epilepsy type n=447 
Chi-square test for testing association between genotype and epilepsy type in training set 
SNP ID (rs)  Odds ratio  P-value 
rs10280428  2.32 3.9 x10-4 
rs740805  0.59 2.9 x10-3 
rs324649  0.61 1.2 x10-3 
rs420817  2.50 2.6 x10-3 
rs15524  1.61 1.8 x10-3 
rs4236482  2.14 1.7 x10-2 
rs209337  0.30 4.4 x10-4 
rs1126617  1.49 3.4 x10-3 
rs2076317  0.54 7.7x10-3 
rs7844150  0.71 0.02 
rs2184226  1.59 0.02 
SNP = single nucleotide polymorphism, P-values uncorrected 
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Table 6.12a Classification of epilepsy type using 16 SNPs and SAS machine learning models 
Predictive performance of each SAS machine learning model on training n=279, validation n=168 and test n=170 data subsets 
 
ML = machine learning, DLT = decision learning tree, NN = neural network, LOGREG = logistic regression SVM= support vector machine, NPV = negative 
predictive value, PPV = positive predictive value, TP = true positive (PGE correctly classified as PGE, FP = false positive (LRE incorrectly classified as PGE), 
TN = true negative (LRE correctly classified as LRE), FN = false negative (PGE incorrectly classified as LRE), PGE= primary generalised epilepsy, LRE= 
localised related epilepsy 
 
 
 
 
ML model n Data subset TP FP FN TN PPV (%) NPV (%) Sensitivity (%) Specificity (%) P-value 
DLT 279 Training  - - - - - -    - 
 168 Validation nd Nd nd nd nd nd   nd 
 170 Test nd Nd nd nd nd nd nd nd nd 
NN 279 Training  192 1 1 85 99.5 98.8   4.6x10-70 
 168 Validation 91 34 25 18 78.4 34.6   0.06 
 170 Test 83 27 35 25 70.3 48.1 75.5 41.7 0.02 
LOGREG 279 Training  174 0 19 86 90.2 100.0   1x10-53 
 168 Validation 61 22 55 30 52.6 57.7   0.14 
 170 Test 57 23 61 29 48.3 55.8 71.3 32.2 0.37 
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Table 6.12b  Classification of epilepsy type using 16 SNPs and SAS machine learning models  
Predictive performance of each SAS machine learning model on training n=279, validation n=168 and test n=170 data subsets 
ML = machine learning, DLT = decision learning tree, NN = neural network, LOGREG = logistic regression SVM= support vector machine, NPV = negative 
predictive value, PPV = positive predictive value, TP = true positive (PGE correctly classified as PGE, FP = false positive (LRE incorrectly classified as PGE), 
TN = true negative (LRE correctly classified as LRE), FN = false negative (PGE incorrectly classified as LRE), PGE= primary generalised epilepsy, LRE= 
localised related epilepsy 
ML model n Data subset TP FP FN TN PPV (%) NPV (%) Sensitivity (%) Specificity (%) P-value 
SVM 279 Training  193 0 0 86 100.0 100.0   2.8x10-74 
 168 Validation 93 35 23 17 80.2 32.7   0.06 
 170 Test 92 35 26 17 78.0 32.7 72.4 39.5 0.10 
ENSEMBLE 279 Training  193 0 0 86 100.0 100.0   2.8x10-74 
 168 Validation 91 34 25 18 78.4 34.6   0.06 
 170 Test 77 31 41 21 65.3 40.4 71.3 33.9 0.03 
PARTIAL 
LEAST 
SQUARES 
279 Training  193       0 0 86 100.0 100.0    2.8x10-74 
168 Validation 91        33 25 19 78.4 36.5    0.03 
170 Test 93        38 25 14 78.8 26.98 71.0 35.9  0.26 
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6.4.6. kNN analysis of epilepsy type 
 The 16 SNPs were also independently tested for association with epilepsy type in the 
test dataset (n=170) (Table 6.13), before application of the kNN algorithm. A weak association 
with epilepsy type was seen with one SNP only in this smaller dataset (rs4740788, P= 0.04). 
 The kNN approach was applied to the PGE vs. LRE analysis as described for objective 
1. The performance of the kNN model within the developmental dataset was again assessed 
using a 20% CV and different k-parameters to identify the optimum k. The k-parameter 
that performed best within the developmental dataset based on the average prediction accuracy 
across the 5-fold CV was a k of 13. The model parameters were therefore N=16 (16 SNPs) 
and k=13 (13 nearest neighbours). Table 6.14 presents the results of the kNN model using the 
developmental dataset (n=447) and the test dataset (n=170). Using the test dataset patients, 
110 individuals were correctly classified as having PGE and 8 individuals were correctly 
classified as having LRE, 44 LREs were incorrectly classified as PGE (false positive) and 8 
PGEs were incorrectly classified as LRE (false negative), with overall PPV and NPV of 71% 
and 50%, respectively. Although the classification performance was markedly improved with 
kNN in comparison to other ML approaches, the model failed to adequately classify PGE and 
LRE patients (test dataset P =0.07). 
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TABLE 6.13 Independent analysis of 16 SNPs and epilepsy type n=170 
Chi-square test for testing association between genotype and epilepsy type in test dataset 
SNP ID (rs)  Odds ratio P-value 
rs10280428  0.41 0.11 
rs740805  0.96 0.78 
rs324649  1.03 0.41 
rs420817  1.21 0.45 
rs15524  1.34 0.57 
rs4236482  1.51 0.37 
rs209337  0.85 0.50 
rs1126617  1.20 0.72 
rs2076317  0.42 0.08 
rs7844150  1.57 0.12 
rs2184226  0.63 0.12 
rs3851100  0.89 0.61 
rs10815018  1.01 0.84 
rs4740788  3.65 0.04 
rs10510403  1.10 0.93 
rs1859690  0.44 0.13 
SNP = single nucleotide polymorphism, P-values uncorrected 
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Table 6.14 Results of the kNN machine learning approach for epilepsy type 
Performance of the kNN 20% and n-1 cross validation in the training (n=447) and test dataset 
(n=170) respectively 
 
TP= true positive (PGE correctly classified as PGE), FP= false positive (LRE incorrectly 
classified as PGE), TN= true negative (LRE correctly classified as LRE), FN= false negative 
(PGE incorrectly classified as LRE), kNN= k-Nearest Neighbour, V= 20% cross validation 
subset of validation cohort, TP= true positive, FP = false positive, TN= true negative, FN = 
false negative, Sens= sensitivity, Spec= specificity, PPV= positive predictive value, NPV= 
negative predictive value, PGE= primary generalised epilepsy, LRE= localised related 
epilepsy 
 
 
 
6.4.7. Biological significance of genetic variants used in ML models 
 The biological investigation of two groups of SNPs associated with seizure type and 
epilepsy type are found in Tables 6.15 and 6.16 respectively. For seizure type ten SNPs were 
intronic region variants and one was a synonymous coding region SNP (Table 6.15). 
Investigation of the genomic structure using www.hapmap.org (release # 24) failed to identify 
any biologically functional variants with a MAF ≥ 1% in European populations that were in 
strong LD (r2 ≥0.8) with any of these SNPs. Further functional analysis (Yuan et al., 2006) and 
assessment of potential TF binding sites (Kent et al., 2002) highlighted the synonymous 
rs6962852 variant (in the CLCN1 gene) to be located in both TF binding domains and in an 
enhancer splice site. Although this synonymous SNP was not expected to alter TF binding 
characteristics (TFSEARCH), it was predicted to alter the number of exonic splicing enhancer 
(ESE) motifs (ESE finder, Fast SNP). Functional mutations in the corresponding CLCN1 gene 
kNN 
model 
TP FP FN TN Sens  
(%) 
Spec  
(%) 
PPV 
(%) 
NPV 
(%) 
Two tail    
P-value 
V1 59 20 3 8 95.1 29.0 75.0 73.0 0.10 
V2 57 19 5 9 92.0 32.1 75.0 64.2 0.08 
V3 55 19 7 9 89.0 32.1 74.3 56.2 0.06 
V4 59 17 3 10 95.1 37.0 77.6 76.9 0.09 
V5 59 23 2 4 97.0 15.0 72.0 67.0 0.22 
V1-5; 
n=447 
289 98 20 40 93.5 29.0 75.0 67.0 2x10-4 
n=170 110 44 8 8 92 15 71 50 0.07 
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have previously been identified in rare familial forms of PGE (Dibbens et al., 2007) but not in 
large cohorts of sporadic PGE, indicating that CLCN2 is probably not a gene that is commonly 
mutated in PGEs (Gardiner, 2005, Dibbens et al., 2007). Limited biological significance and 
a lack of predictive performance in the test dataset would question the relevance of all 11 SNPs 
in susceptibility to a PGE seizure type. 
 Of the 16 variant subset used for epilepsy type classification, only two SNPs were 
located in protein coding regions (one non-synonymous and one synonymous variant) (Table 
6.16) and these were also not in strong LD with (HapMap release # 24, r2≥0.8) any other 
biologically functional variants with a MAF ≥ 1% in European populations that Four of these 
16 SNPs were however in strong LD with each other (Table 6.16). Further functional and 
regulatory region analysis for these is presented in Table 6.17.  Of the 16 SNPs The rs1126617 
(a non-synonymous SNP in the glycosylphosphatidyl-inositol specific phospholipase D1 
(GPLD1) gene was predicted to be a low risk splicing regulation polymorphism that resulted 
in an alteration in a splice site (Fast SNP; ESE/ESS finder). Amongst the remaining 15 SNPs, 
the rs1020848, rs740805, rs420817, rs3851100 and rs10510403 variants were also predicted 
to possess low risk in terms of a potential functional effect. These were promoter or regulatory 
region SNPs that may result in altered TF binding (TFSEARCH).  Further investigation of the 
SNPs and their corresponding genes in the literature also indicated no additional biological 
implication or disease/epilepsy association.  
 
 
Table 6.15 Genetic information for 11 SNPs for epilepsy seizure type classifiers 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP= single nucleotide polymorphism, MAF= minor allele frequency, a.a= amino acid 
change, T= threonine 
SNP ID (rs) Gene Alleles MAF Description a.a change 
rs6962852        CLCN1 C>T  0.28 synonymous P.T87T 
rs488192         SLC6A13 A>G 0.17 intronic  
rs6489330        CACNA2D4 G>A 0.19 intronic  
rs2241103        ABAT A>G 0.09 intronic  
rs4987852       BCL2 A>G 0.08 3'UTR  
rs1457784        KCNQ3 C>A 0.13 Intronic  
rs3738028        KCNN3 T>G 0.35 Intronic  
rs11061995     CACNA2D4 G>A 0.16 Intronic  
rs6478676          GABBR2 G>A 0.43 Intronic  
rs1982673        BCL2 T>G 0.12 Intronic  
rs1426223         GABRB3 C>T  0.28 intronic  
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Table 6.16 Genetic information for 16 SNPs for epilepsy type kNN classifiers 
SNP ID  
(rs) 
Gene Alleles MAF Location Amino 
acids 
LD  
rs10280428 CACNA2D1 A>C 0.08 Upstream   
rs740805 CACNG5 T>C 0.12 Upstream   
rs324649*** CHRM2 C>T 0.39 intronic  **** 
rs420817**** CHRM2 T>C 0.49 intronic  *** 
rs15524 CYP3A5 T>C 0.04 3' UTR   
rs4236482 FAM131B G>A 0.19 intronic   
rs209337 GABRG2 C>A 0.05 intergenic   
rs1126617** GPLD1 G>A 0.36 Exonic P.V30I * 
rs2076317* GPLD1 A>G 0.39 upstream  ** 
rs7844150 KCNQ3 G>T 0.07 intronic   
rs2184226 MTHFR G>A 0.09 downstream   
rs3851100 SCN3B T>C 0.16 intronic   
rs10815018 SLC1A1 A>G 0.39 intronic   
rs4740788 SLC1A1 T>C 0.11 intergenic   
rs10510403 SLC6A1 A>G 0.17 intronic   
rs1859690 ZNF498 A>G 0.04 Exonic P.E388E  
SNP= single nucleotide polymorphism, MAF= minor allele frequency, a.a= amino acid 
change, LD= linkage disequilibrium, V= valine, I=iisoleucine, E= glutamine, LD= linkage 
disequilibrium; (r2≥0.8), * see corresponding SNP 
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Table 6.17 Predicted function and functional effect of 16 SNPs used for predicting 
epilepsy type (http://fastsnp.ibms.sinica.edu.tw/pages/inputCandidateGeneSearch.jsp) 
SNP ID (rs) Gene Possible functional  
effects 
Risk TF binding 
site change 
SE/ 
SS 
rs10280428  CACNA2D1 promoter/regulatory 
region 
1-3 yes - 
rs740805  CACNG5 promoter/regulatory 
region 
1-3 yes - 
rs1126617  GPLD1 splicing regulation 2-3 - yes 
rs4740788  CACNA2D1 intronic enhancer 1-2 - - 
rs420817  CHRM2 intronic enhancer 1-2 yes  
rs3851100  SCN3B intronic enhancer 1-2 yes  
rs10510403  SLC6A1 intronic enhancer 1-2 yes  
rs1859690  ZNF498 sense/synonymous 1-1 - - 
rs324649  CHRM2 intronic with no known 
function 
0 - - 
rs15524  CYP3A5 downstream with no 
known function 
0 - - 
rs4236482  FAM131B intronic with no known 
function 
0 - - 
rs2076317  GPLD1 Upstream with no 
known function 
0 - - 
rs7844150  KCNQ3 Intronic with no known 
function 
0 - - 
rs2184226  C1orf167 Intronic with no known 
function 
0 - - 
rs10815018  SLC1A1 Intronic with no known 
function 
0 - - 
rs10510403  SLC6A1 Downstream with no 
known function 
0 - - 
TF= transcription factor, SE= splicing enhancer site change, SS=splicing silencer site 
change. Risk = Upper and lower risk of functional effect, 0=no effect, 1=very low risk, 
2=low risk, 3=medium risk, 4=high risk, 5=very high risk (http://fastsnp.ibms.sinica.edu.tw/ 
pages/ input_CandidateGeneSearch.jsp). 
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6.5. Discussion 
 Common forms of genetic epilepsies are among numerous common, complex 
disorders for which networks of gene regulation and interactions are thought to confer disease 
risk (Ferraro and Buono, 2006, Ferraro et al., 2012). These genetic factors are likely to be 
inter-related, probably in a highly complex fashion. Recent assumptions regarding the genetic 
architecture of complex epilepsies include the popular CDCV hypothesis (Lohmueller et al., 
2003, Cavalleri et al., 2007). However, the vast majority of the common variants identified so 
far confer only small risks (Dibbens et al., 2007). This has led to the proposal of developing 
novel approaches for simultaneously testing multiple genetic loci of small effect as an attempt 
to increase the capacity of correctly predicting the likelihood of disease occurrence (McKinney 
et al., 2006). ML is one such proposed method for efficient data analysis (Hastie et al., 2001). 
The kNN supervised ML approach was able to predict seizure control in newly treated 
Australian patients with epilepsy but the method has yet to be validated in independent and 
international cohorts (Petrovski et al., 2009, Johnson et al., 2011b). The advantages of using 
ML techniques for gene association data include robustness, higher power and greater 
accuracy than that of parametric statistical approaches, as well as the additional ability to 
model non-linear effects and high-dimensional data (Lee et al., 2008).  
 The studies reported in this chapter applied several ML approaches to test their 
proficiency in the analysis of complex disease association data. Large genomic datasets from 
two independent epilepsy cohorts were explored. ML was used for both identifying 
susceptibility variants associated with PGE and the seizure types defining the main PGE sub-
syndromes. Two SNP subsets, comprising 11 and 16 SNPs were identified as most 
significantly associated with seizure type and epilepsy type respectively, and used in the 
development of two phenotype classifiers.  
 All individual SNP subsets in each identified subset were found to associate with 
seizure or epilepsy type at the p=<0.05 level when univariately tested in the respective 
developmental cohorts, thus indicating some initial significance of each of these SNPs to PGE. 
Most of these however failed when applied to the blinded test cohorts. ML models using the 
SNP subsets in combination were similarly found to associate with phenotype for both 
objectives but again only in the training cohorts in both cases. Some predictive value was 
evident in the epilepsy type classification task when NN and Ensemble approaches were 
applied; Test cohort PPV= 70.3%, 65.3% and Sensitivity= 75.5%, 70.3%, respectively. These 
models were however only applied to the analysis concerning all 1,840 SNPs, thus no 
corresponding data is available for the 16 SNP subset analysis. The NN ML method has 
previously been used in both linkage and association analyses for the identification of disease 
susceptibility genes as well as complex traits (Motsinger-Reif et al., 2008). The second 
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approach, Ensemble is a novel ML method available on SAS that combines the results of 
multiple classifiers and has been shown to achieve a substantially improved prediction when 
compared to single classifiers in several reviews (Ahn et al., 2007, Moon et al., 2007).  
 The main hypothesis was that the kNN ML approach in particular, due to previously 
being able to make successful predictions for complex genomic data (Petrovski et al., 2009), 
may be a more suitable method for developing classifiers of PGE than traditional ML methods 
(Petrovski et al., 2009). Indeed, the Australian patients and genomic data used in the current 
analysis were the same as those used in the original Australian pharmacogenomic kNN 
classifier study (Cavalleri et al., 2007, Petrovski et al., 2009). The kNN ML approach is 
considered to be more user friendly, more easily used for incremental learning, more easily 
tuned, and better for avoiding over-fitting when compared to other ML approaches (Kotsiantis, 
2007). Improved performance was seen with the kNN approach for each classification task 
(p=0.06 and p=0.07 for seizure and epilepsy type analyses, respectively) but the kNN ML 
models similarly failed to predict phenotype when applied to the respective test datasets.  
 
6.5.1. General design considerations 
 There are several explanations for the lack of success with ML approaches to 
predicting PGE and PGE seizure types. These include; i) issues with study design, ii) inherent 
problems with predictive modeling, iii) genomic differences between populations, and iv) 
complexity of the task itself. Some of the general issues with population genomic differences 
and ML modeling, particularly in the kNN method, have been discussed previously (section 
5.4).  
 
Population genomic differences from using international populations 
 The potential influence of ethnicity on genetic transmission (Delgado-Escueta, 2007) 
is likely to be far too diverse for analyses that combine populations.  
 
 Variants common to multiple populations are each likely to be of a small effect size 
and so undetectable in modestly sized cohorts as available for this study 
 
 Despite the adoption of cross validation method the cohorts may also remain 
insufficient in size to allow the partitioning required for model building and 
independent assessment  
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Methodological issues 
 A data reduction step may have excluded potentially causative alleles or loci 
(Larranaga et al., 2006, Kotsiantis, 2007, Joaqu et al., 2010, Derrac et al., 2012); 
 
 The Golub score filter method for SNP ranking is an easy method to implement, 
however it does not consider correlation between features or SNPs (Golub et al., 
1999).  
 
 Principal limitations of classification algorithms exist including limited scalability, 
potential for over-fitting (this can result in false-positive results) (Hastie et al., 2001), 
challenging feature/SNP selection, and difficulty in accounting for gene-gene 
interactions (Moore and Ritchie, 2004).  
 
 Most existing studies using ML approaches have dealt only with candidate SNP data 
in which hundreds rather than thousands of SNPs are modeled (Szymczak et al., 2009, 
Goldstein et al., 2010). 
 
 
Heterogeneous and multigenic nature of the PGE phenotype  
 Likelihood that insufficient numbers of SNPs were employed to detect the multiple 
common variants thought to contribute to the complex PGEs (Kasperaviciute et al., 
2010); The 1,840 variants used in this study constituted fewer than 50% of the 4,041 
SNPs in the original SNP panel; GWAS scans that typically provide in excess 500,000 
SNP genotypes may be more efficient for the identification of susceptibility loci in 
oligogenic traits, (Ferraro et al., 2012, Kearney, 2012).  
 
 Complex PGEs have been investigated primarily on the study of SNPs (Ferraro et al., 
2012) (Schork et al., 2009). Rare variants including CNVs are typically excluded, 
despite these less common genetic defects might equally explain inter-individual 
susceptibility to disease (Mefford et al., 2010, Ferraro et al., 2012).  
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6.5.2. Summary and future perspectives 
 The investigation described in this chapter set out to assess the potential value of ML 
models in epilepsy classification by applying this essentially novel approach to a large subset 
of genomic data in an effort to identify variants of potential significance to complex PGE 
phenotypes. Although the current study was unable to model the available genomic data 
successfully and did not produce classifiers with good predictive performance, overall the 
classifiers that were developed on a subset of SNPs did appear to show improved association 
with seizure and epilepsy type than when the same SNPs were tested individually. These 
present findings further emphasise several points and considerations for future work 
concerning complex epilepsy genomics, namely that; 
 
 There may be tens of thousands of alleles that constitute the broader epilepsy genome; 
 
 Multiple combinations of these could, increase susceptibility or resistance to epilepsy 
in any given individual. 
 
 Identification of all or at least sufficient numbers of these genomic markers to 
differentiate between seizure and epilepsy types remains an elusive task; requiring 
greater study power, in terms of both numbers of cases and genotyping methodology. 
 
 Positive susceptibility loci require independent confirmation and validation in 
independent cohorts; 
 
  In ethnically different populations, such susceptibility loci may be entirely different, 
thus requiring independent validation in multiple ethnic populations before a true 
phenotype association can be proposed. 
 
 
 To conclude, as so little is known about the genetics of epilepsy, the number of 
different possible subsets of susceptibility alleles is almost limitless and thus unravelling the 
phenotypic diversity of complex PGE is and will continue to be an arduous task. The strategy 
used in the present investigation to detect genetic predisposition in PGEs may be an 
improvement over methods used in traditional association studies but still fails to capture the 
genomic heterogeneity that potentially exists.  
 
 
 
  CHAPTER SEVEN 
  
220 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SEVEN 
A CANDIDATE SNP STUDY FOR THE VALIDATION 
OF A MULTICENTRE GENOME WIDE ASSOCIATION 
ANALYSIS FOR PREDICTING TREATMENT 
RESPONSE IN NEWLY TREATED EPILEPSY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER SEVEN 
  
221 
 
CONTENTS  
7.1. INTRODUCTION ...................................................................................222 
7.1.1. Genome wide approach to complex disease genetics .............................222 
7.1.2. Genome wide approach to epilepsy genetics .........................................223 
7.1.3. Genome wide studies in epilepsy ..........................................................223 
7.1.4. Meta-analysis of GWAS for an increase in study power ..........................224 
7.1.5. Phenotypic heterogeneity in epilepsy ...................................................225 
7.1.6. Defining drug response ........................................................................225 
7.1.7. Genome wide association study meta-analysis for predicting treatment 
outcome in newly treated epilepsy .......................................................226 
7.1.8. Biological significance and role of GSTA4 in epilepsy ..............................230 
7.1.9. Aims and hypothesis ............................................................................230 
7.2. STUDY COHORT, MATERIALS AND METHODS .......................................231 
7.2.1. Phenotype definitions for patient selection ...........................................231 
7.2.2. Immediate vs. delayed seizure remission and definitions for time to event 
analysis ...............................................................................................232 
7.2.3. Glasgow validation cohort ....................................................................232 
7.2.4. Clinical data selection and inclusion ......................................................232 
7.2.5. Genetic data selection and inclusion .....................................................233 
7.2.6. Genotyping of candidate SNPs ..............................................................234 
7.2.7. Experimental details ............................................................................234 
7.2.8. Taqman chemistry ...............................................................................234 
7.3. STATISTICAL ANALYSIS ........................................................................235 
7.3.1. Univariate tests with treatment outcome for association analysis ..........235 
7.3.2. Multiple regression analysis with treatment outcome ............................235 
7.3.3. Survival analysis for time to remission data ...........................................236 
7.4. RESULTS ..............................................................................................237 
7.4.1. Univariate analysis of association between SNPs or clinical covariates and 
treatment outcome .............................................................................238 
7.4.2. Multiple regression models ..................................................................243 
7.4.3. Multivariable survival analysis ..............................................................245 
7.4.4. Multivariable survival analysis ..............................................................247 
7.5. DISCUSSION ........................................................................................247 
  CHAPTER SEVEN 
  
222 
 
7.1. Introduction 
As discussed previously, several clinical and genomic factors have been investigated to 
help identify factors that predict treatment response in epilepsy (Cockerell et al., 1995, 
MacDonald et al., 2000, Sillanpaa and Schmidt, 2006, Kaneko et al., 2008, Loscher et al., 
2009). Despite identifying a number of clinical factors associated with poor treatment 
outcomes in newly treated and chronic epilepsy (Hitiris et al., 2007, Kwan et al., 2011) and 
more recently those associated with seizure remission (Callaghan et al., 2011, Bonnett et al., 
2012, Brodie et al., 2012), their predictive power and subsequent clinical utility remains 
limited (Brodie, 2005b, Mohanraj and Brodie, 2005, 2007). No single clinical factor has been 
found to accurately predict seizure control (Brodie et al., 2012), though a combination of one 
or several of these factors may help to define those individuals who are most unlikely to 
respond to drug treatment (Bonnett et al., 2012). PGx efforts have similarly made little clinical 
impact on the search for definite genomic predictors of AED drug efficacy (Loscher et al., 
2009, Johnson et al., 2011b).  Ultimately constructing multivariable, multifactorial models that 
combine both influential clinical and genetic factors, maybe most useful (Johnson et al., 
2011b). PGx research has long recognised that the inherent basis of patient response 
essentially results from multiple variants of small effect (Evans and Johnson, 2001, Grant and 
Hakonarson, 2007). However, most current studies investigate polymorphisms univariately, 
typically in small or modest sized cohorts (Colhoun et al., 2003, McCarthy et al., 2008, 
Loscher et al., 2009).   
 
7.1.1. Genome wide approach to complex disease genetics 
  Genome wide association studies of epilepsy disease genetics have recently been 
published (Kasperaviciute et al., 2010) as have GWAS assessing drug response in epilepsy 
(Kasperaviciute and Sisodiya, 2009, Cavalleri et al., 2011, McCormack et al., 2011, Ozeki et 
al., 2011a). GWAS studies can consider the relevance of variation across the entire genome 
and so are not restricted to exclusively investigating biologically driven or previously reported 
candidate genes (Crowley et al., 2009, Motsinger-Reif et al., 2010). With the growing number 
of GWAS across disease genetics, several limitations of GWAS have similarly become 
apparent (Crowley et al., 2009, Motsinger-Reif et al., 2010, Johnson et al., 2011b). One of the 
main issues for GWAS concerning complex traits is that the “common variant” hypothesis 
predicts weak genetic effects, (inherently due to the large number of low penetrance variants 
being tested). Very large sample sizes are thus required to successfully boost the genetic 
“signal” over the additional “noise” produced by environmental variables and other genetic 
factors.           
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GWA studies additionally only consider common genetic variation which is now 
thought to at best only have a modest role in the predisposition to complex syndromes and/or 
traits (Ferraro et al., Barrett et al., 2009, Kasperaviciute and Sisodiya, 2009, Daly, 2010a, 
Kasperaviciute et al., 2010). The alternative to the common disease common variant 
hypothesis is that multiple rare variants cause disease at high prevalence in the population 
(Motsinger-Reif et al., 2010). Common variants are thought to result in subtle effects on gene 
function, often through changes to gene regulation, whilst rare variants such as non-
synonymous variants can have larger effects on gene function, which could lead to large 
changes in disease risk or trait values (Motsinger-Reif et al., 2010). And so, both these 
hypotheses can have important implications to common phenotypes (McCarthy et al., 2008, 
Motsinger-Reif et al., 2010).  
 
7.1.2. Genome wide approach to epilepsy genetics 
 To date, GWA studies evaluating drug response in epilepsy are scarce (Kasperaviciute 
and Sisodiya, 2009, Cavalleri et al., 2011) and this is likely to be due to the low number of 
well phenotyped epilepsy patient cohorts with DNA currently available. Epilepsy comprises 
of a group of phenotypically and genetically heterogeneous disorders, with an underlying 
genetic predisposition likely in over half of individuals with epilepsy (Kearney, 2012). The 
genetic architecture of the epilepsies is consequently likely to be very complex, reflecting this 
genotypic and phenotypic heterogeneity and high degree of heritability (Kearney, 2012).  
  DNA samples from hundreds if not thousands of phenotyped epilepsy patients is 
expected to be required for epilepsy GWAS to be successful and informative (Kasperaviciute 
et al., 2010, Cavalleri et al., 2011). As published GWAS are underpowered to detect all but 
the biggest effects, the susceptibility variants identified to date, are probably only a subset of 
the influential loci yet to be detected and/or may indicate false positive associations (Guessous 
et al., 2009). Moreover, because the effect sizes of these variants are usually small and the 
number of false positive findings are expected to be large (McCarthy et al., 2008, Guessous et 
al., 2009), additional patient cohorts from independent populations will be necessary as 
replication cohorts (Kasperaviciute et al., 2010). 
 
7.1.3. Genome wide studies in epilepsy 
Currently, only two cases of GWAS analysis of disease susceptibility can be found in 
literature and both of these concern focal or localisation related epilepsy (Kasperaviciute et 
al., 2010, Guo et al., 2012, Kearney, 2012). The first, reported by Kasperaviciute and 
colleagues in 2010, used broad phenotype criteria and included individuals with focal epilepsy, 
regardless of etiology (Kasperaviciute et al., 2010). No genome-wide significance associations 
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were found, thus little was gained in terms of genes for disease susceptibility (Kasperaviciute 
et al., 2010). This is however not entirely unexpected, considering the high degree of 
heterogeneity across specific epilepsy types and the expectation that both rare and common 
variants contribute only small effects to complex traits (Cavalleri et al., 2007, Kwan et al., 
2009, Cavalleri et al., 2011). The second focal epilepsy GWAS, using a two-stage approach 
and a meta-analysis of both stages proved more successful (Guo et al., 2012, Kearney, 2012).  
 
7.1.4. Meta-analysis of GWAS for an increase in study power 
Meta-analysis is a statistical technique for combining the findings from independent 
studies and in medicine is most often used to assess the clinical effectiveness of healthcare 
interventions (Egger and Smith, 1997, McCarthy et al., 2008)(www.cochrane-
handbook.org)(Davey et al., 2011). The joint effort of independent research centers in 
combining and analysing genomic data from similar studies is one approach to improve the 
power of whole genome scans (Nebert et al., 2008a, Cavalleri et al., 2011, Kearney, 2012).  
Aggregate data from several scans has previously facilitated detection of variants with 
small effects (Manolio et al., 2007, Weedon et al., 2008, Zeggini et al., 2008, Lettre, 2012) 
and such data-sharing efforts could also help achieve success in the anticipated wave of cohort-
based GWAS for epilepsy (McCarthy et al., 2008). Meta-analyses of data from multiple 
epilepsy cohort may have sufficient power to detect any main as well as underlying (gene–
gene and gene–environment) genetic effects, explore potential sources of heterogeneity and 
also inform the selection of the most relevant SNPs for replication efforts (McCarthy et al., 
2008). Joint analysis of GWA scans moreover may be used to confirm any reports that have 
previously implicated susceptibility variants with modest effect sizes (McCarthy et al., 2008). 
 Meta-analysis of several GWA studies has already demonstrated considerable value 
in complex disease genetics, with reports of being able to implicate novel disease loci with 
greater confidence (Zeggini et al., 2008, Barrett et al., 2009). Several new disease risk variants 
of smaller effect sizes were identified for type 2 (Zeggini et al., 2008) and type 1, diabetes 
(Barrett et al., 2009) and such meta-analysis of GWAS are likely to similarly prove more 
effective and more powerful for detecting associations in epilepsy disease genetics (Kearney, 
2012).  
 The EPICURE Consortium have recently published a linkage study in which they 
attempted to improve power by undertaking the first genome-wide linkage meta-analysis for 
PGE (Leu et al., 2012). In this meta-analysis significant linkage for myoclonic and absence 
seizures was reported and these were also in several previously implicated gene loci (Leu et 
al., 2012). Authors have since reinforced the need to collaborate and pool cohorts to increase 
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sample sizes to improve strength of evidence in the context of epilepsy genetics (McCarthy et 
al., 2008, Kasperaviciute et al., 2010, Tan and Berkovic, 2010, Leu et al., 2012).  
 
7.1.5. Phenotypic heterogeneity in epilepsy 
Thousands of epilepsy patients have participated in pharmacogenomic studies and have 
also been GWAS scanned (Marson et al., 2006, Cavalleri et al., 2007, Kasperaviciute et al., 
2010) yet GWAS evaluating drug response in epilepsy patients remain limited in number 
(Kasperaviciute and Sisodiya, 2009, Daly, 2010a, Kasperaviciute et al., 2010, Johnson et al., 
2011b). Genomic research towards other complex diseases as a standard now use cohorts of 
over 90,000 individuals, recruited through multi-centre collaborative efforts. The challenge 
for epilepsy PGx research is to similarly develop such multi-centre collaborations (Cavalleri 
et al., 2011).  
 
7.1.6. Defining drug response 
 Treatment response is characterised by the remission of seizures and responders to 
drug treatment are currently defined by the ILAE as ‘individuals being seizure free for at least 
12-months after starting AED therapy’ (Kwan and Brodie, 2010). Classifying response in 
patients with anything less than perfect seizure control however remains challenging 
(Cavalleri et al., 2011).         
 Several difficulties exist with this definition of treatment success. As previously 
discussed in a recent review of PGx studies in newly treated epilepsy (Johnson et al., 2011b), 
clinical outcome is affected by both therapeutic response and the natural history of a specific 
epilepsy (Johnson et al., 2011b). The natural tendency for some types of adult and childhood 
epilepsies is to remit spontaneously over time and so these may appear drug resistant at first, 
only to remit in later life. Consequently when defining treatment outcome one may be 
classifying as drug responders those who are i) seizure free because of a pharmacological 
response to AEDs and ii) those who are seizure-free because their epilepsy has spontaneously 
remitted.   
In addition to this within medicine, there is a tendency for clinicians to dichotomise 
continuous traits. Individuals with epilepsy thus are usually labeled as AED responders (their 
seizures stop) or AED non-responders (their seizures continue), though in reality, across a 
population of patients with epilepsy, there is probably a continuum of therapeutic response 
(Johnson et al., 2011b). So far several response classification schemes have been proposed but 
none capture the underlying complexity and dynamic nature of response in epilepsy (Berg and 
Kelly, 2006, Cavalleri et al., 2011). Further research on defining drug response that both 
incorporates information relating to aetiology, inherent severity of the epilepsy i.e. seizure 
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frequency prior to starting treatment and also considers therapeutic response to AEDs as a 
quantitative trait has been suggested to help resolve these issues (Johnson et al., 2011b).    
Larger cohort studies that also incorporate clinical covariates and additionally classify 
patients according to response to a specific AED may aid the identification of potentially larger 
and more clinically relevant genetic effects. The incorporation of a wide range of clinical 
variables to association studies is becoming an increasing approach to PGx study design 
(Sanchez et al., 2010, Cavalleri et al., 2011, Johnson et al., 2011b). The recent EPICURE 
GWAS meta-analysis attempt mentioned previously (section 7.1.4) presents a good example 
of this concept (Leu et al., 2012). Using a broad trait definition, authors did not detect any 
significant linkage however when stratification by epilepsy subtype was applied, significant 
linkage was found (Leu et al., 2012).   
 
7.1.7. Genome wide association study meta-analysis for predicting treatment 
outcome in newly treated epilepsy  
Clinical covariates are known to have an important influence on outcomes in epilepsy 
and hence in PGx studies (Petrovski et al., 2010, Sanchez et al., 2010, Cavalleri et al., 2011, 
Grover et al., 2011). A recent review by Johnson et al 2011 moreover proposed a novel concept 
of intermediate clinical phenotype where such influential clinical variables were proposed to 
potentially impact the genetic influence on drug treatment response at numerous levels 
(Johnson et al., 2011b) (see Figure 7.1 adopted from Johnson et al 2011). The assumption was, 
that if a genetic factor acts via a measured clinical covariate then adjustment for that covariate 
will confound its detection (Johnson et al., 2011b). Conversely, adjustment for clinical 
covariates will lead to improved detection of genetic factors influencing outcome via an 
independent route to a measured clinical covariate (Johnson et al., 2011b).  
 Authors of the above mentioned review also recently performed a multi-centre meta-
analysis of GWAS carried out for treatment response in newly treated epilepsy (unreported). 
The meta-analysis attempt combined data from two GWA scans (Australian and UK) This 
work is one of the first PGX projects in newly-diagnosed epilepsy. The initial analysis of this 
GWAS meta-analysis identified a single variant associated with treatment outcome, with a 
GWAS significance p-value of <5x10‐ 7 (rs622902) within the GSTA4 gene, and an additional 
nine top ranking SNPs (see Table 7.1 for a list of these top 10 GWAS SNPs). Most of the 
identified SNPs can be found on Chromosome 6 and within the GSTA4 gene. Although the 
MS Genetics Consortium GWAS (Nature, 2011) applied a GWAS meta-analysis cut off p-
value of <5x10-8 other GWAS studies have used <1x10-7 (Davila et al., 2010) and this is 
assumed “suggestive” of a causal association (Meyer et al., 2010). The analysis was performed 
both with the inclusion and exclusion of clinical covariates. The Manhattan plot from the 
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single SNP logistic regressions with the inclusion of clinical covariates for this GWAS meta-
analysis effort, are presented in Figure 7.2. A subsequent re-analysis of the data by the authors; 
with updated clinical cohort information and additional patients identified a narrower set of 3 
associated loci, only one of which was identified in the original analysis (original top GSTA4 
SNP).  
 
 
 
Table 7.1 Top 10 ranking SNPs from the initial GWAS meta-analysis  
SNP ID (rs) Chromosome Position (bp) Gene Allele 
change 
rs622902  6 52954433 GST-A4 C/T 
rs316132  6 52955925 GST-A4 C/G 
rs316133  6 52955510 GST-A4 A/G 
rs367836  6 52951090 GST-A4 A/C 
rs316131  6 52956108 GST-A4 C/T 
rs316130  6 52956159 GST-A4 C/T 
rs316141  6 52954117 GST-A4 C/T 
rs384505  6 52943531 GST-A4 C/T 
rs405729 6 52950740 GST-A4 A/G 
rs316128  6 52957105 GST-A4 C/A 
rs= reference sequence, SNP = single nucleotide polymorphism, bp = base pair 
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7.1.8. Biological significance and role of GSTA4 in epilepsy 
  GSTs could be considered good candidates for epilepsy PGx due to their general role 
in detoxification of xenobiotics (Depondt and Shorvon, 2006). There are eight isoforms of 
soluble GST (α, μ, π, θ, ω, ζ, σ, and κ) and at least three membrane-bound GST isoforms 
(MGST1, MGST2 and MGST3) (Salinas and Wong, 1999, Board et al., 2000). GSTs are 
widely expressed in almost every tissue, though some of the isoforms are tissue specific 
(Carder et al., 1990, Desmots et al., 2001, Listowsky, 2005).  
 GSTs have recently been implicated in the hepatic metabolism and clearing of AEDs 
(Kasperaviciute and Sisodiya, 2009, Tan and Berkovic, 2010, Depondt et al., 2011). Current 
PGx data concerning the role of GSTs in epilepsy particularly that of GSTA4 is however 
sparse (Saruwatari et al., 2010). GSTs are known to be involved in the detoxiﬁcation of 
reactive CBZ metabolites (Madden et al., 1996, Bu et al., 2005) and the deletion of a GSTM1 
allele has furthermore been implicated in CBZ and VPA-related hepatotoxicity in Japanese 
patients (Ueda et al., 2007, Fukushima et al., 2008b, Depondt et al., 2011). It has also been 
hypothesised that higher levels of GSTs in the brain-blood barrier may result in low 
concentration of AEDs potentially leading to medical intractability (Shang et al., 2008). 
Human GST expression in such patients was recently examined and an association between 
expression of the GST-π isoform and intractability was reported (Shang et al., 2008). In several 
animal studies GST isoforms in liver, testis, and brain tissues were additionally reported to be 
induced by some AEDs (Selim et al., 2000, Thyagaraju et al., 2005), though this proposition 
of a mechanism of intractability development however remains to be studied (Shang et al., 
2008). 
 
7.1.9. Aims and hypothesis 
 
Newly treated epilepsy GWAS and meta-analysis study details: 
  The initial results from the meta-analysis suggested that GSTA4 may play a role in 
treatment response (Speed, D et al. [Unpublished]). The initial findings identified that the 10 
top ranking GWAS SNPs (lowest GWAS p-values) were mostly within chromosome 6 and 
located in the GSTA4 gene (all 10 when no clinical covariates considered, and 8 out of 10 
when associated clinical covariates were included in the GWAS analysis). Due to the potential 
biological significance of the GSTA4 gene, our intention was to attempt to replicate this initial 
GWAS meta-analysis finding, in an independent cohort of well-defined individuals with 
newly treated epilepsy, thus adopting a candidate SNP association study approach (McCarthy 
et al., 2008).  
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The epilepsy PGx GWAS meta-analysis was based on two, independent genome-wide 
scans for treatment responsiveness. The two GWAS cohorts of newly treated epilepsy were i) 
a subset of the UK SANAD cohort and ii) the Australian, Melbourne prospective epilepsy 
cohort (both genotyped at the WTSI on Illumina 660Q) (both study populations previously 
described see Chapters 5 and 6 for cohort details)(Marson et al., 2006, Cavalleri et al., 2007). 
Definitions of seizure outcomes and clinical covariates were harmonised across the cohorts to 
allow meta‐ analysis of primary outcome and the clinical covariates included in the analysis. 
The authors of the GWAS meta-analysis designated the larger SANAD cohort as the 
Discovery Cohort and the Australian cohort as the replication study group and a total 552144 
SNPs from both data sets were meta-analysed. The meta-analysis was performed using a 
prospectively agreed definition of 1-year remission of seizures (this was presumed to indicate 
adequate seizure control or treatment response).  
 
Hypotheses of present study: 
 The primary aim of this results chapter was to perform a validation of the findings 
from the initial analysis effort of this first newly treated epilepsy, using individuals from the 
Glasgow data set as an independent cohort of UK patients with epilepsy (see section 2.2.1 for 
Glasgow source population details). A subset of the 10 GWAS identified SNPs were selected 
for genotyping and were to be assessed for association with both treatment outcome and time 
to 12-month remission in our current investigation.  
 
7.2. Study cohort, materials and methods 
7.2.1. Phenotype definitions for patient selection 
The primary outcome of this present study was treatment success with pharmacotherapy. 
Individuals were classified as either responders or non-responders to AEDs. Response was 
defined as achieving a minimum period of 1-year at any stage after starting treatment (Speed, 
D et al. [unpublished]). Thus patients required a minimum follow‐ up period of 1-year after 
starting AED therapy. This definition was chosen as it matches the definition proposed by the 
ILAE (Kwan et al., 2010) and is presently seen as the only relevant seizure outcome 
consistently associated with meaningful improvement in quality of life (Callaghan et al., 2011, 
Cavalleri et al., 2011, Johnson et al., 2011b). 
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7.2.2. Immediate vs. delayed seizure remission and definitions for time to 
event analysis 
In addition to investigating seizure freedom, an additional analysis was performed in 
order to investigate or account for the probability of delayed or late seizure remission in some 
patients that would not necessarily be captured by the definition above (see section 7.3 below). 
This delayed remission was investigated by associating time to 12-month seizure remission 
where time to outcome has been censored. Remission status was defined as above.        
 
7.2.3. Glasgow validation cohort  
Patients from the UK Glasgow cohort (on-going collection of DNA) (see Chapter 2) that 
were identified to have newly treated epilepsy at time of recruitment were utilised for the 
analysis on this Chapter. In total 518 patients were identified as having newly treated epilepsy 
and thus were available for genotyping.  
 All clinical notes for each of these 518 individuals were reviewed in order to confirm 
individual phenotype data and their eligibility. From these patients 13 were automatically 
excluded for either not having epilepsy or newly treated epilepsy on reviewing case notes, a 
further 2 had only one seizure prior to treatment, thus did not qualify as having epilepsy, 5 
were of non‐ European ancestry and, 66 individuals had less than twelve months follow‐ up 
data (required for classification of treatment outcome). The remaining 434 patients were of 
European ancestry, had sufficient DNA for genotyping and clinical information for 
phenotyping and thus were eligible for study inclusion and subsequent genotyping. 
 
7.2.4. Clinical data selection and inclusion  
Clinical information was extracted from clinical databases. This included the general 
patient characteristics and disease phenotype; age at recruitment gender and epilepsy type, 
which are all known to potentially influence treatment outcome (Kwan and Brodie, 2001a, 
Hitiris et al., 2007). Additionally those clinical factors that were explored and/or included in 
the GWAS meta-analyses effort were considered for inclusion in this present study. These 
were i) initial treatment AED (the first AED administered at recruitment or first follow-
up), ii) AED at final follow-up iii) EEG status, categorised as; non-done, normal, not-specific, 
epileptiform (abnormal) and iv) medical imaging status, categorised as; not-done, normal, 
non-specific, focal (abnormal). For the survival (time to treatment) analysis, AED recorded at 
remission was recorded and included as a covariate as opposed to final follow-up AED. For 
the treatment covariates i.e. Initial AED treatment, final AED treatment and AED at remission 
(survival analysis covariate) drug treatment was categorised as either CBZ, GBP, LTG, OXC, 
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VPA (the most commonly used AEDs), Multiple AEDs if more than one AED indicated and 
‘other’ for any other drug or for missing treatment information. 
 
7.2.5. Genetic data selection and inclusion 
Rather than simply select the most significant SNPs from the GWAS analysis (i.e. 
those with the lowest meta p-values), validation SNPs were additionally selected on the basis 
of biological plausibility, functional significance, and expression array data derived from 
analysis of surgically resected, human epileptic brain (temporal lobe). Selection was 
undertaken by a collaborator (Dr Michael Johnson, Imperial College London). Five SNPs were 
ultimately selected for the validation study, the top 2 GSTA4 SNPs identified by the initial 
GWAS meta-analysis (rs316132 and rs622902) (Table 7.1 and 7.2) and an additional 3 SNPs 
(rs17252760, rs12919774 and rs16994558) located in intergenic regions (Table 7.6). 
 
 
 
Table 7.2 Top 10 ranking SNPs of the initial GWAS meta-analysis single-SNP 
logistic regression including clinical covariates 
SNP ID (rs) Chromosome Position (bp) Gene Allele change 
rs316132  6 52955925 GST-A4 C/G 
rs622902  6 52954433 GST-A4 C/T 
rs316131  6 52956108 GST-A4 C/T 
rs316130  6 52956159 GST-A4 C/T 
rs316141  6 52954117 GST-A4 C/T 
rs316133  6 52955510 GST-A4 A/G 
rs367836  6 52951090 GST-A4 A/C 
rs6464296 7 152343151 UNKNOWN G/A 
rs4779485 15 28721754 ARHGAP11B C/T 
rs405729 6 52950740 GST-A4 A/G 
SNP= single nucleotide polymorphism, bp= base pair 
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7.2.6. Genotyping of candidate SNPs 
Genomic DNA samples from the n=434 Glasgow cohort were genotyped for the five 
candidate SNPs at the Department of Molecular and Clinical Pharmacology, University of 
Liverpool, using custom TaqMan® SNP genotyping assays (Applied Biosystems, Warrington, 
Cheshire, UK) in accordance with the manufacturer’s instructions. This assay is based on the 
5’-3’ exonuclease activity of Taq DNA polymerase, using allele-specific TaqMan® 
fluorescent minor groove binding (MGB) probes VIC® and FAM™ (as specified by the 
manufacturer’s instruction).(http://www3.appliedbiosystems.com/cms/groups/mcbsupport/do 
cuments/general documents/cms_042998.pdf). 
 
7.2.7. Experimental details 
Briefly approximately 20ng of genomic DNA (pre-dried sample) was amplified in 
5uL reaction mixtures containing 1x TaqMan universal genotyping master mix and 1x 
TaqMan assay mix (containing a premix of the customised SNP primers and the fluorescent 
probes), in 384-well plates. Reactions were performed on an ABI 7900HT fast Real-Time PCR 
System (Applied Biosystems). A standard protocol for DNA amplification was followed 
where after the Taq enzyme was activated at 95°C for 10 min, 40 PCR cycles of denaturation 
at 92°C for 15 s and 1 min of combined annealing and extension at 60°C were completed on 
the reaction mixes. In total five runs were performed for each of the 424 DNA samples (1 for 
each of the five SNP assays).  As part of quality control, negative controls (DNA replaced 
with water) and 10% duplicates were included in every 384-well plate run. After PCR 
amplification, an endpoint plate read of fluorescence and allelic discrimination was performed 
using the Applied Biosystems Real-Time PCR System and the Sequence Detection System 
(SDS) Software (Applied Biosystems). Fluorescence measurements made during the plate 
read are used to plot fluorescence (Rn) values based on the signals from each well. The plotted 
fluorescence signals indicate which alleles are in each sample. 
 
7.2.8. Taqman chemistry 
  Each TaqMan MGB probe anneals specifically to its complementary sequence 
between the forward and reverse primer sites. When the oligonucleotide probe is intact, the 
proximity of the reporter dye to the quencher dye results in quenching of the reporter 
fluorescence primarily by Förster-type energy transfer. AmpliTaq Gold® DNA polymerase 
extends the primers bound to the template DNA. AmpliTaq Gold DNA polymerase cleaves 
only probes that are hybridized to the target complimentary sequence. Cleavage separates the 
reporter dye from the quencher dye, which results in increased fluorescence by the reporter. 
The increase in fluorescence signal occurs when the hybridized probes are cleaved. 
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7.3. Statistical analysis 
All statistical analyses were performed in SPSS version 18. Deviation from HWE was 
tested for each of the five SNPs using a Chi-Square test (http://ihg.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl), with a p-value of <0.001 assumed to indicate deviation 
from HWE.  The MAF of each SNP was also checked and any SNPs with a study cohort MAF 
of <0.05 were excluded from the analysis (Haploview version 4.1). The SNP MAF was also 
compared to that of the general population (www.hapMap.org). P-values for all genetic and 
non-genetic association tests undertaken in the study were adjusted for multiple testing using 
the FDR and a statistical p-value of ≤ 0.05 after correction was deemed to indicate a 
statistically significant association (Benjamini et al., 2001). 
 Due to the growing acknowledgement of the importance of clinical factors in 
epidemiological association studies (Cavalleri et al., 2011, Johnson et al., 2011b), two 
assumptions were made for this present study 1) genetic factors could act or influence 
treatment response via a measured clinical covariate 2) genetic factors could influence 
treatment response via a pathway un-related to the clinical covariates. We therefore undertook 
the following analyses i) for genetic factors alone; without the adjustment of any associated 
clinical covariates and ii) using both genetic factors and any associated clinical covariates.   
 
7.3.1. Univariate tests with treatment outcome for association analysis 
To evaluate the individual effect of SNP genotype on outcome, two univariate tests of 
association were conducted for each of the five SNPs, one making no assumption of 
underlying mode of inheritance and one assuming an additive mode of inheritance, and the 
minimum p-value referred to in each case. For univariate analysis of each SNP genotype the 
Armitage trend test was used (http://ihg.helmholtz -muenchen.de/cgi-bin/hw/hwa1.pl). For the 
binary clinical covariates (gender, epilepsy type, EEG, imaging initial AED and AED at final 
follow-up, a Chi-square test (SPSS) or Fisher’s exact t-test were used (SPSS and 
www.langrud.com/fisher.htm) and a t-test (SPSS) was used for the single continuous variable 
of patient age at recruitment or study admission.  
 
7.3.2. Multiple regression analysis with treatment outcome 
  The purpose of this analysis was to test for association between each of the five SNPs 
and 1-year remission in the presence of any clinical covariates found to independently 
influence treatment outcome, in order to potentially adjust for non-genetic clinical association, 
with the assumption that these may allow improved detection of any genetic influencers.  For 
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this a multivariate binary logistic regression analysis was performed (SPSS) where two logistic 
regression models were fitted for each of the five SNPs (a baseline and genetic model) and 
compared using the LRT test (described in Chapter 3 and 4). The ‘baseline’ model included 
clinical factors found significant in the univariate analysis (P = 0.05) as covariates. The genetic 
‘model’ was the same but also included a genetic covariate representing an individual SNP. 
For each SNP the ‘genetic model’ was again fitted twice, first making no assumption of the 
underlying mode of inheritance and second assuming an additive mode of inheritance. The 
minimum p-value was referred to in each analysis. 
 
7.3.3. Survival analysis for time to remission data 
Survival or time to event analysis may be a more appropriate analysis as remission could 
have occurred at any time after starting treatment. Survival analyses can account for censored 
observations which include i) patients dropping out of the study, ii) death due to a cause that 
is not the event of interest, iii) termination of the study (the study ends before some individuals 
have the outcome of interest). Survival analysis may therefore help determine or provide 
information on which fraction of the population will remit past the final follow-up, and the 
rate at which seizure remission is achieved. Moreover how particular factors benefit or affect 
the probability of remission can be investigated.  
 In order to perform a time to event survival analyses using the genetic data available 
for this study, time to period of 1-year seizure remission was required to be extracted from the 
available clinical data and treated as an additional covariate. Time to seizure remission (days) 
was calculated using dates available for both treatment initiation (study recruitment or 
admission) and time to achieving remission. A Kaplan-Meier survival analysis and a log-rank 
test were performed to test for a univariate association of remission status for each of the 
binary clinical covariates (gender, epilepsy type, EEG, imaging initial AED, AED at 
remission) and the Cox regression test was used for continuous clinical covariates (age at 
recruitment/admission).  
 For the multivariate survival analysis, for each of the five SNPs two Cox regression 
models were built, a ‘baseline’ model, again containing statistically significant clinical 
covariates only (P = 0.05) and ‘genetic model’ containing both clinical covariates and genetic 
covariates for each SNP. A Chi-square p-value was again generated using log likelihood ratio 
and LRT. For each SNP models were fitted when making no assumption of the underlying 
mode of inheritance and when assuming an additive mode of inheritance and the minimum p-
value referred to in each case. 
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 Finally a bioinformatics analysis was also performed for each of the five-SNPs using 
several freely available as described previously (section 5.2.14), in order to investigate 
potential biological significance.  
 
7.4. Results 
From the 434 individuals genotyped for the five candidate SNPS, 10 individuals failed to 
be successfully genotyped for all five SNPs and so were removed from data analysis. 
Demographics of the remaining 424 patients are summarised in Table 7.3. The majority of 
patients were Caucasians with newly treated epilepsy and treated with one or more AEDs. Of 
the 424 patients included in the data analyses, 304 remained seizure free for a period of 12 
months or more at some point through their treatment, while 120 continued to experience 
seizures, without any period of seizure freedom of at least a year, during their period of follow 
up. Hence of the 424 patients 28.3 % achieved remission and were treated as cases while 71.7 
% failed to achieve remission and were labeled as controls. 
 
 
Table 7.3  Characteristics of UK Glasgow cohort of newly treated epilepsy 
Clinical characteristic   (n=424) 
Age  Mean (±SD)  37 (±16.96) 
Sex N (%) Male 234 (54.7%) 
  Female 190 (44.4%) 
Epilepsy type N (%) IGE 79 (18.5%) 
  LRE 318 (75%) 
  UNC 27 (6.4%) 
Remission  N (%) Yes 
No 
304 (71.7%) 
120 (28.3%) 
SD= Standard deviation, IGE = idiopathic generalised epilepsy, LRE = localisation related 
epilepsy, UNC = unclassified epilepsy  
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7.4.1. Univariate analysis of association between SNPs or clinical covariates 
and treatment outcome 
For the final cohort of n=424 patients, population MAF of each SNP was at least 5%, 
and each SNP achieved HWE. All five SNPs were previously typed by the International 
HapMap project (NCBI build 36, dbSNP build 126) and HapMap population MAFs (HapMap-
CEU European ancestry) did not deviate from those observed in this study. When each of the 
five SNPs were analysed univariately as to test for an independent effect of each of the five 
variants, none of the five SNPs were found to individually influence treatment outcome  (Chi-
square P > 0.05). Results of the univariate tests of association for the five genetic covariates 
are presented in Table 7.4. 
 Non-genetic influence on outcome was also tested univariately. Of the binary clinical 
covariates included in the analysis both epilepsy type and EEG result influenced treatment 
outcome, with a statistically significant p-value of below 0.05 before FDR. Final treatment 
drug (AED at final follow-up) additionally showed a strong association with treatment 
outcome (P < 0.001 after FDR correction). These clinical covariates were thus included in the 
regression models for the subsequent genetic analyses (Table 7.5). Figures 7.3, 7.4 and 7.5, 
present plots for the influence of epilepsy type, EEG and AED at final follow-up on response 
to drug treatment.  
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Table 7.4 Univariate analysis of genetic and clinical factors with drug response   
Univariate regression analysis for the independent association of genetic variables and clinical 
covariates with treatment response in newly treated epilepsy. 
Factor Uncorrected P-value  
Final follow-up AED 0.000  
Initial follow-up AED  0.432  
Epilepsy type 0.018  
EEG 0.002  
Age 0.52  
Gender 0.867  
Imaging 0.21  
rs17252760 0.91  
rs12919774 0.62  
rs16994558 0.22  
rs316132 0.78  
rs622902 0.5  
AED = antiepileptic drug, EEG = electroencephalography 
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Figure 7.3 Bar chart for association between epilepsy type and response (n=424) 
In total 79, 318 and 27 individuals presented with idiopathic generalised epilepsy (IGE), 
localisation related epilepsy (LRE), and unclassified epilepsy (UNC), of which 65, 224 and 15 
individuals achieved 1-year remission respectively.  
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Figure 7.4 Bar chart for association between EEG recording and response (n=424) 
In total 106, 120 and 148 individuals presented with epileptiform, non-specific and a normal 
EEG result respectively. In 50 individuals an EEG (Electroencephalography) was not done. 
Of these 86, 89, 103 and 26 individuals achieved 1-year remission respectively.  
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Figure 7.5 Bar chart for association between AED at final follow-up and response 
In total 29, 106, 78, 13, 3, 94 and 98 individuals were treated with the antiepileptic drugs 
(AED) carbamazepine (CBZ), lamotrigine (LTG), valproate (VPA), oxcarbazepine (OXC), 
gabapentin (GBP), another drug (other), or multiple drugs (multi). Of these 26, 96, 66, 9, 3, 
70 and 32 individuals achieved 1-year remission respectively.  
 
 
 
 
 
 
 
 
 
  CHAPTER SEVEN 
  
243 
 
7.4.2. Multiple regression models 
Results of the LRT from the multivariate binary regression analysis are summarised 
in Table 7.5. Of the five candidate SNPs, none of the SNPs were significantly associated with 
treatment outcome (P = < 0.05, before FDR) when the associated clinical covariates of EGG, 
epilepsy and final follow-up AED were included in the genetic model. Thus none of the genetic 
variants were predictive of treatment response in our investigation. The genomic information 
for all five candidate SNPs are summarised in Table 7.6.  
 
 
 
Table 7.5 Multivariate logistic regression results for treatment response 
Association of each SNP with treatment response in newly treated epilepsy in the presence of 
associated non-genetic factors 
Clinical covariates SNP ID (rs) Uncorrected  
Chi-square P-value 
Epilepsy type, EEG, 
Final follow-up AED 
rs17252760 0.356 
rs12919774 0.127 
rs16994558 0.493 
rs316132 0.346 
rs622902 0.093 
SNP= single nucleotide polymorphism, rs= reference sequence, EEG= 
electroencephalography, AED= antiepileptic drug 
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Table 7.6  Genomic information for the five candidate SNPs investigated 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP= single nucleotide polymorphism, Chr= Chromosome, bp= base pair,  
MAF= minor allele frequency 
 
 
 
 
Table 7.7 Survival analysis univariate Kaplen-Meir and Cox regression analysis of 
association between clinical covariates and time to 1-year remission  
Factor or variable Uncorrected  
P-value 
Age 0.430 
Gender 0.047 
Epilepsy type 0.448 
EEG 0.069 
Imaging 0.556 
Initial AED treatment 0.058 
AED at Remission 1.4x10-5 
EEG = electroencephalography, AED = antiepileptic drug 
 
SNP ID 
(rs) 
Chr. Position 
(bp) 
Closest gene Allele 
change 
SNP 
location 
rs16994558 23 147259820 RPL7L1P11, 
AFF2 
G/A intergenic 
rs622902 6 52954433 GSTA4 C/T intronic 
rs316132 6 52955925 GSTA4 A/G intronic 
rs12919774 
 
16 8455709 TMEM114,  
LOC100131080 
A/G 
 
Intergenic 
rs17252760 15 89784049 MAGEA9B, 
CXORF6840A 
C/A intergenic 
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7.4.3. Multivariable survival analysis 
The results of the Cox regression analyses are presented in Table 7.8. The multivariable 
Cox regression models including patient gender and AED at remission as covariates, again 
none of the five SNPs were associated with time to 1-year remission (LRT; P= > 0.05, for 
each SNP before FDR correction, Table 7.8). Therefore although there was some predictive 
potential of the clinical covariates for time to seizure control there was no influence of any 
genetic factors on time to remission in our analysis.  
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6  Time to 1-year remission analysis for patient gender 
Kaplen-Meir curves as generated by SPSS for univariate analysis of time to 1-year remission 
and patient gender.  
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Figure 7.7  Time to 1-year remission analysis for AED at remission 
Kaplen-Meir curves as generated by SPSS for univariate analysis of time to 1-year remission 
and antiepileptic drug (AED) recorded at 1-year remission. Data stratified by AED 
(antiepileptic drug) recorded at 1-year remission. CBZ = carbamazepine, LTG = lamotrigine, 
VPA= valproate, OXC= oxcarbazepine, GBP= gabapentin, Other= any of AED administered 
and Multi= multiple drug treatment. 
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7.4.4. Multivariable survival analysis 
The results of the Cox regression analyses are presented in Table 7.8. The multivariable 
Cox regression models including patient gender and AED at remission as covariates, again 
none of the five SNPs were associated with time to 1-year remission (LRT; P= > 0.05, for 
each SNP before FDR correction, Table 7.8). Therefore although there was some predictive 
potential of the clinical covariates for time to seizure control there was no influence of any 
genetic factors on time to remission in our analysis.  
 
 
 
Table 7.8 Multivariate Cox regression analysis for SNP association with remission 
Association between each SNP and time to 1-year remission with adjustment for the associated 
clinical covariates identified previously. 
SNP ID (rs) Clinical covariates Chi-square value Uncorrected Chi-square 
 P-value 
rs17252760 
Gender 
AED at final follow-up  
0.851 0.356 
rs12919774 2.328 0.127 
rs16994558 0.469 0.493 
rs316132 0.888 0.346 
rs622902 2.829 0.093 
SNP = single nucleotide polymorphism, AED = antiepileptic drug 
 
 
 
7.5. Discussion 
With a significant amount of individuals (30-40%) presenting non-response and long-
term resistance to adequate management with AEDs, the search for markers of drug efficacy 
in epilepsy has received considerable attention in the challenge to optimise therapeutic drug 
treatment. Outcomes AED therapy can range from immediate remission to frequent 
unremitting seizures with multiple treatment failures and so delineating both seizure 
susceptibility and a predisposition to achieving good seizure control early on remains to be 
attained Duncan et al., 2006. There is a significant lack of study replication across epilepsy 
PGx that can be attributed to many limitations presented to the study of complex disease 
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genetics in general (Tabor et al., 2002, Loscher et al., 2009) and/or that specific to epilepsy 
PGx research (see section 1.5.6). The candidate gene approach to association study design has 
furthermore been disappointing in terms of locating influential susceptibility loci and 
incorporating a multifactorial basis of drug response phenotypes. With this slow progress in 
predicting AED efficacy including treatment responsiveness, large-scale GWAS with bigger 
numbers of cases and controls creating more power for genetic detection are being utilised.  
 Recent GWAS methodologies include two-stage approaches, with a discovery cohort 
and independent replication cohorts and combined meta-analysis of the two stages. Recent 
guidelines have been published to standardise the reporting of association studies to facilitate 
meta-analyses (Little et al., 2009). Moreover inclusion and/or stratification by clinical 
phenotypes could reveal otherwise undetected linkage (Sanchez et al., 2010, Johnson et al., 
2011b, Leu et al., 2012). GWAS meta-analysis powered by international collaboration can 
create sufficiently sized samples for specific drug response phenotypes in epilepsy populations 
(Johnson et al., 2011b). Further independent validation is also vital to confirm the initial 
research findings and for establishing the true genetic causality of any GWAS presented 
association (McCarthy et al., 2008).  
 In order to provide an independent population investigation or partial validation of the 
UK-Australian GWAS for treatment response in newly treated epilepsy, we performed a 
modest candidate SNP validation study using the Glasgow cohort as an independent UK 
population of newly treated epilepsy. Five SNPs were selected from a number of new 
potentially influential loci from the GWAS meta-analysis for response to drug treatment in 
epilepsy. This included two chromosome 6, GSTA4 SNPs that were identified to be potentially 
significant at a genome wide level (p value of at least 5x10-6 -7, with and without inclusion of 
outcome associated clinical covariates) and an additional 3 GWAS associated intergenic 
SNPs, rs16994558, rs12919774 and rs17252760 (a 5' to AFF2 variant, a SNP near 3' of 
TMEM114 and also the ribosomal protein S14 pseudogene gene and a final SNP near the 
CXorf40A locus, the iduronate 2-sulfatase pseudogene (IDSP1) and the MAGEA9B gene 
respectively) (Table 7.8). None of the five SNPs were found to individually predict treatment 
outcome (remission status) or time to 1-year remission in our analysis using an independent 
UK cohort. Our findings therefore suggest little potential significance of the five SNPs to 
seizure control in newly treated epilepsy, when considered in isolation.  
 Given the independent influence of patient clinical characteristics on drug response 
phenotypes in epilepsy (Callaghan et al., 2011) there is a growing appreciation of the 
incorporation of these factors in current epilepsy PGx research (Cavalleri et al., 2011, Grover 
et al., 2011). The concept of potential interaction of both genetic and clinical variables may 
help detect the remaining gene-phenotype association that could exist and/or confirm some of 
the minor genetic effects already reported (Kasperaviciute and Sisodiya, 2009, Loscher et al., 
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2009). With this additional multivariate testing however, we again didn’t find associations 
with the five SNPs in both the time to 1-year remission analysis and treatment response 
outcome (success of seizure control) in the regression analysis. Our findings demonstrated 
some predictive potential of several clinical factors in AED drug response which was similarly 
suggested by the Australian/Australian GWAS analyses and also by previous clinical 
epidemiological studies (Mohanraj and Brodie, 2006, Callaghan et al., 2007, So, 2011, Brodie 
et al., 2012) whilst the influential potential of the five candidate SNPs filtered out from the 
GWAS analysis was nonexistent. Similarly no biological significance of these five SNPs was 
apparent from the bioinformatics analysis (literature searches and online bioinformatics 
prediction tools). Our investigation therefore did not confirm the significance of the genetic 
variants or a role of GSTA4 on seizure control or treatment success in newly treated epilepsy. 
Time-to remission, which was not studied in the original Australian-UK GWAS study, though 
provides a better outcome measure. To some degree time- to event data may better represent 
ease of seizure control and could more accurately indicate whether a patient is likely to remit.  
No associations were nonetheless evident in the genetic analysis using time to 1-year remission 
data. Because of a lack of genotype-phenotype associations and insignificance of any potential 
biological function of either GSTA4 SNPs or any of the intergenic variants, the role of GSTA4 
in drug treatment in newly treated epilepsy cannot be confirmed by our study. 
 A number of clinical predictors for seizure remission have previously been 
investigated for their association with long-term epilepsy outcome (Hitiris et al., 2007, 
Callaghan et al., 2011, Brodie et al., 2012). Although the genetic subset of analysis performed 
for this chapter was largely unremarkable, some clinical covariates also appeared to influence 
treatment outcome or response in our investigation. A diverse range of clinical predictors have 
previously been proposed as poor prognostic indicators, including abnormal neurological 
examination, EEG and brain imaging (Sillanpaa, 1993, Berg et al., 1996, Mattson et al., 1996, 
Berg et al., 2001), a large number of pre-treatment seizures (Sillanpaa, 1993, Kwan and 
Brodie, 2000a, Leschziner et al., 2006, Hitiris et al., 2007) (including their number and 
frequency), presence or absence of a neurological deficit and can also explain some of the 
variability in remission among patients (Callaghan et al., 2011).  
The most consistent determinant associated with long-term epilepsy outcome is however the 
ease of controlling seizures, which includes i) how soon seizures are controlled by AED, ii) 
how frequent seizures recur despite treatment initiation and iv) how many AEDs had to be 
used to control seizures (Mohanraj and Brodie, 2006, So, 2011, Brodie et al., 2012). Although 
information on pre-treatment seizures and seizure frequency was not available for all patients 
in our cohort, we found associations with epilepsy type, EEG findings and AED at final 
follow-up with treatment outcome in the regression analysis.    
 AED at remission was also associated with time to time to 1-year remission in the 
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survival analyses, as was patient gender. Better response to treatment appeared evident with 
the IGE epilepsy type (82%) and slightly better when EEG showed epileptiform abnormality 
in comparison to non-specific abnormality or no abnormality (81%, 74%, and 70% 
respectively). Highest response was moreover evident with the use of VPA as the final AED 
(85%), and VPA also presented with the shortest time to remission in the time-to event analysis 
(474 days). Moreover poor response was suggested with multiple AED treatment (33%) and 
poly-therapy also showed the longest time to remission (913 days). Finally a marginally 
significant difference in time to 1-year remission appeared between the genders. These factors 
have previously been investigated and in several cases were demonstrated to be of some 
clinical utility (Mohanraj and Brodie, 2006, Johnson et al., 2011b, So, 2011).  
 Failure to provide evidence for the significance of the five candidate SNPs and 
validation for predictive potential of the two GSTA4 GWAS filtered out SNPs can be attributed 
first and foremost to the methodological issues that are evident with the methodology of our 
study and also that of which can be associated with the original GWAS analyses. There are 
several universally recognised issues associated with whole genome based association studies 
for PGx (discussed previously in Chapter 1) (Motsinger-Reif et al., 2010). The main 
recognised disadvantage relates to the large sample size requirement (Nebert et al., 2008a, 
Motsinger-Reif et al., 2010). Sample size limitations are a challenge in any GWAS study of 
complex traits that attempt to detect modest effect sizes, but are amplified in many 
pharmacogenomic studies (McCarthy et al., 2008, Crowley et al., 2009, Khoury et al., 2009) 
and even more so when performing independent validation studies (Ioannidis et al., 2001). 
Consortia efforts such as that used for the newly treated epilepsy GWAS meta-analysis are 
suggested to overcome the limitation of sample size and power (Motsinger-Reif et al., 2010, 
Johnson et al., 2011b). Although modest sample sizes were provided by the meta-analyses 
performed for the Australian-UK GWAS study, (discovery cohort, n=831 replication cohort 
n=260) and that of our validation study cohort (n=424), there remains the possibility of limited 
study power, for detecting potential effects across all 3 cohorts. In addition to this, the potential 
effect of population substructure across at least the Australia and the UK cohorts may pose 
further errors in true effect identification, as there may be variation in patterns of LD and 
frequency of alleles of interest between the discovery and validation population (Johnson et 
al., 2011b). 
  As discussed throughout this thesis, defining phenotypes for drug response remains 
one of the main challenges in epilepsy PGx and the importance of a universally accepted 
definition and the collection of phenotype data has become increasingly appreciated in the 
context of GWAS (Nebert et al., 2008a). The widely accepted 1-year period of seizure freedom 
definition used for our research dichotomises drug response or treatment outcome into 
“responder” and “non-responder” categories. Although, this has served extremely useful for 
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the retrospective approach to epilepsy PGx (does not require lengthy follow-up) and is also 
appropriate, given that absolute seizure freedom for at least 12 months is the only relevant 
outcome associated with meaningful improvement of quality of life (Kwan et al., 2010). This 
dichotomisation however may obscure important information for drug response (Johnson et 
al., 2011b), thus a potentially quantitative trait may be being transformed into a binary trait 
and so result in the power of a case-control association study being less than that of a 
quantitative trait analysis (Yang et al., 2010, Johnson et al., 2011b). In this present study a 
time to event analysis was additionally undertaken as an attempt to resolve this issue of 
defining seizure remission. 
 In addition to these general issues with study design there are other potential 
confounders more specific to this validation attempt, namely the approach taken for selecting 
the five candidate SNPs to validate the GWAS findings. These SNPs may not be the most 
influential to treatment outcome in newly treated epilepsy. The five SNPs were selected from 
the unreported GWAS meta-analysis findings, though these were not necessarily the top five 
‘GWAS hits’ (GWAS significance level of P = 5x10-7 for suggestive phenotype association) 
(Meyer et al., 2010). Our five candidate SNPs were selected based on results of gene 
expression data in accordance to strong association with outcome (not all at the suggested level 
of GWAS significance) and with the additional consideration of clinical covariates for 
detecting an improved signal. This approach to SNP selection was for the purpose of adding 
further biological or functional value to the GWAS analysis findings on which this study was 
based. The initial GWAS meta-analysis report identified 10 GSTA4 SNPs that associated with 
treatment outcome at the GWAS significance level, however only the top two in terms of 
lowest Chi-square p-value for association were studied in this investigation. With the potential 
role of GSTA4 gene signified from earlier research and the GWAS analysis, more value may 
have been achieved from investigating all 10 GSTA4 SNPs in addition to those with additional 
potential importance due to gene expression data.  
 GSTA4 appears to be a good candidate gene for influencing drug response in epilepsy 
due to its role as a defense enzyme against pharmacologically active electrophilic compounds. 
Further investigation into GSTA4 may thus be warranted to confirm the potential of this gene 
to AED treatment response. Rather than limiting to a handful of SNPs, genotyping a greater 
number of GWAS associated SNPs with slightly less predictive potential (higher Chi-square 
association values) would provide a richer dataset and so may yield additional new causal loci 
associated with treatment outcome. Moreover carrying out a candidate gene validation study 
for GSTA4 combining all three independent cohorts would add greater power for detecting 
influential markers across phenotypically heterogeneous populations.  
 It is unlikely that a small selection of common variants can successfully predict AED 
responsiveness alone. Several clinical factors are known to determine drug resistance in 
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epilepsy, including aetiology, early age at seizure onset, type of epileptic syndrome and 
seizure, structural brain abnormalities or lesions, high pre-treatment seizure frequency, or 
abnormal EEG findings (Kwan and Brodie, 2002, Loscher, 2005b, French, 2007). Not all of 
the above mentioned clinical variables were however included in our study, due to unavailable 
data. This included pre-treatment seizure frequency (most associated with drug-resistant 
epilepsy (Callaghan et al., 2011) and also identified from the GWAS meta-analysis) and 
neurological deficit (Callaghan et al., 2011), which, if significantly associated with outcome 
or time to remission could have influenced our results. 
 A more comprehensive analysis with complete clinical data sets of all variables of 
particular significance may be required in future analyses. The stratification of patient cohorts 
into subgroups by such demographic and clinical factors has also been suggested as a means 
of acknowledging both the heterogeneity within patient populations and the concept of 
revealing any masked genetic influence. Most studies are performed in multiple types of 
epilepsy and with multiple AEDs, but like many association studies no attempt was made in 
our analyses to separate children from adults or the different epilepsy types, despite there being 
important differences in drug-response and type of AEDs used in each subgroup. 
 Treatment differences between the GWAS meta-analysis and validation cohorts are 
another obvious confounder. Potential differences in methodology and recruitment of 
individuals from one study to another may have additionally influenced our results. Significant 
differences in drug treatment are to be expected with international collaboration studies in PGx 
in general. The Australian clinical drug treatment regimens are largely based on CBZ, VPA 
and LTG. Both UK cohorts also differed slightly in AED treatment due to the source 
populations from which both UK cohorts were derived. As previously described the UK 
Glasgow newly treated population (from which patients from this validation study were 
selected) was largely recruited via a drug trial comparing VPA to LTG, whilst the Australian 
GWAS source population was not recruited as part of a drug-trial, rather a PGx study and were 
mainly prescribed CBZ or VPA, and the SANAD GWAS source cohort was the two arm 
randomised SANAD drug trial of established and newer antiepileptic medications (Marson, et 
al. 2007a, b), where LTG  again dominated initial treatment. This would explain the highly 
significant association identified with AED treatment in both our survival analysis for time to 
1-year remission and the general regression analyses for predicting response to treatment (see 
chapter 5 for a discussion on differences in AED treatment between populations and the 
potential genetic effects). We performed univariate and regression analyses on the Glasgow 
UK population using data on initial AED treatment, final AED treatment and/ or AED at 
remission, but this was not stratified by drug type, rather each treatment variable was treated 
as a single covariate.   
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 GWASs can not only identify novel associations for further study, but can help 
counter the selective reporting and pursuit of false positive findings that may occur when PGx 
studies are limited to candidate genes (Guessous et al., 2009). PGx has however focused 
mainly on SNPs as a source of common variation. Single and common variants within genes 
alone have poor predictive value, it is thus unlikely only common polymorphisms and only 
five variants at that are solely responsible for the different drug response phenotypes. GWAS 
are generally underpowered, to detect effects of other sources of variation such as rare and 
novel SNPs that are now becoming appreciated to also contribute to the genetic heterogeneity 
of drug response.   
To summarise future research efforts for predicting seizure remission are likely to 
benefit from the use of broader definitions of response in larger patient cohorts. This may 
power detection of modest effects for a common biological pathway for all 3 populations, but 
a strategy that i) considers underlying epilepsy etiology, ii) incorporates clinical covariates 
(e.g., seizure/syndrome type, age at onset) or at the very least considering all strongly 
implicated clinical factors (i.e. pre-treatment seizure frequency and neurological 
deficit)(Blanca Sanchez et al., 2010, Cavalleri et al., 2011, Johnson et al., 2011b) and iii) 
classifies patients according to response to a specific AED should help in the identification of 
potentially larger and more clinically relevant AED-specific genetic effects (Cavalleri et al., 
2011).  
In addition to large collaborations and consortia meta-analysis, in recent times studies 
are now taking advantage of large-scale deep genome-sequencing to develop a better 
understanding of the human genome and these are better powered to detect mutations and rare 
variants, and it is very likely that such approaches will also be used in the future for 
pharmacogenomic studies in epilepsy.  
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8.1 Recent progress in antiepileptic drug pharmacogenetics 
The first AED was PB, discovered to have antiepileptic properties in 1850s and PHT, 
was then later developed in 1912. Epilepsy is now typically managed with AEDs, of which 
there are currently over 20 with around a dozen in common use (Rogawski and Porter, 1990, 
Cavalleri et al., 2011).  Although the recognition that genetic factors play a role in individual 
response to AED therapy came about in the 1960s with the discovery of congenital enzyme 
deficiency, (Kutt H, 1968) it was not until the late 90s that the first association with genetic 
polymorphisms in the phase I enzymes CYP2C9 and CYP2C19 with PHT metabolism was 
reported (Mamiya et al., 1998, Aynacioglu et al., 1999, Nakajima et al., 2005). This was 
confirmed by several other experimental studies (Aynacioglu et al., 1999, Mamiya et al., 2000, 
Kerb et al., 2001, Allabi et al., 2005) and initiated numerous searches for additional DME 
candidate genes for AED response (Saruwatari et al., 2010). 
  In terms of AED efficacy or response phenotypes, CYP2C9*2 and *3 polymorphisms 
were the first variants implicated in altered AED dosing in early research concerning PHT PK 
(Odani et al., 1996, Odani et al., 1997, Mamiya et al., 1998) and also more recently confirmed 
by several lines of evidence not only for PHT, but also for the AEDs, PB, VPA and ZNS 
(Mamiya et al., 2000, Hung et al., 2004, Tate et al., 2005, Chaudhry et al., 2009, Loscher et 
al., 2009, Saruwatari et al., 2010). Additional PK candidate genes were later investigated and 
associations with AED dose have over the years have been found for CBZ PKs with 
CYP3A5*3 and EPHX1 and also variants within UGT1A4 and UGT2B7 for LTG (Loscher et 
al., 2009, Saruwatari et al., 2010). The ABCB1 transporter PK gene was initially implicated in 
AED dosing in 2001 (Kerb et al., 2001, Ebid et al., 2007, Simon et al., 2007). The original 
ABCB1 C3435T variant association with AED responsiveness in individuals with epilepsy 
(Tishler et al., 1995) was subsequently proposed and demonstrated experimentally in 2003 
(Siddiqui et al., 2003).  Additional transporters associated with AED response include 
RALBP1, P1 and P2 proteins with drug resistant epilepsy (Awasthi et al., 2005, Leschziner et 
al., 2007b, Soranzo et al., 2007, Kasperaviciute and Sisodiya, 2009, Loscher et al., 2009)  
 The search for novel candidate genes and functional variants in these and previously 
associated genes continues, but it quickly became clear that PK polymorphisms alone do not 
explain most of the variation in AED dosage or efficacy (Depondt and Shorvon, 2006, 
Kasperaviciute and Sisodiya, 2009). The potential of mutations in drug targets to AED 
treatment, namely the SCN1A gene was initially discovered through early studies of Mendelian 
epilepsies (Guerrini et al., 1998), and in 2005 the first drug target association with AED dosage 
was reported (Tate et al., 2005, Tate et al., 2006).  
 Most recent candidate genes implicated in influencing AED efficacy include that for 
the GST gene (although so far only concerning adverse effects) (Ueda et al., 2007, Zaccara et 
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al., 2007, Kasperaviciute and Sisodiya, 2009), OCTN1 (Szoeke et al., 2006, Loscher et al., 
2009) ABCC2 (Kim et al., 2010, Qu et al., 2012) and GABARA1 all of which are associated 
with AED responsiveness (Kumari et al., 2010). Despite these gene implications the first and 
only clinical impact of genetic variation in epilepsy is the HLA-B*1502 variant as a strong 
predictor of CBZ-induced SJS/TEN in patients from Asia and of Asian descent (Loscher et 
al., 2009, Yip et al., 2012). No such progress has been made in AED efficacy. The limited 
success in AED PGx studies to date has been associated with the lack of concordance in 
research findings, the foremost reason being the variation in treatment regime among 
clinicians, inconsistent phenotype definitions (i.e., definition of resistance versus response to 
AEDs) and heterogeneity in epilepsy phenotypes among studies.  
Drug response phenotype is perhaps the fundamental factor in PGx genetic studies of 
responsiveness and a lack of consensus in its definition has inevitably resulted in difficulties 
in making comparisons across studies (Kasperaviciute and Sisodiya, 2009, Cavalleri et al., 
2011). Two meta-analyses have been reported assessing the role of the Pgp ABCB1 3435C>T 
variant in drug response (Siddiqui et al., 2003, Leschziner et al., 2007a) and these clearly 
demonstrate the importance phenotype definitions when investigating potential genetic 
effects. Neither of these meta-analyses provided evidence for ABCB1 3435C>T association 
with multidrug resistance, though this can be attributed to the huge variation in drug-resistance 
phenotype definitions of the original studies that makes meaningful meta-analysis hardly 
possible (Kasperaviciute and Sisodiya, 2009).   
 There are various other potential explanations for the discordant results, including, 
retrospective design and relatively small sample size and/or short duration of most studies. 
Additional factors include heterogeneity of the epilepsy syndromes with their variable causes 
and prognoses and a reduction in power to high-dimensionality of multigenic data sets under 
investigation (Hirschhorn et al., 2002, McCarthy et al., 2008, Kasperaviciute and Sisodiya, 
2009). 
The multifactorial nature of AED response necessitates the search for multiple genes 
or variants (Loscher et al., 2009, Kumari et al., 2011). Indeed several investigations including 
some of the studies mentioned above have utilised a multigenic approach (Anderson, 2008, 
Petrovski et al., 2009, Johnson et al., 2011b). Moreover the application of ML methods has 
now moved to PGx (Hahn et al., 2003, Ferraro and Buono, 2006, Petrovski et al., 2009, Pander 
et al., 2010, Silva et al., 2011). A growing number observational studies have also recently 
shown that when genotype is considered alongside other genomic factors and clinical 
predictors the proportion of variation in response can increase significantly (Franciotta et al., 
2009, Makmor-Bakry et al., 2009, Petrovski et al., 2010, Sanchez et al., 2010, Johnson et al., 
2011b).  
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With the completion of the human genome project in 2001 and the advent of genomic 
technologies, epilepsy PGx research has now begun utilising a more genome-wide approach 
to research i.e. one that captures greater amount and type of genetic variation (Evans and 
McLeod, 2003, Goldstein et al., 2003, Grant and Hakonarson, 2007, Crowley et al., 2009). 
This genome wide approach has previously proven to speed up the discovery of drug response 
markers in other disease areas and aided the integration of PGx to the clinical practice 
(Takeuchi et al., 2009, Daly, 2010a, Wu and Reynolds, 2012). In 2010, the first GWAS for 
focal epilepsy was published (Kasperaviciute et al., 2010) and this was quickly followed by a 
GWAS meta-analyses concerning PGEs (Leu et al., 2012). The next step for epilepsy PGx 
thus remains GWAS studies for AED efficacy as to finally utilise whole genome data in the 
search for novel prognostic gene and/or SNPs for treatment responsiveness in epilepsy 
(Johnson et al., 2011b).  
 Prospective epidemiological study of newly-diagnosed epilepsy across all age ranges, 
countries, and continents is considered the ideal for studies into drug efficacy (Kasperaviciute 
and Sisodiya, 2009, Cavalleri et al., 2011, Johnson et al., 2011b). As the analysis of already 
available retrospective data is likely to continue, for the time-being carefully designed long-
term follow-up studies would identify the patterns of outcome and delineate the different 
phenotypes for successfully identifying drug response markers for valid pharmacogenomic 
investigations. Multicentre GWAS meta-analyses are the way forward for this, and are 
presently being constructed (Johnson et al 2012 unpublished)(Leu et al., 2012).  
 A recent Australian-UK GWAS meta-analysis effort for newly treated epilepsy 
presents the first GWAS study for drug response and seizure remission in newly treated 
epilepsy (Speed et al., 2013). Through the careful consideration and standardisation of patient 
phenotypes as well as using prospective drug response data, incorporating influential clinical 
covariates and utilising multi-centre collaborations, this GWAS study is an advancement in 
AED PGx. Researchers however conclude a lack of limited study power to detect common 
genetic determinants of weak to modest effects (Johnson et al 2012 unpublished).  
 The growing consensus in the field of pharmacogenomics and disease genomics that 
all genomic mutations i.e. common, rare, SNP, CNV, insertions or deletions, microsatellites 
are possible sources of variability with a combination of small and/or large effects on complex 
disease/traits. There is also an increasing trend towards there complete ascertainment. This 
concept of whole genome sequencing is moreover on the rise due to advances in whole genome 
sequencing technology. A GWAS utilising CNV with encouraging findings has already been 
reported for complex forms of epilepsy (Mefford et al., 2010). Arguments thus exist for the 
benefits of the candidate gene approach, genome-wide and now whole genome approach to 
genetic analysis. The former nevertheless provides an increasingly economical method of 
locating all common variation, and the latter at present, continues to provide information of 
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markers of interest (Daly and Day, 2001, McCarthy et al., 2008, Guessous et al., 2009). 
Besides candidate gene studies are clearly a low-cost method of validating larger scale studies 
quickly and efficiently. And so in combination, high-quality phenotyping across multiple 
research centres, dense genomic patient profiles from GWAS and whole-genome sequencing 
and effective PGx validation of the most influential markers could provide a more 
comprehensive investigation to finally locate genetic factors that can guide epilepsy treatment 
(Cavalleri et al., 2011). 
 
8.2 Thesis findings and potential future direction  
PGx studies in epilepsy and in particular newly treated patients are currently small in 
number. The available studies however clearly demonstrate the relatively modest and 
multigenic influence on AED response that is also largely dependent on individual patient’s 
demographical and clinical characteristics. Our findings similarly indicate a complex interplay 
of multiple genetic factors from well-known pharmacological pathways of AEDs in 
combination with clinical prognostic factors underlie the treatment path and responsiveness to 
AED therapy. We also show the potential benefits of new statistical methods for more 
efficiently capturing these relatively small effects with better efficiency. 
 
8.2.1 Genetic markers for predicting antiepileptic drug dose requirement 
PGx studies concerning AED dosing have largely concentrated on PK DME genes 
and primarily the genes for the CYP2C9 and CYP2C19 enzymes (Loscher et al., 2009). The 
first PD gene studied was SCN1A in a report that found a splicing variant rs3812718 to be 
related to variable CBZ and PHT doses (Tate et al., 2005). In Chapter 3 and 4 dosing of AEDs 
was studied using maintenance dose and/or maximum dose data in two independent 
investigations that either searched for potential markers associated with AED dose in PK 
candidate genes (CBZ DMEs) or PD genes (AED target; NaV channel).  We failed to find 
predictive genetic markers for AED maintenance dose in either drug pathway investigation.  
 In Chapter 3 a comprehensive search for markers within several genes was performed 
as to capture enough variation across whole genes, yet our search was not successful. A major 
caveat of the study in Chapter 3 is that we only investigated selected candidate genes that were 
limited to the PK of CBZ. Previous reports however managed to identify single DME SNP 
variants that appeared to influence AED dose using a limited candidate SNP search within 
CYP450 genes namely CYP2C9, 2C19 and 3A5 (Hung et al., 2004, Makmor-Bakry et al., 
2009, Park et al., 2009, Saruwatari et al., 2010). Small-scale genetic investigations (i.e. those 
that assesses only a handful or small selection of candidate variants) is a problem with many 
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PGx candidate gene efforts as they run the risk of not capturing all potentially influential 
variants and thus pose a greater chance of reporting false positive or false negative findings 
(Daly and Day, 2001, Ferraro et al., 2006). Moreover contradictory research findings exist for 
most if not all studies for AED response (Loscher et al., 2009). Though the predictive power 
of the CYP2C9 and CYP2C19 variants are proven, these are mainly concerned with PHT 
metabolism and are yet to demonstrate general clinical utility (Anderson, 2008). The 
previously reported CYP2C9 and CYP3A5 polymorphisms were not included in our study or 
the final data analysis after quality control checks, thus we were unable to assess their potential 
function to CBZ dosing.  
 Our attempt to replicate the association between maximum dose and the SCN1A 
rs3161362 SNP in Chapter four using retrospective recruited patients with newly treated 
epilepsy receiving CBZ only was unsuccessful (n=168) (Tate et al., 2005). Similar to our 
finding two independent research groups using Japanese and Italian patients also failed to 
associate maximum dose requirements of CBZ and rs3161362 genotype, when investigating 
drug responsiveness in drug-resistant and responsive patients (Abe et al., 2008, Manna et al., 
2011). The primary analysis in Chapter 4 was however for maximum and/or maintenance dose 
regardless of AED administered. This was performed using all patients thus a larger cohort of 
individuals (n=586) and proved more successful. Our follow up investigation of the original 
drug target variant using data for several AEDs in addition to CBZ was thus positive. 
Regardless of whether drug target or DME gene variation is more influential of AED dose, the 
most important question is the predictive value of our genetic findings. In Chapter 3 one PK 
gene, UGT2B7 was the main gene implicated in influencing CBZ dose, though not statistically 
proven in the data analysis. The SCN1A SNP accounted for 6.5% and 2.5% of the variation in 
PHT and CBZ dose requirement respectively (Tate et al., 2005), which may not be adequate 
for it to be considered clinically significant. Moreover our study, which considered a wider 
selection of drugs similarly only appeared to explain limited dose variation. 
 The work presented in Chapter 4 also demonstrates the complexity of gene-
environment interactions where the type of AED used for treatment was shown to effect 
maximum dose. When maximum drug dose was stratified by AED type we observed 
significant association between the SCN1A SNP and maximum dose requirement, with some 
indication of potential specificity to LTG and no effect evident with CBZ (Thompson et al., 
2011). This finding was not in line with Tate and colleagues (Tate et al., 2005, Tate et al., 
2006) who demonstrated association with CBZ and also with PHT, at a greater extent. Our 
sample population was considerably bigger than that of Tate et al and in addition to this we 
carried out a non-specific study of AED usage. Using a non-specific drug data analysis 
provided us with a larger number of patients and thus better power to detect effect size. A non-
specific drug analysis moreover removes bias towards a particular AED, which may no longer 
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be widely prescribed in clinical practice (Glauser et al., 2006, Hakami et al., 2012). Given this 
drug specific effect that appeared to cause modest dose changes and equally moderate level of 
dose variability attributable to the rs3812718 SNP, genetic variation in the SCN1A gene may 
have a significant effect on dosing in newly treated epilepsy patients and so necessitates further 
enquiry (Kasperaviciute and Sisodiya, 2009).     
PK is known to be responsible for variable serum concentration of drugs and their 
doses for therapeutic effect. The SCN1A variant genotype can be implicated with higher doses 
of AED in our analysis. Our data indicates drug-gene interactions may influence drug dose 
and we also show association between rs3812718 genotype and standardised maximum dose 
requirement regardless of AED. We did not however take opportunity to explore a multigenic 
effect of functional DME polymorphisms and the SCN1A variant in combination or even 
multiple variants across SCN1A and/or additional drug target genes, which may have provided 
more definitive results for the studies in Chapter 3 and 4. With the patient DNA available for 
the Glasgow samples we will be able to confirm our findings with maximum dose and 
rs3812718 genotype (investigated in the SANAD cohort) in this independent epilepsy cohort. 
With the wealth of clinical data available for both cohorts, we could also perform a more 
comprehensive investigation of the non-genetic contribution to the variability in AED dosage 
requirement and the multigenic contribution to clinical AED usage. 
 
8.2.2 Utilisation of multigenic machine learning models for AED response  
  The work presented in both Chapters 5 and 6 demonstrate some advantage in the use 
of the kNN supervised ML approach for analysing complex genomic data. In Chapter 5 we 
could not independently replicate the predictive potential of Australian multigenic classifier 
developed by Petrovski et al 2007 using UK newly treated epilepsy patients. Through an 
international collaboration with the study authors, Professor O’Brien and Dr Petrovski in 
Melbourne, Australia, we did however observe some predictive success of the five-SNP 
classifier when data was stratified by CBZ and VPA. Similar to Chapter 4 these findings 
signify a potential drug specific effect in the genetic contribution to AED response and so lend 
support to the inclusion of non-genetic or clinical covariates in the search for predictive 
markers in PGx analysis (Sanchez et al., 2010).  
 The 2007 report by Petrovski et al presents the first PGx study utilising the novel 
statistical method of ML for treatment response (Kasperaviciute and Sisodiya, 2009, Johnson 
et al., 2011b) thus demonstrating greater power of ML methods for studying the complex 
phenotype of drug response. In a later study the authors indicated the prognostic value of 
neuropsychiatric factors for initial 12-month seizure control and additionally reported that the 
five-SNP classifier presented greater prognostic value when considered alongside this 
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neuropsychiatric data (ABNAS score) (Petrovski et al., 2010). The consideration of the 
complexity of epilepsy related phenotypes in genomic research is finally being recognised as 
fundamental to accurately predicting treatment response. Researchers have now proposed 
future efforts should also consider etiology as a covariate in analysis of responsiveness to 
specific AEDs (Kasperaviciute and Sisodiya, 2009, Cavalleri et al., 2011). Great consideration 
of clinical covariates that associate with treatment response was similarly given in our studies 
thus we performed extensive data stratification before the development of any prognostic 
models (Sanchez et al., 2010). Drug responsiveness in epilepsy has previously been studied 
greatly in the context of drug-resistance or the unresponsive phenotype in individuals with 
chronic epilepsy. This research moreover lends most focus to Pgp, however not all AEDs are 
thought to be substrates of Pgp and similar discord is present for the influence of Pgp variants. 
However the notion is presently that if Pgp does have an effect on AED responsiveness this is 
likely to only be minute in nature (Kasperaviciute and Sisodiya, 2009). 
 In Chapter 6 the kNN ML was also used for investigating genetic factors influencing 
complex epilepsy syndromes. The clinical utility of prognostic markers or models can only be 
considered after independent verification. The 11-SNP and 16-SNP kNN classifiers that were 
developed for PGE sub-syndrome type (i.e. JME vs. CAE) and PGE respectively in our studies 
were however unable to classify individuals with any great deal of confidence. Similarly 
utilisation of other ML approaches we could not confidently identify predictive markers for 
PGE sub-syndrome. Two widely used ML developed classifiers (NN and Ensemble) were 
however able to predict PGE patients from non-PGE controls with greater confidence.  This 
was not the primary study aim but demonstrates that ML methods are likely to be more suitable 
for epilepsy phenotype data.  
 One cannot over emphasise the significance of sample size for complex phenotypes 
(Cavalleri et al., 2011, Ferraro et al., 2012). This is moreover exaggerated when considering 
independent validation, which requires additional patient groups. An advantage of ML 
approaches in this context is thus the ability to test any results internally in separated data 
before developing an overall prognostic model, and then independently testing in other cohorts 
before suggestion of any genomic association. The number of cases in a test cohort was thus 
crucial for both studies and can be considered a major contributor to kNN model failure. To 
improve on the investigation in Chapter 5, for future investigations the UK cohorts can be 
combined to form a large cohort of newly treated epilepsy in which new variants with 
potentially more significance to a UK epilepsy population can be identified. Several ML 
approaches are available including those that model gene-gene interactions that are likely to 
occur in complex data sets and these may be more suited to developing models for predicting 
disease occurrence.  
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8.2.3 Genome wide association study for newly treated epilepsy and drug 
responsiveness  
Although we could not establish any predictive potential of the five-SNPs proposed 
to be of particular significance to treatment response in newly treated epilepsy (Speed et al., 
2013) in Chapter 7, our findings did confirm the non-genetic influence in epilepsy treatment 
prognosis. The prognostic potential of several clinical covariates in the ease and early success 
of AED treatment was demonstrated. With our case control analysis of 12-month remission 
status, the predictive potential of EEG, epilepsy type and treatment AED was identified. This 
is in line with what is indicated in literature (So, 2011), where as of yet only clinical predictors 
of modest effect have been located (Loscher et al., 2009, Callaghan et al., 2011, So, 2011).  
 In a recent study several factors were associated with a decreased cumulative 
probability for a 12-month or greater seizure remission including presence of developmental 
delay, symptomatic generalised epilepsy syndrome, longer duration of intractability, and most 
notable number of AEDs failed which was also an independent negative predictor of seizure 
remission (Callaghan et al., 2011).  We did not perform such a detailed non-genetic analysis; 
however there were a greater number of responders in both LRE and IGE patients and the least 
number of responders with multiple AED treatment (usually an indication of failure of at least 
2 AEDs) in our study cohort (Kwan and Brodie, 2001a, Kwan and Sperling, 2009).  
 Chapter 7 specifies that to develop the most accurate predictive models for treatment 
outcomes, multiple sources of information should be integrated including clinical 
characteristics genomic data, historical data and neuropsychiatric data (Johnson et al., 2011b). 
This is consistent with the concept that the determinants of seizure recurrence are 
multifactorial; therefore, many different non-genetic covariates as well as genetic variants are 
likely to provide optimal prediction for numerous individual patients with epilepsy (Bhathena 
and Spear, 2008).  
 Because both our results and that of the GWAS findings have validated the value of 
previously recognised predictors in newly treated epilepsy, the GWAS and the results for this 
current Chapter appear to be valid with little chance of false positive findings. Chapter 7 also 
shows that with time to 12-month remission data a more accurate representation of seizure 
control can be provided than that provided by the binary classification of response (Johnson 
et al., 2011b). Whilst no genomic advances were made in this chapter, GSTA4 can be 
implicated as a candidate gene for seizure control from the original GWAS study report and 
so would benefit from further analysis. Moreover the study presented in Chapter 7 is the first 
to analyse data from a GWAS analysis for newly treated epilepsy. Although no genomic 
significance was identified from the initial GWAS investigation, there appears some 
speculation of the GSTA4 gene and the rs622902 variant in treatment responsiveness in 
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epilepsy, not necessarily from our data but that of the original GWAS international meta-
analysis effort. Further work can include a comprehensive analysis of variation across the 
GSTA4 gene in both UK cohorts of newly treated epilepsy available to us, using a tSNP 
approach to search for novel susceptibility markers for AED responsiveness.  
 
8.2.4 Research conclusions 
Several approaches were employed for each study. Genomic variation was considered 
in drug pharmacokinetic proteins, in drug target proteins and finally across multiple candidate 
genes, thus providing three broad hypothesis as sources housing potential influential genomic 
variation. In addition to this several methods were considered for SNP selection and genomic 
data assessment. 
 
Summary of research findings 
 Genetic variation in DME genes alone is unlikely to have a significant effect on the 
dose required for effective drug treatment.  
 
 Genetic variation in neuronal ion channel proteins as AED targets may be more 
influential in treatment response than pharmacokinetic pathway variation; the 
previously implicated NaV channel gene rs3812718 gene polymorphism may alter 
maximal drug dose requirement of some AEDs but not others. 
 
 
 Machine learning demonstrates greater power as a novel approach to complex 
genomic data analysis; Treatment differences across populations and limited cohort 
size may dampen the predictive power of an Australian treatment response classifier 
 Machine learning may also be a better method for modelling genomic data for the 
common genetic epilepsies, however the PGE sub-syndromes remain far too complex 
to characterise using candidate genes and modest mixed population cohorts, requiring 
larger homogenous patient cohorts and whole genome analysis for future research. 
 
 Initial findings of a multicentre GWA study was not validated in an independent UK 
cohort of treatment response, however GSTA4 variation could be influential in 
treatment outcome in epilepsy and the gene warrants further in depth analysis.  
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8.2.5 Overall thesis conclusions 
AEDs provide the main treatment method for seizures in epilepsy yet 
characteristically present variable levels of success in terms of their effectiveness for treating 
the many types of epilepsy syndromes that exist. Changes in AED therapy including 
successive treatment regimen and drug switching have been reported to influence seizure 
outcome (Mohanraj and Brodie, 2006, Luciano and Shorvon, 2007, Brodie et al., 2012, Wang 
et al., 2013). The prescribing practice in the context of epilepsy may therefore be a major 
indicator for the considerable number of individuals who continue to experience seizures 
(Lhatoo et al., 2001, Sander, 2004, Luciano and Shorvon, 2007, Brodie et al., 2012). AEDs 
could therefore benefit from the application of the concept of personalised medicine through 
PGx study as to maximise pharmacotherapy for epilepsy treatment with minimal complication. 
Better understanding of the common genetic variation contributing to the individual patient 
differences in response to AEDs has so far provided greater insight of the genomic basis of 
AED dosing to progress from a trial and error methodology and improve overall drug efficacy 
in terms of achieving long-term seizure remission. Clinical prognostic indicators are few in 
number and genomic influencers are more or less non-existent.  
 This thesis demonstrates that both the control or treatment of seizures in epilepsy and 
the effective use of AEDs for this intention is complex, and reliant on many factors including 
common and rare genetic polymorphisms, clinical covariates and environmental interaction, 
all of which need to be elucidated before any unknown heritability can be detected. Whether 
such complexity can ever be incorporated into clinical practice is unclear. The characterisation 
of this heritability is heavily reliant on robust phenotypes of variability for both AED response 
and the disease itself, as well as cohort collaboration for greater statistical power for detection. 
A timely effort to effectively achieve these initial steps alone is expected.  Progress in AED 
PGx has not expanded as rapidly as initially anticipated. PGx for improving seizure control 
however remains a worthwhile ground of epilepsy research as in the long run can ultimately 
help provide rapid treatment, reduce mortality and morbidity and decrease medical costs which 
currently burden this common neurological disorder greatly.  
 
8.2.6 Patient Impact of pharmacogenomics 
 
Pharmacogenomics holds the promise of selecting the right drug at the right dose for 
the right person for better outcomes in terms of successful seizure control, adverse effects and 
time to remission (Johnson et al., 2011b). From a clinical perspective, identification of genetic 
variants either by GWA or sequencing is merely the first step in understanding genetic factors 
influencing individual response to pharmacotherapy. Any identified factors can only be 
considered for clinical application after robust assessment of each association to determine its 
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true clinical utility (Kasperaviciute and Sisodiya, 2009). From previous candidate and whole 
genome complex disease association studies it is clearly evident that despite successful 
replication of markers even if of high risk or odds ratios, their performance in terms of 
predictive accuracy and specificity for a clinical phenotype such as treatment outcome remains 
poor (Ferraro et al., 2012).  
One of the growing trends in complex disease genomics is the establishment of the 
function of any identified genetic variants (Ferraro et al., 2012). Knowledge of biological 
function provides a good foundation for subsequently interpreting the potential influence of 
genetic associations on a disease phenotype and so can greatly support any identified genetic 
association. Functional studies can include those investigating changes in gene expression, 
splicing and protein function and should be performed in conjunction with genetic studies to 
improve data interpretation and strengthen data analysis. Another essential endpoint is clinical 
phenotype in this case pharmacological phenotypes. Pharmacological phenotypes require 
careful selection before study design and this can be directed through their potential clinical 
utility i.e. locating genetic variants that can predict ADRs or drug efficacy. Correlation 
between pharmacological phenotypes and functional genetic variants remains the biggest 
challenge for future large-scale genomic studies and is critical for clinical translation.  
Eventually pharmacogenomics will lead to the development of rapid high-throughput 
assays to optimise patient diagnosis, the use of which will additionally create medical, ethical, 
legal, and regulatory pressures and these should be considered now, before they emerge 
(Cavalleri et al., 2011).  
 
8.2.7 Impact of pharmacogenomics on drug development 
 
With the advancements in disease genomics, a rational approach to new and better 
therapies has become a realistic prospect. In terms of new or emerging drugs, PGx can be 
applied to drug design in several ways. Firstly PGx research can be used to ‘rescue’ any 
existing drugs that have been withdrawn from the market, most likely due to serious or 
common AEs in a number of people. Retrospective genotyping of such clinical trial 
participants could identify the genetic make-up of the often small proportion of patients who 
suffered these, as to prevent their use in these genetic groups in the future. Subjects’ eligibility 
to participate in additional clinical trials will be decided by the results of such PGx tests. A 
subgroup of individuals may also for genetic reasons, in contrast respond well to a drug 
without side effects. Individuals from both response phenotype groups, will thus benefit from 
a drug being placed on the market with the provision that specific genetic tests will be 
administered prior to drug prescription.        
 In terms of drug research and development, the only way forward would be to couple 
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new drug trials with PGx studies. Pharmacogenomics approaches would focus on the 
identification of genetically determined drug targets involved in disease and/ or genetic 
polymorphisms associated with treatment response. Such research could assist pharmaceutical 
companies to develop more effective drugs with fewer side effects. In pharmacotherapy for a 
particular disease, numerous polymorphisms may influence drug metabolism or disease 
development. These polymorphisms must be identified before PGx and pharmacogenomic 
products can be developed. The complexity of both the human genome, and human diseases, 
however will make it difficult and time-consuming to produce this information.  
 
8.2.8 Next generation sequencing and platforms for data analysis 
NGS is the next stage in the genetics of complex traits and also likely to impact drug 
response (di Iulio and Rotger, 2012). This will help unravel the complexity of the human 
genome in terms of genetic variations that are yet to be discovered and the biological 
mechanisms that surrounds these variants. The impact of NGS technologies on genomics is 
expected to be far reaching and will change the field of disease genetics including that which 
influences disease treatment for years to come (Zhang et al., 2011). Future PGx studies are 
consequently likely to focus on exome genotyping in search of novel genetic markers 
associated with AED sensitivity. Whole genome sequencing in patients will allow the 
detection of underlying rare mutations that in combination with the data for common genomic 
variation is more appropriate for studying the multigenic nature of treatment responsiveness 
in epilepsy. This could hopefully identify unresponsive individuals from responsive 
individuals and also improve the clinical management of patients who require unusually high 
or low drug doses to control their seizures. NGS technologies will have a striking impact on 
genomic research and the entire biological field. One problem with next generation sequencing 
projects is the handling of massive amounts of sequencing data that must be organized, cleaned 
up, assembled, and analyzed. Sequencing of an entire genome can generate millions of pieces 
of sequence that must be assembled. Easy to use computing programs are thus desperately 
needed to make data interpretation manageable and fast. A variety of software tools are under 
development and many are available online for NGS data analysis. Their functions fit into 
several general categories each of which poses a challenge to be met for efficient analysis of 
NGS data: 
 
i) Software packages or applications for the alignment of NGS reads to a reference 
sequence; The most important step in NGS data analysis is the successful alignment 
or assembly of short reads to a reference genome and this critical step is further 
challenged by the emergence of new NGS short-read technology. 
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ii) Packages for genome annotation and functional prediction of mutations; After the 
successful alignment and assembly of NGS data, the next challenge in NGS data 
analysis is the interpretation of data- A large number of presumed ‘novel’ genetic 
variants are present by chance in any single human genome and this makes it difficult 
to identify which of the numerous characterised variants are actually causal 
 
iii)  End-user software packages and cloud computing; The former provides a user-
friendly interface, easy to use data input and output formats, and integrates multiple 
computing programs into one software package. It is difficult for many research 
laboratories to successfully conduct NGS projects due to the high level of information 
technology support required. A possible solution is cloud computing. In cloud 
computing, a user can use a virtual operating system (or “cloud”) to process data on 
a computer cluster for high parallel tasks (allows scientists to rent both storage and 
processing power virtually by accessing servers as they are needed). 
 
8.2.9 Future work in epilepsy pharmacogenetics  
 Many of the research studies for epilepsy PGx have focused on patients resistant to 
antiepileptic drug therapy. Classification of this response phenotype requires treatment failure 
with multiple agents thus is often concerned with long-term or chronic epilepsy. In this thesis 
we investigated responsiveness to drug therapy in newly treated epilepsy patients. The benefit 
of scanning the entire genome for new susceptibility loci for AED efficacy has become evident 
and subsequently more robust genetic influences on drug response in epilepsy are anticipated 
(Crowley et al., 2009, Loscher et al., 2009, Daly, 2010a). The GWA approach does offer an 
opportunity to locate associations not previously considered in epilepsy candidate gene 
studies, whilst also providing the required statistical power to detect multiple modest genetic 
effects that are assumed to determine AED response (Ferraro et al., 2012). An independent 
GWAS study for studying the influence of common genetic variation.
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Appendix 1.1 Carbamazepine Drug Metabolising enzyme MALDI-TOF MS PCR and Extension Primers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Assay Chromosomal 
position 
Forward Amplification Primer 
Sequence (5'>3') 
Reverse Amplification Primer 
Sequence (5'>3') 
Extension Primer Sequence  
(5'>3') 
 
rs35073925 1 226027630 ACG TTG GAT GAC AGC GTT 
TCG GGA GGT TTC 
ACG TTG GAT GCT CTC CCT 
CAT CAG GCT GTA 
CTC CAC ATC CCT CTC AG  
rs11572081 1 96826966 ACG TTG GAT GGT GTT CAA 
GAG GAA GCT CAC 
ACG TTG GAT GGT CAA TGA 
CGC AGA GTA GAG 
GAG TAG AGT CAC CCA CC  
rs35796837 1 75043593 ACG TTG GAT GGT TCA AGC 
ACA GCA AGA AGG 
ACG TTG GAT GTG ACA ATC 
TTC TCC TGT GGG 
CTG TGG GAT GAG GTT GC  
rs11572126 1 96814915 ACG TTG GAT GTG TGC AAA 
AAT GGA AAA GCC 
ACG TTG GAT GTG GAA ATT 
GAG TCC TCT CCC 
GGT CCT CTC CCT GTA 
GTT 
 
rs10799326 1 226009918 ACG TTG GAT GCC TCT GAG CTC 
AGT ATC TTG 
ACG TTG GAT GGT TGC AAA 
CCA GCA TGA TTT 
TAA ACG TGA CTG GAA GAT  
rs1058930 1 96818119 ACG TTG GAT GGC TAA TAT CTT 
ACC TGC TCC 
ACG TTG GAT GAA GAA CAC 
CAA GCA TCA CTG 
ACA ATC CTC GGG ACT TTA 
T 
 
rs10915884 1 226023875 ACG TTG GAT GTT CTG TTC CAG 
GAT CCC ATC 
ACG TTG GAT GAA CTG TCA 
CAG CCA AGA AGG 
AGG GTC TAA AGA GAC ATG 
A 
 
rs4292394 1 69972949 ACG TTG GAT GAG AGT CTT 
ACC TAG AAG GTC 
ACG TTG GAT GTT CTG TGG 
AGA TTT GAT GGG 
TTA GGT CTC AAT ACT CGG 
CT 
 
rs2292566 1 226019653 ACG TTG GAT GTG ACA TAC 
ATC CCT CTC TGG 
ACG TTG GAT GCA GGT GGA 
GAT TCT CAA CAG 
CCA CCC TCA CTT CAA GAC 
TAA 
 
rs1536430 1 96817776 ACG TTG GAT GGG CAT ACA 
GGA AGC CCA TTT 
ACG TTG GAT GAA TAT CCT 
ACC ACA AAC TG 
CAC TAC CAC AAA CTG AAG 
ATG 
 
rs10264272 1 99262835 ACG TTG GAT GGC CCA CAT 
ACT TAT TGA GAG 
ACG TTG GAT GTC AAC AAT 
CCA CAA GAC CCC 
TCT CAC CCT TTG TGG AGA 
GCA CTA A 
 
rs11572079 1 96827118 ACG TTG GAT GAA GGT TGT 
GAG GGA GAA ACG 
ACG TTG GAT GAA TTC TCC 
CAG TTT CTG CCC 
CCC CCA GTT TCT GCC CCT 
TTT TTT TA 
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SNP Assay Chromosomal 
position 
Forward Amplification Primer 
Sequence (5'>3') 
Reverse Amplification Primer 
Sequence (5'>3') 
Extension Primer Sequence  
(5'>3') 
 
rs17861157 3 75043592 ACG TTG GAT GTG ACA ATC TTC 
TCC TGT GGG 
ACG TTG GAT GGT TCA AGC 
ACA GCA AGA AGG 
GGG GCG AAG GGG CCT 
AGA GCC AG 
 
rs11572082 3 96826922 ACG TTG GAT GGA CTC TAC TCT 
GCG TCA TTG 
ACG TTG GAT GGC CAC CCC 
TGA AAT GTT TCC 
CCC CCA GGA CGT CAC TAG 
TGA AGA 
 
rs4987161 3 99366081 ACG TTG GAT GGG GTC TTG TGG 
ATT GTT GAG 
ACG TTG GAT GGC ATG GAT 
GTG ATC ACT AGC 
CCC CCT GTG ATC ACT AGC 
ACA TCA T 
 
rs2671272 3 226015116 ACG TTG GAT GGC CCA GCA TTG 
TTA TCT AGC 
ACG TTG GAT GTG CAG GTT 
ACT CTG AAC AAG 
CGG TTA CTC TGA ACA AGA 
ACA GTC T 
 
rs2234922 3 226026406 ACG TTG GAT GAC TTC ATC CAC 
GTG AAG CCC 
ACG TTG GAT GAA AAC TCG 
TAG AAA GAG CCG 
GAA AGT CAG CAA GGG CTT 
CGG GGT A 
 
rs11572127 3 96814689 ACG TTG GAT GTA GGG TAC ATG 
TGC ACA ATG 
ACG TTG GAT GAT AAA TGG 
CAA ACC ATG TC 
AAA TGG CAA ACC ATG TCA 
TTT TAA AG 
 
rs35407132 3 75042301 ACG TTG GAT GAC CTG GCA CTG 
TCA AGG ATG 
ACG TTG GAT GTG GAG CCA 
ATG CGG ATC TG 
AGG GAG CCA ATG CGG ATC 
TGC AGG AC 
 
rs28365062 3 69964271 ACG TTG GAT GCC AGG AGT TTC 
GAA TAA GCC 
ACG TTG GAT GCT ATT CCT 
GTC AGG AAG ACC 
TCT ACT CCT GTC AGG AAG 
ACC CAC TAC 
 
rs2234700 4 226032896 ACG TTG GAT GGA ACC TCA CCC 
ACT TTT CAG 
ACG TTG GAT GCA GGA TGA 
AGG TCT ATG TGC 
CCT TCC CTT TTG AGC TA  
rs3738042 4 226013388 ACG TTG GAT GAC TGC CTT GAC 
CCA CAG TGC 
ACG TTG GAT GGT GCA TAA 
AAT ATT GGT GGA G 
TAT TGG TGG AGC TCT TC  
rs1051740 4 226019633 ACG TTG GAT GCT GGC GTT TTG 
CAA ACA TAC 
ACG TTG GAT GAC TGG AAG 
AAG CAG GTG GAG 
GTG GAG ATT CTC AAC AGA  
rs11572103 4 96818106 ACG TTG GAT GAA GAA CAC CAA 
GCA TCA CTG 
ACG TTG GAT GGC TAA TAT 
CTT ACC TGC TCC 
CTT ACC TGC TCC ATT TTG A  
rs4653695 4 226033083 ACG TTG GAT GAC ATC CGC AAG 
TTC CTG TC 
ACG TTG GAT GCC AAG AAA 
AGC CTG GAG GG 
GGA GCC TGG AGG GCA CTT 
G 
 
rs28365095 
 
4 99277605 ACG TTG GAT GTT TCA GCA GCT 
TGG CTG AAG 
ACG TTG GAT GTA GCT GAG 
TGC TGC TGT TTG 
GGC TGT TTG CCT GGA GCT 
TC 
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SNP Assay Chromosoma
l position 
Forward Amplification Primer 
Sequence (5'>3') 
Reverse Amplification Primer 
Sequence (5'>3') 
Extension Primer Sequence  
(5'>3') 
 
rs2234698 4 226019500 ACG TTG GAT GTT TGC TCC AGG 
ACT TAC ACC 
ACG TTG GAT GTG AAG CCA 
TAG TGG AAG CAG 
GGT GGG GTG AAA CGG 
AAC TT 
 
rs762551 4 75041917 ACG TTG GAT GTC TGT GAT GCT 
CAA AGG GTG 
ACG TTG GAT GCA GCT GGA 
TAC CAG AAA GAC 
CTC AAT CTA CCA TGC GTC 
CTG 
 
rs1934980 4 96808973 ACG TTG GAT GAA CTG ATG TCT 
TTG CTT GGG 
ACG TTG GAT GTA CAA ATG 
GGA GAG TGG AGC 
CCT CGA GTG GAG CAA GAT 
GAC 
 
rs6600894 4 69983092 ACG TTG GAT GCA TCC ATT TTC 
ACA ATA GCT G 
ACG TTG GAT GGT ATT TTT 
CTT TGT AGA GAC C 
CTT TGT AGA GAC CTT TCA 
CAT T 
 
rs7439366 4 69964338 ACG TTG GAT GGC TGA CGT ATG 
GCT TAT TCG 
ACG TTG GAT GTG GAG TCC 
TCC AAC AAA ATC 
TCA ACA TTT GGT AAG AGT 
GGA T 
 
rs776746 4 99270539 ACG TTG GAT GGT AAT GTG GTC 
CAA ACA GGG 
ACG TTG GAT GAC CCA GCT 
TAA CGA ATG CTC 
TTC CAG AGC TCT TTT GTC 
TTT CA 
 
rs2069522 4 75039233 ACG TTG GAT GTT CTC CCA TTC 
ATG GCC TTC 
ACG TTG GAT GTC AGC AGA 
GCT TAG CCT ATC 
GGT GTC CTA TCT GCA TGG 
CTG CC 
 
rs1934952 4 96797500 ACG TTG GAT GCC AAG CCT GAT 
ATT CCA TGA 
ACG TTG GAT GGA TGA AGA 
GAG TGT ATG ACC 
GGA GCG TGT ATG ACC AGA 
GCT GA 
 
rs3753663 4 226035289 ACG TTG GAT GTT AGA ACG CTG 
CCC TGG GAC 
ACG TTG GAT GAG CCT GGG 
ATT GGG AGG AAA 
AGA CGC AAA ATG AGA CTC 
ACA CAG 
 
rs45468096 4 75043539 ACG TTG GAT GTC TTG CTG TGC 
TTG AAC AGG 
ACG TTG GAT GTT TGA CCT 
TGG AAG TGC CAG 
CCT TGT GCC CCC TCA GAA 
CAG TGT C 
 
rs2292568 4 226027659 ACG TTG GAT GAT GTG CAT GTA 
GCC GCT CTC 
ACG TTG GAT GTG AGA GGG 
ATG TGG AGC TG 
CGA GGG ATG TGG AGC TGC 
TGT ACC C 
 
rs11572172 4 96797752 ACG TTG GAT GGC ACA GAT TAC 
CAG GAA TCG 
ACG TTG GAT GGA CAG AGA 
CCT TCC TTC AAG 
GCA CAT TTT ACC ACA ATA 
GAT AAA TA 
 
rs34143170 4 226027548 ACG TTG GAT GTG CCT TCA GCC 
ACG TGA AAG 
ACG TTG GAT GGG GTC AGG 
GTA GAG AAG TTG 
GGG TGT AAA ACC AAA GCC 
ATG TTC AA 
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SNP = single nucleotide polymorphism, PCR = polymerase change reaction, MALDI-TOF MS = matrix-assisted laser desorption/ ionisation-time of 
flight mass spectrometer, Chromosomal positions are provided from HapMap Data release 23, March 2008, NCBI B36, dbSNP b126.  
Sequenom MALTI-TOF was performed with 5 different multi-plex assays consisting of 23, 21, 21, 20, 6 SNPs respectively. 
SNP Assay Chromosomal 
position 
Forward Amplification Primer 
Sequence (5'>3') 
Reverse Amplification Primer 
Sequence (5'>3') 
Extension Primer Sequence  
(5'>3') 
rs2069524 4 75040276 ACG TTG GAT GTA GAG ACG 
GAG TTT CAC CAG 
ACG TTG GAT GAA TCC CAG 
CAC TTT GAG AGG 
GGG AGC AGC ACT TTG 
AGA GGC CGA GA 
rs4646450 5 99266318 ACG TTG GAT GTA ACA AAG 
AGC GAG AGG ACG 
ACG TTG GAT GGC CTT GTC 
CAG AAT ACA CAC 
ATT CAC TTC ACG TGG CA 
rs3738040 5 226013041 ACG TTG GAT GCT GTG CAA 
TTG TCA GAA GGC 
ACG TTG GAT GTC TAA GGG 
CCT GTG AGA GAG 
CTG TGA GAG AGG CAG GG 
rs35694136 5 75039613 ACG TTG GAT GGA TTG TTT 
GAG CTC AGG AGG 
ACG TTG GAT GAC AGA GTC 
TTG CTC TGT CAC 
TCA CCC AGG TTG GGG TTC 
rs1058932 5 96796861 ACG TTG GAT GCT GAA GAA 
TGC TAG CCC ATC 
ACG TTG GAT GTA ATA GTG 
GGA ATG TCC TTG 
TTG CAG GTG ATA GCA GAT 
C 
rs45550332 5 226032979 ACG TTG GAT GTA TTC CTA 
CAT GGT TCG TGG 
ACG TTG GAT GAG GAA CTT 
GCG GAT GTC CTG 
AGC TCC GGC TCC TCA AAG 
GC 
rs7435335 5 69971335 ACG TTG GAT GCA GTT AAC 
CAA ATT CAG CAA G 
ACG TTG GAT GAT GAA GAA 
TCT GTT GGT GTC 
TTG GTG TCA TGA ATA AAA 
ACA 
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Appendix 1.2 Details and allele frequencies of 91 tagging SNPs from carbamazepine Drug Metabolising 
Enzymes genotyped in 159 epilepsy patients 
Gene SNP 
Chromosomal 
position 
SNP 
Alleles 
SNP location 
and function 
HWE P-
Value 
% Call 
rate  
MAF 
(this study) 
MAF (public 
database) Ref. 
EPHX1 rs35073925 226027630 A>G Exon 5 1.00 99 0.00 0.01 NCBI B36 
CYP2C8 rs11572081 96826966 G>A Exon 7 0.00 96 0.02 0.06 NCBI B36 
CYP1A2 rs35796837 75043593 G>A Exon 2 1.00 91 0.00 0.01 NCBI B36 
CYP2C8 rs11572126 96814915 G>A Intron 4 1.00 99 0.10 0.11 NCBI B36 
EPHX1 rs10799326 226009918 T>C Intron  1.00 84 0.12 0.12 NCBI B36 
CYP2C8 rs1058930 96818119 C>G Exon 5 1.00 98 0.04 0.03 NCBI B36 
EPHX1 rs10915884 226023875 C>T Intron 3 0.37 80 0.18 0.19 NCBI B36 
UGT2B7 rs4292394 69972949 G>C Exon 4 0.75 99 0.40 0.35 NCBI B36 
EPHX1 rs2292566 226019653 G>A Exon 2 1.00 99 0.15 0.13 NCBI B36 
CYP2C8 rs1536430 96817776 C>T Intron 4 1.00 98 0.02 0.02 NCBI B36 
CYP3A4 rs12721617 99359911 A>C Intron 3 1.00 97 0.01 0.01 NCBI B36 
CYP2C8 rs2275622 96827178 C>T Intron 7 0.79 97 0.38 0.32 NCBI B36 
CYP2C8 rs2275620 96802598 A>T Intron 2 0.55 100 0.40 0.39 NCBI B36 
EPHX1 rs2740168 226020988 G>A Intron 3 0.08 96 0.39 0.37 NCBI B36 
CYP2C8 rs2071426 96828323 A>G Intron 8 0.89 96 0.32 0.29 NCBI B36 
UGT2B7 rs10028494 69970937 A>C Intron 4 0.40 83 0.23 0.11 NCBI B36 
CYP1A2 rs34067076 75042389 G>A Exon 2 1.00 97 0.00 0.02 NCBI B36 
CYP3A4 rs2246709 99365719 A>G Intron 6 0.43 99 0.27 0.35 NCBI B36 
CYP3A5 rs10264272 99262835 C>T Exon 7 1.00 100 0.00 0.04 NCBI B36 
CYP2C8 rs11572079 96827118 T>C Intron 7 1.00 99 0.00 0.03 NCBI B36 
TMEM63A rs2292558 226037318 G>C Intron 3 0.96 98 0.10 0.14 NCBI B36 
EPHX1 rs2260863 226019774 C>G Intron 3 0.45 98 0.26 0.28 NCBI B36 
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Gene SNP 
Chromosomal 
position 
SNP 
Alleles 
SNP location 
and function 
HWE 
 P-Value % Call rate  
MAF 
(this 
study) 
MAF 
(public 
database) Ref. 
CYP2C8 rs1341159 96815619 C>G Intron 4 1.00 98 0.00 0.27 NCBI B36 
CYP3A4 rs4646440 99360870 C>T Intron 3 1.00 98 0.00 0.01 NCBI B36 
CYP3A5 rs28371764 99277593 C>T 5' UTR 1.00 99 0.03 0.07 NCBI B36 
UGT2B7 rs4348159 69972952 C>T Intron 3 0.01 86 0.06 0.06 NCBI B36 
CYP3A5 rs6976017 99249999 G>A Intron 2 1.00 99 0.04 0.04 NCBI B36 
EPHX1 rs6965 226033476 T>C 3' near gene 0.00 91 0.49 0.36 NCBI B36 
CYP1A2 rs11636419 75047600 A>G 3' UTR 1.00 86 0.00 0.03 NCBI B36 
EPHX1 rs3753660 226012776 T>C Intron 1 0.91 98 0.13 0.13 NCBI B36 
CYP3A5 rs1419745 99260092 A>G Intron 4 1.00 99 0.04 0.02 NCBI B36 
CYP1A2 rs2069525 75040372 T>A/C/G 5' near gene 1.00 99 0.03 0.08 NCBI B36 
EPHX1 rs3753658 226012686 G>T Intron 1 0.51 86 0.18 0.20 NCBI B36 
UGT2B7 rs3924194 69971092 C>G Intron 3 0.26 99 0.17 0.17 NCBI B36 
CYP2C8 rs1934956 96828160 C>T Intron 7 1.00 98 0.12 0.16 NCBI B36 
CYP3A5 rs28365083 99250236 C>A Exon 3 1.00 98 0.01 0.02 NCBI B36 
UGT2B7 rs10050146 69971576 C>T 5'near gene 0.17 99 0.03 0.03 NCBI B36 
TMEM63A rs360063 226036309 G>A Intron 4 - 7 - 0.40 NCBI B36 
CYP1A2 rs2470890 75047426 T>C Exon 6 0.54 96 0.35 0.36 NCBI B36 
CYP3A5 rs15524 99245914 T>C 3' UTR 1.00 92 0.09 0.07 NCBI B36 
CYP3A4 rs2242480 99361466 C>T Intron 3 0.56 92 0.09 0.17 NCBI B36 
CYP2C8 rs11188150 96802737 C>T Exon 3 1.00 96 0.00 0.01 NCBI B36 
EPHX1 rs1877724 226013355 C>T Intron 1 0.25 97 0.28 0.19 NCBI B36 
CYP3A4 rs12333983 99354114 T>A 3' near gene 1.00 99 0.11 0.12 NCBI B36 
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Gene SNP 
Chromosomal 
position 
SNP 
Alleles 
SNP 
location 
and 
function 
HWE  
P-Value 
% Call 
rate  
MAF  
(this study) 
MAF 
(public 
database) Ref. 
CYP3A4 rs1851426 99382936 C>T 5' near gene 1.00 96 0.04 0.03 NCBI B36 
EPHX1 rs4149229 226032928 G>A Exon 7 1.00 98 0.01 0.04 NCBI B36 
CYP3A4 rs4646437 99365083 C>T Intron 5 0.84 98 0.11 0.13 NCBI B36 
CYP2C8 rs11572080 96827030 G>A Exon 7 0.61 98 0.15 0.05 NCBI B36 
CYP3A4 rs4986910 99358524 C>T Exon 2 1.00 97 0.00 0.01 NCBI B36 
CYP1A2 rs17861162 75048753 C>G 3' UTR 1.00 98 0.00 0.18 NCBI B36 
EPHX1 rs4149230 226033030 G>C Exon 7 1.00 97 0.03 0.02 NCBI B36 
EPHX1 rs2740170 226024797 C>T Intron 3 0.82 96 0.20 0.23 NCBI B36 
UGT2B7 rs7375178 69969679 C>A Exon 2 0.42 98 0.39 0.48 NCBI B36 
EPHX1 rs2854461 226011644 C>A Intron 1 0.90 96 0.35 0.38 NCBI B36 
EPHX1 rs35561387 226027569 A>G Exon 5 1.00 96 0.00 0.03 NCBI B36 
CYP3A4 rs2740574 99382096 A>G 5' near gene 1.00 98 0.04 0.03 NCBI B36 
UGT2B7 rs4356975 69972463 C>T Intron 3 0.81 95 0.30 0.31 NCBI B36 
CYP1A2 rs17861157 75043592 C>A Exon 2 1.00 95 0.01 0.04 NCBI B36 
CYP2C8 rs11572082 96826922 G>C Intron 6 0.66 98 0.14 0.12 NCBI B36 
CYP3A4 rs4987161 99366081 T>C Exon 7 1.00 97 0.00 0.02 NCBI B36 
EPHX1 rs2671272 226015116 C>T Intron 1 0.91 98 0.21 0.23 NCBI B36 
EPHX1 rs2234922 226026406 A>G Exon 3 0.82 90 0.16 0.18 NCBI B36 
CYP2C8 rs11572127 96814689 G>C Intron 4 - 0 - 0.07 NCBI B36 
CYP1A2 rs35407132 75042301 C>T Exon 1 1.00 98 0.00 0.03 NCBI B36 
UGT2B7 rs28365062 69964271 A>G Exon 3 0.90 96 0.11 0.18 NCBI B36 
EPHX1 rs2234700 226032896 T>C Intron 7 1.00 98 0.00 0.03 NCBI B36 
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SNP = single nucleotide polymorphism, PCR = polymerase change reaction, SNP frequency data was compiled from HapMap and NCBI dbSNP databases. 
Chromosomal positions are given in base pairs as per NCBI B36 assembly, dbSNP b126. 
Gene SNP Chromosomal 
position 
SNP 
Alleles 
SNP location 
and function 
HWE 
P-Value 
% Call 
rate 
MAF (this 
study) 
MAF (public 
database) 
Ref. 
EPHX1 rs3738042 226013388 G>A Intron 1 - 7 - 0.28 NCBI B36 
EPHX1 rs1051740 226019633 T>C Exon 2 0.59 97 0.30 0.33 NCBI B36 
CYP2C8 rs11572103 96818106 A>T Intron 4 0.01 98 0.01 0.03 NCBI B36 
EPHX1 rs4653695 226033083 A>C 3'UTR 0.68 82 0.16 0.15 NCBI B36 
CYP3A5 rs28365095 99277605 G>A 5' UTR 1.00 98 0.01 0.02 NCBI B36 
EPHX1 rs2234698 226019500 T>C Exon 2 1.00 98 0.04 0.03 NCBI B36 
CYP1A2 rs762551 75041917 A>C Intron 1 0.70 97 0.28 0.31 NCBI B36 
CYP2C8 rs1934980 96808973 T>C Intron 4 0.95 98 0.13 0.19 NCBI B36 
UGT2B7 rs6600894 69983092 G>A 3' near gene 0.38 97 0.16 0.22 NCBI B36 
UGT2B7 rs7439366 69964338 C:T Intron 3 0.55 98 0.40 0.50 NCBI B36 
CYP3A5 rs776746 99270539 G>A Intron 10 0.00 97 0.50 0.06 NCBI B36 
CYP1A2 rs2069522 75039233 T>C 5' near gene - 49 - 0.08 NCBI B36 
CYP2C8 rs1934952 96797500 G>A Intron 1 0.78 98 0.35 0.37 NCBI B36 
TMEM63A rs3753663 226035289 T>A Intron 3 - 19 - 0.03 NCBI B36 
CYP1A2 rs45468096 75043539 C>T Intron 2 - 2 - 0.02 NCBI B36 
EPHX1 rs2292568 226027659 G>C Exon 5 1.00 97 0.03 0.03 NCBI B36 
CYP2C8 rs11572172 96797752 A>C Intron 1 1.00 95 0.03 0.06 NCBI B36 
EPHX1 rs34143170 226027548 C>T Exon 5 1.00 98 0.06 0.08 NCBI B36 
CYP1A2 rs2069524 75040276 A>G 5' near gene - 0 - 0.08 NCBI B36 
CYP3A5 rs4646450 99266318 G>A Intron 9 0.47 99 0.18 0.18 NCBI B36 
EPHX1 rs3738040 226013041 G>A Intron 1 0.91 98 0.07 0.12 NCBI B36 
CYP1A2 rs35694136 75039613 T>N 5' near gene - 0 - 0.24 NCBI B36 
CYP2C8 rs1058932 96796861 C>T 3' UTR 0.95 99 0.13 0.19 NCBI B36 
EPHX1 rs45550332 226032979 G>A Exon 7 1.00 100 0.00 0.01 NCBI B36 
UGT2B7 rs7435335 69971335 G>A Exon 7 0.98 100 0.10 0.18 NCBI B36 
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Appendix  1.3    SNPs captured by the 91 tagging SNPs across carbamazepine Drug Metabolising Enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tagging SNP Tagged SNPs Gene Chromosome location 
rs2071426 rs2071426 CYP2C8 96828323 
 rs1934982 CYP2C8 96802124 
 rs6583967 CYP2C8 96814475 
 rs1934957 CYP2C8 96815114 
 rs11572139 CYP2C8 96808886 
 rs1341164 CYP2C8 96800873 
 rs2185571 CYP2C8 96824975 
 rs1934983 CYP2C8 96801929 
 rs11572093 CYP2C8 96824406 
rs1341159 rs1341159 CYP2C8 96815619 
 rs11572082 CYP2C8 11572082 
 rs1934951 CYP2C8 1934951 
 rs2275622 CYP2C8 2275622 
 rs2275620 CYP2C8 2275620 
 rs1934952 CYP2C8 96797500 
 rs1536430 CYP2C8 96817776 
 rs11572126 CYP2C8 96814915 
 rs11572127 CYP2C8 96814689 
 rs11572079 CYP2C8 96827118 
 rs11572172 CYP2C8 96797752 
  rs1934956 CYP2C8 96828160 
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Tagging SNP Tagged SNPs Gene Chromosome location 
rs11572082 rs11572082 CYP2C8 96826922 
 rs11572150 CYP2C8 96807128 
 rs11572174 CYP2C8 96797571 
 rs10509681 CYP2C8 96798749 
 rs11188153 CYP2C8 96805090 
 rs11572169 CYP2C8 96799774 
 rs11572107 CYP2C8 96817233 
rs1934980 rs1934980 CYP2C8 96808973 
 rs1934951 CYP2C8 96798548 
 rs1058932 CYP2C8 96796861 
 rs1934980 CYP2C8 96808973 
 rs1341162 CYP2C8 96810612 
 rs1113129 CYP2C8 96811045 
 rs10882520 CYP2C8 96799688 
 rs11572101 CYP2C8 96818362 
rs2275622 rs2275622 CYP2C8 96827178 
 rs7095531 CYP2C8 96811841 
 rs1891073 CYP2C8 96804911 
 rs6583968 CYP2C8 96816357 
 rs1934953 CYP2C8 96797470 
 rs1934984 CYP2C8 96801805 
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Tagging SNP Tagged SNPs Gene Chromosome location 
rs2275620 rs2275620 CYP2C8 96802598 
 rs1934985 CYP2C8 96801753 
 rs1891071 CYP2C8 96805371 
 rs7910936 CYP2C8 96804451 
  rs1341163 CYP2C8 96810552 
rs1934952 rs1934952 CYP2C8 96797500 
  rs11572177 CYP2C8 96797270 
rs1536430 rs1536430 CYP2C8 96817776 
rs11572126 rs11572126 CYP2C8 96814915 
rs11572127 rs11572127 CYP2C8 96814689 
rs11572079 rs11572079 CYP2C8 96827118 
rs11572172 rs11572172 CYP2C8 96797752 
rs12333983 rs12333983 CYP3A4 99354114 
  rs2404955 CYP3A4 99353279 
rs1851426 rs1851426 CYP3A4 99382936 
  rs2687105 CYP3A4 99376946 
rs4646440 rs4646440 CYP3A4 99360870 
rs4646437 rs4646437 CYP3A4 99365083 
rs2242480 rs2242480 CYP3A4 99361466 
rs12721617 rs12721617 CYP3A4 99359911 
rs2246709 rs2246709 CYP3A4 99365719 
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Tagging SNP Tagged SNPs Gene Chromosome location 
rs11773597 rs11773597 CYP3A4 99382451 
rs1419745 rs1419745 CYP3A5 99260092 
 rs776741  CYP3A5 99279136 
 rs4646447 CYP3A5 99268390 
 rs4646453  CYP3A5 99260362 
 rs4646449 CYP3A5 99266443 
 rs4646456 CYP3A5 99245275 
 rs4646458 CYP3A5 99245013 
  rs4646446 CYP3A5 99275083 
rs6976017 rs6977165 CYP3A5 99269397 
 rs6976017 CYP3A5 99249999 
  rs6956305 CYP3A5 99241310 
rs15524 rs4646457 CYP3A5 99245080 
 rs15524 CYP3A5 99245914 
 rs776746 CYP3A5 99270539 
rs4646450 rs4646450 CYP3A5 99266318 
 rs3924192 UGT2B7 69970964 
 rs6858558 UGT2B7 69969543 
 rs7698645 UGT2B7 69971910 
 rs4541594 UGT2B7 69972272 
 rs6600884 UGT2B7 69968066 
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Tagging SNP Tagged SNPs Gene Chromosome location 
 rs7439152 UGT2B7 69969006 
 rs6600891 UGT2B7 69971596 
 rs12642938 UGT2B7 69976217 
 rs12513195 UGT2B7 69972086 
 rs7375178 UGT2B7 69969679 
 rs4351080 UGT2B7 69972319 
 rs7442453 UGT2B7 69969180 
 rs6600893 UGT2B7 69978901 
 rs4521414 UGT2B7 69973525 
rs7375178 rs9995928 UGT2B7 69976663 
 rs10050146 UGT2B7 69971576 
rs10050146 rs10050146 UGT2B7 69971576 
rs7435335 rs7435335 UGT2B7 69971335 
rs3924194 rs3924194 UGT2B7 69971092 
rs6600894 rs6600894 UGT2B7 69983092 
rs4356975 rs4356975 UGT2B7 69972463 
rs4348159 rs4348159 UGT2B7 69972952 
rs10028494 rs10028494 UGT2B7 69970937 
rs2470890 rs11854147 CYP1A2 75052771 
  rs2470890 CYP1A2 75047426 
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Tagging SNP Tagged SNPs Gene Chromosome location 
rs10799326 rs10799326 EPHX1 226009918 
 rs3738043 EPHX1 226015299 
 rs10753410 EPHX1 226008101 
 rs3766934 EPHX1 226015017 
  rs3753661 EPHX1 226014342 
rs2292558 rs2740174 EPHX1 226033969 
 rs2671267 EPHX1 226025690 
 rs2292558 EPHX1 226037318 
 rs1051741 EPHX1 226032229 
rs2671272 rs2854450 EPHX1 226012577 
 rs2671272 EPHX1 226015116 
rs2740170 rs2740171 EPHX1 226025528 
  rs2740170 EPHX1 226024797 
rs2292568 rs2292568 EPHX1 226027659 
rs6965 rs6965 EPHX1 226033476 
rs3753663 rs3753663 EPHX1 226035289 
rs2234698 rs2234698 EPHX1 226019500 
rs2260863 rs2260863 EPHX1 226019774 
rs2292566 rs2292566 EPHX1 226019653 
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SNP = single nucleotide polymorphism 
 
 
 
 
Appendix 1.4 Australian five-SNP classifier PCR and extension primers for MALTI-TOF MS 
 
 
 
 
 
 
 
 
 
 
 
Chromosomal positions are provided from HapMap Data release 23, March 2008, NCBI B36, dbSNP b126, Sequenom MALTI-TOF was performed with 1 multi-plex assay. 
 
 
Tagging SNP Tagged SNPs Gene Chromosome location 
rs1051740 rs1051740 EPHX1 226019633 
rs10915884 rs10915884 EPHX1 226023875 
rs2234922 rs2234922 EPHX1 226026406 
rs360063 rs360063 EPHX1 226036309 
rs2740168 rs2740168 EPHX1 226020988 
rs1877724 rs1877724 EPHX1 226013355 
rs3753658 rs3753658 EPHX1 226012686 
rs3738042 rs3738042 EPHX1 226013388 
SNP Assay Chromosomal 
position 
Forward Amplification 
Primer Sequence (5'>3') 
Reverse Amplification 
Primer Sequence (5'>3') 
Extension Primer Sequence  
(5'>3') 
rs658624 1 118018767 ACGTTGGATGTAAGGT
CTGGCTCATGACAC 
ACGTTGGATGTAAGTCA
TCCACATAGGTGC 
CACAAACCAGGCAGAAA 
rs2808526 1 101326687 ACGTTGGATGACTGCC
TGTCACACAGTATC 
ACGTTGGATGACAGGC
CTAACTGGGACAAC 
CTGCTCTTCAACCCCAAG 
rs678262 1 118021740 ACGTTGGATGCCCAA
AGGGTAGCTCAGAAA 
ACGTTGGATGGACTGTT
CAGCTGTATAGAC 
AGCTGTATAGACCAGGTA 
rs4869682 1 36656718 ACGTTGGATGACCAG
GGCTGCAATGCAAAT 
ACGTTGGATGGAGAAT
CTGACTTGTCTAGC 
ACTCCTTGAGAAGAGGA
GC 
rs2283170 1 2583141 ACGTTGGATGCCTCAG
GAGGGACACAGAG 
ACGTTGGATGATCCTTC
TGCTCGGCTGCTT 
CCCATGGAACGTGCAGCCCG 
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Appendix 1.5  Custom and predesigned primer assays from TaqMan for five GWAS candidate SNP genotyping 
   
SNP TaqMan SNP 
Genotyping 
Assay 
Chromosomal 
position 
SNP Forward Amplification 
Primer Sequence (5'>3') 
Reverse Amplification 
Primer  
Sequence (5'>3') 
Reporter 1 (VIC 
Sequence 
Reporter 2 
(FAM) Sequence 
rs17252760 Custom 148653916 rs17252760 TGCCATCAGTTACCTT
TAAAACTACATGT 
GGATTCATTTGTCC
TGTGAGAG 
AGAA 
TCCCACAAAC
CCC 
CTCCCATAA
ACCCC 
SNP TaqMan SNP 
Genotyping 
Assay 
Chromosomal 
position 
SNP                                       Context sequence   
rs12919774 Pre-designed 8515708 rs12919774 AGGAGAAAATTTCCTCTACTCTGAG[A/G]TCAAGCCATTCTACCAAAAAATAAG 
AGGAGAAAATTTCCTCTACTCTGAG[A/G]TCAAGCCATTCTACCAAAAAATAAG 
GGCCCACTCTTATTTCCCAGTTCTG[C/T]TGCTAGAACATCAAGAGGTGTAGTC 
AGGTGGCAGGCCAGGTTTGGCCCAG[A/G]AGTTACAGTCTGCACATTAGACTTG 
 
rs16994558 Pre-designed 147452128 rs16994558 
rs316132 Pre-designed 52847966 rs316132 
rs622902 Pre-designed 52846474 rs622902 
Chromosomal positions are provided from NCBI B36, dbSNP b126.  
The context sequence refers to the nucleotide sequence surrounding the SNP site, where SNP alleles are in brackets and the order of the alleles corresponds to the 
association with reporter dyes, where Allele 1 = VIC and Allele 2 = FAM  
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